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Experimental studies of the immunological and antitumour effects of 
the anerobic diptheroid bacterium Corynebacterium parvum are described. 
C. parvum injected systemically into mice resulted in potent 
stimulation of the lymphoreticular system and augmented humoral 
immunity; however, cell mediated immunity was suppressed. The C. 
parvum activated macrophage was determined to be the basis for all these 
phenomena, exerting both stimulatory and inhibitory effects. 
Using mouse tumour models both systemically and locally injected C. 
parvum could be manipulated to achieve therapeutic effects. The form of 
ant itumour immunity generated varied according to the particular C. 
parvum tumour antigen interaction; following systemic injection, the 
reuslting antitumour activity was immunologically non specific and 
mediated directly be activated macrophages, whereas after local interaction 
of C. parvum with tumour antigen strong specific cell mediated antitumour 
immunity resulted. 
Subsequent experimental studies were designed to elucidate further 
these stimulatory and antitumour effects of C. parvum with a view to 
providing a rational basis for the clinical evaluation of C. parvum against 
human cancer. These have comprised:-
(a) Manipulation of dose, route and time of C. parvum injection. 
(b) Tissue distribution studies following injection of labelled C. 
parvum preparations. 
(c) The role of immunity against C. parvum in its antitumour effects. 
(d) The principles of combining C. parvum immunotherapy with 
conventional anti-cancer chemotherapy. 
(e) Analyses of the active component of C. parvum. 
(iii) 
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PART I INTRODUCTION AND OVERVIEW 
This thesis comprises my investigations into the immunological and 
antitumour effects of the anaerobic diphtheroid bacterium Corynebacterium 
parvum (now classified as Propionobacterium acnes; see (29)(a). 
Experimental work started in 1969; C. parvum had recently been 
reported to be a potent lymphoreticular stimulant and an adjuvant for both 
humoral and cell mediated immunity in mice, and also to be capable of 
inhibiting the growth of mouse experimental tumours. Similar effects were 
known to occur following infection of mice with living tubercule bacilli 
(BCG) but the attraction of C. parvum was that it was apparently active 
when injected as a killed bacterial suspension. The earlier C. parvum work 
had been with a particular strain (963 B) which was no longer available. 
Thus, at the outset it was necessary to screen several strains and select an 
active one for further investigation. A range of Corynebacteria, both 
aerobic and anaerobic, were obtained and assessed for both lymphoreticular 
stimulatory and adjuvant activity in mice. Several species were found to be 
active, the majority being anaerobic, but activity could not be correlated 
with any particular biochemical reaction (1). One strain, CN6134, showed 
high activity in all tests and was selected for further study. 
The initial approach to understanding the mechanism(s) underlying the 
immunostimulatory effects of C. parvum in mice was to determine the 
involvement of different cell types. The status of the thymus-processed (T) 
a numbers in parenthesis refer to published papers in Part II. 
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1 ymphocyte was assessed by the ability of lymphoid cells from C. parvum 
stimulated mice to respond in vitro to the T cell specific mitogen 
phytohaemagglutinin (PHA). 
Contrary to expectation, since C. parvum had previously been 
described to boost in vivo T cell mediated immune competence, the PHA 
responsiveness of spleen cells from mice pretreated with intravenous (i.v.) 
C. parvum was found to be inhibited. Other recognised T cell functions, 
mixed lymphocyte and graft versus host reactivity, were similarly impaired; 
however, the deficit apparently did not extend to bone marrow derived (B) 
lymphocytes since the in vitro response of spleen cells to B cell mitogens 
was not impaired. The inhibition of T cell reactivity was restricted to 
spleen and peripheral blood lymphocytes there being no impaired lymph node 
response even after direct stimulation by locally injected C. parvum (2). 
The mechanism underlying the failure of C. parvum stimulated spleen T 
lymphocytes to respond to PHA in vitro was analysed in detail and shown not 
to be due to any intrinsic defect of the T lymphocyte but rather that the T 
lymphocyte was inhibited from responding by C. parvurn activated 
macrophages (3). 
The finding that C. parvum was capable of suppressing the in vitro 
expression of cell mediated immunity was intriguing in that it had been 
reported to have antitumour effects and, at the time, tumour immunity in 
experimental mice was considered to be due almost exclusively to cell 
mediated immunity. The next step was therefore to determine whether C. 
parvum could depress cell mediated immunity in vivo. This proved to be the 
case; mice pretreated with systemic C. parvum and sensitized with sheep 
red blood cells developed markedly reduced levels of delayed type 
hypersensitivity (DTH) against sheep cells. The effect was not due to any 
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inhibitory effec ts of antibody and showed some features reminiscent of 
depressed in vitro PHA reactivity, namely, it occurred after systemic 
rather than local injections of C. parvum and again the spleen was 
implicated in t he suppressor mechanism (6). Since the proposed use of C. 
parvum was for the therapy of existing tumours (i.e. host already sensitized 
to tumour antigens) it was relevant to note that in vivo suppression of DTH 
did not occur if antigen sensitization was before, or at the same time as, C. 
parvum administration. 
In parallel studies on the development of OTH associated bacterial 
infection in mice, C. parvum pretreatment suppressed the development of 
specific OTH associated with a subsequent infection with Salmonella 
enteritidis (8). It was, however, capable of protecting mice against an acute 
lethal injection with S. enteritidis which was in keeping with an earlier 
demonstration of C. parvum mediated pro tection against infection with a 
range of bacteria (7) . The finding that C. parvum induced protection 
against S. enteritidis and yet inhibi.ted the production of specific DTH was 
particularly interesting in that the elimination of such intracellular bacteria 
was considered to depend on the development of specific cell mediated 
immunity and associated DTH. Our data, however, were consistent with the 
idea that the early inactivation of S. enteritidis after C. parvum treatment 
was due to their non-specific destruction by C. parvum activated 
macrophages with both the liver and spleen (8). 
Although systemic C. parvum had had an inhib itory influence on 
various T cell functions associated with cell mediated immunity, the fact 
that it augmented the IgG antibody response to T cell dependent antigens in 
mice implied that the antibody helper cell activity of T cells was not 
similarly impaired. The ability of C. parvum to potentiate B cell activity 
4 
was also evident from its adjuvant effect on the T cell independent antibody 
response to the antigen type 3 pneumococcal polysaccharides whereas 
another bacterial adjuvant , Bordetella pertussis, was ineffective. These and 
further data suggested that, as for the demonstrated T cell inhibitory 
effects of C. parvum, the potentiation of 8 cell activity was indirect and 
again mediated by C. parvum activated macrophages (4,5). Further work by 
a colleague comparing the ability of C. parvum with other conventional 
adjuvants to augment the antibody response to another T cell independent 
antigen confirmed the apparently unique lack of T cell involvement in the 
adjuvant effect of C. parvumb. 
My first experiments concerning the antitumour activity of C. parvum 
were a study of the effects of systemic C. parvum pretreatment on the in 
vivo growth of a variety of experimental mouse tumours; variable degrees 
of protection were obtained being generally greater with the more 
immunogenic tumours. Mice could be afforded a degree of protection 
against immunogenic tumours by immunization with irradiated homologous 
tumour cells and systemic C. parvum given before this treatment diminished 
the protective effect. Thus it was apparent that the somewhat anomalous 
immunosuppressive effects associated with C. parvum stimulation extended 
to immunity against tumour antigens (10). 
Moving to the Trudeau Institute presented me with the opportunity to 
continue the C. parvum tumour studies using a tumour model known to be 
susceptible to immunotherapy with BCG. This was the poorly immunogenic, 
carcinogen induced, transplantable mouse mastocytoma P815 and it was 
grown as solid tumour in the footpad. The early emphasis concerned the 
b del Guercio, P. (1972) Nature, New Bioi. 238, 213. 
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best route of administration (11,12). C. parvum given systemically shortly 
after tumour establishment significantly inhibited tumour growth although 
no complete regressions were achieved. On the other hand a local injection 
of C. parvum directly into the tumour site was markedly inhibitory with a 
proportion of tumours regressing completely. C. parvum injected locally in 
t he region of the tumour (i .e. stimulating the tumour draining lymph node) 
was also effective but only minimal tumour inhibition occurred when the 
injection was at a distant site. 
Investigation of the mechanisms underlying the antitumour effects of 
C. parvum administered systemically or locally revealed striking differences 
bet ween the two routes of injection. After systemic C. parvum the effects 
were immunologically non-speci fie i.e. not amplifying a speci fie anti tumour 
response; they occurred in immunologically compromised (T cell deprived) 
mice and did not result in the generation of specific antitumour immunity. 
Macrophages taken from non- tumour bearing mice stimulated with systemic 
C. parvum inhibited the growth of tumour cells in vitro and this non-
specific effect of C. parvum activated macrophages was concluded to be the 
major mechanism by which systemic C. parvum achieved its ant itumour 
effect in vivo (11). Following local administration of C. parvum, 
macrophages were only minimally tumour inhibitory and, again in contrast 
with systemic C. parvum, the effects of C. parvum injected directly into the 
tumour lesion were entirely T cell dependent and resulted in the generation 
of strong, specific cell mediated immunity (12). Further characterization of 
the specific immunity resulting from local interaction of C. parvum with 
tumour antigens was achieved by substituting irradiated tumour cells for 
live cells thereby obviating complications associated with tumour growth 
(13). The immunity was cell mediated and could be generated with very low 
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doses of C. parvum. In keeping with the observed antitumour effects of 
locally injected C. parvum, the successful generation of speci fie immunity 
did not require that the injection sites of C. parvum and tumour antigen be 
coincident but that they did require common lymphoid drainage. Most 
importantly, local injection of C. parvum plus irradiated tumour cells 
proved capable of inhibiting the growth of established tumours thus 
establishing the potential of C. parvum for clinical use in a specific active 
immunotherapy context in situations where suitable tumour material was 
available. 
It seemed likely that the observed differences between systemic and 
local C. parvum injections might be attributed to differences in in vivo 
distribution of the organisms. C. parvum was successfully labelled with 
either fluorescein or radioactive iodine without modifying its stimulatory or 
antitumour activities, and the relative distribution and persistence of these 
labelled preparations injected e ither locally or systemically was monitored 
in both normal and tumour bearing mice. The patterns obtained were 
readily reconciled with the characteristic profiles of lymphoreticular 
stimulatory and antitumour activity previously observed for the two 
injection routes. Also discovered was the marked resistance to degradation 
of the active strain of C. parvum compared with an inactive strain (19,20). 
In addition to being an immunostimulant, C. parvum was an 
immunogen and mice treated with C. parvum, especially repeatedly, 
developed high levels of both cell mediated and humoral specific immunity 
(17). It was apparent from experiments in which 'pre- emption' of cell 
mediated immunity against C. parvum had reduced the efficacy of 
subsequent intralesional therapy that immunity against C. parvum might be 
implicated in its antitumour activity (12). This concept was confirmed by 
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the contemporary studies of others; a particular mouse fibrosarcoma was 
responsive to intralesional C. parvum therapy only in mice presensitized to 
C. parvumc and macrophage activation occurred as a result of contact of 
C. parvum with specifically sensitized T lymphocytesd. These data had 
important implications for the clinical use of C. parvum (e.g. individual 
patients may vary in their immune responses to C. parvum, in particular 
relatively anergic advanced cancer patients may respond only poorly) and 
prompted furt her studies. Unlike the mouse fibrosarcoma model, the 
susceptibility of mastocytoma PSIS to either local or systemic C. parvum 
was neither dependent upon nor modified by C. parvum presensitization (14). 
Clearly, different tumours may be expected to vary in their susceptibility to 
this aspect of C. parvum mediated antitumour effects. Suspicions about the 
interpretation of such experiments concerning the role of C. parvum 
immunity were aroused by the finding of significant levels of 'natural' 
antibodies in many rodents and patientse. These most probably arose from 
prior infection with cross-reacting organisms and raised the question of 
whether a true primary response to C. parvum was ever attainable. To 
achieve just this we resorted to germ free mice and compared their 
responsiveness with their conventional counterparts. The results showed 
that the stimulatory effects of C. parvum could be fully established in the 
absence of previous sensitization (15). 
c Tutt le, R.L. and North, R.J. (1975) J . nat. Cancer Inst. 55 1403-1409. 
d Bamford, R. and Christie, G.H. (1975) Cell. Immunol. 17 150-155. 
e Walberg, G., Duncan, G.S. et al. (1977) Infect. Immun. 15 1004-1007 . 
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There was by now considerable clinical interest in C. parvum which 
influenced considerably the future development of experimental animal 
studies. For example, it was apparent that whereas experimental mouse 
tumours grew rapidly allowing time for only one or few C. parvum 
injections, most human tumours grow slowly over a period of years and C. 
parvum was likely to be given repeatedly over a long period. Also it was 
apparent from the accumulating clinical toxicity data that the acceptable 
dose levels were to be considerably less than those that had been used in 
mice. For these reasons many of the immunological phenomena observed 
after single high doses of C. parvum in mice were re- evaluated using 
repeated, low, human equivalent doses. Both multiple, low dose systemic 
and local injections resulted in the development of high levels of both cell 
mediated and humoral immunity against C. parvum, however, the levels of 
non-specific stimulation and antitumour activity were significantly higher 
after systemic injection. A further, and most encouraging, finding was the 
failure to detect non-speci fie T cell suppression after multiple low dose 
regimens (17). 
It was hoped that some of the clinical toxicity associated with C. 
parvum might be circumvented by using active fractions of the organism. 
To this end research aimed at determining the active component(s) of C. 
parvum was undertaken. Purified cell walls were prepared, analysed and 
compared with the whole organism for activity. Cell wall preparations 
retained immune- and anti-genicity and localised and persisted in vivo in the 
same manner as whole cells but they lacked completely both stimulatory and 
antitumour activity. Considering these findings with the isolation attempts 
of others it was concluded that the antitumour activity was not associated 
with a single molecule capable of being isolated in pure form and that an 
assoc iation of both cell wall and non cell wall components was required (23). 
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Clinicians considering using immunotherapy frequently questioned the 
relative merits of C. parvum and BCG, in particular whether the apparent 
advantages of being able to use a killed preparation might be offset by 
reduced potency. To contribute to this debate the potent iation of specific 
antitumour immunity by either BCG or C. parvum was compared; larger 
amounts of BCG than C. parvum were required to produce similar degrees of 
immunity; also, stronger and more protective immunity was mediat ed by C. 
parvum than BCG (16). Encouraging results in the treatment of lung cancer 
patients by post-resection injection of BCG into the pleural space was 
reported by McKneally et al. f and, since the comparative mouse study had 
shown C. parvum apparently to be more potent than BCG, the Ludwig Lung 
Cancer Study Group decided to evaluate intrapleural C. parvum clinically 
(22). Experimental support for this trial took the form of experimental 
mouse studies undertaken to define the distribution of C. parvum following 
intrapleural injection and also the antitumour effects against lung 
associated tumours (21). 
My final series of experimental studies with C. parvum was an analysis 
of the principles involved in combining immunotherapy with the more 
conventional cancer chemotherapy. There were already animal data 
indicating that such combination therapy may be a promising form of 
treatment, the individual antitumour effects being additive or even 
synergistic. A potential antagonism between the immunostimulatory effects 
f McKneally, F .F., Maver, C.M. and Kausel, H.W. (1977) Lancet I 593. 
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of C. parvum and the invariably immunosuppressive chemotherapy was 
already apparent from my previous demonstration of the abolition of the 
antitumour activity of C. parvum activated macrophages by cortisone (24), 
and particular attention was therefore focussed on this aspect. Using a 
mouse fibrosarcoma model the modification of both immunologically 
specific and non-specific C. parvum mediated antitumour effects by drug 
treatment at various times was observed and related to the overall 
therapeutic outcome (25,26,27). The timing between the two forms of 
treatment was a critical factor and the principles established provided 
useful guidelines for the consideration and design of clinical chemo-
immunotherapy trials. 
Towards the end of 1979 it was considered that sufficient data had 
accumulated to assure the meaningful design and evaluation of trials of C . 
parvum against human cancer and consequently my experimental animal 
studies ceased. The continuing number of subsequently published 
experimental studies attests to the usefulness of C. parvum as a potent 
reagent for analysing various aspects of the immune system; an interesting 
development from the antitumour viewpoint has been the evidence for 
potentiation of Natural Killer (NK) cell activity by C. parvumg, a property 
which might have been predicted from our observation of the ability of C. 
parvum to induce interferon (9). 
g Ojo, E. (1979) Cell. Immunol. 45 182-187. 
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The potential of C. parvum as a human anti-cancer agent was widely 
recognised and during the late seventies and early eighties numerous clinical 
trials were set up. Many have now been completed and, despite the various 
manipulations and strategies employed, to date there has been a 
disappointing overall lack of significant therapeutic effects. This may 
reflect, at least in part, the now recognised low antigenicity of human 
tumours compared with many of the animal models. Also that we may have 
to understand further and optimize- the use of immunotherapeutic agents 
with particular regard fo r the fine balance between immunostimulation and 
. . h Immunosuppression • 
Two clin ical studies did, however, indicate a particular role for C. 
parvum in the management of human cancer. Successful suppression of the 
rapid reaccumulation of peritoneal or pleural fluid can contribute 
significantly to the palliative care of patients with disseminated cancer and 
C. parvum injected into the peritoneali or pleuralj cavities controlled such 
effusions, apparently without the toxicity often associated with drug 
control. It was for this purpose that in 1981 C. parvum was licenced and 
marketed as 'Coparvax'. 
(h) Davies, M. (1983) Immunol. Today!!, 103-106. 
(i) 
Webb, H.E., Oaten, S.W. and Pike, C.P. (1978) Br. Med. J . 1 338- 340. 
C) 
J Millar, J .W., Hunter, A.M. and Horne, N. W. (1980) Thorax 35 856-858. 
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LYMPHO-RETICULAR STIMULATORY PROPERTIES OF 
CORYNEBACTERIUM PARVUM AND RELATED BACTERIA 
C. ADLAM* AND M. T. Scorrt 
Departments of Aerobic Bacteriology* and of Experimental Immunobiologyt, 
Wellcome Research Laboratories, Beckenham, Kent 
KILLED suspensions of the anaerobic diphtheroid Corynebacterium parvum 
were shown by Halpern et al. (1964) to possess a marked capacity for stimu-
lating the lympho-reticular system. Treated mice showed large increases in 
spleen and liver weight and increased ability to clear intravenously injected 
carbon from the circulation. It has since been shown that C. parvum acts as 
an adjuvant (Neveu, Branellec and Biozzi, 1964; Biozzi et al., 1966) and that 
treatment of animals with this organism can protect them from tumour-cell 
(Halpern et al., 1966; Woodruff and Boak, 1966), protozoal (Nussenzweig, 
1967) and bacterial challenge (Adlam, Broughton and Scott, 1972). Protection 
is also afforded against graft-versus-host disease (Howard et al., 1967). In 
addition to these properties, C. parvum resembles Bordetella pertussis, an un-
related organism that may also act as an adjuvant (Kind, 1957) and possesses 
the ability to induce splenomegaly (Morse, 1965), in being able to sensitise 
susceptible strains of mice to endotoxin (Howard, 1968) and to histamine 
(Adlam et al.). 
The work of Prevot and Tran Van Phi (1964), who showed that several 
diphtheroid species other thaq C. parvum stimulate the reticulo-endothelial 
system to take up injected carbon more rapidly, suggested that the properties 
possessed by C. parvum might be common to several related species. This 
possibility was also indicated by the work of Farber and Smith (1969), who 
showed that a strain of C. acnes possessed reticulo-endothelial stimulatory 
properties similar to C. parvum. In addition, both C. rubrum (Katsh, 1960) 
and C. avidum (Giambanco, Armani and Falcone, 1966), like C. parvum 
(Neveu et a!.), may be satisfactorily substituted for the mycobacterial com-
ponent of Freund's complete adjuvant. 
In the present work, several species of corynebacteria were quantitatively 
Received24 Apr. 1972; accepted 18 July 1972 
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tested for lympho-reticular stimulatory activity and an attempt has been made 
to relate their biochemical reactions to their stimulatory ability. The following 
parameters of lympho-reticular stimulation were examined : increase of spleen 
and liver weight; carbon clearance; adjuvant effect; and sensitisation of mice 
to histamine. 
METHODS 
Bacterial strains. Strains obtained from various sources (table I) were maintained as 
freeze-dried seed cultures in the Wellcome Culture Collection. 
Media. Bacterial growth media were Wellcome Reagents, unless otherwise indicated. 
TABLE I 
Culture collection numbers of strains of corynebacteria 
Culture collection numbers 
Strains Pasteur Sourcest NCTC* ATCCt Institute Wellcome of strains 
C. acnes 11828 CN 6280 (1~ C. acnes CN 6276 
C. anaerobium 4685 CN6134 ~h 
C. betae CN 4229 (3~ C. diphtheriae§ 7429 296 CN2000 (3 
C. diphtheroides 2764 CN 6295 (1~ C. equi CN 4686 (3 
C. granu/osum 3024-B CN 6292 (1) 
C. laevaniformans 15923 CN 6366 (4~ C. liquefaciens 3044-B CN 6290 (1 
C. lymphophi/um CN 6294 (1) 
C.parvum (a) 10387 11829 CN 5888 NCTC 
~b) 10387 11829 CN 6293 ~1) 
c) 10387 11829 CN 6156 5) 
C.parvum 10390 12930 643-C CN 5936 NCTC 
C.pyogenes 637-B CN 6291 (1) 
* National Collection of Type Cultures, Central Public Health Laboratories, Colin dale Avenue, 
London, N.W.9. 
t American Type Culture Collection, Rockville, Md, USA. 
:i: Sources of strains: (1) Professor R. F. Smith, Department of Microbiology, Temple University 
School of Pharmacy, Philadelphia, Pa., USA. (2) Professor M. Raynaud, Institut Pasteur, Annexe 
de Garches, Garches, 92 Hauts-de-Seine, France. (3) Wellcome Culture Collection. (4) Dr J. 
Miranda, Wellcome Research Laboratories. (5) Dr K. C. Milner, Department of Health, Education 
and Welfare, National Institute of Allergy and Infectious Diseases, Rocky Mountain Laboratory, 
Hamilton, Montana, USA. 
§ Park Williams no. 8 strain. 
Growth of bacteria. Strains of C. acnes, C. anaerobium, C. diphtheroides, C. gram4losum, 
C. liquefaciens, C. fymphophilum, C. parvum and C. pyogenes were grown anaerobically. 
Organisms from freeze-dried vials were sub-cultured in Robertson's meat broth (20 ml) 
containing 5 per cent. horse serum and 1 per cent. glucose. After static incubation for 7-10 
days at 37°C organisms were transferred to l per cent. glucose broth (100 ml) and re-
incubated for 7-10 days. For bulk growth this culture was used to seed 2-1 bottles containing 
glucose broth which were then statically incubated at 37°C for 7-10 days. 
C. betae and C. faevaniformans strains were grown aerobically on nutrient agar slopes 
for 48 hr at 20°C before subculture into 2-1 bottles of brain heart infusion broth (Oxoid 
Ltd) and incubation with shaking at 20°C for 3 days. The C. equi strain was subcultured 
in brain heart infusion broth (20 ml) and incubated at 37°C for 5-7 days. F or bulk growth 
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this culture w~s used to seed 2-1 bottles containing brain heart infusion broth which were 
then incubated with shaking at 37°C for 5- 7 days. The C. diplztheriae strain was grown in 
100-ml bottles of papain digest of beef (Ramon, Pochon and Amoureux, 1941) supplemented 
with ferric citrate (10 fLg per ml) to abolish toxin formation (Edwards and Seamer, 1960). 
For bulk growth this culture was used to seed 300-ml bottles of media whlch were shaken 
at 3rc for 48 hr. 
Killing and harvesting bacteria. Only killed organisms were used for animal inoculation. 
All cultures were killed by addition of formalin to 0·5 per cent.; after standing overnight, 
they were centrifuged and washed three times in pyrogen-free physiological saline before 
being suspended in the same medium with 0·01 per cent. thlomersalate as preservative. 
Dry weight of bacteria. Organisms were washed three times in filtered glass-distilled 
water (Sartorius filter, 0·2 JLm pore size ; V. A. Howe and Co. Ltd, 88 Peterborough Road, 
London, S.W.6). Samples (1·0 ml) of known optical density were dispensed in triplicate 
into weighed bottles and dried at 60°C to constant weight. 
Carbohydrate fermentation. A dense suspension of organisms was inoculated into 1 per 
cent. peptone sugars and the formation of acid noted over a 3-wk period. Incubation was 
at 37°C except in the case of C. betae and C. laevaniformans strains whlch were incubated 
at 20°C. For anaerobic strains, 0·2 per cent. nutrient agar was added to the peptone medium. 
Gelatin liquefaction. Tubes of nutrient gelatin were stab-inoculated and examined 
periodically over 3 weeks by placing in the refrigerator at 4°C for 30 min. 
Catalase production. A dense suspension of organisms was mixed on a microscope slide 
with a drop of freshly prepared hydrogen peroxide (5 per cent.). The production of effer-
vescence was noted. 
Bromocresol purple milk. Tubes of milk medium containing indicator (Cowan and Steel, 
1965, p. 160) were inoculated with organisms and examined daily for 14 days for acid and 
clot production. 
Indole production. This was tested for by the method of Cowan and Steel (p. 158) using 
Ehrlich's reagent as indicator. 
Nitrate reduction. This was tested for by the method of Cowan and Steel (p. 161). 
Inoculated broth was incubated for 5 days and the reaction elicited by the addition of 
sulphaoilic acid and ot-napbthylamine. 
Measurement of lympho-reticu/ar stimulation 
Increase in organ size. Groups of ten female W-Swiss mice (16-20 g, S. Schofield and 
Co. Ltd, Intake Head, Delph, Oldham, Lanes) received a single intravenous injection of 
organisms in varying doses. Animals were killed by cervical dislocation at varying days 
after treatment and their spleens, livers and lungs weighed immediately; body weights were 
also measured. Mean values for organ weights were corrected for body weights so that they 
could be expressed as mg per 20 g body weight. Control animals that had received thio-
mersalate saline were included in each experiment. 
Carbon clearance. Groups of eight female CBA/T6 mice (16-20 g, reared at the Well-
come Laboratories) received a single intravenous injection of organisms (I ·4 rug dry weight). 
At intervals thereafter animals were assayed for their ability to clear intravenously injected 
colloidal carbon from the circulation. Phagocytic indices (K values) were calculated by 
the method of Biozzi, Beoacerraf and Halpern (1953). Control animals injected with thio-
mersalate saline were inoculated in each experiment. 
Adjuvant effect. Groups of ten male CBA p mice (16-20 g, reared at the Wellcome 
Laboratories) received a single intravenous injection of organisms (1·4 mg dry weight). 
Four days later the animals were given intravenous injections of 0·25 ml of a 10 per cent. 
suspension of washed sheep red ceUs (WeJicome Reagents, Ltd) in saline (5 x lOS cells) and 
were afterwards bled (0·05 ml per mouse) at intervals. Sera pooled from teo animals were 
assayed for their haemagglutination titre by microtitration in conical plastic wells (Linbro 
Chemical Co. Inc., 681 Dixwell Avenue, Newhaven, Conn. 06511, USA). Serial two-fold 
dilutions of sera in physiological saline were added in 0·05-ml volumes to an equal volume 
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Fig. 1.—The weights of internal organs of mice at different times after injection of varying doses
of Corynebacterium anaerobium.
Groups of ten mice received killed organisms intravenously; numbers identifying the curves
are dry weights (mg) of organisms injected. Animals were then killed at intervals and organ
and total body weights determined. Organ weights were corrected for body weights; standard
errors are shown for the animals that received 2-4 mg of bacteria. The solid bar indicates organ
weights and standard errors for all control animals studied during the course of the experiments.
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of washed sheep red cells (1 per cent.); duplicate titrations were made. After incubation 
(1 hr at 37°C, then overnight at 4°C), titres were recorded as the reciprocal dilution of the 
last well showing agglutination. 
Histamine-sensitising effect. Groups of ten female W-Swiss mice (16-20 g, Bromfield 
Ltd, 81 Windsor Avenue, Newton Abbot) received a single intravenous injection of organisms 
at varying doses. Each animal was challenged 7 days later with an intraperitoneal injection 
of histamine phosphate (1 mg histamine base; B.D.H. Ltd, Poole, Dorset). Deaths were 
recorded over a 24-hr period. Control animals that had received intravenous thiomersalate 
saline were included in each experiment and were challenged with 5 mg histamine base per 
mouse. 
RESULTS 
Increase in organ size. Mter a single intravenous injection of an active 
strain, the spleen, Hver and lung weights were markedly increased. As an 
TABLE II 
Spleen, liver and lung weights of mice after the injection of different strains of corynebacteria 
Strain Species Spleen index* Liver index* Lung index* CN number at 14 days at 10 days at 10 days 
6134 C. anaerobium 5·09±0·26 2-49±0·09 1-45± 0·08 
6280 C. acnes 5·06±0·35 2·55 ± 0·09 1·53± 0·10 
6276 C. acnes 4·84±0·19 2·41 ± 0·11 1-36± 0·06 
6295 C. diphtheroides 4·78±0·28 2-49± 0·13 1·38±0·05 
6291 C.pyogenes 4-69± 0·20 2-36± 0·04 1-32± 0·03 
6290 C. liquefacieiiS 4-67± 0·17 2-46± 0·10 1-40±0·09 
6294 C. lymphophilum 4·58± 0·32 2·46± 0·10 1·71 ± 0·08 
6293t C.parvum 4·10± 0·36 1·89±0·08 1-12± 0·04 
5936 C.parvum 3·94± 0·33 2·17±0·14 1·27± 0·06 
6292 C. granulosum 3-40± 0·39 2·29± 0·11 1·28±0·05 
4686 C. equi 2·73±0·21 1-89±0·09 1·01±0·02 
6156t C.parvum 2·52±0·19 1·41±0·09 1·26±0·12 
6366 C. /aevaniformans 1·83± 0·16 1·04± 0·03 1-16± 0·04 
5888t C.parvum 1·37±0·09 1·01±0·03 1·24±0·02 
2000 C. diphtheriae 1·21 ± 0·10 1·00±0·02 1-17± 0·03 
4229 C. betae 1-12± 0·05 1·10±0·01 1-10± 0·04 
* Groups of ten mice received a single intravenous injection of killed organisms (2·4 mg dry 
wt). Animals were killed and organs weighed after 10 or 14 days. Figures in the body of the table 
are organ indices with standard errors. Organ index = mean organ weights of treated animals. 
mean organ weights of control animals 
t The same strain obtained from three different sources. 
example, positive responses to varying doses of C. anaerobium are shown in 
fig. 1. Mter an injection of 2·4 mg (dry weight) of this organism, a five-fold 
increase in spleen weight and a three-fold increase in liver weight occurred. 
Maximum weights of spleen and liver were reached 10-14 days after treatment. 
A small but significant increase in lung weight was observed between 7 and 14 
days after injection. 
The extent of increase in organ weights produced by all organisms tested 
is shown in table II. For ease of comparison, strains are arranged in approxi-
mate order of maximum activity. Organ-weight increase is expressed as an 
index by comparison with control values. The kinetics of organ-weight increase 
were similar for all active strains, and a marked increase in spleen weight was 
always accompanied by an increase in liver and lung weights. Although 
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greatest activity was shown by anaerobic strains, not all were active and not 
all aerobic strains were inactive since C. equi showed moderate activity. A 
culture of C. parvum (CN 5888) obtained from the National Collection of Type 
Cultures was inactive, although two cultures of the same strain (CN 6293 and 
6156) obtained from American laboratories possessed some activity. 
Carbon clearance. Experiments with C. anaerobium showed that maximum 
carbon clearance was produced 4 days after bacterial inoculation, the kinetics 
of the response (fig. 2) being similar over a wide range of dose of organisms. 
o-os 
0 • 1 14 21 
Days aher injection 
F1o. 2.-Enhancement of carbon clearance from the circulation by Corynebacterium anaerobium. 
Groups of eight mice received different doses of killed organisms inlravenously. Carbon 
clearance indices (K values) were determined at intervals subsequently. Standard errors of 
values are shown for the animals that received 1·2 mg dry weight of organisms. The single 
control point shows the mean value and standard error of control animals throughout the 
experiment. K values: 0 - 0 after 1·2 mg; • - • after 0·9 mg; t:, - t:, after 0·3 rng 
of organisms; - A- in controls. 
Fig. 3 shows the results of carbon-clearance assays for eight of the strains 
of corynebacteria. K values of phagocytosis are shown in the form of a histo-
gram with high carbon clearance strains on the left. Whereas C. anaerobium 
and C. acnes (CN 6134 and 6276) were most active and C. granulosum and C. 
lymphophilum (CN 6292 and 6294) also showed activity, C. parvum and C. 
diphtheriae (CN 5936 and 2000) were doubtfully active. C. betae and another 
C. parvum strain (CN 4229 and 5888) were inactive. 
Adjuvant effect. Experiments with C. anaerobium showed that peak ad-
juvant activity to sheep red-cells was produced by injecting the organisms 4 
days before the red cells. Table ID shows the results of an experiment in 
which nine of the strains of corynebacteria were used in this way. Results have 
been expressed as log2 haemagglutination titres, strains being arranged in the 
order of highest titre attained. Strains CN 6294, CN 5936, CN 6290, CN 6292, 
CN 6134, CN 6295 and CN 6276 showed marked activity that reached a peak 
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6-8 days after injection of sheep cells. Strains CN 5888 and CN 2000 were 
inactive. 
Histamine sensitisation. Table IV shows the combined results of two 
experiments in which strains were tested for their ability to sensitise mice to 
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FIG. 3.-The ability of different strains of corynebacteria to enhance carbon clearance from the 
circulation. Groups of eight mice received a single intravenous injection of killed organisms 
(1·4 mg dry weight). Four days later carbon clearance assays were performed and the phago-
cytic indices (K values) so obtained are indicated by the heights of column.s in the histogram, 
with standard errors. The Wellcome Collection (CN) number of each strain is shown at the 
foot of the relevant column (see table I for identity of strain.s). NaCI = K value in control 
mice receiving saline. The numbers in parentheses are the probabilities (P) of significance of 
differences between test results and controls. N.S. = Not significant. 
In terms of dry weighl of organisms required to sensitise, C. lymphophilum 
possessed the highest activity and strains of C. acnes, C. anaerobium, C. diph-
theroides, C. granulosum and C. liquefaciens were quantitatively similar in 
activity. C. pyogenes and C. parvum (CN 5936) were low in activity and the 
remaining strains were inactive or caused a low-grade irregular sensitisation 
unrelated to dose of organisms injected. 
Taxonomy. The results of the biochemical tests are shown in table V. All 
corynebacteria tested fermented glucose and produced catalase. In addition, 
all strains with the exception of C. equi fermented galactose, mannose and 
fructose. C. equi was exceptional, not only in its inability to ferment any 
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TABLE ill 
Adjuvant activity of corynebacteria: haemagglutinin tit res ill mice given injections of sheep 
red cells after pre-treatment with different strains of corynebacteria• 
Strain LO&l haemagglutination titre o n dayt Species CN number 2 4 6 8 10 
6294 C. lymphophilum 2·0 9·5 13·5 15·5t 11·5 
5936 C.parvum 2·0 10·5 14·5 13·5 13·5 
6292 C. granulosum 3·5 10·0 14·0 12·5 1 1·5 
6290 C. /iquefaciens 2·0 10·5 13-5 13·5 13-5 
6134 C. anaerobium 2·0 9·0 13·0 13·0 13·0 
6295 C. diplrtheroides 2·0 10·0 13·0 13·0 12·0 
6276 C. acnes 2·0 10·0 13·0 13·0 12·0 
5888 C.parvum 2·0 8·5 10·0 11·5 11·5 
2000 C. diplrtheriae 2·0 8·0 10·0 10·0 10·5 
Saline control 2·0 9·0 10·0 10·0 10·0 
• Groups of ten mice received a single intravenous injection of killed organisms (1·4 mg dry 
wt); 4 days later they were given 5x 108 sheep red cells; then they were bled at intervals. 
t After the injection of sheep red cells. 
t In bold type, peak titre. 
TABLE IV 
Histamine sensitisation by corynebacteria: death rates of mice given i11jections of various 
strains of corynebacteria and subsequently challenged with histamine• 
Strain 
Number of deathst in mice given the following 
doses of organisms (mg dry weight) 
CN number Species 
0·80 0·27 0·09 0·03 
6294 C. lymplrophilum 20 19 18/19 17 
6295 C. diplrtlzeroides 18/ 19 16 12 9 
6134 C. anaerobium 16/ 19 19 8 10 
6276 C. acnes 19 17 10 4 
6290 C. /iquefaciens 19 18 9 3 
6280 C. acnes 19 14 12 3 
6292 C. granulosum 19 13 8 8 
6291 C.pyogenes 17 11 5 1 
5936 C.parvum 17 10 J 2 
4686 C. equi 14 9 3 3 
5888:t C. parvum 7/19 5 6 6 
6293t C.parvum 4/16 8 6 9/19 
2000 C. diphtlzeriae 5 6 5 7 
6366 C. /aevani/ormans 4 3 2 2 
6J56:t C.parvum 3 3 1 2 
4229 C. betae 0 1 5/19 5 
Saline control 3/40 
• Groups of mice received varying doses of organisms intravenously. Seven days later, animals 
were challenged with 1 mg histamine base intraperitoneally (salincx:ontrol animals received 5 mg 
ba.se). Deaths were recorded 24 hr after challenge. 
t Number of deaths per 20 mice, unless othe.wise indicated. 
t The same strain obtained from three different sources. 
v 
TABLB V 
Biochemical reactions of the strains of corynebacteria t--
~ 
c:; d ~ 1:1 0 0 
t Fermentation of .8 "€ ·u 0 . c:; 0 ~ :::1 9 0 "0 .... :::1 " e 0 • "0 :::1 ~ ~ 0 C' P. 0 ~ ~ .., ~ :::1 ~ ..... :.:::1 " 0 0 £ e ~ (") Wellcome I ~ 01) ~ .., 0 0 V> V> £ ·5 0 ~ 0 0 ·e P. ~ "' "' ·a .c 0 (;j 0 0 c: c: ~ .9 R Organism number(CN) 8 0 0 B c ti ·u s: :0 - c: ·a 8 " ti ... (ij :a ~ ..s ii s: ~ :0 l£3 ..s :§ ·;;; 3 0 0 ... ~ 0 s (ij :::1 0 (ij ..: 2 :; .. .c m ... (ij 0 ~ "0 ~ 0 u "0 8 ~ 6 m :::1 ~ ~ cii c ... ::E 0 0 0 p'. p'. < s: .s < c z .9 " ~ ,..I en f- IJ.. cn cn ...... ~ c 
Anaerobic species ~ ~ C. acnes 6276 + - ± + + - + + + + - + + - - + - + - - ± + + + + + + R C. acnes 6280 + - - ± + - + + + + - ± - - - + - - - - + + + + + + + 
C. anaerobium 6134 + - + + + + + + + + - + + - - - - - - - + + + ± + + + ~ 
C. granulosum 6292 + - - - - - + + + + - - - - - - - + ± - + + + + + + + ::::! 
C. liquefaciens 6290 + - - - + - + + + + - + + - - ± - - + - - + + + + + + 0 
C. lymphophilum 6294 + - - + - + + - + + - + + + + - - + - - + + - - - + + ~ 
C.parvum 5936 + - - - ± - + + + + - ± - - - - - - - - - + + ± + + + t;z:, 
C. parvumt ?b~ 5888 + ± + + - + + + + + - + - + - - - - - - ± + - + - + + '"< 
6293 + - + + - + + + + + - + - + - - - - - - ± + - ± - + + 
~ (c) 6156 + - + + - + + + + + - + - + - - - - - - - + - ± - - + C.pyogenes 6291 + - + + + + + + + + - + + - - + - - - - + + + + + + + 
~ 
Aerobic species ~ 
C. betae 4229 ± + + - ± - + + + + - - - + - ± + ± - + ± + - + - - + ~ 
C. diphtheriae 2000 + - - ± - + + - + + - + + + + - - - + + + - + + - - + ~ C. equi 4686 ± - - - - - - - - - - - - - - - - - - - - - - + - - + 
C. laevaniformans 6366 + + + + + + + + + + - + + + + ± + + + + + - - + - + + ~ 
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of the sugars tested (except for weak glucose fermentation), but also in its 
production of a bright pink pigment. C. betae and C. laevaniformans were 
the only strains possessing bright yellow pigmentation. 
As a group, the anaerobic strains showed similar biochemical reactions. 
Particularly close patterns of reaction were observed amongst the two C. acnes 
strains, C. anaerobium, C. liquefaciens, C. pyogenes and the C. parvum strains. 
All three cultures of C. parvum NCTC 10387 (CN 5888, CN 6293 and CN 6156), 
although obtained from different sources, gave very similar reactions. 
TABLE VI 
Publications by other authors describing the properties of the same strains of corynebacteria 











Wellcome Reference Authors' conclusions number (CN) and recommendations 
rmU!und Bodily (1968)' } 
6280 Zierdt, Webster and Rude Used as reference C. acnes (1968) 
Reid and Joya (1969)t 
2000 Lampidis and Barksdale (1971 " Mitis" strain 
6295 Zierdt et a/. Transfer to C. acnes 
6292 { Zierdt et a/. } Transfer to C. acnes Moss eta/. (1969) 
6366 Dias and Bhat (1962, 1964) New species producing 
Ia evan 
6290 r;orot" a/. } Transfer to C. acnes Moss et al. 
Werner and Mann (1968) Mixed culture of C. parvum 
5888 and C. acnes 
Reid and Joya Transfer to C. acnes 
5936 Werner and Mann Transferto C. acnes f Moore, Holdeman and Not a typical C. pyogenes 
6291 l Cummins (1968) 
} Zierdt et al. Transfer to C. acnes Moss et al. 
• Strain termed Propionibacterium acnes by authors. 
t Strain termed C. liquefaciens by authors. 
DISCUSSION 
The taxonomy of the corynebacteria remains a matter of considerable 
controversy. Several workers are of the opinion that some of the anaerobic 
species described by Prevot (1966), e.g., C. anaerobium, C. avidum, C. diph-
theroides, C. granulosum, C. liquefaciens, C. lymphophilum. and C. parvum 
should be re-classified as C. acnes (Zierdt, Webster and Rude, 1968; Moss et 
a/., 1969; Reid and Joya, 1969). Others disagree with this view (Moore, 
Holdeman and Cummins, 1968), and some consider that the C. acnes species 
contains two distinct groups of organisms (Brzin, 1964; Voss, 1970). To add 
further confusion, there seems little doubt that the type species C. diphtheriae 
differs markedly from these anaerobic species (Barksdale, 1970), and that C. 
pyogenes and the plant diphtheroids do not resemble C. diphtheriae (Cummins, 
196~; Barksdale). Table VI gives literature references to work in which the 
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strains of corynebacteria studied were identical with those used in the present 
work. 
The question arises as to how many of these species possess the lympho-
reticular stimulatory activity described for a strain of C. parvum by Halpern 
et a!. (1964). In addition it may be asked how far other stimulatory strains 
possess the attributes of C. parvum. The present work has confirmed that 
several species of corynebacteria besides C. parvum possess lympho-reticular 
stimulating properties. The increase in lymphoid organ size produced by 
active strains was similar to that previously described for C. parvum (Halpern 
et al., 1964) and the uniformity of kinetics of organ-weight increase produced 
by active strains suggests that these organisms contain similar if not identical 
stimulating material. Organisms that were able to act as adjuvants to sheep 
red cell agglutinin formation also increased lymphoid organ size and possessed 
the ability to sensitise mice of the strain used to histamine. Conversely coryne-
bacteria lacking adjuvant activity also failed to cause histamine sensitisation or 
to produce marked increases in lymphoid organ size. 
In the present study, enhancement of carbon clearance, even by strains 
highly active in organ weight-increasing ability, was lower than that originally 
observed with a strain of C. parvum (Halpern eta/., 1964). However, different 
strains of mice have been shown to vary in response to C. parvum treatment in 
this respect. A large increase in organ size was not always paralleled by con-
comitant enhancement of carbon clearance (Stiffel eta/. , 1970). Nevertheless, 
in the present work, only those strains that increased organ size and possessed 
adjuvant and histamine-sensitising effects also caused a marked increase in 
carbon clearance. 
The biochemical reactions exhibited by the strains confirm the close relation-
ships amongst the anaerobic corynebacteria noted by other workers. As found 
by Zierdt et a/. and Reid and Joya, gas production and gelatin liquefaction 
proved to be unreliable criteria for distinguishing between species. For example, 
the C. anaerobium strain when grown in bulk occasionally produced gas from 
glucose broth, which would place it in the C. parvum group of organisms 
according to Prevot. Also C. parvum strain CN 6156 did not liquefy gelatin, 
but is surely the same species as strains CN 5888 and CN 6293. 
It must be concluded that the ability to stimulate the lympho-reticular 
system cannot, at this stage, be linked with any specific biochemical test. This 
is shown particularly well in the case of C. equi which possessed moderate 
capacity to increase spleen and liver weight and to sensitise to histamine, but 
was exceptional in its lack of biochemical reactivity. In addition, the three 
strains of C. parvum (NCTC 1 0387) had almost identical biochemical reactions 
but differed markedly in ability to increase organ weight. 
The strai n of C. pyogenes used in these studies is probably atypical since it 
produces catalase and indole and reduces nitrate (Moore et al.; Roberts, 1968). 
Its cell-wall amino acid composition is similar to that of other C. pyogenes 
strains but different from that of C. acnes (Cummins and Harris, 1956). This 
would suggest that the ability to stimulate the lympho-reticular system does 
not depend on the qualitative nature of these cell-wall amino acids. In view 
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of the work of Moss et al., the cell-wall fatty acids may be a more important 
guide to the possession of stimulatory activity by any individual strain, but 
this remains a subject for further study. 
SUMMARY 
Several aerobic and anaerobic species of corynebacteria were examined for 
their ability to stimulate the lympho-reticular system of mice. Whereas active 
strains produced marked increases in spleen, liver and lung weight, possessed 
adjuvant activity, and were capable of sensitising mice to histamine, inactive 
strains possessed none of these attributes. Enhancement of carbon clearance 
was observed only in strains that possessed the other stimulatory properties 
but was not as great as previously observed by other workers for Coryne-
bacterium parvum. The majority of active strains were anaerobic and possessed 
quantitatively similar stimulating activities. No correlation was observed 
between biochemical reactions of strains and lympho-reticular stimulation. 
Thanks are due to Professor R. F. Smith, Professor M. R aynaud, Dr J. Miranda and 
Dr K. C. Milner for generous gifts of strains, and to Sheila Hiorns and Christine Tieman 
for technical assistance. 
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Biological Effects of the Adjuvant Corynebacterium Porvum 
I. Inhibition of PHA, Mixed lymphocyte and GVH Reactivity 
MARTIN T. ScoTT* 
Depa·rlmeut of E:rperimenta/ flll lllllllobialom·, Wei/come Research Laboratories, 
Becl~ellham, Kc11 t, E11gla11d 
R eceived March 6. 1972 
Spleen and peripheral blood lymphocytes from mice injected 7 days pre-
,·iously with bacterial adjuvant Cor').'ll ebacterium pan111111 were found to be 
refractory or markedly unresponsive to PHA stimulation ilr 'ilitro. Other 
recognised T -cell functions-mixed lymphocyte and g raft-versus-host reac-
tivity \\'ere similarly reduced. The~e results are interpreted as sholl'ing that 
the T-lymphocyte is affected by C. parvum. Studies ll'ith poke\\'eed mitogen 
(P \\').1) gave no evidence for a similar effect on the B lymphocyte. 
INTRODUCTION 
Injection of killed suspensions of Corynebacterium jlar·uu111 results in massive 
proli fcrat ion of the cells of the lymphoreticular system ( 1 ) and increased antibody 
production to subsequently injected antigens (2) . Other effects of this organism-
antitumour actiYity ( 3) . protection against bacterial infection ( 4), raising the 
threshold for tolerance induction ( 5) and induction of autoimmunity (6) a re all in 
keeping with its role as an adjuvant a t both cellular and humoral levels. Augmen-
ta tion of cell-mediated immunity is fu r ther reflected in its ability to induce delayed 
hypersen iti1·ity to unrelated antigens (2). 
T he present exper iments were undertaken as part of a series designed to eluci-
date the mechanism whereby C. parv11111 might be effecti,·e in ~ome o{ the biological 
systems described. The approach has been to examine the phytohaemagglutinin 
(P l--l :\ ) responsiveness of lymphoid cells from mice treated with C. parvum . The 
P II ,.-\ responsh·eness is restr icted almost exclusively to thym us-der ived cells-T-
lymphocytes ( 7) and has been correlated with rell -mNliated immunocompetence. 
T here ha,·e been numerous reports that lymphocytes from various immunologi-
cally tleficient states have shown impairment in their in v itro t ransformat ion by 
PHA (8-10) but, thus far, th is study would appear to constitute the first exami-
nation of PHA responsiveness of lymphocytes from animals with ' 'elevated" im-
mune status . 
MATER IALS AND METHODS 
.·111i111als . . -\dult mJce of inbred strain CB A-p were used throughout the PHA 
studies. 
* Present address : Trudeau lnstitutc I nc., P .O. Box 59. Saranac Lake. ~.1·. 12983. 
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Bacteria. Corynebacterium parvum suspension (Batch X o. EZ 17 4. 7 mgf ml ) was 
prepared by the \Vellcome Research Laboratories, Beckenham, Kent. £;,gland . . \ 
formalin-killed suspension of C. dip!ct/ceriae (Park-Williams Strain :Xo. 8 ) \\"<lS 
kindly provided by Dr. C. Adlam. Standard doses of 0.2 ml were inj ected intrave-
nously 7 clays prior to preparation of cell suspensions. 
Cell suspensions. Spleen and lymph nodes (pooled axillary. brachial. inguinal 
and mesenteric ) were homogenised in Eagles Minimum Essential ).1 edium 
( .1\IEl\1 ) using ground glass homogeni'sers. The resulting cell suspensions were fi l-
tered through both coarse and tine stainless steel sieves and washed in ME:-I. 
Lymphocyte suspensions from blood were prepared as follows. l\l[ ice were as-
phyxiated with carbon dioxide, the thoracic cavity opened and 0.25 ml of heparin-
ised saline ( 100 units/ml ) injected into the left ventricle. The heart and major 
vessels were incised, the blood of six or seven mice was pooled and the red cells 
sedimented by addition o( 0.75 vol of 3.57o dextran in sal ine. After incubation at 
3rC for 30 min, the plasmafclextran-leucocyte layer was removed and the cells 
centrifuged at 4°C and washed twice with cold MEM. 
Response to FHA in vitro. All lymphoid cell suspensions were adjusted to a 
final concentration of 106/ml in lVIEM containing 107o calf serum (Flow Laborato-
ries) . One-milliliter aliquots were dispensed into round bottomed Sterelin tubes 
and 0.1 ml of the appropriate concentration of PHA (Purified Phytohaemag-
glutinin, Wellcome Reagents Ltd., London) diluted in ME:rvi was added. Cultures 
in triplicate were incubated at 3rC in vacuum desicators containing a final gas 
mixture of 107o oxygen, 87.57o nitrogen and 2.5% carbon dioxide. 
After 48 hr, 0.25 p.Ci of (1-IC]-thymidine (i·'C-T) in 0.1 ml Hanks' Balanced 
Salt Solution was added to each culture which was incubated for a further 24 hr. 
The amount of radiolabel incorporated into the acid precipitable material was as-
sessed by liquid scinti llation counting as described by Ivanyi et a/. ( 11 ) except that 
Whatman glass fibre papers (2.5 em GF /B) were substituted. The results are ex-
pressed in counts per minute or as a ratio (stimulation index) : cpm in experimen-
tal cultures/cpm in control cultures. 
Response to poheweed m·itogen in vitro. Aliquots (0.1 ml ) of pokeweed mitogen 
(Grand Island Biological Co. ) reconstituted in 5 ml sterile saline were added to 
cultures and uptake of 14 C-T assessed as for PHA. 
Mixed lyrnphocyte ?'eactiou ( MLR) . Spleen cells (lOG) from normal CBA-p 
mice, or mice that had been inj ected 7 days previously with 0.2 ml C. pa.rvu1-n in-
travenously, were mixed with an equal number of inactivated syngeneic or alloge-
neic (DBA/ 2) normal spleen cells. Inactivated target cells were taken from mice 
which had received 1000 rads whole body irradiation from a 6°Co source immedi-
ately prior to use. These cells showed no increased DNA synthesis on stimulation 
with an optimal PHA close, such controls being included in each e-xperiment. Cul-
ture conditions were as described for FHA stimulation. The HC-T was added after 
72 hr and the cultures terminated at 96 hr for assay of isotope incorporation. 
Graft-versus-host reactivity . The graft-versus-host (GVH) action of lymphoid 
cells from parental ( C57BL) mice was assayed by their ability to cause splenome-
galy when injected into (CBA-T6T6/C57BL)F1 hybrid mice. Spleens were as-
sayed 9 clays after injection of cells. 
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T-ce/1-deprived mice. Six- to eight-week-old mice were thymectomised and 6 
days later given 900 rads whole body irradiation. T he next day they received 
5 X 106 syngeneic bone marrow cells int ra venous) y and spleen preparations 
were made 5- 6 weeks after reconstitution. 
EXPERIMENTAL 
lm111unostimulalory, adjuvant a11d anliluiiiOm· effects of C. parvum. T he strain oi 
C. pa:rvtwt used has been demonstrated to cause splenomegaly, hepatomegaly, in-
creased carbon clearance and to show ad juvant activi ty when injected intravenously 
7 days before sheep erythrocytes ( 12) . P retreatment wi th C. par<JitJn 7 days prior 
to challenge with syngeneic tumour cells also affords the mice considerable 
protection, in terms of survival (Scott, unpublished resul ts). 
Effect of prelrealmeut wilh C. parvwn on the PHA responsiveness of various 
lymphoid populo/ ious. Spleen, lymph node (pooled ) and peripheral blood cells 
from mice which had recei vecl 0.2 ml oE C. parvum suspension (7 mgj ml ) intrave-
nously 7 days previously, were tested fo r their ability to respond to various concen-
trations o{ PHA in vitro. Popliteal lymph node cells from mice which had received 
0.025 ml C. par·uu111 suspension subcutaneously in both hind footpads were s imi-
la rl y tested after 7 days. 
a. Spleen cells (Fig . l A) . Cells from normal mice responded to PHA in 
terms of greatly increased DNA synthesis. The optimal PHA dose for 1 X lOG 
cells was 0.001 ml PHA/ml medium, both higher and lower doses resulting in re-
duced stimulation. 
Cells from C. parvnm-stimulated mice were found to be refractory to all doses of 
PHA. The DNA synthes is was decreased compared with unstimulated cells only 
with the highest dose, suggesting that PHA was here having a cytotoxic effect. 
The background incorporation of HC-T into C. parvum-stimulated cells in the ab-
sence of PHA was not sign ificantly diffe rent from that of normal unstimulated 
cell s. 
b. Lymph node cells (Fig. l B) . Cells from both normal and C. pa·rvum-stimu-
latecl mice responded to PHA, the dose responses of both cell populations being 
similar. Again, the background 1 ''C-T incorporation of normal and C. parvum-
treatecl cells was not eli fferent. 
c. Draining (popliteal) lymph node cells (Fig. ! C) . The background 14C-T 
incorporation into C. parvum-stimulated lymph node cells was significantly higher 
than that of pooled lymph nodes from normal mice. Treated cells showed no 
reduced response to an optimal PHA dose but a ten-fold increase in PHA con-
centration a lmost abolished the response of these cells. As with C-parvum-treated 
spleen cells, there was again evidence of cytotoxicity with the highest PHA dose. 
d. Periphera l blood lymphocytes (Fig. lD) . Blood lymphocytes from C. par-
Vlwz-treatecl mice showed markedly decreased PHA responsi,·eness compared with 
cells from normal animals. 
Kinetics of PH A responsiveuess of C. j>arvuJII-1 rea ted spler11 cells. The routine 
culture procedure. pulsing with thymidine after 48 hr, might have missed any p re-
mature response by the C. parvu111-treated cells . To exclude this possibility, treated 
and normal spleen cells were incubated with or wi thout the optimal .PHA dose 
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(0.001 mljml MEM) and HC-T added at 6, 18. 30 and 54 hr. Cultures were ter-
minated 18 hr after addition of the isotope (Fig. 2). PHA stimulated a detectable 
increase of the DNA synthesis by normal cells between 36-48 hr, but no prema-
ture response on the part of the C. parvum-treated cells was observed. 
PH A responsiveness of increasing 'lllllnbers of C. parvu111-treatcd spleen cells. 
The optimal response of normal spleen cells to a particular close of PHA is de-
pendent on cell density ( 13). A remaining possibility therefore was that, during the 
splenomegaly induced by C. parvum treatment, there had been a division of non-
PHA responsive cells (B cells and macrophages) which had effectively diluted the 
PHA responsive cells. If this were the case, then one might expect to detect such a 
residual population by increasing the number of cells in the test system. Increasing 
numbers of cells were stimulated with a PHA dose which was optimal fo r 106 cells 
(Fig. 3) . While the normal cells produced the expected response curve, no residual 
PEA-reactive cells among C. parvnm-treated spleen cells were revealed. 
PHA responsiveness of spleen cells ajte·r treatment with C. diphtheria~~. Co-ryne-
bacterium parvl£ln is not only an adjuvant but also a potent immunogen. The fol-
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Frc. 1. PHA responsiveness of lymphocytes from mice inj ected with C. par~·lwl. Cells from 
normal mice ( 0 • • • • 0), cells {rom C. parvum-trcated mice (·• --• ). Spleen cells, pooled 
lymph node cells and peripheral blood lymphocytes (A, B, D) were assayed 7 days after iv 
injection of C. parvum. Draining lymph node (popliteal) cells (C) were assayed 7 days 
after footpad injection of C. pm~Jull!. Vertical bar~ represent ± standard error (n = > 5) . 
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Pre. 2. Kinetics of the PHA responsiveness of spleen cells from normal mice CO o o o o 0) 
and those which had received C. parvum iv 7 days previously ( e --e ) . Vertical bars 
represent :!:: standard error ( 11 ~ 3) . 
lowing experiments were designed to determine whether the refractory state of C. 
pan:tou-treated cell s was merely part of the general response to a recent dose of 
bacteria l antigen or "·hether it was peculiar to C. parv 11111 with its known imlllu-
nostimulatory properties. 
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Frc. 3. The response of varying numbers of spleen cells from normal mice (0 o o o o 0 > and 
those which had recci,·cd c·. parvum iv 7 days pre,·ionsly ('e ---e ) to a dose of PH.\ 
optimal for I x 10" spleen cells. Vertical bars represent ± standard erro•· (11 = 3) . 
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the basis of the primary bacterial agglutinin response to a comparable dose of each 
( Scott, unpublished results ) . C or:ynebacteri·u1n diphtheriae, however, bas no immu-
nostimulatory properties as assessed by splenomegaly, adjuvanticity, increased car-
bon clearance ( 12) and anti tumour activity (Scott, unpublished results). The 
PHA response of spleen ceiis from mice injected intravenously 7 clays previously 
with an equivalent amount (d ry weight) of C. diphthe1·iae was tested (Fig. 4). No 
significant difference in PHA responsiveness was found between C. diphtheriae-
treated and normal spleen cells. The PHA phenomenon observed after C. parvum 
treatment would therefore seem to be associated with the immunostimulatory prop-
erty of this organism. 
Mi:red lymphocyte 1•eactivit·y of C. parvum-treated spleen cells. In view of the 
apparent inability of C. pa,rvnm-treated spleen cells to respond to PHA . another 
function of T-cells "vas next examined-their ability to respond to histocompati-
bility antigens in vif?'O in a mixed lymphocyte reaction (MLR) . 
One way MLRs were set up with normal CBA-p spleen cells or C. pm·vu1·11-
treated spleen cells reacting against irradiated DBA/2 normal spleen cells. Control 
cultures contained irradiated normal CBA-p spleen cells. Stimulation, as judged by 
increased DNA synthesis of mixed cultures compared with control cultures, oc-
curred with both normal and C. parvwn-treated cells, but stimulation was consist-
ently less with C. parvwn-treated cells (Table 1) . 
GV H reactivity of C. parv1m1-treated spleen cells. The GVH reactivity is an-
other known function of T -cells and, in the light of the PHA and MLR results, C. 
parvmn-treated cells were tested for their ability to cause a GVH reaction . 
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Frc. 4. PHA responsiveness of spleen cells from normal mice CO • • • • 0) and those which 
had received C. diplrtherioe iv 7 days previously (-e --e ). Vertical bars represent ± standard 
error (t~ = 3). 
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TABU.; I 
R"A CTI VJTY OF c. P<trt'lllri -TREA'J'f.:D S I' LEEN CELLS 1::0: A 0:-~ " \\' A\' :\1lXEJ) 
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1\'orma l spleen cells 
C. /Jan•twz-treated spleen cells 












"Stimulation index : cpm CBA-p + irradiated DBA/ 2/ cpm CBA-p + irrad iated CBA-p. 
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b Stimulation index of C. pan·um-lreated cells exprcs.~ed as percentage of s timulation index 
norma l cells. 
7 days previously were inj ected either intraperitoneally or intravenously into 
( CBA-T6T6 X CS7BL)F1 mice. To control for any splenomegaly that may result 
from a carry over of persisting C. parvwm with the cell s, syngeneic cell transfers 
from both normal and C. parvum-treatecl F 1 mice were included (Table 2) . Indeed, 
a significant degree of splenomegaly ( iv P = < 0.05, ip P = < 0.001) did result 
from such transfers indicating persistence of intracellular C. pctrvu lll after 7 clays. 
Coryncbacferiuzn pm-vmn·treated cells did, however, cause G\"H splenomegaly in 
the parent~ F, t ransfers, a lthough this was considerably less than that caused by 
normal cells. 
T he response of C. pw-vwn-treated spleen cells to pokeweed 111ilogen (PW.M) . 
The phytomitogen P\ iVM has been demonstrated to stimulate both T- and B-lym-
phocytes ( 13, 14) . S ince the T-cells of C. parvnm -treated spleens were sbo"·n to 
be unresponsive. the PvVM response of such cells should gi\'e some indication of 
the status of the B-cell population with respect to their abili ty to be stimulated. 
T he P\1\11\1 responsiveness of C. parv11111-treated spleen cells was markedly de-
pressed compared to spleen cells from normal mice (Fig. 5) . l:l.owever, since 
P\VM stimulates both 13- and T-cells. and the T -cells are already deemed to be un-
responsive, it may be that the decreased PvVi\I response after C. parv u 111 merely 
Dose of spleen 
cells injected 
JOS ip 
5 X 107 iv 
T ABLE 2 
G -\'-11 R EAC'r i VJTY OF C. pan·um-TI<EATlW S PLEE:-; C !!LLS IX 
(CBA- T6T6 x CS7BLJP', ADULT cVIIcJ' 
Donor spleen ce lls 
Syngeneic 
(CBA- T6T6 X CS7BL}I: , 
:\formal 
39 .+ ± 2 . J " 
42 . 1 ± 0.9 
C. par:•ulu-
treated 
-!5. 7 ± 1.9 
52.1±0.8 
Parental C57 BL 
:"\ormal C. pan'wiHreated 
96.-l ± 5.9 ( 2 . 4)~ 61.8 ± 2 .2 ( 1.4) 
109.0 ± 4.9 (2 .6) 89 .9 ± 4. 9 (1. 7) 
" l~el ative spleen weigh r (mg/ 10 g body 1\'t ) ± SE of recipient Jo', mice 9 days a fter spleen 
cell injection (16 mice per group). 
~ Relati,·c spleen index- relati,·e spleen weight with parenta l cells/re lat ive spleen weight wilh 
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F1c. 5. PWM 1·esponsiveness of spleen cells from normal mice ( 0 • • • • 0), T -cell-depr ived 
mice (Q-0) and mice which had recei\·ed C. f>arvum iv 7 days previously ( e - - e ) . 
Vertical bars represent ± standard error (n = 6 ). 
reflects the residual B-cell response. In order to resolve this the P\~M response of 
spleen cells of T-cell-deprived mice was assayed and found to be not significantly 
different from C. parvnm-treated cells (Fig. 5) . 
DISCUSSION 
Spleen cells and peripheral blood lymphocytes from mice pretreated vvith intrave-
nous bacterial adjuvant, C. parvum, have been demonstrated to be markedly unre-
sponsive or refractory to stimulation by PHA. It seems likely that the unaltered 
PHA response of lymph node cells after intravenous C. parvwm is because the ma-
jority of particulate matter injected via this route is rapidly removed from the 
bloodstream and localised in the macrophages of the liver and spleen. Indeed, al-
though intravenous C. parvwm caused marked splenomegaly and hepatOmegaly, no 
significant increase in the weight of a representative (inguinal) lymph node was 
detectable (Scott, unpublished results) . If the PHA effect is a local one dependent 
on the presence of C. parvum then the "intermediate" results obtained with 
the popliteal lymph node cells after footpad injection may be reconciled with a rela-
tively small amount of C. parvmn being present in the node after footpad injection. 
A marked increase in lymph node weight was always evident after treatment but 
an element of this may be attributed to trauma at the injection site. 
A prerequisite for the understanding of the mode of action of immunological ad-
j uvants would seem to be the determination of which of the cells involved in the 
immune response are affected by them. The ability to respond to PHA is a prop-
erty of T -lymphocytes ( 7) and the present findings thus indicate this to be one 
type of lymphocyte at least which is affected by the adjuvant C. parv11111. It seems 
paradoxical, however, that treatment which is known to enhance T-cell-mediated 
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processes should result in inhibition of PHA responsiveness. At this stage it can 
only be conjectured that C. parvum has in some way, nonspecifically stimulated the 
T -cells. rendering them incapable of responding to a further mitogen. 
T hat C. parvum affects T-cells is interesting in the light of the recent fi nding of 
the T -cell dependence of potentiation of antibody formation by a variety of adju-
Yants, including the bacterial vaccine Bonletella pert us sis ( 15). F urther evidence 
fo r T-cell involvement in adjuvant expression comes from the histological stud ies 
o f Taub et al. ( 16) who demonstrated hypercellularity in the thymus-dependent 
area of draining lymph nodes after footpad injection of both antigenic and non-an-
tigenic adjuvants. Synthetic polynucleotide adjuvants have also been reported to 
act on a T-cell population ( 17) although there is contrary evidence that the B-cell 
is the target fo r such ad juvants ( 18) . 
The finding that mixed lymphocyte and GVH reactivity, both T -cell functions, 
are reduced after C. pm-vum treatment is in keeping with the lack of PHA respon-
siveness. It is possible that the actual red uction in GVH reactivity may be less 
than ind icated by the data in Table 2, since some persisting C. parv111n has been 
shown to be transferred with the cells. I-Io·ward et a!. ( 19), using the same GVH 
system, demonstrated that pretreatment of F 1 mice with C. parvum abrogated 
GVH in terms of reduced splenomegaly. What is not known in the present system 
is whether the amount of C. par.JIIm transferred with the spleen cells is sufficient 
to he effective in this manner. T hat some MLR and GVH reactivity was still de-
tectable despite the generally complete lack of PHA responsiveness may be recon-
ciled with the fact that rat lymphocytes which par ticipate in MLR and GVH may 
be separated from PHA-rcactive cells on density gradients (20) . T he MLR of 
mouse spleen cells has also been demonstrated to be reduced after treatment with 
anti -8 serum and complement. without affecting PHA responsiveness (21) . 
The poor PWJ\:I response of T-cell-cleprived mice shows that P \Vl\1 in this sys-
tem was not very effective at stimulating B-cells. The similarity between the re-
sponse of cells f rom C. parvnm-treated mice and T-cell-deprived animals suggests 
that the depressed P \iVM response after C. parvum is not clue to an effect of C. 
parvum on the B-cells. However, the recent demonstration by Howard (personal 
comm unication) that C. parvum pretreatment has an adjuvant effect with the thy-
mus-independent antigen pneumococcal polysaccharide type 3 (Sill ) might sug-
gest at least a degree of B-cell involvement. 
To date there appears to have been a fairly good correlation between the PHA 
and MLR responsiveness of lymphocytes and over-all immune status, cell-mediated 
in particular (8-10, 22). The present fi nding of drastically red uced responsiveness 
of lymphocytes from animals with elevated cellular and humoral immune status 
urges caution concerning the validity of such tests as rneasu res of immunocompet-
ence under some circumstances. 
T he mechanism of the depression of PHA responsiveness after C. parvum has 
been the subject of further study and the results and their significance are set out 
in the following paper (23 ). 
It has since been demonstrated that E . Coli endotoxin stimulates exclusively B 
cells ( Gery et al., 1. I'lllmwn.ol. 108, 1088, 1972). Subseq uent experiments have 
shown no difference in the endotoxin response of spleen cells from normal and 
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C. parvum-treated tmce, providing further evidence for no effect of C. parvum 
on B. cells. 
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Biological Effects of the Adjuvant Corynebacterium Parvum 
II. Evidence for Macrophage-T-Cell Interaction 
MARTIN T. ScoTT* 
Department of Experime11ta/ lmii111110biolorJ.I'. 111 ell come J?rscorch l.oborotaries, 
Bcckcnlwm. Ki'llt, Enyland 
r<.cccivcd March 6, 1972 
The mechanism underlying the markedly reduced PHA responsi,·encss of 
spleen and per ipheral blood lymphocytes from Coryncbactcrillm f>orvllnt-
treatecl mice is due to inhibition of the responsive T -lymphocytes by C. 
f>OJTtll/1-activatcd macrophages. Inhibition is a result of a qua litative rather 
than quantitati,•e change in the macrophage population a nd CVH-acti,·ated 
macrophages behave similarly. Cor)•ttebaclcriwn por"<mm-activatecl macro-
phages need to be viable and will inhibit normal lymphocytes. This inhibitory 
effect appears to be mediated through cell- cell contact. 
INTRODUCTION 
Spleen cells and blood lymphocytes from mice pretreated with the bacterial adju-
,·am Corynl'barlcriulll f>arvnm have been found to be refractory or markedly unre-
sponsive to stimulation by phytohaemagglutinin (PHi\) in vitro ( 1). As other 
recognised T (thymus-derived) cell functions l mixed lymphocyte and 
graft-versus-host ( G \ ·I-I) reactivity J were s imilarly impaired, it was concluded 
that the T-lymphocyt~.: is affected by this adjuvant. The present study concerns the 
nature of the PI !A unresponsiveness and presents evidence for macrophage-T -cell 
interaction under the inRuence of C. parvu111. 
MATERIALS AND METHODS 
Animals. J\clul t mice of the inbred strain CI3A-/> were used throughout. 
1Jacl11ria . Corynebacleriu111 j>arvu111 suspension (Batch ~o. El174, 7 Illg/ml ) 
was provided by the \ Vellcome Research Lahorator ies, Beckenham, Kent, E ngland. 
:\ standard close of 0.2 ml was injected intra1•enously. 
Cell susp!'nsions aud the rcsponsr /o P 1-1 <'1. The p reparation of lymphoid cell 
suspensions and their responsiveness to PHA assayed by I'~C] -thym idine incorpo-
ration arc described in detail in the preceding paper ( 1) . _ \ ny deviations from the 
routine procedure a re descr ibed in the t~'<t Except where stated, PHA was used 
at the opt imally stimulating dose of 0.001 mlj ml culture. 
Colu111n filtration of cell suspensions. \i\Tater-jacketed glass columns (26 em X 1 
cm ) were fi lled wi th glas:; beads ( 3 111111 diam) . The volume when fill ed was 10- 11 
*!'resent address: Trudeau Inst itute. Inc., P.O. Box 59. Saranac Lake. :\.Y. 12983. 
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mi. Spleen cells ( 10 ml ) ( 10' j ml) in Eagles Minimum Essential 1\Iedium ( :ME:\1 ) 
contain ing !O ro foetal calf serum were applied to the column and allowed to adhen:: 
fo r 15 min at 37° C. The nonaclherent cell population was eluted by addition of 10 
ml of fresh serum containing medium at 37°C, centrifuged and resuspended at 
JO!l/ml ready for culture. Peripheral blood lymphocytes were fractionated similarly 
using fewer cells in the same final volume. 
Magnetic separation of phagocytic cells. The technique described by McCullagh 
(2) . with slight modification, was used. Spleen cells were incubated in centrifuge 
tubes with carbonyl iron powder for 1 hr at 37°C. The cells were resuspended and 
the tube drawn upward between the poles of a powerful magnet, the resulting su-
pernatant being transferred to another centrifuge tube. T his process was repeated 
six times. The cells remaining in the supernatant were centrifuged and resuspended 
in l\IIEM containing serum at 106 / mi. 
Carbon clearance. The rate of clearance from the blood of intravenously injected 
colloidal carbon (0.1 ml/g body wt of 16 mg/ ml suspension) was as described by 
Biozzi et al. (3) . Groups of eight mice were used. 
GVH mice . Adult (Cl3A-T6T6 X C57BL)F1 mice were inj ected intravenously 
with I 08 CS7BL spleen cells. Spleen weights were markedly increased at 8 days, 
when spleens were removed and cell suspensions prepared. 
EXPERIMENTAl 
The effect of col~mtn filtration on normal and C. parvum-trea.tetl spleen cells. 
Spleen cells from normal mice and animals injected intravenously with 0.2 ml C. 
parvum suspension 7 days previously were compared for their ability to respond to 
PJ-{A after removal of adherent cells by glass bead column fract ionation (Fig. 1). 
Unfractionated C. parvum-treated ( CP) spleen cells were totally unresponsive to 
Pl=-IA stimulation as described previously ( 1) . T he nonadherent cell populations of 
such spleens were, however, fully responsive to PHA. Although removal of adher-
ent cells from normal spleens resulted in somewhat higher mean PHA responsive-
ness, this was not statistically significa nt at any of the doses tested. 
Effect of removal of phagocyt,ic cells on C. parvum-treated splee1~ cells. Glass ad-
herence is a generally accepted procedure for the removal of phagocytic cells from 
various cell populations, although some nonphagocytic cell types adhere to glass 
after ant igen stimulation in vivo ( 4). As C. pa:rvum is a potent immunogen as well 
as an adjuvant (Scott. unpublished results) it seemed desirable to use a more dis-
cri minative technique fo r removal of phagocytic cells-magnetic separation. 
The effect of removing phagocytic cells with carbonyl iron was similar to column 
fractionation (Fig. 2) and PHA responsiveness was again restored to a level com-
parable with normal spleen cells . U nlike column fractionated cells, the isotope in-
corporation into unstimulated iron-fractionated cells was consistently higher than 
into unstimulated whole cells. 
The effect of colun1.n filtration on C. parvum-treated blood lymphocytes. Periph-
eral blood lymphocytes isolated from mice which had received C. pa1·vum intrave-
nously 7 days previously were fract ionated and the nonadherent cell population 
tested for PHA responsiveness compared with unfractionated cells (Table 1 ) . T he 
PHA response of lymphocytes from CP mice, as compared with normal animals, 











FIG. 1. The effect of the removal of g lass-adherent cells by glass bead filtration on the PHA 
responsiveness of normal spleen cells and those from mice which had received C. parvum 
intravenously 7 clays previously. Normal spleen cells 0 • • • • 0, filtered normal spleen cells 
• --e , C. parvum-treated spleen cells 0 • • • • 0, fi ltered C. pan,mn-treated spleen cells 




ML. PHA PER Ml. CULTURE 
F!G. 2. The effect of the removal of phagocytic cells by magnetic separation on the PHA 
responsiveness of spleen cells from mice which had 1·cccived C. pa.rvnm intravenously 7 days 
previously. Whole cells 0 • • • • 0, fractionated cells • --e . Vertical bars represent ± 
standard error ( 11 = 3). 
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TABLE 1 
THE EFFECT 01> GLASS BEAD FIL'rRAT!ON OF BLOOD LY)II'H OCVTES FRO)/ C. par;•um-TRBATED 
M ICE ON THEIR PHA R ESPONSf\'ENESS 
cpm : Unstimulated 
cpm: PHA-stimulated 
Stimulation index h 
Normal 
388 .0 ± 135.6 « 
29' 879. l ± 4942. 5 
104.1 ± 19.9 
" Mean ± standard error (n = 5) . 
Blood lymphocytes 
C. parvum-treated 
C. parm m.-treated 
filtered 
------------------
350.3 ± 64 . 3 
3762.0 ± 225 . 7 
11.7±2.7 
5-!6. 9 ± 188.7 
12 ,855.2 ± 2695 .0 
25.5 ± 2.9 
b Ratio of cpm PHA-stimulated cellsj cpm unstimulated cells. 
was greatly reduced as anticipated. Removal of glass-adherent cells from the CP 
population consistently resulted in increased PHA responsiveness. However, in 
contrast with spleen cells, the degree of PHA responsiveness restored to blood 
lymphocytes was never complete, in that stimulation remained well below that of 
unfractionated normal blood lymphocytes. 
The uatnre of 1'1Wcropltage-lned-iated inhibition of lymphocyte PHA responsive-
ness. The implication of the fractionation experiments is that potentially PHA-
responsive lymphocytes are present in CP spleens and peripheral blood but are inhib-
ited by the presence of phagocytic cells. Cor·y nebacterium parvum1 has a 
stimulatory effect on macrophages evidenced both histologically and by increased 
carbon clearance (5 ). Is the inhibition phenomenon due merely to the presence of 
increased numbers of macrophages or does it result from some qualitatiYe change 
in these cells? Tt has been reported that an excess of macrophages in some in vitro 
immunological systems exerts an inhibitory influence ( 6, 7, 8). 
The proportion of glass-adherent cel ls in both normal and CP spleens was com-
pared quantitatively by add ing equal numbers (lOS) of spleen cells to columns and 
counting the numbers of nonadherent cells eluted under identical conditions. The 
yields from seven comparisons of normal and CP spleens were not significantly dif-
ferent, being 4.01 ± 0.31 X 107 ( ± standard error ) and 3.8 ± 0.44 X 107 , re-
spectively. On this basis the inhibition phenomenon would appear to be attributable 
to a qualitative rather than a quantitative change in the spleen macrophage popula-
tion. 
Inhibition of PHA responsiveness of nonnallymphocytes b·y CP spleen cells. A s 
a first step toward analysing the inhibition phenomenon in greater detail, CP 
spleen cells were added to normal spleen or lymph node cells and the mixtures as-
sayed for any reduction in PHA responsiveness. Complete inhibit ion resulted when 
normal and CP cells were mixed in the ratio 1 :1 (Table 2). 
If the implication of the column experiments that the inhibiting cells are glass-
adherent is correct, then this population alone should be inhibitory. 
It proved impossible to elute glass-adherent cells retained during column filtra-
tion with versene, since it caused aggregation during centrifugation. The cells were 
recovered in the following manner : 1-ml aliquots (2 X 106 ) normal or CP spleen 
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TABL E 2 
1:-;HI IJ ITIO:\ OF PHt\ R ESPONSI\'ENl>SS OF NOR~IAL SPLEEN CELLS BY AODIT ION 






Normal + C. pon•1on-
treated cells 
cpm : Cnstim ulated 
cpm: P H A-stimulated 
. t imu lation index b 
1363 ± 379 .7 " 
15,1 52 .6 ± 28 12 .2 
12 . 8 ± 2 . 8 
a ~'lean ± standard error (n = 3). 
807. 6 ± 3 72 .9 
867. 6 ± 619.4 
0 . 8 ± 0 . 2 
6 R;~tio or cpm P HA-stirnulated cells/ cpm unstimulilted cells. 
2515 .1 ± 402 . 0 
3605 .6 ± 976.1 
1.4 ± 0 . 2 
cells were incubated in cul ture tubes fo r 3 hr at 37°C. After gentle agitation, the 
o,·erlying liuid and nonadhering cells were removed and replaced with 1 ml fresh 
med ium with or without 106 normal spleen cells . T hese cul tures were assayed for 
PHA reactivity in the standard manner . P re limina ry experiments affi rmed that the 
g lass-adherent cells thus prepared f rom normal spleens were considerably less 
PHA-responsive than whole cells. Table 3 shows that the PHA response of normal 
spleen cells was a lmost completely inhibited by the presence of glass-adherent CP 
cells but not by those from normal spleens. 
To test whether CP macrophages need to be alive to inhibit lymphocyte PHA 
responsi,·eness, suspensions of normal and CP spleen cells (2 X 10 6/ ml ) were 
killed by heating at 56°C fo r 30 min . (Cell death was confirmed by the absence of 
["H) -uricline incorporation during 3 hr after treatment. ) 0.5 ml a liquots of killed 
cells or of cell -free supernatants of heat-killed cells prepared by centri fugation and 
Mill ipore filtration were added to 0.5 ml (101;/ml ) normal spleen cells. J\ 11 cultures 
''"ere assayed rout inely fo r PHA responsiveness (Table 4) . 
There \\'<IS no difference in the PT·IA response of normal spleen cells incubated 
with supernatant from either heat-killed normal or CP spleen cells. A lthough PHA 
stimulation of normal spleen cells was less when incubated with heat-killed CP 
cell s than with heat-killed normal cells . the inhibition was mininml compared with 
the a lmost total inhibition with live CP cells (Table 2) . 
Thf' cf]f'ct of supernatants f rom unstimulated and PI-/A-stimulated CP spleen 
ulls on tltf' PllA rf'sj1onsc of 110nna/ ly111phocytcs. The absence of inhibition with 
supernatants from heat-killed CP cells does not exclude the possibility of soluble 
inhibito rs that m ight be released from metabolising cells. A sol uble human lympho-
cyte-clerived factor which inhibits DNA synthesis after PH. stimulation has been 
described (9) . Normal spleen cell s were tested fo r their PHA responsiveness when 
grown in medium from either normal or CP spleen cells cultured with or without 
PJ I :\ for 3 days. T hese media were prepared by centrifuging the 3-day cultures at 
2 X 10" rpm for 10 min at 0°C and lV[i llipore filtering the supernatant;;; 0.9 ml 
aliqums oi the supernatants were d ispersed into fresh culture tubes and 0.1 ml 
( 1 06 ) normal spleen cells added . These cultures were then assayed fo r PH A. re-
sponsiveness (Table 5 ) . There was no d i ffcrence in response between cells incu-
bated in supernatants from norlllal or CP spleen cell cul t ures. T he stimulation indi-
ces fo r cells g rown in med ia from PHA-st imulated cultures were less because of 
TABLE 3 
INJHBITION OF PHA RESPONSIVENESS OF NORMAL SPLEEN CELLS BY THE GLASS ADHERENT FRACTION 
OF C. parvum-TREATED SPLEEN CELLS 
Glass adherent normal spleen cells 
cpm: Unstimulated 
cpm: PHA-stimulated 
Stimulation index b 
a Mean ±standard error (n = 3). 
Alone 
586. 0 ± 37 . 0 a 
2642 . 0 ± 936.5 
4.6 ± 1.9 
b Ratio of cpm PI-IA-stimulated cells/ cpm unstimulated cells. 
+ Whole normal 
spleen cells 
3252 . 8 ± 390.3 
31,409 .5 ± 285 .0 
9.7 ± 0.2 
TABLE 4 
Glass adherent C. parvum spleen cells 
Alone 
1424.0 ± 267 . 5 
910 8 ± 482 .3 
0.6 ± 0.2 
+ Whole normal 
spleen cells 
3929 .5 ± 279 .0 
7253.8 ± 971.3 
1.9 ± 0.2 
THG Er:Fr::CT or~ H EAT-KILLED C. parvu.m-TREATED Sr•LEEN CELLS ON THE PHA RESI'ONSIV£NESS OF NORMAL SPLEEN CELLS 
Normal spleen cells cultured with 
Supernatant from killed Supernatant from killed Killed normal Killed C. />(mm m-
normal cells C. par1mm-treated cells cells treated cells 
cpm: Unstimulated 220.0 ± 61.5" 198.0 ± 51.0 270.5 ± 52 . 5 208.8 ± 2.3 
cpm: PHA-stimulated 12,601.5 ± 758.5 10,449.8 ± 879 .3 11,446.5 ± 2519 .5 5256 . 8 ± 2661.8 
Stimulation index b 61.1 ± 13 . 6 57 .8 ± 19.4 45 .9 ± 18.3 25.3 ± 13.0 
a M~"'ln ± standard error (1t = 3). 








PHA RESPONSIVENESS 01' NOR~IAL SPLEEN CELLS GROWN IN MEDIUM FROM 3-DAY CULTURES OF BoTH UNSTIMULATED AND 
PHA-STIM ULATED C. parvmn-TREATED SPLEEN CELLS 
cpm : Unstimulated 
cpm : PHA-s t imulated 
Stimulation index b 
• Mean ± standard e rror (n = 3). 
Normal spleen 
cells 
269.3 ± 41.8 • 
3965.5 ± 1414 .0 
14.3 ± 3.1 
b Ratio or cpm PHA-s timulated cells/cpm unstimulated cells. 
Normal spleen cells grown in medium from 
C. parvmn-treated 
spleen cells 
183.5 ± 41.5 
3434 .3 ± 1805.8 
17.4 ± 5.9 
PHA-s timulated 
normal spleen cells 
1227.0 ± 606.5 
4896.3 ± 1233. 3 
4.6 ± 1. 3 
PHA-stirnula ted C. parvum-
t reated spleen cells 
661. 5 ± 312 . 0 
3910.5 ± 1649 . 5 





























the residual activity of the PHA. However, cells incubated in supernatants from 
PHA-stimulated normal and PHA-stimulatecl CP cells responded equally well to 
freshly added PJ-IA. 
T hese results failed to demonstrate an inhibitory substance produced by CP 
spleen cells with or without the presence of PHA. They also exclude the possibility 
that failure to respond was merely clue to depletion of essential nutrients. It is 
clearly impossible to exclude the release of an inhibitory substance which acts lo-
cally, but which becomes too diluted in the medium to be detectable. 
Relal.i,cmship between the it~ltib·ition phenomenon and carbon clearance. The inhi-
bition of PHA responsiveness after inj ection of adj uvant C. parvum is attributable 
to a change in the macrophage population. Modification of macrophages after C. 
parvmn is also evidenced by an over-all increase in phagocytic capacity ( 5) . To see 
whether these two criteria for macrophage activity might be related, the rate of 
clearance of colloidal carbon and the PHA responsiveness of spleen cells were com-
pared in parallel at varying t imes after C. parvwm (Fig. 3) . 
Maximal increase in carbon clearance (th reefold ) was present 4 clays after C. 
panmm. This fell by clay 7, but was still maintained above background at day 21. 
PHA responsiveness was significantly reduced at day 4, but was not maximally de-
pressed until day 7. Although it rose slightly by day 14, it remained markedly de-
pressed at clay 21. The different kinetics would seem to indicate a Jack of identity 
between these parameters. 
PH A responsiveness of GV H spleen cells. Similar intense reticuloendothelial 
stimulation to that induced by C. pm-vnm also occurs during a GVH reaction ( 10) . 
Certain striking similarit ies, considered in the Discussion, suggested that the GVH 
situation might provide a source o( similarly activated macrophages. Eight-day 
GVI-1 spleens were therefore examined for PHA responsiveness ( F ig. 4 ) and 
found to be completely unresponsive. The controls sho,.vn in the graph are spleen 
cells [rom normal F 1 hybrids but mixtures of equal numbers of parental and F 1 
ceJJs were equally responsive. Removal of glass-adherent cells from GVH spleens 
resulted in the recovery of significant PHA responsiveness (Fig. 4), although this 
was min imal in comparison with the response of normal and fi ltered CP cells. 
However, as GVH disease is known to destroy lymphocytes preferentially ( ll ), 
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DAYS AFTER C.PARYUM 
Ftc. 3. Compa rison of kinetics of increase in carbon clearance activity • --• and depression 
of PHA rcsponsivene s 0 • • • • 0 after intravenous C. f/On>tull. 
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ML PHA PER ML CULTURE 
Frc. 4. The effect of remo,·al of glass-adherent cells by glass bead filtration on the PHA 
responsi\'eness of spleen cells from mice undergoing GVH disease (IQS C57BL spleen cells 
iv ~ (CBA-T6T6 X C57BL)F11 spleens removed 8 days later) . GVH cells •-~• 
fi ltered GVH cells 0 · • · · 0, normal F 1 hybrid cells 0-- 0 . Vertical bars represent ± 
standard error (11 = 3). 
GVH spleens wou ld be expected to be deficient in PHA-responsive cel ls. If, how-
ever , the GVH situation is analogous to C. parvum treatment, then GVH spleen 
cells ought to be capable of inhibiting the PHA responsiveness of normal lympho-
cytes. This pred iction was verified (Table 6) . 
DISCUSSION 
T he present findings ind icate that the inhibitory effect of C. parvum on the 
PHt\ responsiveness of T· lymphocytes is not a direct one but mediated by macro-
phages which have themselves been modified by the adjuvant. 
TABLE 6 
lntlll iTIOJ' Of PHA R~;sPOl'SI\'"NESS or l\oR~tAL (CB:\- T6T6 x C57BL)F, SPLEEN Cm.Ls 
n\' ADDITION OF GVH" SrLEE:-< CEt.LS 
cpm: Unstimu lated 
cpm: PHt\-:;t imulated 
Stimulatio n index • 
i'\onnal r, cells 
392. 7 ± 50. 2 b 
7180.5 ± 747.9 
18. 3 ± 1.9 
GVH cells" 
366.7 ± 22.1 
-t71.7 ± 72.2 
1.3 ± 0.2 
Norma l F, + 
GVH cells 
11 97.7 ± 128. 1 
3803 .5 ± J 16.0 
3 . 2 ± 0 . 1 
• 108 C57 BL spleen cell$ were injected intravenously into adult (CBA- T6T6 X C57 BL)F, mice. 
plcens were remo,·ed 8 days later. 
b :\lean ± standard error (11 = 3). 
• Ratio of cpm PH.-\-st imulated celb/ cpm unstimulated cells. 
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There is evidence from the mixed lymphocyte reaction (6 ), ·in ·vitr o graft reac-
tion (7 ) and in vitro response to sheep cells (8 ) . that although glass-adherent cells 
are necessary for these reactions, they are inhibitory when present in excess. Al-
though macrophage prolife ration occurs after in jection of C. pa·rvzm1-, the results 
showed no disproportionate increase in the number of glass-adherent cells after C. 
parvwm. treatment. 
The adjuvant activity of various substances correlates with their ability to labi-
lise lysosomal membranes in macrophages ( 12) and some adjuvants e..'<ert a cyto-
toxic effect on macrophages ( 13). The acljnvant-stimulatecl macrophage is there-
fore likely to be in a delicate condition and more susceptible to any cytotoxic action 
of PHA than its normal counterpart. That the inhibition of the PHA response of 
lymphocytes is clue to adverse culture conditions created by the breakdown prod-
ucts of dying macrophages is unlikely since heat-killed CP cells, their supernatants 
or supernatants from live CP cells were not inhibitory. For these reasons it is as-
sumed that cytotoxic action of PHA on macrophages is not the inhibit ing factor . 
What then is the nature of the inhibition? The failure to inhibit with superna-
tants from CP spleen cells shows lack of ident ity between the present inhibiton and 
the soluble lymphocyte-derived facto r described to inhibit PHA-stimnlated DNA 
synthesis (9) . T he same experiment would also exclude any soluble inhibitory fac-
tors produced by the C. parvum-stimulated macrophages, thereby implying that in-
hibition must be due to cell-cell contact. The inefficacy of heat-killed cells indicates 
that the activated macrophages must be viable. 
It is hardly surprising that any effect of C. parvwm on lymphocytes is mediated 
by macrophages since the immediate fate of injected bacteria is to be phagocytosed 
and contained. The only direct contact between lymphocytes and C. parvum. would 
presumably be via receptor sites for C. pa:rvnm on the lymphocyte surface, i.e., for 
C. parvum as an antigen. T he ad juvant effect of a variety of substances appears to 
act selectively v ia the macrophage. In experiments with beryllium salt, Bordetella 
pertussis ( 14) and Esche1'ichia coli lipopolysaccharide ( 15), treatment of lypho-
cytes with these adjuvants before using them to reconstitute irradiated recipients. 
gave no detectable adjuvant effect, whereas adj uvant processed by macrophages 
was effective. ~Jo over-all change in antigen handling by the stimulated macro-
phages was detectable and an effect other than that of antigen processing of presen-
tation seemed likely ( 14, 15 ) . Both groups of workers suggested that the most 
likely interaction betvveen adjuvant-activated macrophages and immunocompetent 
lymphocytes was for the macrophage to stimulate proliferation of the lymphocyte 
population. Efficient antigen presentation would be insured by having the lympho-
cytes dividing and differentiating at the time of antigen presentation. It is difficult 
at this stage to reconcile such a stimu lus with the present finding of inhibited PHA 
responsiveness unless perhaps macrophage stimulation of the T -lymphocyte in some 
way blocks stimulation with PHA. Even so, it is still unclear why no macrophage-
stimulated lymphocyte proliferation is detectable in vitro. Askonas and Jaroskova 
( 16) point out that such a stimulus could be effected by release of soluble stimulat-
ing factors or by membrane-membrane interaction. If, in fact, PHA inhibition 
after C. parvu1'ft, treatment does represent lymphocyte stimulation by macrophages. 
the latter suggestion is correct. 
BIOLOGICAL EFFECTS OF ADJUVANT C. par vmn. II 479 
There are many stri king similarities between mice undergoing C. parvu.m stimu-
lation and the proliferative stage of GVH disease. T hey show marked splenomeg-
aly, increased carbon clearance (5, 10), raised sensit ivity to endotoxin atttributed 
to increased sensitivity o[ the macrophages ( 17) and increased protection against 
bacterial infection clue to macrophage activation ( 18, 19) . T hat GVH spleen cells 
behave similarly to CP spleen cells with regard to PHA provides fur ther evidence 
for the role of the macrophage in PHA inhibition and underlines the similari ties 
between the two states. 
The diverse nature of substances expressing adjuvant activity would seem to ex-
clude any unified hypothesis of adj uvant action. There is, however, accumulating 
evidence that the cell type primarily affected by a variety of ad juvants is the mac· 
rophage and this has now been demonstrated to be true for C. parvnm. Although, 
at this stage, the in vivo correlate of C. parvum-activated macrophage inhibition of 
lymphocyte PH/\ responsiveness must remain conjectural, it may constitute a 
cell-cell interaction peculiar to stimulated conditions. Should this be the case, it 
would seem to be a useful assay fo r activated macrophages. 
ACKNOWLEDGMENTS 
1 express my gratitude to Miss C. Tieman for technical assistance and also to D r. J. G. 
Howard and Dr. P. Byfield for helpful comments. 
REFERENCES 
I. Scott, M. T., Cell.fiHIIIIIHOl. (submitted for publication). 
2. McCullagh, P ., Aust. J. Exp. Biol. lv/ed. S ci. 48, 551, 1970. 
3. Biozzi, G., Benacerraf, B., Stiffel, C., and Halpern, ,B. N ., C. R. S oc. Bioi. (Paris) 148, 431, 
195-l . 
4. Salerno, A., and Pontieri, G. 11., Clin. E.~:p. lmmlllrol. 5, 209, 1969. 
5. Halpern, B. N., Prevot, A. R. Biozzi, G., Stiffel, C., Mouton, D., Morar d, ] . C., Bouthill ier, 
Y., and Decr eusefond, C., J. Reticu/oendotlrel. Soc. 1, 77, 1964. 
6. Jones, A . L., Clin. E:~:p. l mmuno/. 8, 927, 1971. 
7. Lonai, P., and Feldman, M., lmmwrology 21, 861, 1971. 
8. Hoffman, M., l mmrmology 18, 791, 1970. 
9. Smith, R. T., f n "In vitro ~ fethods in Cell-Mediated Immuni ty" (B. R. Bloom and P . R. 
Glade, Eels. ) , p. 59. Academic Press, New York, 1971. 
10. Howard, ]. G., Brit. J. Exp. Patlral. 42, 72. 1961. 
I I. Da,·is, \V. E., Cole, L. ]., and Schaffer. V•l. T., Trallsf>/aulatiou 9, 529, 1970. 
12. Spitznagel,]. K., and A ll ison, A. C., .1. lmmrotol. 104, 11 9, 1970. 
13. Munder, P. G., Modolell , M., Ferber, E., and F ischer, H ., In "Mononuclear Phagocytes" 
(R. van Furth, Ed.), p. 445. Blackwell Scientific P ublications, Oxford and Edinburgh, 
1970. 
14. Unanue, E. R., Askonas, B., and Allison, A. C., J. hrrmwrol. 103, 71, 1969. 
IS. Spitznagel, ]. K., and All ison, A. C., J. Immrmol. 104, 128, 1970. 
16. Askonas, B., and Jaroskova, L., In "Mononuclear Phagocytes" (R. van Furth, Ed.), p. 595. 
Blackwell Scientific Publications, Oxford and Edinburgh, 1970. 
17. Howard, ]. G., In "Structure et Effets Biologique de Produits Bacteriens P rovenant de 
Bacilles Gram-Negati fs" p. 331. CNRS, Paris, 1968. 
18. Adlam, C., Broughton, E. S., and Scott, M. T., Nature (Loudon) New Bioi. 235, 219, 1972. 
19. Blanden, R. V., Trallsf>/au tatioa 7, 484, 1969. 
4 
Reprinted from CEt.l.t:l.AR hrMUNOWG\' , Volume 7, No. 2, May 1973 
Copyright © 1973 by Academic Press, fnc. Printed in U.S.A. 
CEI.IXI.t\R DDI U~OI.OG\' 7, 29Q-3Q J ( 1973) 
Biological Effects of Corynebacterium parvum 
IV. Adjuvant and Inhibitory Activities on B Lymphocytes 
j AMES G. HowMw. GEORGE H. C.HKISTJE. AKD MARTIN' T. Scorr 1 
Department of Expcriuumlal I muwnobiology, 11/ ell come Research Laboratories, 
Langley Court. Beckcnham, Ke11/ BR3 3BS 
Recei<Jed September 18, 1972 
The PFC reSI)011S(' to the thymus-independent antigen srn ( type 3 pneumococcal 
polysaccharide) was amplified in mice injected 4 days previously with killed Coryne-
bacterium. parvum. This adj uvant act ivity was demonstrable with high (2-50 1-1g) but 
not low (0.1-0.5 #g) doses of Sill. Induction of tolerance was unaffected. Depression 
of the response resulted from simultaneous injection of SJII with either C. par<Jruu 
or Bordctel/a. pertussis, while prior treatment with the latter was witl1out effect. Re-
sponsiveness to SIII was transiently but potently su1>pressed in spleen cells transferred 
into lethally irradiated, C. parvum pretreated mice. 
Although C. flaruwn is an effective B cell adjuvant, other data imply that it acts 
indirectly on these lymphocytes. It is argued that both adjuvant and suppressive activ-
ities o£ C. paruum on the B cell response to SIII a re most probably mediated by 
acti 1•atccl macrophagcs. 
Investigations on the mode of action of ad juvants have recently centered around 
wh ich type of lymphocyte, the thymus-derived (T ) cell or the bursa-equivalent (B) 
cell, is the site of stimulation. An obligatory role for T cells in the adjuvant activity 
of Bordete/la. pertussis has been a rgued on the basis of studies with thymus-deprived 
mice ( 1, 2) . This view has been qual ified by the large-scale investigation of Dresser 
(3) who fou nd that the stimulating effect of B. pertussis was directly on H cells 
when large closes of antigen •vere used, whereas amplification of responses was 
mediated via T cells with smaller doses. Confl icting reports which ha1·e appeared 
concerning the class of lymphocyte affected by polynucleotide ad juvants ( 4-6) may 
have a similar basis. 
Corynebacterium parvu1'n is a potent stimulant of the reticuloendothelial system 
(7) and also possesses acljll\'ant (8) and antitumor activities in vivo (9). Stimula-
tion ' vith C. parvum is accompanied by a range of depressed T cell activities ( 10) 
attributable to the direct influence of activated macrophages ( 11 ) . T he present com-
munication describes and analyzes the effects of C. parvum on the B cell response 
to the strictly thymus-independent antigen SIII (type 3 pneumococcal polysac-
charide) . 
l P resent address : Trudeau Institute, Tnc., Saranac Lake, NY 12983. 
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MATERIALS AND METHODS 
Mice. Adults of the CBA-T0T 0 inbred strain were used throughout. In any experi-
ment. mice were of the same sex and did not vary in weight by more than 5 g. 
Antige11s. The preparation and proper ties of the fo1lowing antigens used have 
been publi shed previously: Sill ( 12) ; H(-labeled Sill ( 13) ; Levan ( 14). Sheep 
erythrocytes ( SE) were supplied by these laboratories. 
Corynebacterium pa.rvllln. A standard suspension of killed C. parvum (strain 
CN6134) with a concentration of 7 mg/ ml (batch EZ 174) was prepared in these 
laboratories. 
Bordetella pertussis. A standard suspension (VC 3148) of killed bacteria with a 
concentration of 8 x 101 0 per ml was supplied by these laboratories. 
Spleen cell suspensions were prepared by a conventional procedure (15). 
Plaqne-forllling all assays. Direct PFC counts on spleen cells were used through-
out as a measure of the response to SJII. which is solely IgM in the CBA mouse. 
The technique using SE sensitized with type 3 pneumococcal culture filtrate ( 16) 
lias been described in detail elsewhere (17). Direct P.FC assays using levan and SE 
were according to the techniques described by Miranda (I 4) and Dresser and 
Wortis ( 18), respectively. 
Thymectomy. Adult mice were surgically thymectomized or sham-operated ( 19). 
Irrad·iation. 1\ fi ce received a standard close of 900 R whole-body irradiation from 
a 6°Co source with a dose rate of approximately 80 R/ min. and a foca l distance of 
18 em. 
Clearauce of HC-SIJJ from the circulation. Estimations of the levels of 14C-SIII 
in the serum were made using a Beckman liqu id scin ti llation counter. The techn iques 
and calculations involved have been descri bed previously ( 13). 
In vitro stitnulation of spleen cells with mitogens. The effect on T and B lympho-
cytes was studied with phytohemagglutinin (PHA) and E. coli lipopolysaccharide 
(LPS), respectively (20). The preparation of spleen cell suspensions, their culture 
and stimulation with PHA have been described previously ( 10). LPS from E . col·i 
~ 1o5 
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F1G. 1. Effect of C. por~·ullt pretreatment on the PFC response in the spleen 6 days after 
various doses of S ill . • - • Normal mice. 0 ·· · ·0 Mice injected with 0.7 rng C. porvum 
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FJG. 2. Effect of C. por-vum pretreatment on the course of the P'FC response in the spleen 
to 5 J.tg SIII. • - - • Normal mice. 0 .. · · 0 Mice injected with 0.7 mg C. pa/"1!11111 4 days 
before Sill. Standard errors indicated ( 11 = 5). 
extracted by the hot phenol-water method was kindly provided by Dr. L. Nagy of 
these laboratories. Prior to use 1 mg/ ml was dissolved in culture medium and 0.1 -ml 
al iquots of various dilutions added to the cultures. As ·with PHA, 14C thymidine was 
added 48 hr later and the cultures terminated after a further 24 hr for assay of 
isotope incorporation ( I 0). The results are expressed as a stimulation index:: the 
ratio of cpm in e.'<.peri mental culture/ cpm in control culture. 
RESULTS 
The Adjuvant Effect of C. parnun on the B Cell Response to Sllf 
Groups of five mice which had been pretreated with 0.1 ml C. parvnnt iv 4 clays 
previously were challenged with various doses of SIII iv and the PFC responses in 
the spleen compared after 6 days with those in normal mice (Fig. 1). No adj uvant 
effect of C. parvum. was detectable with small immunizing doses of SIII (0.1 and 
0.5 ~g), whereas a one-order increase in PFC level was detectable using larger doses 
(2, 5, 20, and 50 ~g) . Induction of tolerance by 500 ~g SIII was not impaired by 
C. parvum treatment. T he time course of the augmented response to 5 ~g Sill is 
shown in Fig. 2. The increase in PFC on Day 2 was similar in both C. parvum-
t reated and normal mice, but showed divergence thereafter, the former group reach-
ing a higher peak and substaining a greater response through Days 4-10. Although 
C. parvum produced an average 3-fold increase in the spleen cell count, this experi-
ment implies that its adjuvant effect involves an increase neither in the nw11ber of 
SUI-reactive B cells nor the initial rate of prolife ration of PFCs. 
It is obligatory to inject C. parvmn severai days before antigen to develop an 
adj uvant effect. Simultaneous administration with SIII was found to reduce signifi-
cantly the PFC response (Fig. 3). T he effect of injecting 2 X 109 B. pertussis ( iv) 
with 5 p.g Sil l was also studied, as this ad juvant is conventionally given together 
·with antigen. Again, some depression of the PFC response >vas found (Fig. 3) , 
although the dose of B. pertussis used effectively augmented the response to 5 X 108 
sheep erythrocytes. This inhibitory activity was even more potent in another experi-
EFFI~CTS OF C. l'Afllli".ll OK H LY>\TPIIOCYTES 
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F 1G. 3. E ffect of simultaneous administration of C. fW I"i 'lllll or B. perluJ·,·is with 5 ~-tg Sill on 
the PFC response in the spleen. • --• Normal mice. 0 · · · ·O ·Mice given 0.7 mg C. pornu11. 
0-·- ·-0 Mice given 2 X 10° B. f>t!rlussis. Standa rd errors indicated ( 11 = 5) . 
ment in which the effects on the response to 5 1'-g s nr of prior or simultaneous 
treatment with B . perlnssis were compared. T he followi ng PFC counts ( log, 0 ± SE 
with antilog) were obtained on Day 6: no adj uvant 5.030 ± 0.124 (107,150), 
H. pcrlussis 4 days before STII 5.107 ± 0.094 ( 127,940). 13. pertussis with Slll 
.).870 ± 0.114 (7,41 5) . Thus, no adjuvant effect was obtained by pretreatment . 
whi le simultaneous injection with Slll was highly inhibitory to the immune response 
to this antigen. 
The results in Fig. 2 suggest that C. parv 11111 treatment does not induce an intr insic 
change in the B lymphocyte population, but rather that the augmented response to 































SPLEEN CELLS (x106) TRANSFERRED i.v. 
········-~· 
1- tG. 4. Failure of C. panmm-imluced adjuvant effect on B cells to transfer adoptively. PF'C 
response to 5 1-'g SIII in 900-R irradiated mice repopulated \\'ith various doses of syngeneic 
spleen cells from normal donors ( • --• ) or mice injected with 0.7 mg C. f>or< 'lllll 4 days 
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F IG. 5. Responsiveness to LPS of spleen cells from normal mice ( • --• ) and mice injected 
with C. parvwn 4 days previously (0 · · · ·0). (Standard erTOrs indicated. 11 = 3) . 
suppor ted first by the result of cell-transfer exper iments. Various doses of spleen 
cells from C. parvum-treated and normal mice were transfered to groups of 900 R 
irradiated mice which were then challenged with 5 p.g Sill (Fig . 4). Up to 509"o 
'more cells from C. pa,rvum-treated donors were required to confer equivalent re-
sponsiveness, commensurate with the increased cellularity of the spleens. (The 
highest cell close transferred ( 130 X 106 ) showed a reduction in efficacy, the basis 
for which has not yet been sought.) Secondly, spleen cell s from normal and 
C. pm-vum-treated mice responded similarly in vitro to stimulation by the B cell 
mitogen E. coli LPS (Fig. 5). 
Various experiments were carried out to see whether the sti mulatory effect of 
C. parvum on the B cell response to Sill might be mediated by either T cells or 
macrophages as (a) the S III response is augmented by T cell activity in GVH 
reaction (21) and (b) macrophages suppress some T cell activities in C. parvmn-
stimulated animals ( 11 ) . 
Results from the use of conventional thymus-deprived mice were inconclus ive. 
Adult thymectomized animals, lethally irradiated, and repopulated with 5 X 106 
syngeneic bone marrow cells were tested 2 mo later. Although C. parvnm pretreat-
ment failed to evoke any ad juvant effect against Sill in these mice, no significance 
could be attached to the experiments in view of the inconsistent activity of C. parvum 
in the irradiated controls with an intact thymus (the latter animals had been pre-
vious! y shown to have persistent hyporesponsiveness to Sill ( 22). 
More provocative observations were made with adult thymectomized, nonirradi-
atecl mice. Such animals did not differ from sham-operated controls on testing 21 
days after operation. After 87 clays, a lthough the mean PFC response to Sill was 
21 times higher in the thymectomized than in the control mice, this difference was 
not significant ( P = 0.2). C. parvwm was, however, ineffective in mice 87 clays 
postthymectomy (Table 1). Consideration of the interpretation of this experiment 
will be deferred to the Discussion. 
Possible macrophage involvement might depend on a change in antigen handling 
or the release of stimulatory factors. W ith regard to the ·first, a difference was found 
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EFFECT OF c. />MVUtn 0:-1 THE PFC RESPONSE TO S I J J IN A DOLT 








PF'C per spleen 5 days after 5 .ug Sill" 
Sham-operated mice 
5..109 ± 0.145 (256,450) 
4.869 ± 0.073 ( 73,960) 
4.845 ± 0.154 ( 70,000) 
Thymectomized mice 
5.379 ± 0.086 (239,330) 
4.950 ± 0.053 ( 89,130) 
4.768 ± 0.153 ( 58,610) 
295 
4.424 ± 0.191 ( 26,550)* 4.839 ± 0.080 ( 69,020)* 
• Log,o ± SE with anti logs in parentheses (n = 5). 
*Not significant (P = 0.2). 
in 3 days was similar in both C. parvum-treated and normal mice. thereafter the 
former group sustained a higher circulating '·tail" of antigen than did the controls 
(Fig. 6). This is attributable to exocytosis of indigestible antigen from phagocytosed 
reservoirs ( 13) which occurs at a greater rate when the macrophages are hyper-
active (23), as is the case with C. parvHm-treated animals. The persisting l•C-SIII 
levels in the latter were reduced to near those in controls by 900-R whole-body 
irradiation prior to injection (Fig. 6). 
Nonspecific stimulatory activity of macrophages was sought initially by measuring 
the response to srn of spleen cells transferred to lethally irradiated mice which had 
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DAYS 
8 10 12 
FJG. 6. Serum levels of ' 'C-SIJI after its inj ection iv ( 1 mg per 20 g body weight) in (a) 
normal mice ( 6.--6.), (b) mice injected with C. panmm 4 days previously ( • --- - • ), 
(c) as (b) but given 900 R immediately before in jection ( • -1-1-1-• ). (Standard errors indi-
cated, n = 8). 
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"home" to a spleen containing predominantly radioresistant C. parvum-act ivatecl 
lllacrophages. The unexpcctccl outcollle of this approach is described in the fullu\\'-
illg section. 
1'he Inhibitory Effect of C. parvum 011 the Jj Cell N.esponse to Sll I m L ethally 
Irradiated Repopulatecl M·ice 
A comparison was made of the PFC response to SUI in C. parvum-treatecl and 
normal mice which were irradiated with 900 R and repopulated with 8 X 107 syn-
geneic spleen cells (Table 2) . A consistent inhibitory effect was fou nd in the 
ad juvant-treated groups, in which PFC counts ·were suppressed to as low as < 1. o/o 
of normal. T he following points emerge from Table 2 : ( I ) the inhibitory effect was 
minimal in recipients which had been pretreated with smaller doses of C. pa.rvwm--
10 and 2<fo of the standard 700 p.g used throughout (Expt. A) . (2) Suppression of 
the response was consistently greater when the Sill challenge was delayed l day, 
rather than given immediately after irradiation and repopulation (e.g., E x pt. B) . 
(3) The responses to optimal (S JLg) and suboptimal (0.5 JLg) immunizing doses of 






THE [ N HIIHTORY EFFECT OF" C. pMvum I NJECTED PRIOR TO LETHAl. I RKADIATION 
OF RECII'Il::NT MICE OK THE RESPONSE TO S ill OF TKANSFERR£0 SvNGE:-IEIC 
DoNoR SPI, EEN CELLS 
Do;;e of Interva l PFC per spleen 5 days after S ill" 
C. parvum (pg) between Dose of 
4 days before repopulation S ill for 
900 R a nd a nd S l! I challenge Controls % Response 
8 X 107 challe nge (pg) 
C. paroum 
(~o C. in c. />llrlll/111 
mice 
splec11 cells (days) parvum) mace 
700 3.862 ± 0.079 l 19.7 
( 7,280) 
70 () 5 4.407 ± 0.059 4.568 ± 0.06 1 69.0 
(25.520) j ( 36,980) 
14 -!.4.60 ± 0.043 78.0 
(28,8-10) 
() 4.1 25 ± 0. 128 5.130 ± 0.072 9.9 
(13,340) (134,900) 
700 5 
3.063 ± 0.119 5.184 ± 0.032 0.75 
( 1,555) (152, 760) 
0.5 2.765 ± 0.163 4.087 ± 0.140 4.8 
(582) ( 12,220) 
700 
5 4. 103 ± 0.109 5.105 ± 0. 126 9.9 
(12,680) (127,350) 
• Log1o ± SE wi th antilog in parentheses (r1 = 5). 
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TABLE 3 
VAR IATI ON IN THE EXTENT OF l t-:tHI.liTlON OF RI>SI'ONSE TO VARIOUS ANTIGENS PROOUCEO BY 
C. parvtt111 TRI>.H~IENT PRIOR TO LETHAL IRRADIATION AKD REI'OI'Ul.ATION 
WITH SJ>LEEK CELLS 
PFC per sple<.: n" Serum ant ibodyb 
Antig<·n 
C.P. !\'! ice• Controls4 C.P. !\lice• ControJsoi 
5 ~'g S I 11 .3.720 ± 0. 110 -L879 ± 0.0~9 9.7 ± 0.6• 1~.0 ± 0.3 
( 5,250) (75,680) 
10 l'g Levan 3.5-t6 ± 0.238 .t.213 ± 0.062 7.,) ± 0.31 8 . .3 ± 0.3 
( 3,515) (16,330) 
5 X 108 S RBC H05 ± 0.107 ~.753 ± 0.0.36 6.5 ± 0.51 9.0 ± 0 . .3 
(25,410) (56,620) 
" Log,o ± SE with a ntilog in parentheses (n = 5). 
1' Log1 ± SE. 
< C. P. mice: C. P<trvum Day 0, 900 R, and !Oi syngeneic spleen ce lls Day~. antigen Da y 5, a nd 
PFC assays Day LO. 
'1 Controls : As above, without C. parvum prctr<.:atmcnl. 
• Hemolytic a ntibody assayed. 
I H emagglutinating antibody a ssayed. 
TABLE .t 
LosS OF IN HI UITOR Y I NFLUENC~: OK S l I I RESPONSE IN I K RADI ATED C. par:•mn-TREATED MICE 1J y 
DEL.A\'IN(; INJ I·:CTIOK OF ANTIGEN OF R£1'01'U LATING SPLEEN CL'Ll.S. 
Day of admin is-
tra tion after 
900 R PFC per spleen 5 days after S l II " 
Expcrin1cut 
8 X 10 ' C.P. m ice!. 
spleen Sill 
cells 
A Uelay in 0 .3.282 ± 0.139 
(1,910) 
S ill () 2 3.846 ± 0.205 
( 7 ,020) 
challenge< 0 3 ~.264 ± 0.048 
(18,3 70)•1 
0 6 .3. 709 ± 0.033 
( 5, 120) 
13 Delay in 2 4.723 ± 0.102 
(52,840) 
;;plcen cell 
.l .j 4.739 ± 0. 114 
repopu la t iou (54,820) 
" Log 10 ± SE with ant ilog in parentheses (n = S). 
"C.P. mice = injected with 700 l'g C. par~·um iv 4 day>< before irradiation. 
• S I II challenge = 0.5 l'g (Expt :\); S J.lf{ (Expt B). 
d p < 0.05. 
• i\ 01 tested. 
Control 
~ . 1 7~ ± 0.091 
( 14.930) 
~.060 ± 0.055 
(1 1,480) 
~. Ill ± 0.043 
( I 2,9 1 O)d 
.3 .820 ± 0. 16-l 
( 6,6 10) 
N.T.• 
4.84 7 ± 0.055 
(70,300) 
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FJG. 7. Responsiveness to PHA and LPS of spleen cells removed from normal ( • --• ) 
and C. pan•11m pretreated CO ··· ·0) mice l day after they had been lethally in-adiated (900 R) 
and repopulated with 10' syngeneic spleen cells. (Standard errors indicated, 11 = 3). 
standard dose of C. parvum in to irradiated normal mice repopulated with spleen 
cells. In this model only a minimal depression of the response to SIII was detected). 
The immunosuppressive potential of C. parvnm pretreatment in this model was 
assessed with two other antigens in parallel with SII1- the thymus-independent 
polysaccharide levan and sheep erythrocytes (Table 3). The PFC response to levan 
\vas 21 ro normal, although the hemagglutinin titer was reduced by only 1 log2 uni t. 
T he PFC response to SRBCs was 44% . while the hemagglutinin titer fell 2.5 units. 
The extent o{ in hibition is Jess striking with these antigens and was not explored 
in further detail. 
The potent inhibitory inAuence on the Sill response in the C. parvunHreatecl 
radiation chimeras was found to ue relatively transient in experiments where either 
spleen cell repopulation or antigen challenge were delayed (Table 4). No significant 
PFC suppression was found when the cells were injected 1 or 3 clays postirradiation, 
instead of on the same day (Expt. B). T he intense depression of response found in 
mice repopulated immediately after irradiation and challenged with Sill 24 hr later 
had largely disappeared when injection of antigen was made after 48 hr (Expt. A) . 
A slight overshoot in the direction of stimulation was found after Day 3 challenge. 
Rapid recovery of responsiveness to Sill was also found in a cell-transfer system. 
Lethally irradiated mice were injected ""ith 7 X 10' spleen cells from donors which 
had been themselves irradiated with 900 R and repopulated with 7 X 10' spleen 
cells 1 clay previously, with or without C. parvmn pretreatment. No difference in 
PFC response to 5 p.g SIII was found bet;veen the two groups. 
Although it seems likely that suppression of SIII responsiveness in C. parvum-
pretreated radiation chimeras would involve inhibition of cellular proliferation . no 
impairment in reactivity in vitro to the nonspecific mitogens PHA and LPS (acting 
on T and B cells, respectively) was apparent in spleens removed fro m C. pm-vum-
treated mice 1 day after irradiation and repopulation (Fig. 7). These results are in 
keeping with the cell-transfer experiments and suggest that the suppression is 
enti rely reversible by removing cells from an inhibitory environment, rather than 
a process involving lymphocyte damage. 
The likeli hood that the immunosuppressive influence of C. parv Hm described is 
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a ttributable to a rad iation-induced e ffect on activated macrophages is considered 
in the Discussion. 
DISCUSSTOJ\ 
The B cell response to the T -independent a ntigen S UI \\'as considerably aug-
mented by the adjuvant acti vity of C. parvum. v.:hen the upper range o( immuno-
genic doses of the polysaccha ride was used. No such effect was elicited by 8 . per-
tussis . which either dimini shed the PFC leYel when g iven together with SIII o r 
did not cha nge it when inj ected, like C. panm111. -+ days previously. The failure o f 
B. pertussis to act as an adjuva nt for a large dose of Sill contrasts with Dresser's 
finding (3) that it would a ug ment the response of 8 cells to higher doses of sheep 
erythrocytes in T-depri1•ed mice. Further eYiclem:e of the efficacy of C. j>arv u111 as 
a B cell adjuvant has recently come from stud ies on DN P coupled to levan, a 
T -independent carrier. The antihapten response. which requires both hapten and 
carrier-specific B cells ( 24) could be ampli fied by C. /IGI"i/ 11111 , but not by J3. per -
tussis or F reund's adjuvan t ( 25 ) . In the present experiments . the kinetics of the 
adjuvant effect. the inability to tra ns fer it adoptively and the normal in v itro re-
activity of spleen cells to the B cell mitogen LPS all suggest that C. parvum -incluced 
amplification of the PFC response to Slil is clue to some extrinsic control rather 
than to a direct e ffect on 13 lymphocytes. The most likely candida tes to fit this role . 
T cell s a nd macruphages, will be considered. 
The first point to be made is that the STII response ca n be a mplified by T cell 
activi ty . both nonspecifically in the initial stage of GVH reaction (2l ) a nd specif-
ically when STTI is co upled to a thymus-dependent carrier against which mice have 
been pr imed ( 2G) . The recent in "<'itro experiments of Basten and Feldmann (27 ) 
support the view that these effects a re clue to release o f two d istinct extracell ula r 
facto rs from T cells . Certa in obser vatio ns . howe1·er. arg ue against activa tion of 
thymus-derived lymphocytes as being an essential step in the adjuvant e ffect of 
C. parv um on the SIII r esponse. Fir st. no a mplification was found using suboptima l 
doses of polysaccha ride . the dose range fo r which a potentia l T cell-mediated activity 
would be expected to be most in evidence (e.g .. 3) . ( The possible objection that 
sma ll amounts o f SIII wo uld be deviated by intense macrophage activation a ft er 
C. pan·u m seems improbable in v iew of (a) the cleara nce data presented o n HC-Sll J 
a nd (b) the stimulation produced again st smaJJer doses of S ITT by G V [-f reaction 
(21) where macro phage activation is even more pronounced ( I 5 ) . Second. a variety 
of T cell functions ( PHA responsiveness. MLC a nd GVH reactivity) a re inhibited. 
not stimulated . by the same C. parv u111 pretreatment which we h<ll'e stud ied ( 10) . 
U nfo rtunately, our a ttempts to demonstra te an obligate role for T cells by means 
o f deprived. irrad iated mice were precluded by the inconsisten t effect of C. parv wn 
in irradiated repopula ted controls, which respond poorly to Slli ( see 22) . The 
resul ts with adul t thymectomized, no nirradiated mice deserYe comment. however. 
as they impinge on the debatable "suppressor'' T cell. T he confl icting evidence 
relating to this still hypothetica l mecha nism for regulation of the r esponse to 
T -independent antigens is reviewed elsewhere (see 28) . but two positive findings 
cannot be clisregarcled. (1) 1\LS treatment aug ments the Sll 1 response ( 29) a nd 
the effect can he abrogated by T cell repla~.:ement (30) . (2) Adu lt thymectomy is fol-
lo wed after a few weeks by heig hten<::cl responses to PVP ( 3 1) . !\ simila r trend to 
the latter is recorded here with S II T, a lthough the d iffe rence was not la rge enoug h 
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to be statistically significant with g roups of five mice. As the response of such 
thymectomized mice was not increased further by adjm·ant, it could be postulated 
that suppressor T cells ( like other T cell activities) might be inhibited by C. parvum. 
This seems high ly improbable. however, in view of the recent demonstration by 
Manning. Reed. and J uti Ia (32) that congenitally thymuslcss (nude) mice show 
PFC responses to STTJ indistinguishable from those in siblings with intact thymuses. 
A n important ro le fo r macrophages in the cellular events underlying adj uvant 
acti ,·ity was establ ished (for some agents. at least) by the experiments of Unanue, 
:\ skonas, and ..-\ llison ( 33). Subsequent experiments by Askonas and J aroskova 
( 34) suggested that ad j uvant-acti valed macrophages stimulated the differentiation 
and proliferation of antigen-triggered lymphocytes. either by membrane contact or 
by release of a factor. Activity of this type has recently been demonstrated in vitro 
in the supernatant Ouid of macrophage cultures ( 35). The suggestion was made by 
. \ skonas and JaroskoYa that the adjm·ant-induced change in macrophages in volved 
Jabilization of lysosomes. 
There are strong grounds for bclic\·ing that macrophage acti,·at ion is the primary 
eYent behind the B cell-stimulating actiYity of C. parv11111. ( I ) This bacterium is 
among the most potent known stimulants of the reticuloendothel ial system (7), 
producing the appearance of large numbers of hyperphagocytic macrophages rich 
in lysosoma l enzymes. The delayed onset of ad juYant activity produced by C. parvum 
is coincident with the development of this RE stimu lation. (2) C. parvum-activated 
macrophages exert a d irect inhibitory acti,·ity on T cells ( II ). These same phago-
cytes might induce the opposite efT ect in B cells if the la tter have a much higher 
threshold for stimulation than T cells, as has been shown with B. pertussis (3). On 
this basis. one would predict that even higher Je,·els of macrophage acti,·ity would 
inhibit B cells also. The stimulating factor in macrophage cultures studied by Hoff-
mann and D utton ( 35) was strongly inhibitory to an i11 vitro immune response when 
used in higher dosage. In the present experiments a potent immunosuppressi,·e effect 
was exerted on B cells transferred to C. panmm-pretreated ( but not normal) irradi-
ated recipients, which was a transient and wholly reversible phenomenon in which 
no intrinsic change or damage of lymphoid cells was implicated. The possibility that 
transferred cells were suppressed by an effecti,·e scaling-up in the level of "activity'' 
emanating from stimulated macrophages aftrr radiation damage is currently under 
investigation. Finally, it is worth noting that irradiated normal recipients repop-
ulated with 8 X 10' spleen cells and immediately challenged with STII have con-
sistently shown PFC responses two to five times g reater than intact, nonirradiated 
mice ( unpublished data ) . These stimulato ry and inhibito ry influences might be 
<Htributable solely to quantitative differences in the same causal event. 
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Cellular mechanisms underlying the 
adjuvant activity of Corynebacteriu1n 
parvun1: interactions of activated macro-
phages with T and B lymphocytes 
JAMES G. HOWARD, MARTIN T. SCOTT* and GEORGE H. CHR ISTLE 
Departmem of Experimemal f11ummobiology, Wei/come Research Laboratories, Beckenham 
Abstract The effect of an intra venous injection of kil led Corynebacterium parvum 
4-7 days previously has been studied in mice with regard to various functions of 
T a11d B lymphocytes. The following T cell activities are inhibited: (I) Graft-
versus-host reaction (by pretreatment of host or donor), (2) Mixed lymphocyte 
reactivity, and (3) P HA responsiveness of spleen or blood lymphocytes (but not 
lymph node cel ls). Removal of macrophages from the spleen cells of C. parvum-
treated donors restores full responsiveness to PHA. Conversely, these cells (or 
their glass-adherent fraction) will inhibit normal cells. 
Splenic B cells in C. parvum-treated mice react normally to the mitogen lipo-
polysaccharide. A strong adjuvant effect is demonstrable on the lgM response to 
higher immunizing doses of the T-independent antigen type 3 pneumococcal 
polysaccharide (SUI). By contrast, Bordetella pertussis exerts only an inhibitory 
influence on the response to Sill. The reactivity of spleen cells to SIII is transiently 
but potently suppressed when they are transferred into mice irradiated with 
900 R and pretreated with C. parvum. 
Both l9S and 7S components of the response to the T-dependent antigens, sheep 
and rat erythrocytes, are amplified by treatment with C. parvun1. The former 
persists longer and can be el icited by otherwise sub-immunogenic doses, while the 
latter is most pronounced after lligher doses. A comparison between thymus-
deprived and intact mice implies that (l) C. parvum-treated deprived mice give 
19S and 7S responses comparable to those of intact mice without adjuvant, and 
(2) C. parvum does not inhibit the normal cooperative funct ion ofT cells. 
From these and other data we conclude that C. parvum inhibits T cell-mediated 
immunity and exerts a powerful adjuvant effect on B cells. It is argued that both 
stimulatory and suppressive influences are mediated by activated macrophages, 
which also seem likely to play a central role in determ ining co.ncurrent increased 
resistance to tumours. Possible mechanisms whereby these macrophages might 
operate are discussed briefly. 
* Present address: Trudeau Institute, Inc., P.O. Box 59, Saranac Lake, N.Y. J2983, USA 
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The striking stimulatory activity of Corynebacteriwn parvum on lymphoreticular 
tissues was origi nally discovered during a systematic search within this genus 
for species which might in this respect resemble certain of the re lated myco-
bacteria. ln the event, C. parPum has turned out to be the most potent bacterial 
stimulant of the macrophage system currently available (Ha~pern eta/. 1964). A 
single injection of killed organisms provokes a prolonged and intense hyper-
phagocytic response due to the emergence of very large numbers of highly 
activated macrophages. C. parvum also possesses a strong adjuvant property 
which is demonstrable either by substituting it for mycobacteria in com plete 
Freund's adjuvant (Neveu eta/. I 964) or by injecting it in saline a few days be-
fore, but not together with, antigen (Biozzi et a/. 1966). (The second of these 
approaches is considered in this paper.) Another attribute which C. parvum 
shares with M ycobacterium tuberculosis (strain BCG) is the capacity to increase 
resistance to a wide range of experimental mouse tumours, but it has, un li ke 
BCG, the additional advantage of being effective in the form of a killed vaccine 
(W oodruff & Boak 1966; Halpern eta/. 1966; Currie & Bagshawe 1970; Smith 
& Scott 1972). 
We describe here a series of experiments on the intluence of pretreatment with 
C. parvum on the function ofT and B lymphocytes, which we undertook for 
two reasons : (I) Preliminary studies suggested that modulation of the immune 
response by C. par~>um had important qualitative as well as quantitative dicffer-
ences from the effect of other commonly used adjuvants. (2) We felt that more 
detailed information on this asp ect might assist the delineation of the mechan-
isms by which C. panum augments resistance to tumours. Unless stated other-
wise, all experiments were performed in CBA strain mice. A standard suspen-
sion of killed C. parvum (stra in CN6l34) with a co ncentration of 7 mg/ml (Well-
come Research Laboratories) was used throughout, with the exception of 
earlier experiments (described in Table I) which used t he original Pasteur 
strain 9368. 
EFFECTS ON T CELL FUNCTION 
One of the earlier attempts to analyse the cellular mechanisms underlying these 
activities of C. parvum concerned a prono unced red uction in mortality rate 
which followed the induction of a graft-versus-host (GV H) reaction by parental 
lymphoid cells in pretreated adult F I hybrid recipients (Table 1) (Howard eta!. 
1967). The effect was more striking than that obtained by a nalogo us pretreat-
ment with BCG (Biozzi et a/. 1965) and from karyotypic analysis was clearly 
attributable to an inhibition of the proliferation of the donor cells (Table 1). 
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TABLE 1 
Inhibition of GVH reaction induced by 10s parental strain spleen cells following pretreatment 
of Fl hybrid recipients with C. parvum 
Strain combination: 
C57BL/6 -+ (C57BL/6 x CJH) F1 
Recipients Mice dying/ 
110. iujected 
Untreated 24/25 
C. parvum given 
4 days before 
spleen cells 6/30 






C57BL -7 ( C57BL x CBA- TGTG) F! 
% douor mitoses 
day 2 day 12 
18.0 88.4 
0.2 2.7 
We suggested at the time, on the negative grounds of having excluded several 
alternatives experimentally, that amplification of allogeneic inhibition might be 
the causal mechanism. TlliS view is no longer tenable in the light of more recent 
studies, to be described now, which have revealed the phenomenon as part of a 
more widespread depression ofT cell function. 
(I) Pretreatment of C57B L donors with C. parvum considerably weakens the 
GYH reactivity of their spleen cells in (CBA X C57 BL)Fl recipients, as 
assessed by the relative spleen index (Table 2) (Scott l972a). (2) A parallel 
depression was found in the mixed lymphocyte reactivity (M LR) of CBA spleen 
cells in a one-way system with lethally irradiated DBA/2 cells. Stimulation, as 
TABLE 2 
Reduced GVH react ivity of spleen cells from C. parvum-pretreated C57BL donors in (CBA X 
C57BL)Fl adult mice 
Relative spleeu weight ( mg/ lOg body wt.) ± S. £. 
of recipieuts ( n = 16) 9 days after 
iujectiou of 108 spleen cells from: 
Donor geuolype Normal douors 
Parental (C57 BL) 96.4 ± 5.9 




C. parvum-treated donors 
61.8 ..1: 2.2 
45.7 ± 1.9 
1.4 
R elative sp leen weight with parental cells 
n = 
Relative spleen weight with Fl cells 
(Data from Scott 1972a.) 
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judged by increased DNA synthesis in mixed compared with control cultures 
(conta ining irradiated syngeneic cells), was consistently reduced by treating the 
cell donors with C. parvum (Scott J972a). (3) Scott ( 1972a) found that yet an-
other T cell function, responsiveness to phytohaemagglutinin (PHA), is even 
more strikingly suppressed. Spleen cells, pooled lymph node cells a nd blood 
Leucocytes were isolated seven days after the intravenous injection of 1.4 mg of 
C. parvum and tested for stimulation of DNA synthesis as measured by the 
30 A. SPlEEN 
20 
10 




0 0·0001 0·001 




ml PHA PER ml CULTURE 
0·001 0·01 01 
FtG. I. PHA responsiveness of lymphocytes from mice injected with 1.4 mg C. parvum seven 
days previously (e- e), compared with normal mice (0 · · · ·0 ). The injection was intravenous 
in the case of spleen cells (A), pooled lymph node cells (n) and blood lymphocytes (o). Draining 
popliteal lymph node cells were assayed after footpad injection. Standard errors shown; 
n = > 5. (From Scott 1972a with permission of Cellular Immunology.) 
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incorporation of [14C] thymidine. The responsiveness ofT cells in spleen and 
blood to the entire range of stimulating doses of PHA was totally suppressed, 
whereas the responsiveness of lymph node cell suspensions was unaffected (Fig. 
I A, nand n). Tnhibition of reactivity to supra-optimal doses of PHA was fou nd 
in cells of the draining popliteal lymph node, however, when C. parvum had 
been injected into the footpads (F'ig. I c). The [ 14C]thymidine pulse was routinely 
added after 48 hours of culture with PH A in vitro, as the possibility of a prem-
ature response by cells from C. pan·um-treated donors was excluded. Analogous 
treatment with another member of the same genus, C. diphtheriae, which is 
devoid of macrophage-stimulating and adjuvant activity, failed to modify 
responsiveness to PHA. 
This refractoriness of spleen cells from mice treated with C. parvum has 
proved to be reversible (Scott 1972b). Normal responsiveness to PHA reappear-
ed after the removal of glass-adherent cells or, more specifically, of macrophages 
by magnetic elimination of cells which take up carbonyl iron (Fig. 2). Conver-
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FJG. 2. Recovery of responsiveness to PI-lA by spleen cells from donors pretreated with 
C. parvum, after the removal of macro phages by magnetic separation. TCllal cells ( 0 · · · · 0 ); 
macrophage-depleted cells (e-e). Standard errors shown; 11 = 3. (From Scott 1972b with 
permission of Cellular Immunology.) 
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when they were mixed with spleen cells (or their glass-adherent fraction) from 
C. parvurn-treated donors. 
These findings imply that the functional depression ofT cells after the injec-
tion of C. pal'l'um is attributable to the influence of activated macrophages. The 
normal response to PHA of lymph node cells after intravenous injection of the 
bacteria would merely reflect their failure to localize in the nodes when ad-
ministered by this route. 
Impressive evidence has recently been obtained of the suppression by C. 
pal'llum of T cell-mediated immunity in ''il'O. The development of contact 
sensitivity in mice to picryl chloride or oxazolone was found by Asherson & 
Allwood (1971) to be depressed by prior intravenous injection of C. pal'l'um. 
J. E. Castro (unpublished results) has obtained a prolongation of up to 3- 4 days 
in the mean survival time of skin allografts across an H- 2 barrier in mice 
(A~CBA) by injecting C.parvum one week before or on the day of grafting. All 
these in 1•itro and in vivo observations are consistent with the conclusion that, 
with regard to cell-mediated immunity, T lymphocyte function is depressed, not 
stimulated, by prior treatment with C. parvum .in saline. Although the experi-
ments with PHA indicate that this is an indirect effect under the influence of 
activated macrophages, it remains to be proved formally that this is a general 
control mechanism exteDding to all the T cell functions descr.ibed. We shall 
discuss later how the macrophage might fulfil this role, after the function of B 
cells and the cooperative function ofT cells in C. parvum-treated mice have been 
considered. 
It must be stressed that all these examples of depressed T cell function follow 
the systemic administration of C. parvum. When injected locally as the bacterial 
component of complete Freund's adjuvant, it potentiates the development of 
delayed hypersensitivity (Neveu eta/. 1964). 
EFFECTS ON B CELL FUNCTION 
The suppressed reactivity to PHA ofT cells in C. pan•um-treated mice is not 
paralleled by the homologous response of their B cells to the mitogen E. coli 
Upopolysaccharide (LPS). The extent to which spleen cells from treated and 
normal mice are stimulated in vitro by various doses of LPS is similar (Howard 
et al. 1973). 
We have found that pretreatment with C. parvum exerts a strong adjuvant 
effect on the B cell response to the thymus-independent antigen type 3 pneu-
mococcal polysaccharide (SJU) (Howard et a/. 1973). Immunity to Sill is ex-
clusively humoral and is strictly independent of T cell cooperative function 
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(H oward et al. 1971), although it can be amplified by T cell activity during the 
earl y phase of the GYH reaction (Byfield eta!. 1973). Prior injection of C. 
parvum did not increase the counts of direct plaque-forming cells in the spleen 
after small immunizing doses of sur (0. 1- 0.5 CJ.g), but produced an 8- to 10-
fold rise with higher doses (2- 50 flg) (Fig. 3). The induction of toLerance by 500 
flg of SilL was not impaired. The time course of the response to an optimal 
immunizing dose of 5 vg (Fig. 4) indicates that the initial rate of exp ansion of 
PFC was not increased and suggests that the number of Sill-reactive B cells had 
not been augmented by the adjuvant. Rather, C. pal"l'um pretreatment appeared 
to sustain the response at a higher level. lt was obligatory to inject C. par rum 
several days before SJJJ ; simultaneous administration significantly reduced the 
PFC response. A comparison was made with the effect of Bordete/la pertussis, in 
view of the fact that its adjuvant activity is predominantly T ceU orientated, 
except with very high doses of antigen (Allison & Davies 1971 ; D resser 1972) . 
Injection of 2 X J 09 B. pertussis organisms four days before 5 !Lg SIH was with-
out effect, while their adminjstration together with this antigen was highly sup-
pressive ; in one experiment the response fell to I 0% of normal. Th.is· is note-
worthy, because injection of the same batch of B. pertussis with sheep erythro-
cytes revealed its customary immunostimula tory effect. 
Our colleague P. del Guercio ( I 972) has recently found similar evidence of the 
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F10. 3. Adjuvant effect of injecting 700 ~1g C. parvum four days before various doses of Sill. 
Response measured by counts of direct plaque-forming cells (PFC) after six days. C. parvum-
treated mice ( 0 · · · · 0 ); normal mice (e - e ). Standard errors shown; 11 = 5. (From H oward 
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FrG. 4. Effect of C. parvum pretreatment on the course of the splenic PFC response to 5 ~tg 
S11l. Conventions as in Fig. 3. (From Howard et a/. 1973 with permission of Cellular Im-
munology.) 
another thymus-independent antigen, dinitrophenol coupled to levan (DNP-
LE)- a complex which appears to involve both DNP- and LE-specific B cells 
(del Guercio & Leuchars 1972). Whereas pretreatment with C. parvum effectively 
augments the anti-hapten response to DNP- LE, both Freund's adjuvant and B. 
pertussis are ineffective. The failure of these other agents to display their adju-
vant property with T-independent antigens may be a reflection of their pre-
dominant stimulatory influence on T cells. Our own efforts to implicate T cells 
in the effect of C. parvum on the anti-SUI response by studying thymus-deprived 
mice have been thwarted so far by the .inconsistent behaviour of irradiated 
controls, which remain chronically hyporesponsive to this antigen. 
The suggestion from Fig. 4 that C. parvum does not produce an intrinsic 
change in splenic B LympllOcytes was borne out by the absence of any adjt(vant 
activity with regard to Slll after the transfer of spleen cells into irradiated 
recipients. We consider that the extrinsic influence most likely to explain the 
augmented response to T-i11dependent antigens is the activated macrophage, 
for the following circumstantial reasons: (I) C. parvum is phagocytosed witl1in a 
very short time of being injected into the circulation; (2) the lag period before 
the onset of a demonstrable immunopotentiating effect coincides with the 
emergence of activated macrophages ; and (3) macrophage function influences 
the activity of T cells in C. parvum-treated mice. We sought evidence of this 
postulated stimulatory activity by measuring the anti-Sill response of spleen 
cells transferred into lethally irradiated mice that had been previously injected 
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with C. parvum, on the ground that donor cells would 'home' to a spleen 
consisting predominantly of radioresistant activated macro phages. The result of 
this approach was dramatically converse to expectation, for the response was 
profoundly suppressed in C. parvum-pretreated, irradiated recipients of normal 
spleen cells when SUI was injected up to 24 hours after repopulation (Table 3). 
TABLE 3 
The inhibitory effect of 700 ~1g C. parvum injected before lethal irradiation of recipient CBA 
mice on the response to Sill of transferred syngeneic donor spleen cells 
Slll lnlervaf between P FCs per spleen (day 5) % response 
c/wffenge repopulation and in treated 
( J,.ig) clwffenge (days) Treated mice Controls mice 
5 0 13 340 134 900 9.9 
1560 152 800 0.75 
0.5 1 580 12 220 4.8 
2 7020 11480 61.1 
3 18 370 12 910 142 
All mice irradiated with 900R and repopulated with 8 x 107 syngeneic spleen cells. Treated 
mice were injected with 700 J..lg C. parvum four days before irradiation. Geometric means of 
five animals shown. (Data from Howard et at. 1973.) 
T his effect was entirely reversible and disappeared when challenge was delayed 
until 48 hours or if the cells were transferred to secondary recipients. I n parallel 
with this suppression of the anti-SIIJ response in C. parvum-treated mice, 
normal irradiated recipients generally showed PFC levels somewhat higher than 
those in intact mice. We considered the possibility that both suppression and 
stimulation might result from some damaging effect of lethal irradiation on 
activated and normal macrophages respectively. To test this hypothesis, we 
have recently compared the effect of crystalline silica (kindly provided by Dr A. 
C. Allison), wltich selectively damages macrophages. The same dual effect has 
been obtained. Injection of silica together with SHI depresses the response in C. 
parvum-treated mice while augmenting it in normal animals. The possible 
nature of what seem likely to be macrophage-determined effects will be discussed 
later. 
EFFECTS ON THE RESPONSE TO THYMUS-DEPENDENT ANTIGENS 
Jn view of the inhibitory influence of C. pan,um treatment on various func-
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tions ofT cells associated with cell-mediated immunity, the question arises of 
whether or not their 'helper' role is affected similarly, in which case adjuvant 
activity might involve predom inant ly 19S at the expense of the more h.ighly T-
dependent 7S antibody. We have recently looked at the effect of C. parvum on 
responses to sheep a nd rat erythrocytes, estimating the total and 2-mercapto-
ethanol (2M E)-resistant haemagglutinin titres after a wide range of doses of both 
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FtG. 5. Adjuvant effect of injecting 700 J..(g C. parvum four days before various doses of sheep 
erythrocytes (SE). Mean antibody ti tres (11 = 5) on days 4 and 7. Total a ntibody : C. parvum-
treated mice (e - e ); controls (0-0). 2-Mercaptoethanol-resistant ant ibody : C. parvwn-
treated mice ( .A. 1111 .A.), controls ( ll 1111l; ). 
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log10 dose of RE i.v. 
FIG. 6. Adjuvant efl'ect of C. parvum pretreatment on the response to various doses of rat 
erythrocytes (RE). Experimental design a nd conventions as in F ig. 5. 
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TABLE 4 
The effect of pretreatment with 700 pg C. parvum on the response to various doses of sheep 
erythrocytes in terms of direct and indi rect splenic .PFCs 
Dose of C. parvum PFCs per spleen« 
slleep red cells treatment Direct 
( i.v.) ( 4 days before c!wl!euge) Day4 Day 7 
JQS + I 739 000 940 600 
877 400 25 500 
JOG + 52 400 328 000 
40 700 35 000 
J05 + 9850 19 700 
600 250 
" Geomelric means of five mice. 
(Data of G. l-1. Christie & J. G. Howard, unpublished.) 
Indirect 
Day 7 






assayed in the mice injected with sheep e rythrocytes (Table 4). Indirect" PFC 
counts and 2M E-resistant antibody titres were taken as measures of a 7S anti-
body response. Pretreatment with C. pan•um amplified 19S (2M E-sensitive) 
antibody formation in response to lower doses of both antigens, so that a 
response was detectable after only I 05 rat or sheep e rytluocytes, wh.ich failed to 
stimulate normal mice. T he data in Table 4 also show t hat the IgM response 
(direct PFCs) after higher doses is more sustained in C. parPum-treated mice, 
remaining elevated at day 7 when indirect PFCs are already numerous. A 
pronounced augmentation of the 7S response to hjgher doses of both antigens 
was detectable serologically and, for sheep erythrocytes, by indirect PFCs. 
As C. parvum appears to exert such a potent adj uvant effect on B cells, we 
in vestigated whether its abi li ty to amplify 7S responses might involve a T cell 
by-pass mechanism. Thymectomized and normal mice were irradiated with 
900R, repopulated with 5 x 106 bone marrow cells and immunized with 108 
sheep red cells 20 weeks later (Table 5). The thymus-deprived group gave small 
direct PFC and no indirect PFC responses by day 7, whereas when C. pan•um 
was ad ministered to them four days before challenge they developed direct and 
indirect PFC levels of simi lar magnitude to those found in immunized control 
mice. On the other hand, the considerably greater responses in the control 
recipients of C. pan'um implies that the normal cooperative activity ofT cells is 
not impaired by the adjuvant. Titrations of2ME-resistant a ntibody also indicated 
a similar increase in the 7S catego ry as did the indirect PFCs in this experiment. 
Is the considerable amplifying effect of C. pan•um on 7S as well as l9S antibody 
production in T-deprived mice due to its potent ability to stimulate B cells? 
Although the development of a 7S response in these mice is particularly st rik-
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TABLE 5 
A comparison of the adjuvant effect of 700 ).lg C. parvum on the response to sheep erythrocytes 
in thymectomized a nd intact bone marrow-reconst ituted mice 
C. parvum treatment Response 7 days after J08 sheep red cells ( i.v.)b 
( 4 days before PFCsfspleen Haemagg/ulinin ( logz) 
Recipients" challenge) Direct Indirect Total 2-ME resistant 
Thymectomized + 37 960 133 500 9.5 5.8 
6980 210 7.0 < I 
Controls + 630 400 3 427 000 14.6 12.2 
67 800 74 360 9.4 7.2 
a 900R irradiation and repopulation with a n intravenous injection of 5 X JOGbonemarrow 
cells, with or without prior thymectomy. 
b Geometric means of five mice. 
(Data of G. H. Christie & J. G. Howard, unpublished.) 
ing, it is not unique. Dresser ( 1972) found that T-deprived mice would develop 
7S responses to sheep red cells (although only with a very high immunizing 
dose) under the influence of B. pertussis. ChiiJer & Weigle (1973) have a lso 
shown clearly that the B cell mitogen LPS can stimulate mice to give a 7S 
response to human gammaglobuiin when their T cells are tolerant of this 
antigen. The standard thymectomized irradiated, marrow-repopulated mouse 
does, however, retain a few T cells. To exclude the possibility that C. parvum 
might operate by some functional expa nsion of these, we have also exam ined 
its effect in congenitally thymus-less (nude) mice. Unfortunately, the adjuvant 
has proved to be toxic in these animals, so that we have not yet obtained a 
decisive answer by this approach. 
EFFECTS ON T AND B CELLS LN RELATION TO ANTI-TUMOUR ACTIV ITY 
l n the face of the cumulative evidence of s uppression of relevant T cell 
activity, it seems l1ighly unlikely that an increase of cell-mediated immunity 
could determine the augmented resistance to tumours induced by C. parvum. 
Direct support for this contention is provided by recent observations that tl1is 
property of inducing tumour resistance is fu lly effective in mice deprived ofT 
cells by thymectomy or by treatment with antilymphocyte serum (J . E. Castro, 
personal communication; Woodruff & D unbar, this volume, pp. 287- 300). 
Amplification of the humora l response or some component of it remains a 
possible, if unlikely, bas is for a phenomenon which affects a diverse range of 
neoplasms. A recent experiment performed by Biozzi eta/. ( 1972) seems to 
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argue against an exclusive determinant role for antibody. They have studied two 
lines of mice (Ab/ H and Ab/L), genetically selected for high and low antibody 
responses, which can be demonstrated with any (including histocompatibility) 
antigen and involve all classes of immunoglobulins. A wide separation in 
antibody levels is sti ll present after the injection of C. parvum. Fl hybrids be-
tween strains AKR and Ab/H or Ab/ L retain respectively high and low respons-
iveness but, significantly, C. parvum induces resistance to the AKR lymphoma 
even more effectively in (AKR x Ab/ L)FI than it does in (AKR x Ab/ H)FI. 
These negative considerations strengthen the suspicion that in tumour 
resistance too it is the intensely activated macrophage which is the principal 
mediator of C. parvum-induced activity. Adequate evidence is now available of 
the cytotoxic capacity of macrophages against tumour cells in both specific and 
non-specific in vitro models (see Evans & Alexander 1972; Hibbs eta/. 1972). 
Furthermore, the cytotoxic activity of macrophages against fibroblast target 
cells has been correlated with their degree of activation (McLaughlin et a/. 
1972) . Our coll.eagues R. Bomford & M. Olivotto (personal communication) 
have recently noted that C. parvum-activated macrophages are considerably 
more effective than their normal counterparts in inhibiting the proliferation in 
ritro of a radiation-induced CBA leukaemia. Further elaboration of this argu-
ment is beyond the intended scope of this contribution. 
REGULATORY INFLUENCE OF C. PARVUM-ACfJVATED MACROPHAG ES 
Our hypothesis, a lbeit based on an incomplete framework of data, is that the 
h.igflly activated macrophages whicll appear in response to C. par~>um occupy a 
central position as mediators of the described effects on T and B lymph.ocytes 
and on tumour cell growth. Many further obvious experiments need to be done 
before we can assess the general validity of this contention. How might these 
cells exert s uch an influence? One important factor with regard to adjuvant 
activity may be an improved or prolonged presentation of antigen. Frost & 
Lance (this volume, pp. 29- 38) have found that C. parvum is one of the strongest 
inducers of ' lymphocyte trapping', which their evidence implies is a macro-
phage-mediated effect. This mechanism would facilitate extended contact be-
tween antigen-charged phagocytes and lymphoid cells and could provide a 
plausible explanation for the abi li ty of C. pan•um to stimulate a primary 
response to otherwise sub-immunogenic doses of sheep and rat erythrocytes. 
On the other hand , our finding that an adjuvant effect on the anti-SUI response 
occurs only with. higher immunizing doses of polysaccharide suggests the 
additional operation of another mechanism. 
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Macrophages are a mandatory requirement for the induction of an immune 
response to many, although not all, antigens and seem to be essential for 
lymphocyte differentiation and proliferation in vitro (e.g. Sjoberg et a/. 1972). 
There is compelling evidence that, afte.r taking up B. pertussis, macrophages 
present a magnified proliferative stimulus to antigen-triggered lymphocytes 
(Unanue et a/. 1969; Askonas & Jaroskova 1970; Allison, this volume, pp. 
73- 94). With regard to C. parvum, this concept is wholly compatible with the 
data on B cell function, but why should some T cell activities be suppressed? 
One explanation would be quantitative, that the macrophage ' influence' is 
stimulatory or inhibitory accord ing to dosage and that the effective thresholds 
forT cells (and perhaps tumour cells also) are lower than those for B cells. 
Hoffmann & Dutton (J 971) described a factor released in macrophage cultures 
which would substitute for macrophages in stimulating in vitro responses to 
sheep erythrocytes, but was highly inhibitory when used in higher concentra-
tion. The conversion by irradiation or silica of the stimulatory effect of C. 
parvum on the anti-SIB response into inhibition may be due to a scaling-up in 
the release of some such factor. Alternatively, these opposing effects may be 
determined by different macrophage activities which might invol ve either 
membrane contact or release of factor(s). Although the experiments of Hoff-
mann & Dutton suggest the latter, no evidence has been obtained so far for an 
extracellular factor in C. parvum-induced suppression of T cell reactivity to 
PHA or proliferation of R I Leukaemia cells in vitro (Scott 1972b ; R. Bomford & 
M. Olivotto, personal communication). Current understanding of the regulatory 
influence of macrophages over lymphocyte function is highly fragmentary and 
awaits further study, for which activation by C. parvum seems to provide a 
valuable approach. 
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Depression of Delayed-Type Hypersensitivity by Corynebacterium 
parvum: Mandatory Role of the Spleen 
MARTIN T. SCOTT 
Trudeau, Instilllte, i11corporated, P. 0. Bo.'l' 59, Sara11ac Lake, New York 12983 
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Mice pretreated with iv Co1·ynebacterium panmm showed markedly reduced OTH 
reactivity to subsequently injected SRBC without concomitan:ly increased antibody 
levels. No DTH depression occurred if C. parv um was g iven at the same time, or 
after, antigen. Neither antigen scusitization at the draining lymph node level nor the 
subsequent loss of sensitized cells from the node was impaired by iv C. parmm1 pre-
treatment. Splenectomy before C. parvum completely abolished its depressive effect, and 
lymph nodes, even when directly stimulated by local injection of C. parVItJn, were 
unable to substitute for the spleen in DTH depression. Increased u1>take of sensitized 
cells by the C. parvum stimulated spleen has been demonstrated, and the discrepancy 
between the spleen and lymph node performance is discussed in terms of the depression 
of T-cell activity by C. paruuw-activated macrophages described previously. 
INTRODUCTION 
The anti-tumor activity of the reticuloendothelial stimulant ( 1, 2) and adjuvant 
(3, 4) Coryneba.cterium parvum has been demonstrated in both mice (5, 6) and 
humans (7) . As an adjuvant, it appears unique in its ability to increase B-cell 
proliferation without the cooperation of T cells ( 4, 8) . Other ad juvants, e.g., 
Freund's complete adjuvant (9) and Bordetel/a pertussis ( 4, 9, 10), require T cells 
to manifest their adjuvant properties at least where low antigen doses are concerned 
(11). That C. parvum actually depresses T-cell activity was fi rst suggested from 
in vitro experiments showing the PHA responsiYeness of lymphoid cells from C. 
parvum-treated mice to be depressed ( 12). This effect was attributable to inhibition 
of potentially reactive T cells by C. parvum-activated macrophages ( 13). Subsequent 
reports describing C. parvtml. depression of in vivo development of contact sensitivity 
to picryl chloride in mice ( 14, 22), along with the present report of impaired 
expression of DTH to sheep red cells ( SRBC), provide in vivo evidence in support 
of the in vitro finding of T-cell inhibition by this adjuvant. In addition to its role 
in T-cell depression, the C. parvum-activated macrophage is now also reasoned to 
be the cell type instrumental in other C. pm-vum-mediated effects- namely, adjuvant 
and antitumor activi.ty (8). 
Tumor immunity is considered to be largely attributable to cell -mediated mechan-
isms, and, in light of the apparent T -cell depression by C. Pm-vwm, the use of this 
agent in tumor therapy may seem anomalous. Indeed, under certain experimental 
conditions, C. parvum has been shown to impair active immunity to irradiated tumor 
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cells (S). The following work was therefore initiated to study further the nature 
of depression ofT-cell reactivity at the whole animal level. 
MATERIALS AND METHODS 
Animals 
Specific pathogen-free outbred CD-1 mice (Charles River Farms, Wilmington, 
MA) were used throughout except in experiments with thymectomized repopulated 
mice when (C57BL/6 X DBA/2)F1 - (B6D2F1 ) were substituted. Similar 
results were obtained with both strains. 
T-Cell-Deprived Mice 
Four- to 6 wk-old B6D2F1 mice were thymectomized and 1 wk later given 900 R 
of gamma irradiation from a 137Ce source. Terramycin ( 125 ,ug/ml) was given in the 
drinking water. The same or following day they received S X 106 syngeneic bone 
marrow cells iv. The mice were used S-6 wk after reconstitution and 1 wk after 
antibiotic treatment had been discontinued. 
C nrynehcu:terium parvum 
C. parv1~m (batch number EZ 174, 7 mg/ml, Burroughs Wellcome) was kindly 
donated by Dr. C. Adlam, and 0.1 ml (700 ,ug) was injected either iv or sub-
cutaneously (sc) as described. 
Splenectomy 
Surgical splenectomy was performed under ether anesthetic and controlled for 
by sham splenectomy. 
Delayed-Type Hypersensitivity (DTH) to Sheep Red Blood Cells (SRBC) 
SRBC in Alsevers solution were purchased from the Animal Blood Center (P.O. 
Box 2, Syracuse, NY) . Mice were sensitized by the injection of SRBC suspensions 
in saline either sc into the neck region (0.1 ml) or sc into the footpad (0.05 ml using 
a 30-gauge needle). Delayed-type hypersensitivity reactivity was elicited at various 
times after sensitization by sc injection of 108 SRBC into a previously uninjected 
hind footpad, and footpad swelling was measured 24 hr later with a Schnelltaster 
dial gauge caliper A02T (H. C. Kroplin, Schluchtern, Hassen, West Germany) . 
Injection of sc SRBC caused no 3-hr footpad swelling (Artlms reactivity) , and iv 
SRBC were used to study this phenomenon as described in the test. Footpad thick-
nesses are recorded as the difference between the antigen-injected footpad and the 
contralateral foot in units of 0.1 mm. The successful use of SRBC suspensions in 
DTH sensitization of mice has been described previously ( 15, 16) and conforms to 
all the established criteria by which DTH is recognized, including cell transfer and 
sensitivity to anti-8 serum ( 16) . 
Assay for Lymph Node DNA Synthetic Act'ivity 
At each time point indicated, five mice were injected iv with 20 p.Ci of tritiated 
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Fxc. I. (a) Kinetics of DTH (24-hr swelling) to SRBC elicited by footpad injection of 
10s SRBC at various times after sensitization with 2 X 10' SRBC sc in either normal mice 
( 0 -0) or mice that had received C. parvmn iv (700 l'g) 7 days prior to sensitization 
(X-X) . Figures in brackets arc the reciprocal log~ hemagglutination titers ± standard error. 
Vertical bars represent± standard error (1~S). (b) Arthus reactivity (3-hr swelling) elicited, 
as above, 6 days after sensitization with 2 X 10' SRBC iv in either normal mice (N) or mice 
that had received C. pat-vnm iv (700 #g) 7 days prior to sensitization (CP). Normal non-SRBC-
sensitizecl controls are included (horizontal bars) . Vertical bars and figures in brackets are as 
for (a) . 
the popliteal nodes were removed and homogenized individually in sro TCA. They 
were further extracted fo r DNA as described previously ( 17), and the uptake of 
tritiated thymidine was counted in a Beckman LSlOO liquid scintillation counter. 
I-I emagglutinat-ion Assay 
Microtitrations were performed in V-shaped plastic wells by serially diluting 
sera with saline. To 0.1 ml of diluted serum was added 0.1 ml of 1% SRBC 
suspension. All tests were incubated for 30 min at 37°C and then overnight in the 
refrigerator. Titers were recorded as log2 of the reciprocal of the last dilution 
showing agglutination. 
EXPERIMENTAL 
Effect of C. parvnm Treatment on DTH and Artlws R eactiruity 
Mice were in jected with C. pm·vum iv and 7 days later received a 2 X 107 SRBC 
sc in the back of the neck. Control mice received only sc SRBC. Delayed-type hyper-
sensitivity reactions were elicited in the sensitized mice 3, 6, or 10 days after 
sensitization by injection of 108 SRBC into a hind footpad and comparing the swell-
ing at 24 hr with that of the contralateral (Fig. l a). Control mice developed 
considerable DTH, which peaked at Day 6, whereas C. parvumHreated mice showed 
markedly reduced responsiveness at all three test periods. The remaining DTII 
reactivity was, however, significant at both Days 6 and 10. Serum hemagglutinin 
ti ters at Day 6 in the two groups were not significantly different (Fig. la) . No 
significant Arthus reactivity developed in mice sensitized with sc SRBC, so, to 
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C PARVUM : DAYS BEFORE(- ) OR AFTER(+) SRBC 
F1c. 2. The effect of C. parvmn on DTH to SRBC when given at various times relative to 
SRBC sensit ization. C. parvmn (700 J.!g) was injected iv either before (-) or after (+) 
sensitization with 10s SRBC sc into the neck. DTH was elicited by footpad injection of 108 
SRBC 4 days after sensitization. Control animals received no C. parvzmr. Vertical bars repre-
sent ± standard error (n::;::S). 
examine the effect of C. pa.rvum pretreatment on Arthus reactivity, similar groups 
of mice were sensitized with 2 X 107 SRBC iv. Footpad challenge was 6 days later, 
and swelling was measured at 3 and 24 hr (Fig. 1 b) . Arthus reactivities ( 3 hr) in 
control and C. parvum-treated mice were similar despite higher antibody levels in 
the latter group. Neither group developed DTH following this dose of iv SRBC. 
Relationship between Time of C. parvum and Antigen Injection 
C. parvw»~ was injected iv into mice at the times shown in Fig. 2, relative to a 
sensitizing injection of 108 SRBC sc into the neck. Delayed-type hypersensitivity 
was elicited by footpad challenge 4 days after sensitization and measured 24 hr 
later. C. parvutl' injected iv 7, 4, and 2 days prior to SRBC sensitization was equally 
suppressive (DTH about 30% normal). However, there was no statistically signi-
ficant impairment of reactivity when C, Parznrm was given either at the same time 
as, or 2 days later than, antigen (Fig. 2). It may have been that DTH was not 
depressed when C. pa,rvum was injected 2 days after antigen merely because it had 
been active in the body only 2 days before DTH el icitation, whereas in the pretreat-
ment groups it had been active for a longer period. To control for this, further 
experiments in which mice received C. pa1'VIt'm at Day +2 (after sensitization) and 
were challenged in the footpad at Day +8 ( i.e., 6 days after C. parvmn and corn-
parable to those which received C. pa,rvum at Day -2 and ·were challenged at Day 
+4) were performed, and again no significant DTH depression was found. That 
the degree of DTH inhibition is unrelated to the time that C. parvnm has been 
acting in the animal is further evidenced by the fact that C. pa1·vum at Days -7, 
-4, and -2 were equally suppressive rather than giving graded responses. 
The Effect of C. parvu111. Pretreatment on the Lymph Node Proliferative Response 
to Antigen in Norm.al and T -Celi-Deprived Mice 
To determine whether depressed DTH reactivity resulted from impaired antigen 
sensitization, the proliferative response in the lymph node draining the site of 
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DAYS AFTER SRBC 
F1c. 3. Kinetics of DNA synthesis in the popliteal node in response to a hind footpad injec-
tion of lOS SRBC in either normal mice (0-0) or mice that had received C. parvum ( 700 f.'g) 
iv 7 days previously (X-X) . Histograms : DNA synthesis, as above, 4 days after SRBC injec-
tion in T-cell-cleprived mice that received C. paJ-vum (700 p.g) iv 7 days previously (open) or 
no pretreatmem (horizontal bars). Background isotope incorporation by non-SRBC-stimulatecl 
nodes of normal mice is shown (6) . Vertical bar s represent ± standard error (n=S). 
antigen stimulation was compared in normal and C. pm·vum-treated mice (Fig. 3) . 
Instead of injecting the sensitizing SRBC into the neck a.s before, 108 SRBC in 
0.05 ml of saline were injected sc into a hind footpad. and the incorporation of 
tritiated thymidine in the popliteal node was assessed at the days indicated. P revious 
exper iments had determined that footpad ::;ensitization was equally as effective at 
producing DTH as injections into the neck and also that it was susceptible to 
depression by C. parvmn pretreatment. There was no impairment of the prol ife rative 
response of the lymph nodes in C. parmmHreatecl mice, t here being. in fact, an 
overall increase in responsiveness due to a prolongation of the response. The levels 
of lymph node DNA synthesis in both normal and C. parvun1. mice 2 days after 
SRBC were not signi ficantly different (Fig. 3). 
Other workers have shown that the lymph node proliferati,•e response to SRBC 
is T -cell dependent in that it does not occur in T-cell-deprivetl mice ( 18) . How-
ever, it has also been suggested that the adjuvant effect of C. parvum. on the SRBC 
response might involve a T -cell-bypass mechanism (8). To test whether such a 
bypass was operating in the present experiments, they vvere repeated with T -cell-
depr ived mice (see histograms, Fig. 3). Such mice were incapable of responding to 
SR13C whether they had been C. parvum pret reated or not. which showed the 
response to be entirely T-cell dependent following C. parvum. treatment. 
The Effect of C. fJarvmn Pre/reaf1nent on Loss of Sensitized Cells from Dymph 
Nodes 
Since antigen sensit ization was apparently unimpaired in C. parvum-treated 
animals, it was next considered that the sensitized cells may be less well able to 
leave the node and get into circulation. Lymphocyte trapping has been demonstrated 
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DAYS AFTER ISOTOPE 
FIG. 4. The effect of C. parvum pretreatment on the loss of SRBC-sensitized cells from the 
popliteal lymph node. Cells dividing in response to SRBC were labeled as follows : 108 SRBC 
were injected into both hind footpads and 20 p.Ci tritiated thymidine was injected iv 2, 3, and 4 
days later. Popliteal lymph nodes were removed and assayed for residual radioactivity 30 min, 
1, 2, and 3 days after final isotope injection. Mice received either C. parvmn (700 p.g) iv 7 
days prior to SRBC injection (X-X) or no pretreatment (0-0). Vertical bars represent 
± standard error (t1=5). 
to occur following stimulation with various adjuvants, and indeed C. parvttm is 
unusual in the marked degree of trapping it causes ( 6). To follow the fate of cells 
dividing in response to a footpad injection of SRBC, 108 SRBC were injected into 
both hind footpads of either normal mice, or mice that had received iv C. parvu.nt 7 
days previously. Two, 3, and 4 days after SRBC, 20 p..Ci iv of tritiated thymidine 
was injected into all animals. Lymph nodes were then assayed for residual radio-
activity 30 min, 1, 2, or 3 clays after the final injection of isotope (Fig. 4) . It has 
been shown that the node DNA synthetic response to SRBC is identical in normal 
and C. parvHm-treated mice over the labeling time period (Fig. 3). Presumably 
some cells are leaving the node over this period and therefore any retention by the 
node following C. Pm·vum treatment would be expected to result in a higher total 
amount of label in the first instance. However, 30 min after the final isotope injec-
tion, the degree of labeling in control and treated nodes was identical, indicating 
any such cell loss to have been proceeding at the same rate. Moreover, the subsequent 
rate of loss of label from both groups was the same (Fig. 4). 
The Effect of Sp!et~ectomy on C. parvwm-mediated Inhibition of DTH 
The accumulated data indicating that the lymph node was unaffected by iv C. 
Parvum and therefore not instrumental in the inhibition of DTH led to the con-
sideration of the role of the spleen. Intravenous C. parmtm causes marked splen-
omegaly, due largely to macrophage proliferation ( 4), and at 7 days spleen weight 
had increased three- to fourfold. Surgical splenectomy was performed 3 days prior 
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Frc. 5. The effect of splenectomy on DTH elicited by footpad inj ection of l OS SRBC 4 days 
after sensitization with l OS SRBC sc into the neck in either normal mice (N) or in mice that 
had received C. parvma (700 J.tg ) 7 days prior to sensitization (CP). Splenectomy was per-
formed either 3 days before (cp-3) or 3 days after (cp+ 3) C. parvmn. Vertical bars represent 
± standard error (tFS). 
to, or 3 days after, iv C. pa.rvum injection. Non-C. parvum-inj ected mice were 
similarly splenectomized, and the requisite intact controls were included. Seven days 
a fter C. parv·um, 108 SRBC were inj ected sc into the neck, and DTH reactions were 
elicited in the footpad 4 days later (Fig. 5). C. parmm~ pretreatment caused the 
usual profound depression of DTH in the intact animal. However, in animals that 
were splenectomized 3 days prior to C. parvtim inj ection, the DTH depression was 
completely abolished. Splenectomy alone did not affect the DTH level. Splenectomy 
3 days after C. parvum treatment resulted in an incomplete restoration of DTH 
depression being significant only at the 10% level. Again, splenectomy itself caused 
no significant change in DTH levels of untreated animals. 
The Effect of Serum from C. paruum-Stimulated Aninw1s 
There was the possibility that it might be a humoral product of the C. parm~m­
stimulated spleen rather than the spleen itself which was mediating DTH depression. 
J n mind was antibody to C. parvum, since splenectomy is known virtually to abolish 
antibody production to iv injected particulate antigens. To test this, serum was pre-
pared from mice which had received C. pa.rvum iv 10 days previously. ( High titers 
of agglutinating antibody to C. panmm at this time had been previously demon-
strated-unpublished results, M. T. S.) . F ive-tenths millili ter of undiluted serum 
was injected iv into normal mice, followed immediately by a sensitizing dose of 
SRBC into the neck; DTH was elicited in the footpad 4 days later. Control mice 
received normal serum. Neither normal nor C. parvu,m serum caused any detectable 
change in DTH reactivity compared with untreated mice. Further experiments in 
which the immune serum was mixed with C. pa.rvum prior to injection (i.e., to 
form antigen- antibody complexes) were similarly without effect. 
The Effect of C. Parvmn on Cell Trapping by the Spleen 
The mandatory role of the spleen in DTH depression, combined with the 
apparently normal sensitization of SRBC reactive cells and their subsequent loss 
from the regional lymph node, were suggestive of trapping of such cells in the C. 
parvt.tm-stimulated spleen, Local administration of C. pa.r vu;m causes increased 
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Frc. 6. Comparisons of iv and sc C. parvum pretreatment on DTH to subsequently injected 
SRBC. (a) DTH elicited by footpad inj ection of JOS SRBC 4 days sensitization with lOS 
SRBC sc into the neck in normal mice (N), mice that received C. pa1"1mm (700 f.Lg) iv 7 days 
prior to sensitization (CP iv), and mice that received C. parvum (700 f.Lg) sc into the neck 
7 days prior to sensitizat ion (CP sc) . (b) DTH elicited as above in the right hind footpad 4 
days after sensitization with JOS SRBC sc into the left hind footpad in normal mice (N) or 
mice that had received C. parvll'm (350 J.lg) sc into the left hind foot 7 days prior to sensitiz-
ation (CP sc) or mice that received C. parvnm (350 f.Lg ) iv 7 days prior to sensitization (CP 
iv) . (c) Delayed-type hypersensitivity elicited by footpad inj ection of lOS SRBC 4 days after 
sensitization with 105 SRBC iv in either normal mice (N) or mice that had received C. par-umn 
(700 f.Lg) iv 7 days prior to sensitization. ( a-c) Vertical bars represent ± standard error 
(n=S) . 
lymphocyte trapping in the draining nodes, as demonstrated by increased uptake 
of subsequently injected labeled lymphocytes ( 19), and it was fully expected that 
this would also be true of the spleen following iv C. pa·rvmn. T o confirm this, labeled 
SRBC reactive cells were prepared as follows: mice were injected with 108 SRBC 
sc into both hind footpads, and 20 p.Ci of tri tiated thymidine was inj ected iv 3 and 4 
days later. One hour after the final isotope injection, popliteal lymph nodes were 
removed and cell suspensions were prepared by gentle filtration through a fine 
stainless-steel sieve. The suspensions were washed and filtered through cotton 
gauze, and 5 X 107 cells were injected iv into either normal mice or mice which 
had received iv C. parvum 7 days previously. Immediately after cell transfer and 
4 and 12 hr later, the recipients received cold thymidine ( 1000 times the isotope 
dose) sc into the neck. Spleens were removed for assay of their isotope content at 
24 hr. The proportion of the injected cells taken up by the normal and C. pa·rvum-
stimulated spleens may be compared by considering the total amount of isotope 
acquired per spleen. The counts per minute per spleen were 2879±248 ( SE) and 
5361±427 for the normal and C. parvun~-stimulatecl spleens respectively, which 
reflects an increased uptake following iv C. parvum. 
The Effect of Direct Stimulation of Lyn~ph Nodes by C. pm~tl'lmt, 
The fact that splenectomy prior to C. parvmn injection completely restored DTH 
responsiveness suggested that the lymphoid elements remaining after splenectomy 
were incapable of mediating DTH depression. However, iv C. parvum causes 
relatively little stimulation of the peripheral lymph nodes, since the bulk of the 
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TABLE 1 
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inoculum is taken up by the liver and spleen. It was therefore decided to stimulate 
the lymph nodes directly with C. pm·vum prior to their processing of injected 
antigen. ln the first series of experiments C. parvum was injected either iv or sc 
into the neck, and 7 days later 105 SRBC were injected sc into the neck. Delayed-
type-hypersensitiYity was el icited in a hind footpad 4 days later. The usual depres-
sion of DTH resulted from the iv C. porv1.tm injection. However, animals which 
had recei\'ed C. Parvu.m sc were fully reacti,·e (Fig. 6a). 
Injection of material sc into the neck region may stimulate a variety of regional 
lymph nodes, depending on the exact location of the inj ections. It was considered 
that should the injection sites of C. pa:rvmn and SRBC not be coincident, then 
antigen may have "escaped" through lymph nodes either unstimulated or not 
sufficiently stimulated with C. pm-vu 111 . To eliminate this. a second series of experi-
ments was undertaken to ensure passage of antigen through a maximally stimulated 
node. C. parvum was injected iv, as before, or sc into the right thigh immediately 
above the popliteal node, and 7 clays later 1 os SRBC ;,vere injected into the right 
hind footpad . DTH was el icited in the left hind footpad 4 clays later. Intravenous 
C. pm·vum again depressed DTH reactivity, and again mice which had received 
the adjuvant sc were fully reactive (Fig. 6b). To confirm and also to assess the 
degree of stimulation of the popl iteal lymph nodes after injection of C. porvum 
into the thigh, groups of mice were assayed for increase in popliteal lymph node mass 
and DNA synthesis after 7 clays. Table 1 compares these resul ts with those for the 
spleen 7 days after iv C. jlanmm and shows them to be similar in magnitude. 
A control omitted from the above experiments is the level of DTH reactivity 
resulting from antigen processed directly by the C. parvum-stimulated spleen-i.e., 
after iv SRBC sensitization . The reason is that for the antigen doses used only 
sc sensitization resulted in DTH development (see F igs. la and l b). Very low 
doses of iv SRBC were, however, found to cause DTH, and mice were sensitized 
with 105 SRBC iv 7 days after iv C. parvmn. Delayed-type hypersensitivity was 
elicited 4 days later, and the resulting depression was similar to that following sc 
sensitization (Fig. 6c). 
DISCUSSIO r 
The presented observations that iv C. parvwm pretreatment reduces DTH reactiv-
ity contribute to the accumulating evidence that, despite its profound potentiating 
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effect on B cells (3, 4) and its marked anti-tumor effect (S- 7), T-cell responses are 
inhibited by iv C. parvum. Thus far, PHA, MLR, GVH, ( 12) contact sensitivity 
(14), and homograft reactivity (Castro, quoted in Ref. 8) are reported to be 
depressed by this adjuvant. Cell-mediated immunity and humoral immunity are 
considered to coexist in balance (20), but the combination of iv C. par-vum followed 
by sc SRBC shows DTH reactivity to be markedly depressed without a concomitant 
increase in circulating antibody levels. Increase in antibody levels did occur when 
the conventional adjuvant regimen of iv C. parvum prior to iv antigen was used; 
however, Arthus reactivity was not modified. In similar experiments showing 
Freund's complete adjuvant to depress DTH reactivity to picryl chloride, both 
immediate and delayed hypersensitivities were reduced ( 14). 
Sensitization at the level of the lymph node draining the site of antigen injection 
in animals pretreated with iv C. parvum was not impaired as assessed by the degree 
of antigen-induced DNA synthesis. That iv C. parvwm had influenced the popliteal 
node was evident from the slight augmentation of the node DNA response. The 
kinetics of this modified response are strikingly similar to those described for the 
adjuvant activity of C. parvum on antibody-forming cells as measured by both 
resetting (3) and plaquing ( 4) techniques; i.e., the early time course of the 
augmented response is similar to the control, but it reaches a higher peak and is 
more sustained. The DNA synthetic response to SRBC described here has been 
shown to be entirely T-cell dependent in both normal and C. parvumt- treated animals, 
and there is no evidence for any C. parvum-mediated T -cell bypass mechanism as 
has been reported to occur with the 7S spleen plaque-forming cell response to 
SRBC (8). 
Splenectomy 3 clays prior to C. pa-rvun~ injection abolished the subsequent DTH 
depression, not only showing that the depressive effect is mediated by the C. 
parvum-stimulated spleen, but also indicating that the remaining lymphoid tissue 
is functionally incapable of replacing the spleen in this respect. This was borne out 
by the subsequent finding that direct stimulation of lymph nodes with C. parvttm 
prior to their processing antigen did not result in DTH depression as discussed 
below. Another interesting point is that the liver, which is highly stimulated follow-
ing iv C. parvum ( 1), also apparently plays no part in the depression of DTH. 
That the effect is mediated by the cells in the spleen rather than any humoral product 
of the spleen is suggested by the failure to depress DTH by large amounts of serum 
from C. parvmn-stimulated animals. Splenectomy 4 days after C. pm·vum admin-
istration significantly restored DTH responsiveness but markedly less so than prior 
splenectomy. This residual depression coupled with demonstrated ineffectiveness of 
lymph nodes may indicate a migration of the relevant cell type from the spleen to 
other sites. 
The finding that there is no T-cell impairment at the lymph node level following 
iv C. parvwn·~, but that it is the spleen that is responsible for DTH depression, is in 
full accord with previous in vitro findings concerning T-cell inhibition by C. parvum. 
Spleen cells from mice pretreated with iv C. parvtt1tt were unresponsive to PHA, 
whereas lymph node performance was unimpaired ( 12). This inhibition of PHA 
responsiveness in vitro has been shown to be mediated by the influence of C. parvwm-
activated macrophages on the potentially reactive T cells ( 13). The interaction 
apparently required contact between the two cell types, which again accords with 
the present finding that it is the spleen cells themselves, rather than any humoral 
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product, that are instrumental in DTH depression. These and further similarities 
which will emerge later in the discussion are consistent with the idea that such 
a C. parvun~-activated macrophage inhibition of T-cell activity is operative both 
in vitro and in vivo. 
Impairment of the ability of T cells to divide in response to PHA in v·itro sug-
gests that there may be a similar impairment of T cells dividing in response to 
antigen in vivo. This is not true, however, in the present system where normal 
sensitization is demonstrated to occur in the peripheral nodes. Subsequent loss of 
these cells from the nodes is also unimpaired, and the demonstrated increased cell 
trapping by the C. pm·v~£1n-stimulated spleen would readily account for their arrival 
in the spleen. Adjuvants have recently been shown to cause lymphocyte trapping 
which lasts over several weeks at a high sustained level and C. pm·vum has been 
commented upon for the marked magnitude of trapping it causes ( 19). The in-
creased splenic trapping described here may merely reflect the increased filtering 
capacity of the enlarged spleen; however, it is interesting to note that the same cell 
type, the activated macrophage, that is deemed to be instrumental in the reported 
immunosuppressive and immunostimulatory effects of C. parv~~m to date ( 4, 8, 13) 
is now also considered to mediate the lymphocyte-trapping phenomenon (21) . The 
fate of the sensitized T cells on reaching the spleen may be conjectured-they may be 
prevented from undergoing further division or they, and any progeny, may merely 
be prevented from leaving the spleen. Whatever, the end result is presently con-
sidered to be reduced distribution of the sensitized cells throughout peripheral 
lymphoid tissue--i.e., those nodes serving the area where the DTH reaction is 
e licited. Such a restricted lymphocyte movement following iv C. pm·vttm, has been 
described recently where there was a failure to recruit lymphocytes by lymph nodes 
undergoing antigen stimulation in C. parvmn-treated mice (22) ; however, no 
increased splenic uptake was demonstrable in these experiments. 
The inability of the lymph nodes to substitute for the spleen in DTH depression 
is interesting, especially when the node itself was stimulated directly with C. 
parv1m~ prior to antigen processing. The degree of stimulation was similar to that 
of the spleen following iv C. pa.rvun~, as evidenced by both increase in mass and 
DNA synthesis. Preliminary histological examination has also shown macrophage 
accumulation in such nodes. Local injection of C. parvum is known to result in 
marked lymphocyte trapping in the draining lymph nodes ( 19, 21), and yet no DTH 
depression occurs. This suggests that the mere retention of sensitized cells by the 
spleen may, of itself, be insufficient to cause DTH depression, and that the 
phenomenon is more dependent on the subsequent fate of such cells in the spleen. 
The discrepancy between the performance of stimulated spleen and lymph nodes 
directly parallels that noted for the PHA response in vitro, where the responsive-
ness of iv C. parvum-stimulated spleen cells was abolished, but cells from popliteal 
lymph nodes stimulated directly with C. pm·mtm responded normally to optimal 
concentrations of PHA ( 12). This further implies that the same C. parvu.rn-
activated macrophage-T-een interaction (13) is instrumental in DTH depression 
in v ·ivo. Recently, Gillette and Boone described the splenic PHA response of tumor-
bearing animals to be depressed and were intrigued to find that lymph node cells 
were not similarly affected (23). RES activity is known to be stimulated in 
animals bearing a variety of transplantable tumors (24) and, furthermore macro-
phages activated by means other than C. parvurn, have been demonstrated to be 
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capable of depressing T-cell acti\"ity in vitro ( 13) . This then may be additional 
e,·idence for the discrepancy between the performance of lymph node and spleen 
with regard to T-cell inhibition. Short of the effect being attributable to merely 
quantitati,·e differences between the spleen and lymph node macrophage populations 
then, the data may indicate either different kinds of macrophages or possibly 
different anatom ical distributions of macrophages in these organs. The correlation 
between the in virro and in vivo data certainly strongly implicates the macrophage, 
but it was hoped to demonstrate their in vivo role less equivocally by using crystal-
line silica. an agent selectively toxic for macrophages. These experiments were. ho\\"-
ever, thwarted by the finding that the siJica itself depressed DTH reactivity. 
That C. parvum is considerably less effecti\"e in depressing DTH reactivity 
when injected simultaneously or after antigen is in keeping with the fin ite time 
required for C. parvum macrophage activation to occur (8) and the idea that 
sensitized cells would be free to distribute themselves normally before the onset of 
trapping. The finding is also relevant to the use of C. parvwm in tumor therapy, 
s ince treatment of an established tumor means that sensitization with tumor antigens 
must in large part precede C. parvum and depression of cell-mediated immunity may 
be thereby circumvented. An ongoing tumor may, however, serve as a source of 
continuous antigen stimulation, and splenectomy as an adjunct to i\" C. Parv11111 
therapy desen·es consideration. In addition. c admini::;tration of C. parvum did not 
cause depression of cell-mediated immunity. and this route of injection has been 
shown to be effective against tumors, at least when combined with chemotherapy 
(25, 26) or injected either directly into the tumor site or at a distant site prepared 
with irrad iated tumors cell s (Scott, in preparation). 
t\ CKNOWLEDGMENTS 
This work was carried out during the tenure of a fellowship from New York Cancer Institute, 
Inc., and was supported by Grant No. NIH-NCI-72-3221 from the National Cancer Institute. 
The able technical assi~tancc of Sandra L. \Varner is gratefully acknowledged. 
REFEREt\CES 
l. Halpern, B. K., Prcvot, A. R.. Biozzi, G., Stiffel, C., Mouton, D., Morard, ]. C., Bouthillier, 
Y., and Decreusefond, C., J. N.etiwlomdolhel. Soc. 1, 77, 196-1. 
2. Adlam, C., and Scott, M. T., J. Med. Microbial. 6, 261, 1973. 
3. Biozzi, G., Stjffel, C., Mouton, D., Bouthill ier, Y., and Decreusefond, C., Imm1mology 14, 
7, 1968. 
4. Howard, ]. G., Christie, G. H., and Scott, M. T., Celt. lmurrll/ol. 7, 290, 1973. 
5. Smith, S. E., and Scott, 1f. T., Brit. J. Cancer 26, 361, 1972. 
6. Woodruff. l\L F. A., lnchlcy, 11. P., and Dunbar, N., Brit. !. Cancer 26, 67, 1972. 
7. Israel, L., and Halpern, B .. Nouv. Presse Mrd. 1, 19, 1972. 
8. Howard, ]. G., Scott, )f. T., and Christie, G. H .. /11 "Immunopotentiation." CIBA Founda-
tion Symposium No. 18, p. 101. 1973. 
9. Allison. A. C., and Davies, A.]. S., Nature l\"1'7.v Bioi. 233, 330, 1971. 
10. Taub, R. N., and Gershon, R. V., J. Immunol. 108, 377, 1972. 
11. Dresser, D. Vv., E11r. !. Immlmol. 2, 50, 1972. 
12. Scott, 1L T ., Cell. I mmw1ol. 5, 459, 1972. 
13. Scott, M. T ., Cell. lmm11110l. 5, 469, 1972. 
14. Asherson, G. L., and Allwood, G. G., Clin. Exp. lmullmol. 9, 249, 1971. 
15. Kcttman,]., Immm1ol. Comm. 1, 289, 1972. 
16. Miller, T. E., Mackancss, G. B., and Lagrange, P. A., 1. Nat. Cw1crr Ins/. 51. 1669, 1973. 
17. North, R.]., Mackaness, G. B., and Elliott, R. W., Cell. lmm1mol. 3, 680, 1972. 
DTH DEPRESSION BY C. PARVUM 263 
18. Davies, A. J. S., Carter, R. L., Leuchars, E., Wallis, V., and Koller, P. C., Immunology 
16, 57, 1969. 
19. Frost, P., and Lance, E. M., In "lmmunopotentiation." CIBA Foundation Symposium No. 
18, p. 29. 1973. 
20. Parish, C. R., Cell. Immunol. 6, 66, 1973. 
21. Frost, P., and Lance, E. M., Immunology, 26, 175, 1974. 
22. Allwood, G. G., and Asherson, G. L., Clin. Exp. Immunol. 11, 579, 1972. 
23. Gilette, R. W., and Boone, C. W., l. Nat. Cancer Inst. SO, 1391, 1973. 
24. Old, L. ]., Clarke, D. A., Benacerraf, B., and Goldsmith, M., A1~n. N.Y. Acad. Sci. 88, 
264, 1960. 
25. Currie, G. A., and Bagshawe, K. D., Brit. M ed. l. 1, 541, 1970. 
26. Pearson, J. W., Pearson, G. R., Gibson, W. T., Chermann, J. C., and Chirigos, M. A., 
Cancer Res. 32, 904, 1972. 
11 84 
(Reprimed from Natr1re New Biology, Vol. 235, No. 59, pp. 219- 220 
F ebn1ary 16, 1972) 
Enhanced Resistance of Mice to 
Infection with Bacteria following 
Pre-treatment with Corynebacterium 
parvum 
KILLED suspensions of Corynebacterium parvum have been 
shown to stimulate the lymphoreticular system1 and to possess 
adjuvant activity2 •3 • Pre-treatment of animals with C. parvum 
increases their resistance to tumour cell chal1enge4 •5 and to 
protozoal infection6 • I n view of these properties it seemed 
probable that C. parvum might induce protection against 
bacterial challenge. We therefore examined the effect of 
C. parvum treatment on the course of three bacterial infections 
in W-Swiss mice. The strain of C. parvum used was supplied 
by Professor M. Raynaud of the Pasteur Institute and has been 
given the Wellcome Culture Collection number CN 6134. 
Table 1 shows the results of an experiment in which mice 
received a single intravenous injection of killed C. parvum 
before an intraperitoneal challenge of living Brucella abortus 
(strain 1914). Considerable protection was afforded to 
animals challenged 1 day to 4 weeks after C. parvum treatment. 
Maximal effect was observed after 4 days. 
The effect of C. parvum treatment on the susceptibility of 
mice to Bordetel/a pertussis infection is shown in Table 2. 
Mice which had received a single injection of C. parvum (intra-
venous or intraperitoneal) were challenged intracranially with 
living, mouse-virulent Bord. pertussis (strain 18/323). The 
LD 50 of this strain by this route was less than 100 organisms. 
Pre-treatment of animals with C. parvum resulted in marked 
resistance to a Bord. pertussis challenge of approximately 
400 LD 50s. In contrast to the protection shown against Br. 
abortus, resistance to Bord. pertussis reached a maximum 2 to 3 
weeks after C. parvum injection. The degree of protection was 
similar when C. parvum was injected intravenously or intra-
peritoneally. 
When C. parvum-treated mice were challenged intravenously 
with Staphylococcus aureus (Wellcome Culture Collection No. 
CN 57) no consistent protective effect was observed. Protec-
tion was, however, apparent when an intraperitoneal C. parvum 
injection preceded an intraperitoneal staphylococcal challenge 
(Table3). 
Experiments are in progress to determine the mechanisms 
by which C. parvwn produces its protective effects in the 
7 
Table 1 Effect of C. parvum • on the Susceptibility of Mice to Br. abortus 
i.p. 
Brucella Interval between C. parvum pre-treatment 
challenge and challenge and No. survivors/ten mice 
No. 
organisms/ Untreated 
mouse - 18ht 4h I d 4d lw 2w 3w 4w controls 
1.J X 109 NDt 0 2 4 I 2 2 0 ND 
5.6x lOB 0 0 8 7 6 4 3 4/9 1 
2.8x JOB 0 0 9 10 9 10 5 5/9 I 
1.4x JOB 1 5 10 10 10 10 10 9 6 
?.Ox 107 10 9 10 10 10 10 9 10 9 
LDso x 10B 0.9 1.3 7.8 9.3 6.2 6.1 4.0 3.6 1.6 
!fiducial (0.6- (0.9- (5.6- (6.6- (4.6- (4.2- (2.6- (2.5- (1.2-2.4) 
(imits) 1.3) 1.8) 13.0) 20.6) 8.9) 8.8) 6.4) 5.4) 
• 1.4 mg dry weight, intravenously/mouse. 
t This group received C. parvum 18 h after challenge. Deaths were 
recorded for 14 days after challenge. 
t Not done. 
systems described. Both adjuvant action and reticulo-endo-
thelial stimulation may be important. Fauve and Hevin 7 have 
recently shown that spleen and liver macrophages taken from 
C. parvum treated animals possess greater bactericidal powers 
than control macrophages and this may be the mechanism by 
which brucella organisms are destroyed in the C. parvum 
treated animal. The failure of C. parvum to protect against an 
intravenous staphylococcal injection may be due to the predilic-
tion of these organisms for the kidney8 , an organ which is not 
believed to be affected by lympho-reticular stimuJation. 
Table 2 Effect of C. parvum • on the Susceptibil ity of Mice to Bord. 
pertussist 
Days between C. parvum pre-treatment and challenge 
Route of and No. survivors/ No. challenged 
injection of 
C.parvum -3 t 0 4 7 14 21 28 
i.v. 0/10§ 0/9 0/5 0/7 5/9 7/10 7/9 
i.p. 0/10 0/10 0/10 3/10 5/10 3/9 6/10 
• 1.4 mg dry weight/mouse. 
t 3.7 x 104 viable organisms/mouse. 
t This group received C. parvum 3 days after challenge. 
§ Deaths were recorded for 14 days. Deaths up to 3 days after 
challenge were discounted. 
Table 3 Effect of C. parvum * on the Susceptibility of Mice to Intra-
peritoneal Challenge with Staph. aureus i" 
Days between Route of 
C. parvum injection Days after challenge with staphylococci 
pre-treatment of 
and challenge C.parvum 0 2 4 14 21 
0 i.p. 10! 0 0 0 0 0 
i.v. 8 0 0 0 0 0 
4 i.p. 10 10 10 9 5 4 
i.v. 10 3 0 0 0 0 
7 i.p. 10 10 8 8 5 5 
i.v. 9 4 l 0 0 0 
14 i.p. 10 10 9 9 6 5 
i.v. 8 6 5 5 l 1 
21 i.p. 9 6 3 3 2 1 
i.v. 9 9 3 2 0 0 
28 i.p. 9 7 4 3 2 2 
i.v. 9 6 0 0 0 0 
Untreated controls 7 4 0 0 0 0 
• 1.4 mg dry weight/ mouse. 
t 7.1 x 107 viable organisms/mouse. 
t Figures in the body of the table are survivors at days after 
challenge. 
Some other mechanism must, however, be acting to protect 
C. parvum treated mice from lethal intracerebral Bord. pertussis 
challenge and it may be significant that C. parvum like Bord. 
pertussis (and to some extent brucella)9 can sensitize mice to 
histamine. T able 4 shows the results of an experiment in 
which mice were challenged with histamine phosphate at vary-
Table 4 Effect of C. parvum *on the Susceptibility of Mice to Histamine 
Dose 
of hist-
amine Interval between treatment and challenge and 
base/ No. survivors/twenty mice 
mouse 
Treatment (mg) 1 h 4h 12h 24h 4d 7d 14d 21 d 28d 
Saline 5 20 20 18 20 20 19 20 19 19 
C. parvum 18 13 15 15 3 2 4 19 20 
• 1.4 mg dry weight intravenously/mouse. 
ing times after C. parvum treatment. Maximal susceptibility 
to histamine was demonstrable 4 to 7 days after C. parvum. 
Most deaths occurred within 2 h of histamine challenge. 
The separate identity of the histamine sensitizing factor and 
the intracerebral protective antigen of Bord. pertussis have been 
a matter or controversy9 • Although C. parvum and Bord. 
pertussis do not cross react antigenically as judged by bacterial 
agglutination, the fact that both protect against the same 
challenge in the same system suggests the existence of some 
unidentified relationship. 
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Effect of Corynebacterium parvum Treatment on t he Growth of 
Salmonella enteritidis in Mice 
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Received for publication 21 January 1974 
The growth of Salmonella enteritidis in mice pretreated with 700 J-Ig of killed 
Corynebacterium paruum was less than that seen in normal CD-1 mice. In 
treated mice, there was an early increased inactivation of the blood, liver, and 
spleen bacterial populations. followed by a prolonged period of slow but 
continuous bacterial growth. The treated mice failed to develop significant 
delayed hypersensitivity and did not show the characteristic antibacterial 
immune response seen in untreated infected animals. Eventually sufficient 
resistance did develop in most of the treated animals to protect them against the 
lethal effects of the challenge infection. The peak C. paruum effect was seen when 
S. enteritidis was injected 7 to 14 days later. Injection cf C. pan•um 24 h after t he 
bacterial challenge actually potentiated the Salmonella infection. There was no 
evidence of an increased specific humoral response by the C. parutlm-treated 
mice, suggesting t hat the slower growth of the S. enteritidis was due to the 
continued enhanced kill ing of the bacterial population by the nonspecifically 
stimulated cells of the reticuloendothelial system. ra ther than to any specific 
augmentation of the host immune response. 
Intravenous injection of killed Corynebacte-
rium paruum into normal mice ( 13) results in an 
intense stimulation of the reticuloendothelial 
system (RES). There is an associated increase 
in resistance to some acute bacterial ( 1) and 
protozoan (18) infect ions and even to some 
tumor transplants (21). Part of this augmenta-
tion of the host's response after the introduction 
of C. paruum into the t issues may be explained 
by its adjuvant action (3, 14) and , since both 
humoral and cellular defenses are involved in 
acquire.d resistance to many facultative intra-
cellular parasites (8, 16). any stim ulus to the 
production of specific humoral factors could 
increase host resistance by promoting phagocy-
tosis and the early inactivation of the challenge 
population. There is good evidence, however. 
t hat the elimination of intracellular microbial 
parasites often depends upon a cell -mediated 
immune response with a resul ting state of 
delayed-type hypersensitivity (DTH) being de-
veloped against one or more microbial antigens 
( 16, 17) . There is an apparent contradiction 
between the overall protection afforded by C. 
paruum given before infection (I) and the 
depressive effect of this agent on T -cell reacth·-
ity (2. 19, 20). This paradox would be resolved if 
host resistance in the C. paruum-treated animal 
was found to depend upon nonspecific activa-
t ion of t he RES (12. t:3). 
The present study examines the effect of 
intravenously injected C. paruum on the devel-
opment of DTH and acquired resistance to 
Salmonella enteritidis. DTH to the Salmonella 
test antigen was found to be severely impaired 
in the C. paruum-treated mice, which were, 
nonetheless, resistant to the challenge, showed 
increased rates of blood clearance, and had the 
capacity to inactivate an enlarged proportion of 
the challenge inoculum. These are all features 
t hat commonly result from stimulation of the 
RES. No doubt they are responsible for the 
survival advantage conferred on the mice by C. 
paruum treatment. However, the simultaneous 
depression of cell-mediated immunity in t hese 
animals was probably respons ible for the slow 
eradication of organisms from the liver and 
spleen and so contributed to the protracted 
salmonella infections observed in some of the C. 
paruum-treated mice. 
MATERIALS AND METHODS 
Animals. Specific patho!(en -free CD-I mice 
(Charles River Farms, Wilmington, Mass. ) were 
maintained, !0 to a cage. on sterile bedding and kept 
under lsocaps ( Carworth Lab Cages. N.Y. l to prevent 
cross-infection (9). They were fed sterile pellets and 
water ad lib. Female mice weighing !8 to 24 g were 
used throughout. 
Organisms. S. enteritidis NCTC 5694 and a strep-
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tomycin-resistant variant (SMR) were maintained 
under conditions described previously (5). Both 
strains were virulent for CD-I mice (intravenous 
mean lethal dose (LD,.) = 5 to 10 x 10°). The method 
for determining the LD,. values has been described 
elsewhere (9). Inocula were grown overnight at 37 C in 
tryptose soy broth (Difco), and then subcultured into 
5 ml of fresh broth and incubated for 5 h at 37 C. The 
cul ture was harvested duri.ng the Late logarithmic 
phase and diluted suitably in sterile saline immedi-
ately before injection into the mice. The number of 
viable organisms in the inoculum was checked by 
plating samples onto tryptose soy agar (TSA) and 
incubating overnight at 37 C. 
Killed C. parvum suspension was kindly provided 
by C. Adlam, Wellcome Laboratories, Beckenham , 
Kent. U.K. The suspension contained 7 mg (dry 
weight) of cells per mi. Mice were usually injected 
intravenously with 0.1 ml of suspension 7 to 10 days 
prior to challenge. Heat-killed Mycobacterium 
tuberculosis H.,R. (11) was homogenized in sterile 
saline to give a suspension containing 7 mg (dry 
weight) of cells per ml, and mice were injected 
intravenously with 0.1 ml of suspension and tested 7 
days later. Heat-killed S. enteritidis (60 C for 60 min) 
was homogenized in sterile saline (7 mg!ml), and 0.1 
ml was injected intravenously into CD-1 mice. The 
mice initially showed some endotoxic reaction, but 
only two of the 50 mice died . 
Enumeration of bacteria in vivo. The livers and 
spleens were removed aseptically from groups of five 
randomly selected mice and homogenized separately 
in cold sterile saline. The homogenates were diluted 
suitably and plated on TSA (6). Heart blood (0.1 ml) 
was plated onto TSA. In challenge experiments, the 
homogenates were plated on TSA, with or without 20 
p.g of streptomycin per ml of agar. Separate counts of 
the drug-resistant challenge and drug-sensitive resid-
ual vaccinating populations were recorded. 
DTH determinations. Mice were injected in one 
hind footpad with 2.0 p.g of protein test antigen 
diluted in 0.03 ml of sterile saline. The antigen was 
obtained from a 72-h culture filtrate of S. enteritidis 
as described earlier (10). The foot swelling, with 
reference to the contralateral foot, was measured at 3 
and 24 h with dial gauge calipers (Schnelltaster, 
Kroplin). An increase of 1.8 U or more (0.18 mm) was 
significant at the 1% level. 
Serology. Mice were bled by heart punctu.re, and 
the serum was separated and heated at 56 C for 30 
min before storage at - 20 C. Hemagglutinin titers 
were measured by using alkali-treated S . enteritidis 
lipopolysacchl!ride (Difco) absorbed onto washed 
sheep red blood cells ( 4). The reciprocals of the serum 
titers were expressed as log2 values ( ± standard 
error). 
RESULTS 
Growth of S. enteritidis in C. parvum-
tre~ted mice. Normal mice were injected intra-
venously with 700 ~g of C. paruum in 0.1 ml of 
saline or with 0.1 ml of saline alone, and 7 days 
later the two groups were infected intravenously 
with about 10' viable S. enteritidis 5694. The 
challenge organism was rapidly cleared from the 
blood of the C. paruum mice and taken up in 
the liver and spleen in approximately equal 
numbers (Fig. 1). Both the liver and spleen 
bacterial counts declined substantially over the 
first 150 min of the challenge period so that by 
this time the survivors represented only 1% of 
the original inoculum. This early, extensive 
inactivation of the challenge infection contrasts 
with the incomplete blood clearance and slower 
rate in decline shown by the liver and spleen 
populations in the control animals (Fig. 1). As a 
result, up to 20% of the inoculum survived the 
initial inactivation period, and this 10-fold 
difference in the size of the 24-h challenge 
populations in the two groups of mice was 
sufficient to account for the higher survival of 
the C.paruum-treatedanimals (Fig. 2) . Thus, it 
can be said that C. paruum treatment, by 
markedly stimulating both blood clearance and 
bacterial inactivation (clearly the effect of a 
nonspecific increase in phagocytic function), 
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FIG. 1. Viable counts of S. enteritidis in the liver 
(Lr), spleen (Sp) and blood (Bl) of C. parvum-treated 
mice (bottom) or in normal controls (top) over the 
first 24 h of the infection. 
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FIG. 2. Survival of mice treated with heat ·k illed 
bacterial suspen.~ions 7 days prior to challen11e u:ith 
10' viable S. enteritidis. 
conferred a clear-cut survival advantage on 
treated animals. However, once this initial 
inactivation was complete, the surviving S. 
enteritidis in the C. paruum-treated mice began 
to multiply in t he liver and spleen. though at a 
slower rate than in untreated controls (Fig. 3). 
The typical immune response developed by 
untreated mice was characterized by a sharp 
change in growth rate of the Salmonelwe about 
day 6, and this was associated with the develop-
ment of high levels of DTH with little evidence 
of Arthus reactivity (F ig. 3) . This has been 
taken as evidence of a cell-mediated immune 
response against the infecting organism (5, 7). 
On the other hand, the C. paruum -treated mice 
developed considerable Arthus (3 h) footpad 
sensitivity after the Salmonelw challenge, but 
most of this foot swelling had disappeared hv 24 
h (Fig. 3), suggesting that the development of 
DTH had been impaired by the C. paruum 
treatmen t. This apparent absence of DTH cor-
related with the inability of the treated animals 
to eradicate the challenge organis ms from the 
tissues . 
Reinfection of the S. enteritidis-infected mice 
on day 12 with 10' viable S. enteritidis SM " .was 
associated with an immediate inactivation of 
the drug-resistant population in both liver and 
spleen (Fig. 3). However, the rate of decline of 
viable SM · organisms in the C. paruum-treated 
mice was considerably slower than in the corre-
sponding controls: 7 days were required to 
inactivate ggc:,.. of the challenge inoculum in the 
treated group compared with 2 days for a 
similar kill in the controls. Much reduced levels 
of DTH were also observed in the C. paruum-
t reated mice after reinfection. This again points 
to an impairment of cell-mediated immunity in 
these animals. 
A curious feature of the Salmonella growth 
curves observed in all of the C. paruum-treated 
mice was a reversal of the initial distribution of 
the challenge popula tion hetween the liver and 
spleen (Fig. I. :1). The rela tive proportions of 
both the li,·er and s pleen bact erial popul ation~ 
frequently remain ed inverted until the infection 
reached near let hal pro port ions . 'T'he reason for 
this shift and it~ :;ignificancc concern i n ~r the 
evolution of the infection in th e treated animal 
is still unknown . 
The earlv inactivat ion of a n intra, ·ennu:: inoc-
ulum of S. enteritidis and its subsequent ly 
slower rate of growt h in the C. paruum-treated 
mice could theoret ically have been due to an 
enhanced production · of s pec ific opson in~ 
against the som atic Salmonella anti~ens . How-
ever, passive hemagglutination tests using puri · 
fied S. enteritidis lipopolysaccharide against 
sera taken from C. paruum -t reated mice fail ed 
to reveal detectable levels of such ant ibodief' 
(Table 1). Even when these mice were chal -
lenged with S . enteritidis. the hemagglutinin 
titers found in sera ha rvested on day 12 of the 
infection were still significantly lower (P < 
0.01) than they were for the Salmonella -infected 
controls. This depressed humoral response by 
the C. paruum -treated animal was ascribed to 
the lowered bacterial population and , thus. to a 
smaller antigenic stimulus . For that matter. the 
reduced growth by S. enteritidis could also be 
thought to account for the appa rent absence of 
DTH in treated mice. If this were so. it should 









FIG. 3. Grou;th of S. enteritidis in normal !top) or 
C. paruum-treated m ice (bottom ) after in t rauenou~ 
challenge: Sp. spleen : Lr. lit,er; 81. blood. Broken 
lines represent a streptom ycin-resistant rechallen}le 
population inject ed on day 12. Open histogram., 
represent the aueraRe 3-h foot su-e/ling (auerage of fh·e 
determinat ions). and the solid bars represent the 24-h 
increases in aeera!(e foot thic-kness follou·in!f inject ion 
of 2 ~g of S almonella test an tipen . 
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TARLE I. Hemall!(lutination titers for mou.<e sera 
after killed C. pan•um ur S. enteritidis pretreatment 
follou ed 7 days later b' infection u·ith living S. 
enteritidi.~ 
Da'' afler inft><'cinn 
Prtl reat ment 
I 6 1:! 
C.part•um <2.0• <:too 3.1 '"0.2:>" 
S. enteritidis 10.0• 8.8 :t 1.10 -' 
Saline < 2.00 3.5 "' 0.4.') 5.6-" 0.77 
C. parvum with- <2.0• - ' - ' 
out challenge 
0 Log, of the inverse hemagglutinin titer for pooled 
sera. 
• Mean ( ±standard error) for five determinations. 
'Not tested. 
immune response merely by increasing the size 
of t he challenge dose 100-fold . Mice were there-
fore injected intravenously with C. parvum 7 
days prior to their challenge with 5 x 10• viable 
S. enteritidis (100 LD.0's). The growth rate of 
the bacterial challenge of the liver and spleen 
was still markedly reduced compared with the 
controls (Fig. 4). but the larger bacterial popu-
lation induced an antibacterial response as 
judged by the inhibition of further growth by 
the organisms in the liver and spleen from day 6 
onwards. Despite this evidence for a cell-
mediated response to the further growth of the 
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F1c. 4. Growth of S. enteritidis in C. paruum-
treated and control mice (top) after the introduction 
of!()() LD,. dose of virulent organisms by the intrave-
nous route. 
treated mice developed barely !>ignificant levels 
of DTH (0. 15 ::- 0.05 mm ). 
Effect of heat-killed M. tuberculosis or S. 
enteritidis on anti-Salmonella immunity. 
There was a po ihility that the slowed 
Salmonella growth in the C. paruum-treated 
mice was due to ant ipenic competition as a 
result of the massh·e inoculum of dead cor' ne-
bacteria. To im·estigate this possibility. r'nice 
were injected with equivalent amounts of two 
other bacterial suspensions. The first was M . 
tuberculosis H37Rv. selected as an unrelated 
organism unlikely to induce a cross-reacting 
humoral response, and the second was heat-
killed S. enteritidis, known to induce high levels 
of specific antibodies in intravenously vac-
cinated mice (7). Groups of mice were injected 
with 1,400, 700, and 350 Jlg of heat-killed C. 
paruum or M. tuberculosis (H 37R,) or with 
either 700 or 350 Jlg of heat-killed S. enteritidis 
(the 1,400 }lg dose proved to be too toxic for the 
mice) . Seven days later, the pretreated mice, 
together with a group of normal controls, were 
infected with increasing numbers of viable S. 
enteritidis, and the LD60 values for each group 
were determined (Table 2). Injection of 350 JJg 
of heat-killed S. enteritidis or M . tuberculosis 
HnR. increased the size of the median lethal 
dose of viable Salmonellae approximately five-
fold. This should be compared with the 10-fold 
increase observed in the C. paruum-treated 
animals (Table 2). Increasing the dosage of C. 
paruum or H,R, to 1.400 Jlg seemed to have 
little further protective effect. 
Growth studies carried out in Salmonella-in-
fected mice pretreated with 700 Jlg of either 
beat-killed HnR. or S. enteritidis indicated 
that both groups of animals had an increased 
ability to kill the challenge organism in liver 
and spleen over t he first 24 h, but that this was 
followed by a nearly normal growth rate until 
peak counts were observed about day 6 (Fig. 5). 
TABU: 2. Effect of pretreatment of mice with 
suspensions of various killed bacteria 7 days prior to 
determination of LD,. values for intravenous S. 
enteritidis 5694 
Median lethal dose• 
Pret reat mem 
1.400 }Jg* 700 1'1( 3.;Q l'g O" g 
C.paruum 5.2° 4.8 4.75 3.65 
M. tuberculosis 4.65 4.6 4.2 3.70 
S. enteritidis 4.25 3.95 3.40 
o Log,. of the median lethal dose of viable orga-
nisms required to kill~ of the mice within 28 days 
of challenge (5, 8). 
• Intravenous C. parvum dosage. 
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F1c. 5. Growth of an S. enteritidis challen~e in 
mice treated with 700 1-'8 of heat-killed M. tubercula· 
sis H.,R. (top) or S . entcritidi,~ 5694 I bottom) 7 days 
preuiou.~ty. Both groups of mice were then reinfected 
intrauenously with 10' S. enteritidis S M11 on day 12 
(broken lines). Histograms represent footpad reactit•· 
ity to the Salmonella test antigen. 
Survival curves shown in Fig. 2 indicate that 
killed HHR. and S. enteritidis both induced 
substantial protection against the Salmonella 
challenge. The observed differences in percent· 
age of survival in t hese two groups was probably 
not significantly different from that obtained 
with C. paruum: however. the growth curves 
were strikingly different, exhibiting both a nor-
mal immune response and high levels of DTH 
(Fig. 5). Strong Arthus (3 h) reactivity devel· 
oped in the S. enteritidis-treated animals, mak-
ing the 24-h reactions more difficult to inter· 
pret. As expected. the serum antibody levels in 
these mice were also greatly elevated (Table 1), 
and blood clearance of the S. enteritidis chal· 
lenge was both rapid and complete (Fig. 5). The 
response to reinfection with S. enteritidis SM" 
showed t hat both the H,.R,. and S. enteritidis-
treated mice were capable of developing high 
levels of cell -mediated immunity despite the 
massive antigenic load of killed bacilli intro· 
duced into the RES prior to challenge. These 
results suggest, therefore, that the immune 
response was impaired only by the C. paruum. 
Time course of the host response to C. 
parvum. Groups of mice were injected intrave-
nously with 700 ,~.~g of C. paruum at various 
times with respect to the S. enteritidis chaJ. 
lenge. When C. paruum was injected 24 hr after 
challenge, the infection progressed more rapidly 
(Fig. 6): when given at the same time, it had 
little or no effect. When the challenge was 
delayed for 7 or 14 days after the C. paruum, the 
growth of S. enteritidis in both the liver and 
spleen was depressed . However, if the time 
interval between treatment and challenge was 
further increased to 28 days. the growth curves 
for S. enteritidis returned substantially towards 
normal. and DTH was again a feature of the 
host response (Fig. 6). 
DISCUSSION 
In terms of host survival (I), C. paruum has a 
protective effect if gi,·en before infection with S. 
enteritidis. but not after (Fig. 6). Because C. 
paruum clearly has a marked stimulatory effect 
on the RES (13). it is probably this factor that 
was responsible for the increase in survival 
shown in Fig. 2, but C. paruum has also been 
reported to act as an immunological adjuvant 
for a variety of unrelated antigens (:1. 14 l . Thus, 
the presence of C. paruum could have stimu · 
lated an accelerated humoral response to the 
su rface a ntigens of S . enteritidis. This possibil · 
ity seems unlikely. however. in view of our 
inability to detect hemagglutinins in the serum 
of C. paruum -treated m•ce at the time of 
challenge or even quite late in the Salmonella 
infection (Table 1). Substantial antibody titers 
were detected in mice given 700 ,~.~g of heat-killed 
S. enteritidis. but the growth patterns of the 
challenge Salmonellae remained essentially 
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F1c. 6. Growth of S. enteritidis in mice receiuing 
700 ~g of heat-killed C. paruum one day after the 
Salmonella challenge (top ri/(ht) or 14 or 28 days prior 
to infection with 10' uiable S. enteritidis (bottom). 
Histograms represent the DTH reactions. 
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with C. paruum were not. Whereas minute 
traces of specific or cross-reacting opsonin may 
be produced in C. paruum-treated mice (thus 
accounting for the increased blood clearance 
and inactivation of organisms during the early 
hours of infection). such factor!; can hardly 
explain the continued slower growth of t he 
Salmonellae over the next 14 days. On t he other 
hand, the presence of large numbers of nonspe-
cifi cally activated macrophages in the grossly 
enlarged livers and spleens of the C. paruum-
treated animals could limit bacterial growth in 
vivo for as long as the stimulatory effect of the 
C. paruum persisted. It is known that C. 
paruum -stimulated macro phages do have an 
increased bactericidal capacity (12). It thus 
seems reasonable to postulate that the re-
strained growth of the Salmonellae in C. 
paruum-treated mice is due primarily to the 
nonspecific effects of RES activation. However, 
there is no question that C. paruum treatment 
also reduced the level of DTH in the Salmo-
nella-infected mice. Furthermore, a challenge 
population of drug-resistant S. enteritidis was 
inactivated more slowly in these mice than in 
control animals. This suggests that an impor-
tant component of the immune response is not 
operating normally in the C. paruum-treated 
mouse. This accords with accumulating evi-
dence that C. paruum tends to inhibit T ·cell 
function. The response to phytohemagglutinin, 
the mixed lymphocyte reaction, the graft-ver-
sus-host reaction (19), and the development of 
contact sensitivity (2) have all been reported to 
be depressed in mice treated with C. paruum. 
Regardless of the mechanism involved, the C. 
paruum effect reached a maximum about day 7, 
but when the challenge and the C. paruum were 
injected simultaneously or even 24 h apart, no 
obvious change in the Salmonella growth curve 
could be seen (Fig. 6). The time lag before the 
treated mice displayed a depressed ability to 
develop DTH presumably represents the time 
required for activated macrophages to develop 
in response to the C. paruum stimulus (15). 
This view is consistent with the idea that the 
activated macrophages in the liver and spleen 
not only directly restrain the growth of the 
Salmonellae in vivo, but are also responsible for 
the treated animal's inability to develop an 
effective antibacterial resistance to the residual 
challenge infection. However, it is interesting to 
note that depression of T-cell function by C. 
paruum-activated· macrophages has been de-
scribed to occur in vitro (20). The picture of an 
overall increased resistance to a lethal challenge 
infection in the face of an apparently reduced 
capacity to mount a cellular immune response 
is also similar to that already described for C. 
paruum-treated mice receiv ing murine tumor 
transplan ts (21). It seems reasonable that the C. 
paruum-activated macrophages within the RES 
could be the primary effector in both systems. 
It is interesting to note that bacterial growth 
was enhanced when C. paruum was given 24 h 
after infection (Fig. 6). This wou ld seem to rule 
out the use of this reagent for therapeutic 
purposes. However, the combination of nonspe-
cific antibacterial activi ty and a possible spe-
cific depression of T-cell-mediated immunity 
(recently extended to include allograft reac-
tions; 15) would seem to raise the possibility of 
using C. paruum to suppress the rejection 
mechanism while achieving a desirable increase 
in the level of nonspecific antimicrobial resist-
ance. Such a situation would be an improve-
ment upon the usual consequence of im-
munosuppressive drug therapy. 
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Protection of Mice Against Viral Infection by Corynebacterium 
parvum and Bordetella pertussis 
By H. KIRCHNER,* M. T. SCOTT;! H . M. HIRT* AND K. M UN K * 
* Institute of Virus Research , German Cancer Research Centre, 
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SUMMARY 
Mice could be sign ificantly protected against infection with herpes simplex 
virus (HSY) by i.p. or i.v. injection of killed Corynebacteriumparvum 7 days before 
infection. This protection was seen in inbred strai ns of mice with a different degree 
of sensitivity to HSV and after both i.p. and i.v. infection. Resistant mice immuno-
suppressed by X -irradiation and showing an increased susceptibil ity to HSV cou ld 
also be protected by a previous injection of C. pal"l'um. Elevated levels of interferon 
were demonstrated in the serum of mice injected with C. parvum 5 to 12 days 
previously. Four different strains of anaerobic coryneforms were compared and 
only those which were able to induce a systemic activation of the lymphoreticular 
system (as reflected by splenomega ly) protected against HSY infection. Protection 
against HSV-infection could a lso be demonstrated by using killed Bordetella 
pertussis. C. parvum a lso protected aga inst Semliki Forest v irus infection in two 
d ifferent strains of mice. 
I NT ROD UCT IO N 
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There is increasing evidence to indicate that macrophages play a critical role in the 
defence agai nst virus infections (A lli son, 1974). In ce rtain schedules of infection macro-
phages appear to represent the fi rst line of defence against the virus. Some viruses such as 
herpes simplex virus (HSV) are etTectively restricted by rnacrophages which support an 
abortive infection without re plication (Stevens & Cook, 197 1). Treatment of mice with silica 
or anti-macrophage serum has been shown to increase susceptibility to experimental infec-
tion with HSY (Zisman eta/. 1970). Therefore, it is logical to try to combat such virus infec-
tions by activating macrophages. Previously, this approach has been little studied but during 
the completion of ou r experiments a few reports have appeared demonstrating that certain 
immunostimulants which a re known to cause a general activation of the lyrnphoreticu lar 
system a re effective in protecting mice against experimental vi rus infections (Starr eta/. 
1976; Glasgow eta/. l977; Morahan eta/. 1977). ln the presentpaper we sum ma rize some of 
our recent data on the protective effect of Corynebacterium parntm and Borde tella pertussis 
in HSY-infection of mice. 
METHODS 
Virus . A stra in ofHSY- 1 designated HSY (WAL) (Kirc hner eta/. 1977a) was used in all 
ex pe riments. This strain, which after repeated passage in mouse brain was high ly pathogenic 
9 
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for mice, was re-adapted to tissue culture and was used after the second passage in human 
embryo lung cells (H EL). A single stock of virus, frozen in small samples at - 70 °C was 
u ed in all experiment . rt contained 7 x ro8 p.f.u .jml when determined by virus plaque assay 
in cultures of H EL. 
Semliki Foret virus (SFV) of the L10 C I strain ( Bradish & Allner, 1972) was a gift from 
Dr C. J . Bradish ( Porton D own, Salisbury, U.K.) to Dr V. Schirrmacher. It was passaged 
once in brains of suckling BALB/ c mice. 
Mice. Male BALB/ c/ A BOM, C57BLj 6j J BOM, and DBA/ 2/ J BOM mice were obtain-
ed from Bomholtgard (Rye, D enmark). They were used in the experiments at the age of 8 to 
12 weeks. STU mice which originally had been obtained from Dr W. Schafer (Tubingen , 
FRG) were bred in our Department by continuous brother-sister mating. 
Bctclerial s limulants. Corynebacterium parvum (CN 6134) was a formalin-killed suspension 
(7 mg dry weight/ ml) from Burroughs Wellcome, Beckenham, Kent, U. K . Other strai ns of 
anaerobic coryneforms designated CN 5888, CN 6276 and CN 5936 were si milarly prepared 
(Ad lam & Scott, 1973) and provided by Dr C. Adlam of Burroughs Wellcome. Dilutions 
were made in saline. 
Killed Borde tel/a pertussis prepared by Behringwerke (Ma rburg, PRG) was provided 
through the courtesy of Dr H of (Wi.irzburg, FRG). It also contained thiomersal and the 
concentration of bacteria in the o riginal suspension was lOll/ mi. It was sto red at 4 °C and 
diluted in saline before use. 
Evaluation of animal experiments. Groups of ro to 20 mice were injected with the immuno-
adjuvants at various times before o r sim ultaneously with the virus infection. The optimal 
doses were tested in initial experiments and optimal protection wa seen with 350 Jtg 
C. parvum or 108 organisms of B. pertussis per mouse. Control groups usually received an 
injection of saline. Various virus doses were also tested in preliminary experiments and 
significant protection could often be observed after infection wi th up to 100 LD50• Routinely. 
mice were infected with 20 to 40 LD50 as indicated in the tables and figures. The time of 
death was recorded daily for 20 days after virus infection since it was known that no deaths 
occurred later than 15 days after infection with HSY or SF V. The percentage of surviving 
mice in the experimental and control group was compared by the chi square test. 
Determination of serum levels of interferon. Mice were bled from the retro-orbital sinus and 
the serum was recovered and diluted in balanced salt solution. The titres of interferon were 
tested in a plaque-reduction assay using vesicular stomatitis virus and L cells. All details of 
this assay and of the reference standards used etc. have been described ( Hirt et a/. r978). 
R ESULTS 
Protection of STU mice by Corynebacterium parvum 
In initial experiments we have used STU mice whichare quitesusceptibleto HSV infection, 
to determine the conditions for protecting mice against vira l infection by Corynebacterium 
parvum. Protectio n was optimal when C.parvum was given 7 days before HSV. L ittle or no 
protection was seen when it was injected 4 days before, or on the day of virus infection. It was 
equally effective in protecting STU mice against an intraperitoneal (i.p.) infection with H SV 
when given by the intravenous (i.v.) route as after i.p. dosage (Table 1). 
Antiviral effects of C. parvum and B. pertussis 
Table 1. Protection of STU mice by treatment with k illed 
Corynebacterium parvum organisms 
No. of mice dead / 
Expt. no. Treatment Timing tOtal no. treated P value 
T 
I I 
I l l 
C. parvum* i.p. 
Saline 
C. parvwn i.p. 
Saline 
c. /)01'1'111/l i.p. 
Saline 
C. {J(/I'V/11/1 i.p. 
Saline 
C. parvum i.p. 
Saline 
C pa/'llum i.v. 
Saline 
7 days before HSV'j' 
3 days before HSV 
7 days before HSV 
2 days before HSY 
On the day of 
HSV infection 
7 days before 
HSV infection§ 
* 350 pg C. parvum (CN 6 I 34). 
4 / 20 l 
17/ 20) 








2/ 20 } 
17/ 20 
'r 5 x I03 p.f.u. (~ 20 LD, 0 after i.p. infection). 
! Not s ignificant. 





Table 2. Protection of mice of d(/ferent strains against infection H'ith HS V by 
Corynebacterium parvum and Bordetella pertussis given 7 days b(ifore infection 
No. of mice dead / 







DBA/2 C. parvum 3 x 104 p.f.u.* i.p. 
Saline 
BALB/ c C. f)OI'V/1111 5 x 10'' p.f.u: j· i.v. 
Saline 
C57BL/ 6 C. parvum 5 x 105 p.f.u.; i.p. 
Saline 
C57BL/ 6 C. parvum I X 10' p.f.u. i.p. 
Saline 
C5iBL/ 6 C. parvum I X lOG p.f.U. i.p. 
Saline + 400 R§ 
DBA/ 2 8. per/llssis I I X JO'' p.f.u. i.p. 
Saline 
C57BL/ 6 B. pertussis I X 101 p.f.u. i.p. 
Saline 
* 20 LD. o in DBA/2 mice after i.p. infection. 













0 / 20 
J8/ 20 
t The LDso for C57BL/ 6 mice after i.p. infection with HSV (W A L) is 1·2 x 10° p.f.u . 
§ 400 R of X-irradiation on the day of virus infection. 
108 killed bacteria were injected 7 days before HSV. 
Protection of strains of mice other than STU by Corynebacte rium parvum 
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DBA/ 2 mice could also be protected against i.p. infection with HSY (Table 2). This pro-
tection was in most instances less im pressive than that observed with STU mice. Clearly, 
however, the mea n number of surviving mice pre-treated with C. pctrvum was significantly 
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Time after injection of C. pafllum (days) 
Fig. 1. Serum levels of interferon in C57BL/6 mice at various 
times after i.p. injection of 350 ftg of Corynebacterium pnrvum. 
BALB/c mice which, in contrast to other mouse strains, are quite susceptible to i.v. 
infection with HSY (Kirchner eta/. 1978) were used to show protection by an i.p. injection 
of C. parvum against this schedule of H SV infection (Table 2). 
lt was previously shown that C57BL/ 6 mice, which arc relatively resistant to i.p. infection 
with HSY, could be killed by high virus doses (Kirchner et a/. 1978). A good protective 
effect was seen when C. parl'llm was given 7 days before infection ofC57BL/ 6 mice with high 
doses of HSY. X-irradiation (400 R) when applied on the day of HSY infection to C57BL/ 6 
mice markedly decreased the LD~0, but these immunodepressed C57BL/ 6 mice could still be 
protected by C. pamun. given 7 days before the virus (Table 2). 
Protection of DBA/ 2 mice agaimt HSV infection by Bordetella pertussis 
DBA/ 2 and C57BL/ 6 mice could be well protected against HSV infection by a previous 
injection of B. pertussis (Table 2). As with C. parvum, protection was seen only when the 
bacteria were injected 7 days before the virus but not when they were given 3 days before 
injection. The optimal dose for protection was 1 o8 organisms per mouse and protection could 
be observed with doses of HSY up to roo L D 50 (data not shown). 
Measurement of serum inte1jeron levels 
C57 BL/6 mice were injected i.p. with 350 ;tg C. parvum a nd serum interferon levels were 
determined at various times thereafter. As can be seen in Fig. 1, significant levels of inter-
feron could be detected between 5 and 20 days after injection of C. parvum. Little or no 
interferon was found earlier than 5 days. 
Testing of different strains of coryneform bacteria 
Four different strains ofanaerobiccoryneforms (selected by Or C. Ad lam for their differing 
spleen weight stimulating abilities) were provided in coded form and tested blind for their 
ability to induce splenomegaJy and to protect D BA/ 2 mice against subsequent HSV infec-
tion (Table 3). Only the two bacterial strajns which were able to increase the spleen weight 
were protective against HSY infection. 
Antiviral effects of C. parvum and B. pertussis IOI 
Table 3· Comparison of the lymphoreticular stimulating ability of various strains of anaerobic 
coryneforms with their ability to protect DBA/2 mice against HSV infection* 
No. of mice dead/ 
Anaerobic coryneform strain Spleen index'[ total no. of mice .P value 
CN 6134 8·2 4/ 20 < o·o1 
CN 5888 1·0 20/ 20 NS:j: 
CN 6276 1'5 r8j 2o S:j: 
CN 5936 6·8 9/ 20 < o ·os 
Controls injected with saline J·o 20/ 20 
• 350 11-g of the appropriate bacterial strain were injected i.p. and 7 days later mice were challenged wi th 
50 LD,u of HSV i.p. 
'I 350 pg of the bacteria were injected i.v. and 14 days later spleens were removed a nd weighed . Spleen 
index: ratio of spleen weights of injected mice compared with saline injected mice. 
t In comparison with the saline group ; NS, not significant. 
Table 4· Effect of previous irradiation of C 57 BL/6 mice on the protection by 
Corynebacterium parvum against HS V infection* 
Treatment 
o. of mice dead/ 
G roup'( 400 R -i rradia tion C . parvum HSV total no. of mice 
I D ayo ro/ 10 
ll Day 7 Day o 0/ 10 
lli Day 10 0/ 10 
IV D ay 10 Dayo L0/ 10 
v D ay 10 Day 7 Day o 8/ 10 
Vl Day 3 Day 7 D ay o 2/ 10 
• Experimental conditions as in Expt. IV of Table 2. 
'f The difference between group II and V was significant (P < o·os) while the difference between group 11 
and VJ was not. 
Table 5· Protection of C57BL/ 6 and DBA/ 2 rnice against i.p. infection with 




Mo use strain 
No. of mice dead/ 
total no. of mice P value 
C. parvum 
Saline 






* Mice were challenged with 100 LD, 0 of SFV. 
'i' 350 f<g C. parvum per mouse, 7 days before infection. 
Effect of previous X-irradiation on the protective effect of 
Corynebacterium parvum on HSV infection 
0'01 
o ·OL 
X-irradiation (400 R) given 4 days before C. parvum abolished the protective effect of 
C. parvum on HSV infection of C57BL/ 6 mice (Ta ble 4). However, no such adverse effect 
was seen when the radiation dose was applied 3 days after C. parvum (i.e. 4 days before virus 
infection). 
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Protection of C 57BLj 6 and DBA/ 2 mice against SFV by injection of 
Corynebacterium parvum 
In contrast to an i.p. infection with HSV (Lopez, 1975) C57BL/ 6 and DBA/ 2 mice were 
found to be equally usceptible to i.p. infection with SFV (Table 5). Both strains of mice 
could be '"ell protected by injection of C. parrum given 7 day before the virus. 
DISCUSSION 
The genetic resistance of mice to mouse hepatitis virus is determined by a difference in the 
ability of macrophages from different mouse strains to replicate this virus (Bang & Warwick, 
1960). Genetic differences in the susceptibility of mice to HSV infection have been also 
reported (Lopez, 1975). However, thus far there is little indication that HSV replicates in 
macrophages (Stevens & Cook, 1971 ; Kirchner et a/. 1976) and other reasons have to be 
sought to explain the genetic resistance of certai n mouse strains to HSV. In th is regard , it 
seems to be of interest that susceptible strains of mice could be eq ually well protected aga inst 
HSV infection by Corynebacterium parvum as C57BL/ 6 mice which are relatively resistant. 
The basis oft he protective effect of C. parvum on a virus infection has not been fully under-
stood. However, protection is obviously more than just a local effect at the injection site since 
protection was also seen when C. parvwn was given by a route other than that of virus infec-
tion. C. parv/1111 has been shown to induce a strong systemic activation of the lymphoreticular 
system (Scott, 1974) which appears to be caused by mobilization of macrophage precursors 
from the bone marrow into the periphery (Baum & Breese, 1976). Not all strains of coryne-
forms are active in this regard and it is noteworthy that those which were inactive (i.e. did not 
induce splenomegaly) also caused no antiviral protection. Woodruff eta/. (1976) have shown 
that the lymphostimulatory effects of C. parl'um in mice could be prevented by previous X-
irradiation. They have suggested that the effect of C. parvum on the macrophage system is, to 
a considerable extent, due to the stimulation of radiosensitive macrophage precursors to dif-
ferentiate into mature cells which are actively phagocytic and cytotoxic. Our data are in 
agreement with their ftndings since we have observed that the antiviral effects of C. parvum 
could be aboli hed by previous irradiation. 
Previously, it has been shown that mice injected with Corynebacterium acnes (which is in 
most properties closely related to C. parvum) displayed a reduced capacity to respond to 
interferon inducers (Farber & Glasgow, 1972). However, we have found that spleen cells of 
mice injected in vitro with C. parvum elaborated increased levels of interferon (Kirchner eta/. 
1977b). Here we have found that significant levels of interferon could also be found in the 
serum of C. parvum-treated mice. 
The data from Glasgow's laboratory and ours arc not necessa rily at variance with each 
other. The interferon produced by spleen cells from C. parvum-injccted mice is produced only 
5 to 1 o days after injection. This markedly contrasts with conventional induction of inter-
feron, such as performed by Farber & Glasgow (1972), where high levels of interferon are 
detected in the serum several hours after injection of the inducer. In interferon research it is 
known that • blocking' occurs when cells which are responding to one type of interferon 
inducer are challenged with a second inducer (Ho & Armstrong, 1975). This may occur when 
the cells of the lymphoreticular system which are already responding to C. parvum are chal-
lenged with another inducer. 
It is clear, however. that at the present stage we cannot prove that induction of interferon 
is the cause of the antiviral effect of C. parvum. Furthermore, although it is quite likely that 
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macrophages play a significant role in this protection, their definitive role also remains to be 
determined. 
Borde tel/a pertussis is known to induce a lymphocytosis in mice (Morse & Riester, 1 967) 
but its effects as an activato r of macrophages have been Jess well studied. ln experimental 
tumour work, divergent results have been reported. In some studies B. pertussis was able to 
protect aga inst a tumour (Likhite, 1974), whereas in others there was little protection 
(Purnell et a/. 1 975) or even an adverse effect (Fioersheim, 1 967). l n our studies, B. pertussis 
also protected mice against HSY infection, and protection was observed agai nst high virus 
doses and in a mouse strai n where protection by Corynebacterium parvum was quite weak. 
The basis for this protective effect of B. pertussis needs to be clarified by further experiments, 
but it seems of interest that B. pertussis also has been shown to be an interferon inducer 
(Borecky & Lackovic, 1967) . 
Lately, a number of immunosuppressive effects of the so-called ' immunostimulants ' have 
been noted (Scott, 1972 ; Kirchner eta/. 1975). The term ' immunomodulant' has been pro-
posed to indicate that these agents may act on a complicated balance between immune-
stimulation and immunosuppression. From these observations it seems reasona ble to 
conclude tha t all of these agents should be handled with care si nce they may be potentially 
immunosuppressive. However, it remains to be determined which of these va rious immune 
functions contribute to host defence. Protection against a virus infection seems to represent 
true immunopotentation. Corynebacterium parvurn is being considered for immunotherapy 
of human tumours. Since virus infections are a common cause of complications in tumour 
patients, the antiviral effects of C. parvum may be of great clinical significance. 
We thank Mr D . Baumgart! fo r his co-operation in the an imal experiments and M s B. 
Mannes for excellent secretarial assistance. Semliki Forest virus was a gift from Dr C. J. 
Bradish and Borde tel/a pertussis was kindly provided by Dr H. Hof, U niversity of Wi.irzburg 
(FRG). 
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BIOLOGICAL EFFECTS OF CORY1 EBACTERIUM PARVUM: 
Ill. AMPLIFICATION OF RESISTANCE AND IMPAIRMENT OF 
ACTIVE IMMUNITY TO MURINE TUMOURS 
S. E . SMITH AND M. T. SCOTT 
Fr·om the Deparlmmt of P:::~·pcrimcntal Jmmunobioloyy. W cllcome Research L!tbomtoriu, 
L<mylcy Court, JJecker~ham,-J(el!l 1Jll3 3flS 
H<'cc-ivt'd 18 Apri l l !l72. Accepted 2 1 Mo.y I 072 
Summary.-T he effect of pre-tr eatment with Coryn ebacterium porvum on the 
growth i11 vivo of a range of experimental mouse tumours with differing character-
istics has been invest i ~a ted. Varying degrees of protection were observed which 
were generally g reater with the more immunogenic tumours. Administration of 
C. parvum 7 days before immunization with irrad iated tumour cells diminished the 
protective effect which could be obtained by immunization alone. T he possible basis 
for these seemin g ly conflicting influences is considered. 
HALPEHK et al. ( 19H4) showed that a 
killed suspension <) f Uorynebaclerium 
7Jftrrum was an \ Ill usually potent stint ulant 
for the rc t.i<'tdo-endotheliul (mucrophugc} 
system. A number of associated effects 
such as adjuvant o.ctiv ity (Neveu, Branel -
lcc unci ]3iozzi , I Ou-t; Diozzi et al., 1 000) 
and increa~cd resistance to ba.ct;crhl>l 
(Adlam, Bronght,on tmd Scott, 107::!) ~~nd 
protozoa l (Nu~scnzwcig, I OU7) infection, 
ha\·c since been report ed. The inhibitory 
effect of C. 1wrvum pre-treatment on the 
growth of n range of experimental mouse 
tumours (Sa rcoma J . Ehrlich uscit.es, 
n. span t.<lll <'Ous nw nlnHu·y en rcinoma., 
a met.hy lchola nthrenc-ind ucccl stwconHt 
and L)lc AKH. lculmem i1t) hn.s been 
described (Halpern et nl., 1 !)GG; \Vooclrnff 
and Bonk, l l)(i(i; Lnmcnsans et al., 1 OGS). 
Although th e rNm lt.<> obt.ainccl h ere varied 
bctwCQil the dilrcrcnt systcmH, in gencml, 
conditions could be found Hndcr which 
C. panrnm uffordccl a degree of protect ion. 
Currie and Tiagshuwe I (1 O?m usef! ~ 
combil)ntion of C. pCLrvum nnd phemo-
thcrnpy against a methylc!1o)ant·l1re~p· 
inducer! fib roso.rcoma with some success, 
whereas Math6, Pouillart' anq Lnpoymque 
(19G9) were unable to it)fl~enc'o an 'estdo'-
• • t • • . ... 
hshed L12l0 tumour wtth a combmat10n 
i • • yflo' 
of G'. parv1m1. u.nd imm unotherapy. 
T he experiments described here o.re 
concerned with two nspcct~ of the an t i-
tumou r activities of 0. parv'um : the effect 
o f simple pre-treatment and of pre-trcat-
mcrlt followed by activo im munization on 
~he growth of a primary tum0111' challenge. 
Several mouse tmnour systems, prov iding 
1t vnrict.y of growth pntkrns and immuno-
genicit ies, lmvc llcon used and the relation-
ship between the effects of C. parvum and 
the chnrnc~cristics of the tumours arc 
d iscussed. 'l.'he investigation formed a 
prelmlo tQ s~itdios n.t the cell level und 
tissue culture lines hnvo been established 
fro m tho t.umours qcscri bod , in order to 
facilitate subsequen~ wol'lt in vitro. 
AIATl~lUi\LS AND l\IF.1'110DS 
Jllire.-Adults of th<' following inhr<'d 
~;tmins f\tl <l 1>\ hybrids, mnintnint•d in this 
Dcpartmot\t, were used: CllA-p (from the 
Dcpartmo•1t of Genetics, UnivcrsiLy of Cam-
bridge}, Dl3A/2 nnd I3ALBfc (from the 
~hester Ueatty Research Institute) and 
IHALB/c x 'lJDA/2)1<\. Groups of 10 mice 
,v~·o . us~d fAr each experimental group 
throughort. 
tt'f Oof1J1tf4aclerium parvum.-A ldllcd sus-
Jl!lna\· on Of C. paryum (Batch No. EZ174 7 mg/ 
l ~ 'J \"' 
~. E. SMl'l'H AND 1\I. '1'. SVO'lwl' 
ml) \1"1\$ pro\' id,•d hy \\'cllromc RcsC'nrch 
Lnhorat mi,•$, Jkckcnhnm, Kent, England . 
A ~<l:l ndard close of 0·2 ml ( 1·-f mg) was 
inj<·c t,'{l ix . or i.p. 
7' umours.-The following lumont·s were 
ohtainl'd from the Chc~tcr Beatty Rcsear·ch 
l n;:titutt• nml mnintninC'cl in ascitic form in 
t h<' mice spt'<·ifil•<l: l t-1 (radiation induced 
CB:\ lrnkm•min; Hewitt, 1 9G~) in CBA-7>; 
ll' ' )llll onHI l::!!l (indu<'<'d hy CCI3 in n C:3H 
mous<', .:\ndCr\'Ont and Dunn , 1955) in CBA-p 
and B.-\LRfc; Adj. PCGA (adjuvant induced 
B.-\ L11fc pln;:mncytomn, Pot.kr and Robert-
son. l !ll\0) in BA Lll/c und L5178 (DBA/2 
leukac·min., Fischrr, I 958) in (BALB/c x 
DHN~l l.•\. 
Tho Cl3AT-3 fibrosarcoma was derived 
originally from n. tissue cultmo line of CBA 
embryo fibrohlnsts 1tnd maintained as a sub-
cutaneous solid tumour in CBA-JJ mice. 
F or both routine passage and expcri-
nwntal usc, tumours were handled as cell 
suspensions in phosphate buffered saline. 
Ascites cells were harvested direct and 
wnshrd one<'. Solid tumours were disso-
cialrd by mincing wit.h scis~<Ot'S and pipctting 
the fragments. The supernatant cells, after 
settling, were washed once. 
lnacl i mJ irm of tumour cells.-Cells were 
inncti,·nted by in vitro irradiation ( 15,000 
rnd) from n 60Co somcc. This procedure did 
not. afl'cct. the viability of tho cells ns judged 
by t rypnn hluc exclusion. 
.· I.~.~C~8men l of r·rsu ll.~.-H<';:ulls nrc dis-
played as cur\'CS of percentage of sun·ivors 
n~ninst days after challenge. Animals whose 
deaths aro not. recorded were kept for 60 days. 
In the case of the subcutaneous CBAT-3 
tumoqr, a ~ em diameter was taken as the 
endpoint, if it occurred before death. 
RESULTS 
t 
Cltan1cfe·risl1·cs of the tummtrs and their 
immunogen icily 
l q1nwnogenicity of the Yarious 
tumours was assessed by the protective 
effect of immunization with inactivated 
tumour cells 10 <.lays before challenge 
with normal tumour cells. Immunization 
agai nst ascitic tumou rs was i.p., but for 
soli<.! tumours the immunizing <.lose was 
split between the i.p. route and a subcuta-
ncow• (H.c.) Hit.o contmlntcml to that of 
tho clutllcngc. 
RI Leukaemia cells arc syngeneic in 
CBA mice and grow rapid ly, causing 
death from inocula of fewc1· t.han I 0 cells. 
Death is abrupt; wi th only modera te 
ascites development;, suggesting that meta-
stasis is a major factor. The tumour as 
first grown hL·re wus moderately immuno-
genic in CBA·7J mice, a single dose of 
106-G X 105 irm<.lintcd cells giving GO% 
protection against a 100 cell challenge. 
This form of the tumom· is rcfe~-red to as 
RI. Wceld y passage thl'Ough mice for 
J 8 months resulted in a variant; fo rm which 
was very much less immunogenic (RI-
va.r .) ; 5 X 105 ir radiated ltl-var. gave 
a lmost no protection agains t a 100 cell 
challenge. Recourse to frozen stored 
material allowed comparisons between 
the original and variant forms. 
Hepatoma 129 g rows rapidly from ino-
cula of less than 10 cells and causes 
d eath wilih gross ascites and no evidence 
of metastases. Om· fon)J is not strain 
specific; originally a C3H tumour, it is 
routinely passaged ir\ CBA against a 
minor histocompatibility barrier and a 
seconda ry strain is passaged in BALBfc 
mice against a s tr·ong histocompatibility 
barrier. There is little tlifferencc bct\\'ecn 
the growth rate 0 1' minimum lethal d ose of 
the ·two strnins. 'l'hc immunogenicit.y of 
irradia ted cells is also s imilar, a dose of· 
bet"·cen 10·1 and 5 X IOJ giving 50% 
protection against a I 00 cell challenge. 
The lack of strain specifici ty is not due to 
masking or loss of histocompatibili t~­
a.ntigcns, since BALB/c mice were readily 
immunized agains t the tumou r by normal 
CBA sp leen cells. 
CBAT-3 fibrosarcoma g rows ns a 
non-metastasizing solid when injected 
s.c. Its Jiapility to become haemorrhagic 
or to break through t he skin makes 
quantitat-ive assessment difficult. \Yhen 
injected i.p. it grows more rapidly as 
localized solid tumours in the peritoneal 
wall and consistently causes death in the 
animals . 
.AssosfH110il~ of tho immunogeni<'it.y of 
irraclintrd' c•c)IH d<'Jl<'tHIH 011 tho roulo of 
i n jecLion· ~ fif '~lsnllcngo coli H. l>rotcction 
I ., 
j 
nTOJ.()(~ I(!AL EFFECTS OV COlll.X/;'/J:IC:'I'IWIUM I'AU I'UM :)G:~ 
is low ag;tin~t s. r. chnllt·n~c \\'it h I 0 1 <·ell:;, 
1 06 - ."i x l Oti irrndintc<l <·eils being n•quirrcl 
to g i,·c 50% protccLion. The t itration 
with i.p. chn llcnge did not reach an 
endpoint. but protcet.ion was at least I 0 
times greater. 
J,fi l7S lwl.·ar111in <:auscs dca t.h 
cs:-entially by massive i.p. growt.h wiLh 
some l<><·al inlilt rat.ion to fo r m solid 
nl<'!'CIIlerial growl h. ' l'he 1>'1 hybrid in 
\\'hich the tumour was passaged was 
within t.he major histocompatib ility gronp 
(H-~tl) of the sLrain of orig in (DJ3Aj2), 
t.hus minimizing nny potential effects of 
allog<'ncic inhibi t ion . The t umour was 
poorly immunogenic in t his system a.nd 
up to 10 7 inudiated cells were required 
for 50% p rotection against a J 00 cell 
ehnllcngc. 
P C'6 plwmwcytoma gives rise to massive 
ascites, with ready formation of a solid 
tumour at t he injection site; it shows no 
evidence of metastasis. It is poorly 
imnwnogcnic, wiLh no protection against 
A B 
~~ l 0 3 <:l'll dudl<·ngo \\'it.h irradiat ed <;ell 
doses of up to 107• 
Pt·oteclive ejjecl$ of pre-treatment with C'. 
JJUTVU?n 
Groups of l 0 mice received 0·2 ml of 
C. 1wrvmn i.v. o1· i.p. 7 <.bys before 
challenge with Lumout· cells. When C. 
JHtrvnm is adrnini!llcrcd 7 d u.ys bcl'orc 
in"jcction of sheep red cells it produces a 
marked adjuvant effect. (Scott, unpub-
lished results) . 
Rl lw kaemia.-Chu.llcnge doses of 
both l 0 and l 00 cells were assayed (Fig 
lA, B). In all cases there was a. defin ite 
protective effect from C'. pat·vum which 
was h ighly s ig nificant t\t t he lower chal-
lenge dose and with little difference 
between the i.v. a.nd i.p. routes of adminis-
tration. It was noticeable that prolonga-
tion of survival of animals incompletely 
protected by C'. pat·vum was accompanied 
by greater ascites development. Very 
little p rotection from r parvum was 
c 
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DAYS AFTER CHALLE NGe~ 
F10. I A- C.-Tho <'ff<'cL of C. p<1nmm (WO·tr<'i\tmC'nt on RT lcul;Komil\ in Cl3A mice. l·.J mg C. 7xrn:um 
i dnys ~cforo chollcn~t? with 1 0~ Hl (n), 10 HI (b) nnu 'lW'l~I·ynrinnt (c) lcukncmil\ coli~. C. 
7lfr rvum t.v.( .... .. ), C. porvwtt 1.p. (-- - -), nono (--f.· • • 
D-1·'.- Tho cffrcL of cmnbincu C. Pflrvum pro·trrnl mrnt unc i immuni~.nl ion on HI lcul;nrmin in Cl\.-\ 
mice. 1·4 m~ C. 7)(crvum i.v. i clny>~ boforo imnnmizution :i:p :·,Wt h .i. Ill' (o), G.IO~ (f) i•·rnclintrd 
loukncmin ct•ll>~ or unro (<J), All mico woro ' ohnllcn~l'll Y.J1! nvitlil !OO HI loukncmin CC'll:~ nflC'r n 
further 7 dnyd. Untrcnto•} mico (--), immuni:roJibn plono (-' -- -), C.7xrn"trm + immuni7.n· 
tion ( .... .. ). " "' • · 
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DAYS AFTER CHALLENGE 
' Fw. 2 A- C.- Tho ciTcot. of C. paruum p•·c·trcntmcnt on Hcpatom~ 12!) in CBA (a, b) and BALB/c 
(c) mico. 1·4 mg C. parvum 7 dny11 before chnllongo with 10 or 100 tumour cells. C. panrnm i.v. 
( ...... ). C. parvum i.p. (--- - ), nono (----- ). 
.0- E.- Tho l:'fTcct of combined C. 1>arvw11 PI'O•trcatmont and immunization on Hepatoma 129 cells in 
DAT.B{c mice. 1·4 mg C. parvum 7 daya boforo immunization i.p. with 5. 10 ' (d), 5 .10$ (e) irrn· 
diutcd tumour cells. Untrcntod mico (-----), immunization nlono ( + + + ). C. paroum i.v. 
+ imnmni7At ion ( ...... ),C. parvum i.p. + immunizat ion(--- - ). 
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DAYS AFTER CHALLENGE 
FlO. 3.- Tpo effect of C. parow1~ pro-tr·oatmont on CBA-T3 fibrosl\rcoma in CDA mico. 1·4 mg 
C. p<"li'VUII& 7 days before challongo with oithor 10• or 10• tumour colla s.o. (top row) or i.p. (bot tom 
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DAYS AFTER CHALLENGE 
F1o. 4.-Tho effect of C. 1>anmm pre-treatment on PC6 plnsmMyt.oma in BALB/c mice (lefL) and 
L5 l i8 lcukllCmia in (13ALB/o X DDA/2)F 1 (right). 1·4 mg C. 7>aroum i days bcforo challenge 
i.p. with 103 o r 10' PC6, or 100 L5178 coll5. C. parvum i.v. ( ...... ), 0. parvum i.p. (--- - ), 
none(--). 
afforded against the poorly immunogenic 
RJ-var. as compared with tho original R I 
(Fig. l C) . 
l leJ>aloma l 29.-Challcngcs of both 
I 0 and l 00 cells in the CHA system and 
100 cells in the JJALllfe system were 
nsfmy<'d (Fig. 2A-C). In CBA mice the 
protective effect was small, with little 
difference between C. parvum i.v. and i.p. 
The situation was quite difi'erent with 
BALB/c mice: whereas C. parvum i.v . 
hq.d little effect, there was a strong pro- · 
tective effect following i.p. administration. 
CBA 1'-3 .fibrosarc01na.- Both s.c. and 
i. p. challenge with 1 03 and l 04 cells were 
irwcstigr~ted (Fig. 3): s.c. challenge with 
I 03 cells proved too small for analysable 
results, a lthough C. parvttm pre-treatment 
both i.p. and i.v. increased the number of 
st~rvivors. At t.he 104 dose there was a 
dofinite effect with C. parvum i.p. but 
vory little with i.v. injection. With i.p. 
challenge of 103 cells both i.v. and i.p. C. 
'Ji(l rvtwt nrTordcd strong protection. This 
protection was maintained by i.p. C. pctrvum 
ugainat a 104 cell challenge, but the i.v. 
route wus again less effective. 
2(} 
L:S178 leukaemia.-1-The effect of C. 
parvu1n pre-treatment against a 100 cell 
challenge was minimal (Fig. 4). 
PC'G 1>lasmacytoma.- Pre-treatment 
again aJT'ordcd only slight protection 
against challenges of 103 and 104 cells . 
(:Fig. 4). 
C01nbinetl'l{re-treatment with C. parvum and 
i1-radiated cells · 
G. P,arvum was injected 7 days before 
imm unization with irradiated cells and 
the 1\nimftls were challenged after a further 
7 days. proups of 10 mice were used. 
RI lwkaemia.-The results of com-
bining ' ir;munization by 5 X 10~ or 
5 X 105 'irradiated cells ";th i.v. C. 
parvmn ~rc shown in Fig. lD- F. C. 
pan:um J)i·c-treut.ment depressed the pro-
tective ef:rect of immunization, more 
rspcrtnp)- \,·ith the lowr r immunizing dose, 
but cxcr'lt'd its normal protcctivr cfi'eet 
when Aivc'n alone. 
lJtf71atomn 120.-'rhc outcome of 
co!l}Hiping immun iza~ion ":ith C'. 1~arvum 
13Jfjr~u,tment wo,s mvest,•gntcd m t he 
~1t~/c s..vstcm. Two immun.izing doses 
:Hill S. 1-:. S:\11'1'11 AND l\1. T. SCO'n' 
TAIILl-.: I.-'l'he Profrcfil'e l!,'ffecl of C. 1Jarvum Pre-treatment Ayain.st Hxperimenlal 
,1/ouse 1'ttm01trs of Varying lmmunoyenicily 
Tumour nnd C. paroum protcctiont 
~t rnin of ExjX'rnncntnl ho.-t 
origin Tumour typo nml chullcngo route Immunogonicity• i.v. i.p. 
nr Ascites lcukncmia CI3A XX ++ ++ 
C'UA i.p. 
Hl-,·nr. Fi\)1'<11<1\I'COilll\ CBA ~X ± ± 
(.;II:\ i.p. 
Hl :!!l Asci tes hcpntomn CBA XXX + + 
C31:-l i.p. 
Hl:?O Ascites hcpntomn llALI3/c XXX ± +++ 
C31:-l i.p. 
L 5li8 Ascites lcul<nomia . (BALU{cx DI3A/2}F1 • X ± + 
i. p. DB.-\ /2 
l'Cli A>'c it.os pln:<mnoytomn . llAL13{o <X ± ± 
BALU{o 
CI3AT- 3 Fihrosnrcomn 
i.p. 
CUA X + + 
CBA f'.C. 
CBA'l'- 3 Fibrolti\I'COmn CBA ~XX ++ +++ 
CBA i.p. 
• Orcl!i('d nccorcling to tlu"o of irnulintml tumour coils giving !iO% protection ngninst n chnllongo of 
10-20 times tho LObo of living tumour coli>< : x x x 10'- 10 6 ; X X JO•-to•; X 10'-10 7• 
t ~ubjoctivo grnding from good ( + + +) to poor (±) protection. 
( 5 x 104 n nd 5 x IOS) were used with 
both i.v. und i.p. C. panmm (Fig. 2D-E). 
Good protection was induced wit h i.p. 
C. parvum alone and such t reatment d id 
not modify the protective effect of 
immuruzation. Administration of C. 
pannun i.v. , which a lone afforded minimal 
protection, completely abolished the p ro-
tective effect of the lower immunizing 
dose of irrudiatcd cells and slightly reduced 
that of the high dose. 
DlSCUSSION 
C. JJan:um p re-treatment was found 
to confer so me degree of protection against 
a variety of highly adapted and rapidly 
g rowing mouse turnom s, in agreement 
" ·ith reports by previous w orkers (Halpern 
et al., 1906; Woodruff a nd Bonk, 1966; 
Lamrnsans et al., 1968). 
lt seemed likely that C. Jlal' l'lt?n would 
be more e ffective against, tho more 
immuno~t'nic tumout"H nnd Hl t<:h ·~ <'Orn•la-
t.ion i:o~ ~(.'I'll i tl t.l\(1 ('Ill ll Jill rison Cl f t.Jl(l 
IIOI'tnnl lltld vnriant IU s t.n~ins. 'J'hn 
varint.ioJl in 1'<':-lll lt.t~ ohtnined wi t.h t.lte 
clitTcn:n l- tumout· HyHtctnli Ht:I'Vt'H to e m-
phasize l-he com plex ity of the mcchuniHmH 
involve~ , but t.he more striking effects 
Were fo~ncl in the immunologiCI\Ily reactive 
situatiopa (Table I). C. parvum causes 
intense ret icu lo-endothelial stim ula tion 
(Halpern et at., 1964) and stimulated 
macrophages have been reported to be-
come n on -specifically cy totoxic to 
tumour cells (Alexander and Evans, 1971 ; 
Hibbs, Lumber t and Remington, 1972). 
Such effects may expla in , for example, 
t he s light p rotection against the v ery 
poorly immunogenic PC6 tumour, but the 
'Suggested corrclntion between immuno-
genic ity and C. pm·vu1n protection implies 
involvement of specific immunological 
defences in addition to a ny non -specific 
activa t.ion. 
The i .p. route for C. JJarvum was 
somewhnt more effective Lhnn the i.v. 
although both routes wore similnr wit h 
respect to spleen and liver enlargement 
a nd ne ither led to an increased p eritoneal 
cell population nt. t he time of chnll<'ngc 
(authors ' unpublis hed obsctTnt.ions). Thnt 
t he differoncc <'annot be cxplninC'cl ~impl_Y 
Ly lol'n l i.p. cll't•<'ls is nlso xlwwn h.'· t ht• 
gronkr l'fli<·lH')' of' i.p. U. Jlll/'1'11 ?11 in t-IH• 
H.t: . ( ! Hi\'1'-:1 I')'HII'tll. 
In vit·w . ot' t ho ktlm,·n ndju\'nnt. 
activity o f fJ. 1JILI'Il /L111, it. \\'1\H Hilt i<·ipnlt'd 
thut com b ination with immunization 
would result in incrcniiccl protection com-
pured wit!) tllo ltttter 1\lonc. However, 




HIOLO(:ICAL EVFECTS OV CORLVH/IA("I'Hll/UM i'AUVUM :J67 
('. JHliT/1111. given b<'fore imnH111ization, 
dc<'rcnscd tho protective cfrcet, uiLhough 
i.p. C. parcum in t.he H t :?!) system did not 
in(i ut•m·t• t.he immune response. J t seems 
t,hnt while O.parvmn t rc;\tmcnt sLimultLtcs 
the defences of the host ng1\inst many 
tumours it nmy t\lso, at lc;1st when given 
i.v., concomitantly d rprcss some part 
of the immune response. Preli minary 
experimen ts boLh in vitro ancl in vit:o have 
so far failed to reveal evidence for produc-
tion of enhancing unt.ibody and the fact 
that, the depression can be overridden by 
larger imm unizing doses also arg ues against 
such '" mechanism. Enha nced growth of 
!dlogoncic t umour cells fo llowing immuni-
zation in conjunction with either complete 
ot· incomplete Freund's adjuvant has 
recently been reported (Zolo., 1972), and 
again no evidence of enhancing antibody 
could be found, the effect being attributed 
to depression of cell-mediated cytotoxicity. 
Evidence of depressed cell-mediated (T 
lymphocyte) responses follO\\'ing 0. pCLrvmn 
treatment comes from the demonstration 
of reduced delayed hypersensitivity 
(Ashcrson and Allwoocl, 1971), PHA 
responsiveness and GVH reactivity of 
lymphoc~·tes (Scott, 1972). 
Schedules for iho immunotherapeutic 
Lreatment of human tumours have often 
included adjuvants, and 0. 1Jarvum has, 
begu n to figure among these (Mathe, 1971). 
The present finding that this agent, at least 
under certain experimental conditions, can 
show an immunosuppressive component 
in its o.ction urges cu.ution in this field. 
We wish to acknowledge the able 
technical assistance of Mrs S. Wishart a.nd 
]t.fiss C. Tieman. Thanks are n,lso due .to 
Dr J. 0. Howard for helpful erit.icism. 
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Corynebacterium parvum as a Therapeutic Antitumor Agent in Mice. I. Systemic 
Effects From Intravenous Injection 1•2 
Martin T. Scott 3• 4 
SUMMARY-Two days after mastocytoma P815 was estab-
lished as a solid tumor in the foot pads of (C57BL/ 6 X 
DBA/ 2)FI mice, intravenous (iv) injection of Corynebac· 
terium parvum caused only transient inhibition of tumor 
growth with no complete regressions. Tumor inhibition was 
reflected in increased survival times. Some toxicity prob-
lems were encountered after the high doses required for 
maximum effect were given, and multiple doses of C. 
parvum were no more effective than single doses. The anti-
tumor effects of C. parvum were still apparent in T-cell-
deprived mi ce. Mice treated iv with C. parvum did not 
develop systemic antitumor immunity, but peritoneal 
macrophages and spleen cells from C. parvum·st imulated 
animals were nonspecifically cytostatic for mastocytoma 
cells in vitro. Thus systemic C. parvum was predominantly 
nonspecific in its mode of antitumor action.-J Nat l Cancer 
lnst 53:855-860, 1974. 
T HE ANTITUMOR ACTIVITY of killed Coryne-
bacterium parvum in mice, rats, and humans has been 
described (1- 4). Various routes of administration have 
been used; this paper describes some aspects of the use 
of systemically administered C. parvum given intra-
venously (iv) as a therapeutic antitumor agent in 
mice. T he companion paper describes the use of 
locally administered C. parvum in the same tumor 
model (5). Systemic injection of C. parvum markedly 
stimulates the reticuloendothelial system, as evidenced 
by splenomegaly, hepatomegaly, and increased carbon 
clearance; all are attributable to marcophage activa-
tion ( 6, 7). Consideration of previous indirect evidence 
led to the deduction that this nonspecific marcophage 
stimulation, rather than any augmentation of specific 
antitumor responses (8), underlies the antitumor 
effects of systemically administered C. parvum. 
MATERIALS AND METHODS 
Mice.- Adult (C57BL/6 x DBA/2)F1 mice (here-
after designated B6D2F1) were used. 
T-cell-deprived mice.-Four- to six-week-old mice 
were surgically thymectomized and, 6 days later, 
given 900 rads whole-body irradiation. T he next day 
they received 5 X I 06 syngeneic bone marrow cells iv 
and were used for experimentation 5 weeks after 
reconstitution. 
C. parvum.-A formol-killed suspension of C. parvum 
(batch #PX289, 7 mg/ml) was obtained from Well-
come Research Laboratories, Beckenham, Kent, Eng-
land. It was diluted with saline. 
Tumor.- The mastocytoma P815 (MA) was ongt-
nally induced by 3-methylcholanthrene in a DBA/2 
mouse. It was obtained in the frozen state from 
Dr. Virginia Evans, Tissue Culture Section, National 
Cancer Institute, Bethesda, Maryland, and has been 
maintained in my laboratory by serial ascites passage 
in B6D2F1 mice for 18 months. Experimental cells 
were obtained by peritoneal lavage with Hanks' 
balanced salt solution (HBSS) containing 20 U 
heparin/ml; all dilutions and injections were made 
with this medium. MA P815 is poorly immunogenic 
in B6D2F1 mice [(9) and these experiments). I njection 
of l 07 irradiated cells iv 7 days before subcutaneous 
(sc) injection of l 06 live cells did not affect the growth 
of the solid tumor. 
Irradiated tumor cells.-Seven days after they received 
106 MA cells intraperitoneally (ip), mice were irradi-
ated with 4000 rads immediately before peritoneal 
lavage. 
In vitro assay for tumor cytostatic activity of C. parvum-
activated cells.-Peritoneal cells were obtained by 
lavage with HBSS containing 10 U heparin/mi. They 
were washed and resuspended in Eagle's minimum 
essential medium (MEM) containing 10% fetal calf 
serum (FCS). Spleen cells were prepared by gently 
pushing spleens through a fine stainless-steel sieve; 
they were washed, filtered, and resuspended in MEM 
with 10% FCS. T arget tumor cells were obtained as 
described above and resuspended in MEM with 10% 
FCS. One ml of the appropriate concentration of 
effector cells was added to 1 ml ( I 05) tumor cells in 
16 X 125-mm tissue culture tubes (Falcon Plastics, 
Los Angeles, Calif.). Cultures were incubated at 37° C 
in a 5% C02 atmosphere. After 24 hours of culture, 
l MCi tritiated thymidine (New England Nuclear 
Corp., Boston, Mass.) was added to each tube; _16 
hours later, isotope incorporation into the acid-
precipitable material was assayed as described in ( 10) 
except that Whatman glass fiber papers (2.5 em 
G F/B) (H. Reeve Angel and Co. Ltd., Londo?, 




MA cells (106) were routinely injected sc into a 
hind foot pad in 0.05 ml HBSS; 30-gauge needles 
were used. Subsequent tumor growt~ in the foot P.ad 
was measured as foot-pad thickness, m 0.1-mm umts, 
with a Schnelltaster dial gauge caliper A02T (H.C. 
Kroplin, Schluctern, Hassen, ~est Germany). T~e 
suitability of the foot pad as a s1te of growth for th1s 
1 Received March 18, 1974; accepted june 4, 1974. . 
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particular tumor and the method of assessing tumor 
growth has been described (9). 
In control mice, tumors became evident after about 
I week and progressed until a foot-pad thickness of 
8-10 mm was attained, usually after 25-30 days. The 
tumor consistently killed control mice; the survival 
time for the whole experimental series was 29.5± 1.3 
days (mean± SE). During this period, tumor growth 
was generally restricted to the primary site; however, 
in mice that survived with primary tumors of 9-10 
mm, tumor growth in the legs and enlargement 
of the inguinal nodes became apparent. This was 
accompanied by necrosis of the primary tumor and 
eventual loss of the foot. Once such necrosis was 
evident, measurements were discontinued and the 
mice were scored only for survival. The tumors 
metastasized; occasional lesions were found at 
autopsy in the liver, kidneys, and spleen. Data from 
from repeated experiments showed that, depite the 
occasional reduction in group size due to death or 
foot loss, the mean tumor size over the period when 
growth was restricted to the primary site provided a 
consistent and reliable measure of the difference in 
rate of tumor growth between control and treated 
animals. The differences in tumor size between the 
various groups at each time point were analyzed 
statistically and relevant differences are noted in the 
text. 
iv C. parvum Therapy 
In the first series of experiments, groups of mice 
received I 06 MA cells sc in the right hind foot pads 
and were treated iv 2 days later with 0.1 ml of various 
doses of C. parvum. The optimal dose for inhibition of 
tumor growth was 700 .ug; higher doses (1400 JLg) 
resulted in some deaths due to toxicity,5 and lower 
doses were less effective in inhibiting tumor growth 
(text-fig. I). The effect of C. parvum became manifest 
between 13 and 15 days and lasted about 8 days, 
whereupon tumor growth was again apparent and 
continued at a rate similar to that in untreated con-
trols. The protective effect of C. parvum was also 
reflected in the markedly increased survival times; 
however, in this and repeat experiments no complete 
regressions occurred. Experiments in which treatment 
was delayed beyond 2 days resulted in reduced 
inhibition of tumor growth. Continued observation of 
mice given C. jJarvum iv showed that they could tolerate 
a much larger tumor mass than their untreated 
counterparts. T he primary tumor in the foot grew to 
8-10 mm (when all untreated animals died) and be-
came necrotic; the foot e\'entually dropped off and 
the tumor continued to grow in the upper region of 
the leg. 
T he time at which the antitumor effect of C. parvum 
became apparent (13-15 days) is coincident with the 
"maximum stimulation" of animals after iv treatment 
with C. parvum, as evidenced by splenomegaly and 
hepatomegaly (7) . In a second series of experiments, 
a second iv dose of C. parvum was given 6 days after 
the first and was timed to prevent the escape from the 
influence of C. parvum seen at =21 days. Text-figure 2 
shows that the effect of the multiple C. parlJUm dose on 
10 
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DAYS AFTER TU MOR 
TexT-FtCURE I.-Effect of various iv doses of C. paroum on the 
growth rate of JOG MA cells injected into a hind foot pad 
2 days earlier. Numbers in parmtheses represent mean 
survival time ± se of those animals that died, and number of 
survivors/No. in experimental group. 
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TexT-FtOURE 2.- Effect of mul tiple iv doses of C. parvum (CP) 
on the growth rate of 108 1\fA cells growing in the foot pad. 
!\l ice received 700 JJg C P iv 2 days after tumor establishment 
(0 ,.. ....... 0 ), 2 and 8 days after tumor <•r ~ ~•), or after 
no treatment <x-X). Numbers in parmthests as for 
text-figure I . 
tumor growth rate was apparently not as good as the 
single dose; however, this was only significantly 
different at day 23 (P< 0.05). Overall survival times 
were not significantly different. In some experiments, 
the mice did not tolerate the multiple high doses of 
C. parvum well (see footnote 5). 
Effect of C. parvum Given iv Against iv Tu mor Challenge 
Injection of low doses of MA (106) iv killed all 
normal mice; the survival time was 20.3± 1.5 days 
(mean ± SE). At autopsy, tumor nodules, often 1-2 
mm in size, were found in both the liver and kidneys. 
To determine any effect of systemic C. parvum on tumor 
cells disseminated via the blood, mice received C. 
parvum iv and were challenged 14 days later with 104 
live ~IA given iv; survival times were noted (text-
fig. 3). There was a marked increase in survival time 
after C. parvum treatment iv; however, mice that 
received C. parvum sc into the neck (i.e., no systemic 
s Deaths due to toxicity were about 5% with a dose of 1400 JJg 
and invariably occurred within 24 hours of l!'catment. Th_ese 
deaths were therefore easy to differentiate from deaths resulung 
from tumor. 
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TEXT· FIGURE. 3.-Protective effect of either 700 JAg C. parvum iv 
or sc into the neck against 101 MA ceHs iv 14 days later . 
Control mice were untreated; groups of 8 animals were used. 
stimulation) survived only as long as untreated con-
trols. T he survival times of the controls and groups 
given C. parvum iv were 22.7 ± 1.2 (mean±sE) and 
30.7±2.7 days, respectively (P<0.025). 
Antitumor Effect of C. parvum Given lv in T-Ceii-Deprived 
Mice 
The growth characteristics of 108 MA in the foot 
pads ofT-cell-deprived mice were similar to those of 
intact mice, but survival times were consistently 
shorter . T ext-figure 4 shows the effect of iv C.jJarvwn 
injections 2 days after tumors were established in the 
foot. The usual marked inhibition of tumor growth 
seen around 14 days in intact mice after iv C. parvum 
administration (700 J.Jg) (text-fig. I) was absent ; 
however, the tumors in the treated mice were signifi-
cantly smaller than in the controls from day 12 on. 
The increased survival time of treated mice was a lso 
significant (P=O.OOl). This represented a 35.9±6.6 
(sr::) % increase in survival time over untreated con-
trols. The comparable figure for intact mice so treated 
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depnved m•ce. C. parvum (700 JAg) was injected 2 days after 
the tumor cells. Con trol T-cell-deprived mice received no 
treatment. Numbers in parmth~ses as for text-figure I . 
spective data accumulated throughout the whole 
experimental series; however, given this limitation, 
the respective increases in survival time were not 
significantly different. 
Immune Status After iv C. parvum Treatment 
The model devised to demonstrate any systemic 
antitumor immunity following iv C. parvum treatment 
was as follows: Mice received 107 irradiated MA 
(4000 rads) cells sc into a hind foot pad. One day later, 
C. parvum was given iv. Seven days after C. parvum 
treatment, the mice were challenged with 106 
live MA in the contralateral foot pad, and growth of 
this tumor was monitored for signs of systemic im-
munity (text-fig. 5). Injection of irradiated MA cells 
alone resulted in a marginal (not significant) increase 
in tumor growth rate, and iv administration of C. 
parwm alone caused its expected inhibition of tumor 
growth with concomitantly increased survival times. 
The combination of irradiated cells followed by C. 
parvum injected in was no more effective than C. 
parvum given ·alone iv; thus no systemic antitumor 
immunity had developed . Included in the graph is a 
positive control showing that such a system can detect 
immunity when the irradiated cells and C. parvum 
are injected sc at the same site. Injection of C. parvum 
sc alone had no effect. 
In Vitro Evidence for Nonspecific Antitumor Activi ty 
Noninduced peritoneal leukocytes from mice that 
had re-:;eived 700 J.lg C. parvum iv 7 days earlier in-
hibited proliferation of MA cells when cultured with 
them in vitro at the ratio of 10:1 (table 1). Normal 
peritoneal leukocytes were, however, without effect. 
Cytostatic activity was more marked if the C. parvum 
was injected ip and peritoneal exudate cells were 
used 4 days later, but thioglycolate-induced periton-
eal exudate cells were without effect (table 1) . To 
characterize the peritoneal leukocytes involved (table 
10 
o- e f MA1CP iv 
........... o / MA 
10 20 
OAYS AFTER TUMOR 
30 
TEXT-FIGURE 5.- Effect of foot-pad injection of 107 irradiated 
MA cells followed I day later by iv C. parvum (700 ~-tg) 
(e-e) on the growth of 106 live MA cells injected into 
the contralateral hind foot 7 days later. Pretreat ment for 
other groups was irradiated MA alone (0 -- 0), C. parvum 
iv alone ( 6r#..16 ), or 107 irradiated MA+ 175 JAg C. parvum 
into rhe hind foot pad ( • • • • ). Control •nice were un-
treated (X- X ). Numbers in parentheses as for text-figure I. 
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2), C. parvum-activated peritoneal cells were irradiated 
in vivo with 4000 rads immediately before culture 
with MA cells. As shown, the !rradiation did not re-
duce the antitumor activity. Further characteriza-
tion was achieved by allowing the C. parvum-activated 
peritoneal cells to settle in the plastic tube for 3 hours 
at 37° C and then thoroughly washing away the non-
adherent cells. MA cells were added to the MA-
adherent cells and assayed for proliferation as before. 
T he cytostatic activity of the adherent cells was 
equivalent to that of whole peritoneal e)o,'Udates, 
indicating that the antitumor activity resides in this 
population. Histologic examination of the adherent 
cells showed them to be more than 80% macrophages. 
cells were significantly more inhibitory (P = 0.001) 
(table 3). 
DISCUSSION 
I tried to demonstrate similar activity of spleen cells 
after iv treatment with C. parvum by the same assay 
system. No significant difference between normal and 
C. parvum-stimulated spleen cells was detectable at a 
ratio of spleen to tumor cells of 10: 1, 50 : 1, or I 00: l. 
At a ratio of 200 : I , normal cells markedly inhibited 
tumor cell proliferation; however, C. parvum-activated 
Treatment of mice bearing the poorly immunogenic 
MA P815 with C. parvum iv resulted in a transient 
inhibition of tumor growth and concomitantly in-
creased survival times. No complete regressions oc-
curred. That a single systemic dose of C. parvum can 
inhibit the growth of previously established solid 
tumors agrees with the findings of other workers who 
used mouse and rat tumor models (1, 2) . In the 
present study, high doses of C. j;arvum, limited only 
by toxicity, were required for the maximum anti-
tumor effect, and this would seem to be substantiated 
by the fact that unrelated studies have employed 
similar high doses (1-3). Attempts to augment the 
effect by using multiple doses of C. parvum were 
unsuccessful; however, increased effectiveness of mul-
tiple doses of C. parvum have been reported with a 
T ABLE 1.- In vitro cytostatic activity of C. parvttm-activated peritoneal leukocytes forMA cells 
Cells 
~1A alone------------ ---------------- -- -------------- - ---------- - --- --Normal peritoneal cells _________________________________________________ _ 
" " " + MA (10: 1) - ---------- - --------------- - --- -- -----iv C. parvmn peritoneal cells t ___________________________________________ _ 
" " " " + ~1A (10:1)---------------------------------
i p C. parvmn peritoneal cellst- __________ _____ _______ -- __ ---- _______ ------
• " " II + MA (10:1) _______________________ __ _______ _ 




33, 776 ± 4737 
435 ± 42 
39, 945 ± 1800 
401 ± 51 
11, 996 ± 2134 
396 ± 48 
3109 ± 749 
37, 363 ± 6574 
• The cpm/culturcs without MA arc minimal and not significantly different, and so have been omitted from tbis calculation. 
t Peritoneal washouts from mice lhat bad received 700 "g C. 7Jaruum lv 7 days earlier. 
t Peritoneal washouts f1·om mice that had received 700 "g C. parvum ip 4 days earlier. 
§Peritoneal washouts from mice that had received 0.5 ml thioglycolate ip (Difco Laborawries Inc., Detroit, Mich.) 4 days earlier. 
TAULE 2.- Characte1·istics of C. pa1·vmn-activated peritoneal leukocytes cytostat1'c for N!A cells 
Cells 
wlA alone-- --------- --- ----- --- - - - -- ----------------------------------
ip C. parvum peri toneal exudate+ MA * ---- -- _____________________________ _ 
' " " " 4000 rads + MAt ____ - - -- -- - _ - - - - _ - - -- -- -- - -
" " " "adherent+NIAt--- -- - - ---- ----- -- ----------
• P eritoneal exudates from mice that had received 700 1'& C. parvum ip 4 days earlier. 




72, 094 ± 18, 966 
2136 ± 347 
1218± 212 
5392 ± 276 
TABLE 3.- In vitro cytostatic activity of C. parvum-activated spleen cells for MA cells 
Cells 
Normal spleen cells ________________ ____________ ___ ____ __ ____ ---- _______ _ 
" " " + MA (200:1)-- --- -------- - -------------------------C. parvwn iv spleen cells* ______ _______ -- _______ -- ___ _____ ___ ---- _______ _ 
" '' " + MA (200 :1)----------------------- - ----------




4360 ± 126 
14, 308 ± 1119 
4900 ± 204 
9528 ± 866 
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mouse mammary carcinoma system (I) . Any in-
creased effectiveness would have to be balanced 
against the increased toxicity of such regimens . . The 
tOxicity of systemically injected C. parvum has been 
noted in other studies (I I, 12), and particularly after 
multiple injections (13), where it was considered to 
have an allergic basis. 
No systemic antitumor immunity was detected after 
systemic administration of C. parvum; this suggests 
that augmentation of specific antitumor responses is 
not a component of the means by which systemic 
C. parvum effects its antitumor activity. Similar nega-
tive results have recently been described with immu-
nogenic tumors in both mice and rats when both 
C. parvum and tumor antigen were administered sys-
temically. T umor growth in animals given ip injec-
tions of C. parvum mixed with irradiated tumor cells 
was the same as in animals receiving C. parvum alone 
(2) . Other considerations support the idea that sys-
temic C. parvum is nonspecific in its antitumor activity. 
In the present study, severe depletion of T cells did 
not reduce the overall effect of C. parvum, as judged 
by percent increase in survival time. Woodruff et a!. 
(11) have also shown that C. parvum-mediated inhibi-
tion of tumor growth is comparable in both normal 
and T-cell-deprived mice. Further experiments with 
C. parvum in high and low antibody responder mice 
may also argue against a determinant role for anti-
body (8, 15) . 
T he nonspecific effects of C. par/Jum have been 
attributed primarily to the stimltlation of the reticulo-
endothelial system after treatment with systemic 
C. parvum (8), and the present experiments have 
demonstrated that C. parvum-activated macrophages 
are indeed cytostatic for tumor cells in vitro. A recent 
report confirms this activi ty of C. parvum-stimulated 
peritoneal macrophages against leukemia and fibro-
sarcoma cells in vitro and also shows alveolar macro-
phages to be similarly activated after iv administration 
of C. parvum (16). Nonspecific in vitro inhibition and, 
in some cases, killing of tumor cells by glass-adherent 
peritoneal cells has also been described after their 
activation with such nonspecific agents as Toxoplasma 
gondii and BCG and also with endotoxin in similar 
assay systems (17-20). The radioresistance of such 
cells (20) and the lack of antitumor activity in 
thioglycola te-stimulated macrophages (17) have a lso 
been documented. T he process is reported to be non-
specifically selective for malignant cells and is en -
visioned as an in vivo surveillance mechanism (18, 19); 
such activated cells, especially since they are not 
restricted to fixed lymphoid organs, would seem 
ideally suited for "mopping up" metastases. T he 
ability of animals stimulated systemically with C. 
parvum to deal with blood-borne tumor cells has been 
demonstrated here. A recent report confirms that 
systemic C. grcmulosum, which is similar to C. parvum in 
its lymphoreticular stimulatory properties (7), greatly 
reduces the number and size of artificial pulmonary 
metastases in mice (21). 
T here are various negative considerations for the 
use of systemic C. parvum as a therapeutic antitumor 
agent for solid tumors. Toxicity problems were 
encountered with the high doses required for optimal 
tumor suppression in the mouse system. Another 
aspect is that cell-mediated immun ity is considered 
essential in the immunorejection of most tumors, but 
there has been accumulating evidence that systemi-
cally administered C. parvum results in a nonspecific 
depression ofT-cell activity (22-25). An instance of 
reduced specific tumor immunity after iv treatment 
with C. parvum has been reported (26) . Recent work 
shows, however, that depression of delayed-type 
hypersensitivity to an unrelated antigen occurs only 
wh en C. parvum is administered iv but not sc- the 
depression phenomenon is mediated, apparently, by 
lymphocyte trapping in the C. parvum-stimulated 
spleen (21) . Finally, no specific antitumor immunity 
develops as a result of systemic C. par/Jum treatment of 
solid tumors. Such immunity would be expected to be 
critical in case of possible "escapes" after only partially 
successful treatment. In light of these considerations 
and the overall effectiveness of iv treatment with 
C. parvum, the companion paper considers various 
aspects of sc C. parvum therapy in the same tumor 
model (5) . 
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Corynebacterium parvum as a Therapeutic Antitumor Agent in Mice. 11. Local 
Injection 1' 2 
Martin T. Scott 3- 4 
SUMMARY- Intratumor (it) injection of Corynebacterium 
parvum into t he solid t umor mastocytoma P815 caused 
marked inhibi tion of t umor growth, increased survival time, 
and 44% com plete regressions. The protective effect of 
it-injected C. parvum was entirely T-cell-dependen t and 
"cured" mice were specifically immune to rechallenge. 
Specific pre-emption of the peripheral immune response to 
C. parvum reduced the effectiveness of it i njections of C. 
parvum; thus its antitum or activi ty was mediated i n part by 
nonspecific "fallout" from the specific im mune response 
(probably delayed-type hypersensitivity) to C. parvum. C. 
parvum injected subcutaneously (sc) at a site distant from 
the tum or only m inimally affected tumor growth, but C. 
parvum stimulation of the tumor-draining node, though less 
effective than it injection, markedly inhibited tumor 
growth. The relative m erits of sc and intravenous C. parvum 
therapy were discussed.- J Natl Cancer lnst 53: 861-865, 
1974 . 
THE PRECEDI:-\G PAPER described the use of 
systemically administered CoT)'nebacterium parvum as a 
therapeutic an titumor agent in mice and showed it to 
be largely nonspecific in its mode of action (1) . This 
repon deals similarly with the subcutaneous (sc) 
administration of C. parvum, primarily inlO the tumor 
~ite, with the same tumor model. C. jJarvum injected 
sc causes marked stimulation of the draining lymph 
node, as evidenced by increase in both mass and 
DNA synthesis (2) . Resulting systemic stimulation, 
judged by hepatomegaly and splenomegaly, is only 
marginal. 
MATERIALS AND M ETHODS 
The tumor srstem.-The characteristics of the masto-
cytoma P81~ (l\ IA) growing in the foot pads of 
(C57BL/6 X DBAj2)F1 (B6D2F1) mice and the method 
of measurement were detailed in (1). Complete re-
gressions were recorded when tumors grew to a foot-
pad thickness of at least 3 mm and then regressed 
completely. On ly mice remaining tumor free for at 
least 100 days were used for rechallen~e experiments. 
C. parvum.- Batch #PX289 from \Vellcome Research 
Laboratories, Becken ham, Kent, England, was used. 
Sltup red blood cells (SRBC).- ' RBC in Alse,·er's 
solution were purchased from the Animal Blood 
Center, yracuse, i\'ew York. They were washed 3 
times in saline before use. 
T-ce!L-deprived mice.-B6D2F1 mice were prepared 
as described in (1) . 
DNA r1ssay.-DKA synthesis in the popliteal 
lymph node after injection of materia l into the foot 
pad was assessed by injecting 20 ,uCi tritiated thymi-
dine (:-\ew England .:\uclear Corp., Boston, .\lass.) 
intravenously (iv) 30 minutes before the node was 
removed. The D.:\A/node was assayed by trichloro-
acetic acid exu·action and liquid scintillation counting 
as described in (3). 
RESULTS 
Effect of lntratumor (it) C. parvum Injection 
Six days after sc injection of 106 live .\IA cells into a 
hind foot pad, mice recei,·cd ,·arious amounts of 
C. parvum in 0.05 ml saline sc into the same site. I n-
jection of C. parvum into normal foot pads caused some 
swelling within 24 hours; this was directly propor-
tion al to the C. parvum dose. The sweJiing a lways 
subsided without lasting effect. Thus in t he experi-
mental groups shown in text-figure I, the initial rapid 
increase in foot-pad thickness after high doses of C. 
parvum is attributable to this nonspecific swelling and 
not to a rapid increase in tumor growth. All concen-
trations of C. parvum injected into the tumor lesion 
inhibited tumor growth rate, and some complete 
regressions occurred with all but the lowest C. parvum 
dose (7 .ug). The optimal dose was 70 ,ug, with 4 of 6 
complete regressions in this experiment. That 350 ,ug 
was Jess efTective than 70 ,ug has been borne out in 
repea ted experiments; the total cure rates to date 
were 20 and 44%, respectively. Injection of C. jJarvum 
it seemed highly efTective, for complete regressions 
were still achieved by treatment g iven as late as 12 
days after tumor establishment, when tumor-bearing 
feet were twice their normal thickness (text-fig. 2). 
As expected, the smaller the tumor mass, the more 
effective the therapy. 
Location of sc Injection of C. parvum 
The question arose as to whether the C. parvum 
needed to be injected directly into the tumor site to 
cfTect its antitumor activity. Mice that had had 106 
live MA cells established in the right hind foot pads 6 
days earlier received 70 J.lg C. jJarvum sc at various sites 
in relation to the tumor (text-fig. 3). C. parvum in-
jected into the contralateral foot pad had a minimal 
effect on the growth rate of the tumor and only 
slightly increased the m·erall survival time of the 
animals. C. jJarvum injected below the knee in the 
right hind leg (i.e., stimulating the tumor-draining 
node but not injected directly into the tumor site) 
caused inhibition of tumor growth rate and pro-
longed survival times; however, no complete regres-
1 Received 1\'farch 18, 1974; accepted June ·~. 197•J.. 
2 Work was perfor med during the tenure of a fellowship from 
ihc Cancer Research Institute, Tnc., 1225 Park Ave., New 
York, N.Y., and was supponed by Public lleal th Service 
contract2NO 1-CP-23221-0 I from the National Cancer Institute. 
3 Trudeau Institute, Inc., P.O. Box 59, Saranac Lake, N.Y. 
12983. 
• The excellent technical assistance of Sandra L. Warner is 
gratefully acknowledged. 
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sions occurred . Injection into the tumor site caused 
the maximum inhibition of tumor growth with the 
usual high proportion of complete regressions. 
Effect of it Injection of C. parvum in T-Ceii-Deprived Mice 
The kinetics of growth of the MAin T-cell-deprived 
mice were similar to those in intact mice, but overall 
survival time was markedly reduced. C. parvum in-
jected into the tumor site 6 days after tumor establish-
ment in T -cell-deprived · mice caused no inhibition of 
tumor growth rate and 'no increase in survival time 
(text-fig. 4). The nonspecific swelling following C. 
parvum injection was evident, however, in such mice; 
apparently this local effect of C. parvum had no 
antitumor effect. 
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TExT-FIGURE I .-Effect of various doses of C. parvum injected sc 
into the tumor site, 6 days after tumor establishment. Num-
bers in parentheses represent mean survjval time ± SE of 
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T EXT-FIGURE 2.-Effect of it injection of C. parvum (CP) on 
tumors of increasing size. At either 6, 8, I 0, or 12 days after 
injection of I QG live MA cells into a hind foot pad, mice 
received 70 Jlf! CP in the tumor site. Numbers ill parenthests 
as in text-figure I. 
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TExT-FIGURE 3.-Effect of sc injection of CP at various sites 
in relation to an ongoing tumor. Six days after injection of 
106 MA cells into the right hind foot pad, mice received 
70 p.g CP in the contralateral foot (.._,,,...._), in the right 
leg below the knee (e-e), or directly it (o•..r .. o). 
Control mice received no treatment (x-x). Numbers in 
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TEXT•FIGURE 4.- Effect of it injection of CP (350 p.g) 6 days 
after establishment of tumor in T-cell-deprived mice. 
Numbers in parenthues as in text-figure I . 
Immune Status of Cured Animals 
To test for systemic antitumor immunity in animals 
whose tumors had completely regressed after it 
injections of C. parvum, these animals were rechal-
lenged with 106 live MA cells in the foot pads contra-
lateral to the original tumor. Another group of cured 
animals was challenged with l06 cells from an unre-
lated fibrosarcoma (Kl) induced in B6D2F1 mice by 
benzpyrene (text-fig. 5). Immuqity to the MA was 
evidenced by the complete disappearance of the tumor 
after a short period of initial growth. Growth of Kl 
in normal and MA-immune mice was similar, showing 
the specific nature of the immunity. 
Delayed-Type Hypersensitivit y (DTH) to C. parvum 
The attribute of nonspecifically stimulating lymph-
oid and macrophage elements with a resultant 
enhancement of resistance to a wide range of tumors 
is shared by C. parvum and BCG. Suppression of tumor 
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Tex T-FIGURE 5.- Mice whose foot-pad tumors ( MA) had 
undergone complete regression following it injections of C. 
paruum (!\ fA immune) were challenged with either 106 live 
MA cells or 106live Kl fibrosarcoma cells in 1he contralateral 
foot pads, and the growth of those tumors was moni tored . 
Control mice (normal) had no previous exper ience of either 
tumor. 
growth at a site of infection with living BCG is 
mediated by the host during a DTH response to the 
infecting organisms (4, 5), and it thus seemed that the 
antitumor activity of it injections of C. j;arvum might 
be similarly efTected. Experiments were undertaken 
to see if delayed-type reactivity develops toward 
C. jJarvum. 
M ice were sensitized with various doses of C. fJarvum 
injected sc into a hind foot pad and, at the intervals 
shown, received an eliciting dose of C. parvum into the 
contralateral foot pad. The thickness of the latter foot 
pad was measured with a Schnelltaster dial gauge 
caliper 3 hours (Arthus reactivity) and 24 hours 
(delayed reactivity) later. Each day, control groups 
of mice received only the eliciting dose of C. parvum to 
control for nonspecific swelling; the resultant figures 
were subtracted from those of the experimental groups 
to give the increase in foot-pad thickness attributable 
to C. parvum sensitization . All doses of C. parvum caused 
delayed reactivity, which peaked 6 days after sensi-
tization; none of the doses caused any significant 
immediate reactivity (text-fig. 6) . The experiments 
were repeated with very low eliciting doses of C. 
pm vum (3 .5 ,ug) that caused no nonspecific swelling, 
and the same results were obtained. Further experi-
ments showed that neither 700 ,ug nor 350 ,ug C. 
tO OTH 24 hr.s A RTHUS 3 hrs 
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parvum injected iv resulted in any detectable delayed 
reactivity. T his accords with the recent report that 
DTH sensitization with particulate antigens is more 
readily achieved with sc than iv injection (6). 
Pre-emption of Local Immune Response to C. parvum 
T o determine the function of the local development 
of immunity to C. parvum, advantage was taken of the 
phenomenon known as "pre-emption," in which the 
capacity to mount a peripheral immune response to 
an antigen is abolished by previous systemic injection 
of the antigen (7) . The mechanism underlying this 
phenomenon is not known, but it is most probably 
based on the principle that the immune response to 
the pre-empting antigen takes place largely in the 
spleen, and subsequent failure of the peripheral lymph 
node response results from sequestration in the spleen 
of those cells capable of responding to the antigen (7) . 
In these experiments, pre-emption was achieved by 
a single iv injection of C. parvum (700 ,ug) 4 days 
before a sensitizing foot-pad injection of C. parvum 
(350 Mg). DNA synthesis in the draining popliteal 
node was compared in normal and pre-empted ani-
mals and found to be a lmost totally abolished in 
pre-empted animals (text-fig. 7, left) . DTH to C. 
p(IY/Jum, which normally arises from foot-pad sensitiza-
tion with C. parvum (text-fig. 6), was also abolished by 
the previous iv injection of C. j;arvum (text-fig. 7, left, 
inset). The specificity of the pre-emption is demon-
su·ated in text-figure 7, right. Mice that received 
C. jJarvwn iv showed an unimpaired node-proliferative 
response to SRBC, an unrelated antigen, ·whereas this 
was abolished by earlier iv injection of a la rge dose 
of SRBC. 
Function of Immune Response to C. parvum in the Anti-
tumor Effect of it-Injected C. parvum 
To determine whether the immune response to 
C. parvum was a component of the antitumo1· effect of 
it-injected C. fJar /Jlan, experiments were designed to 
test whethet its effect would be modified in animals 
tha t were pre-empted to C. parvum (i.e., unable to 
develop a peripheral immune response to C. j;ervum). 
Live :YIA cells were injected into a hind foot pad, and 
2 days later the mice received the pre-empting dose 
of C. j>arvum iv; 4 days latet, C. j>arvum was injected 
into the tumor site and the tumor was monitored for 
SENSITIZATION 
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TexT- FI GURE 6.-DTH and Arthus reactivity 
to CP. Mice received various sensitizing 
doses of CP sc into a hind foot pad. At rhe 
times shown, an eliciting dose of CP (350 
,..g) was injected sc into the contralateral 
foor pad and the foot-pad thickness was 
measured at 3 and 24 hours. For each time 
point, a group of normal mice received the 
eliciting injecLion of CP. Graph shows the 
difference in foot-pad thickness between 
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ThxT-FICURE 7.-Spccific ablation of the peripheral immune 
response to C. paruum by pl'ior systemic injection of C. par11um. 
Left: Rate of DNA synthesis (incorporation of tritiated 
thymidine into DNA) in popliteal lymph nodes after foot 
pad was inoculated with 3.5 JJf:{ C. flanmm in normal mice 
(x- x) or mice that had recieved C. parvum (700 JJg) iv 4 
days earlier (e-e). l11set: 24-hour foot-pad swelling (DTH 
reactivity) in response to a foot-pad injection of 350 JJg 
C. parvum in normal mice (crossed bars), in mice that had been 
sensitized with 350 IJ.g C. parvum sc in the contralateral foot 
pad 6 days before (hori(.Oillal bars), or in mice that received 
C. parvum (700 IJJ; )i v 4 days prior to such sensitization (solid). 
Right: DNA synthesis in popliteal lymph nodes in response 
to a foot pad injection of lOS SRBC in normal mice (x- x) 
or in mice that had received either 700 JJg C. pa111Um iv 
(e-e) or l()t SRBC iv (&~..or ... & ) 4 days earlier. Vertical 
bars represent ± SE (n=5). 
subsequent growth compared with all the requisite 
controls (text-fig. 8). C. p(lfvum given iv alone produced 
its usual transitory inhibition of tumor growth and 
increase in survival time (1). C. parwm injected into 
the tumor caused marked inhibition of tumor growth 
and some complete regressions. Injection of C. pc.rvum 
iv prior to it injection of C. parvum reduced the effect 
of the it injection. The growth rate of the tumor 
was similar to that seen after iv administration of 
C. parvum a lone, as was the mean survival time of 
animals that died. The reduction in effect of it-
injected C. parvum by prior iv treatment with C. parvum 
was not significant at the o,·erall survival level ; how-
ever, rhe differences in the mean sizes of the pro-
gressively growing tumor became significant at day 
30 (P < 0.025). The experiment was repeated with 
similar results: it-injected C.jJarvum alone resulred in a 
sun'ival time of 49.2±6 days (mean ± SE) with 2 
cures. T he pre-empted group's sun·ival time was 
45.0± 2 days with I cure, and the difference in tumor 
size between these groups was significant from 20 
days. That some regressions did occur in the pre-
empted groups is significant, since C. parvum gi,·en iv 
alone 2 days after tumor establishment has never 
caused any complete regressions (1). 
DISCUSSION 
C. parvum injected directly into the site of an ongoing 
tumor is highly inhibitory for tumor growth and 
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TEXT•FICURE a.-Effect of CP on inhibition of tumor growth 
by it injection of CP. Mice received either CP (350 JJg) 
injected it 6 days after tumor establishment <•-•>. 
CP (700 IJ.g) iv 2 days after tumor ( •,.,~• ), or CP both iv 
and it at 2 and 6 days after tumor, respectively (Ori•O ). 
Control animals received no treatment. Numbers in 
parentheses as in text-figure I . 
causes some complete regressions. Optimal results 
were achieved when the C. parvum was injected into the 
tumor site; however, stimulation of the tumor-drain-
ing lymph node by C. parvum not injected into the 
tumor site also markedly inhibited tumor growth, 
but did not achieve any complete regressions. These 
findings agree with a recent report describing com-
plete regressions of mouse adenocarcinomas after 
it C. parvum injection (8). With both the adenocar-
cinoma model and this ~IA, mice whose tumors had 
regressed completely under the influence of it-injected 
C. parvum exhibited strong specific antitumor immunity 
upon rcchallenge (8). This was so despite the fact 
that the YfA is extremely poorly immunogenic in 
B6D2F 1 mice (1). 
The antitumor effect of it-injected C. parvum is not 
atu·ibutable to any intrinsic antitumor activity of the 
C. parvum itself, but requires mediation by the host's 
own immune system as evidenced by the abrogation 
of the effect in T -cell-deprived mice. 
The optimal it dose ofC.parvum was 70 ,ug; 350 ,ug 
was consistently less effective. This dose discrepancy 
may be due to overstimulation of the draining node 
by the higher dose of C. p,?rvum. Destructive changes 
in regional lymph nodes after foot-pad injection of 
highly virulent strains ofBCG have been reported (9) . 
Pre-emption of the peripheral immune response to 
C. parvum shows that a component of the mode of 
antitumor action of it-injected C. parvum results from 
the development of the immune response to C. parvum 
itself. T hat the development of DTH reactivity to 
BCG is responsible for its antitumor effect (4, 5), 
along with the demonstration of the T-cell-dependent 
nature of C. parvum reaction, suggests that the DTH 
component of the immune response to C. parvum may 
also be responsible. This is, however, equivocal, since 
pre-emption of the peripheral immune response to 
C. parvum abolished all aspects of that response as 
measured by cell proliferation. Other studies have 
also described tumor regression at the site of DTH 
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reactions to skin-sensitizing agents (10). Since stimu-
lation of the tumor-drain ing node by C. parvum not 
injected into the tumor site caused marked inhibition 
of tumor growth, interaction between C. parvum and 
tumor cells may also occur by means of the regional 
lymphatics. ::\ot all the antiwmor activity of C. parvum 
is attributable to a nonsr.ecific "bystander" effect, 
since ablation of the Feripheral immune response to 
C. parvum did not completely abolish its antitumor 
effect. The residual activity is readily attributable to 
the intrinsic noPspecific antitumor activity of C. 
parvum-activared macrophages as described in (1). 
Indeed, 4 days after an it injection of C. parvum, 
histologic studies have shown large numbers of macro-
phages throughout the tumor (8). That the antitumor 
is not tOta lly correlated with DTH reactivity to C. 
parvum is funher e,·idenced by the finding that, 
whereas all closes of C. j;arvum (350-7 Jlg) produced 
equivalent high Je,·els ofDTH (text-fig. 6), the highest 
and lowest doses were considerablv less efficient at 
destroying the wmor (text-fig. I). ' 
I njection of C. j)(lrvum it has thus been shown, in 
this and other tumor systems, to be highly effective in 
causing complete regressions of large rumors (8) . Ref-
erence to the previous paper (1) a llows a comparison 
of the present antitumor effects with those of sys-
temically administered C. parvum. The it injection is 
considerably more effective than iv injection in inhib-
iting tumor growth ; C. parl!um injected iv only 2 d ays 
after tumor establishment (compa red with 6 days for 
the it injection) caused only transient inhibition of 
growth and no comple te regressions. The it injection 
has the added advan tage of producing systemic speci fie 
an ti tumor immunity which C. parvum injected iv fai led 
to do. C. jJarvum injected sc near, bm not into, t.he 
tumor site again caused more inhibition than C. 
parvum iv, though both ·were less effective than the 
it injection . Likhite and Halpern (8) obtained simi lar 
results wi rh mulriple injections of C. jJarvum used 
against a mammary adenocarcinoma in mice; sc in -
ject.ions of C. jJarllum near the tumor site were less 
effecti,·e than it injections but more effecti,·e than 
intraperitoneal injections ( 8) . 
The l\IIA P815 metastasizes but does not readily 
lend itself to a study of metastases, since the lesions 
are highly inconsistent. VVid1 regard to the effect of 
sc inoculations of C. parvum on blood-borne tumor 
cells, predous work has demonstrated that C. jHtrvum 
inje~ted sc into the neck region confers no protection 
agamst a subsequent low-dose .MA challenge iv, 
whereas C. parvum injected iv markedly increased 
sun·ival times (1) . Another study of a fibrosarcoma 
that produces consistent experimental metastases in 
the lung after iv injection describes, however, that sc 
injection of C. jJarvum significnntly reduced the number 
of metastases genera ted on the lung ( 11). 
Other considerations favoring local rather than 
~ystemic. ad ministration of C. parvum are as follows: I t 
tS effecu,·e at relatively low doses, thus eliminatincr 
the toxicity problems encountered wi th the hiah dose~ 
requ!r~d fot· the antitumor effects after ~ystemic 
aclnumstratton of C. jJCm.mm (1). Also eYiden t is the 
clinical preference for local rather than systemic 
administration of any par ticulate material. Fur ther 
·work has now also shown that local administration of 
C. p(lfvum circumvents the possibility of nonspecific 
T -cell depression that often accompanies systemic 
injection of C. jJarvum (2) . For optimal effects, C. 
jJarvum given sc should be administered either directly 
inro the tumor or as close as possible to the tumor site. 
Ongoing studies show that this problem may be 
alleviated to a certain extent by utilizing the marked 
systemic immuniry that results from an injection of 
C. jJarvwn mixed with irradiated tumor cells (Scott, 
in prepara tion) . 
I t appears that the mode of action of it-injected 
C. parvum is sin1ilar to that of BCG in that a specific 
immune response to these agents nonspecifically sup-
presses tumor cells at rhe site of reaction ( 4, 5) . The 
apparent advantage of C. parvum over BCG is that it 
is effecti\·e in killed form, thereby circumventing such 
problems as loss of viabili ty and only retrospective 
knowledge of actual dose administered . Further, a ll 
dangers of resulting systemic infection are eliminated . 
Recent data indicates that sc injection of viable BCG 
is nor as effective in reducing the incidence of pulmo-
nary metastases in mice as is C. granulosum (12), which 
is closely related to C. parvum in its lymphoreticular-
stimulating properties (13). Studies designed to 
compare the antirumor capabilities of C. jJarvum and 
BCG against i\IIA P8 15 are now in progress. 
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Potentiation of the Tumor-Specific Immune Response by Corynebacterium parvum 1 ' 2 
Martin T. Scott s,• 
SUMMARY-Strong, specific, cell-mediated antitumor immunity 
resulted from the sc injection into mice of Corynebacterium 
parvum (CP) mixed with Irradiated cells from mastocytoma 
P815 (MA), whereas injection of irradiated MA alone was with· 
out effect. Maximum immunity was achieved with small doses 
of CP, and the injection sites of CP and irradiated MA did not 
need to be coincident but required common lymphoid drainage 
for immunity to result. The process was largely T·cell depend· 
ent but not dependent on the development of a specific im· 
mune response to CP; it was also demonstrable and effective 
in a therapy situation. No such immunity was evident after 
systemic administration of CP and irradiated MA. Simultane· 
ous systemic injection of CP and irradiated MA did, however, 
nonspecifically reduce the enhancing , effect of systemic injec· 
tion of irradiated MA alone. J Natl Cancer lnst 55: 65-72, 
1975. 
SOME ANEROBIC CORYNEFORM$ with lymphoreti· 
cular stimulating properties, notably Corynebacterium 
parvum (CP) and C. granulosum, exhibit antitumor ac-
tivi ty in animals (1-8) and man (9, 10) wh en given in 
the form of killed vaccines. Interest in these organisms 
as anticancer agents originally arose because of their 
marked stimulatory effect on phagocytic cells, and mac-
rophages activated by CP and C. granulosum have sub-
sequently been demonstrated to nonspecifically inhibit 
tumor cell growth in vitro (7, 11-1 3) . Evidence has ac-
cumulated that the in vivo antitumor effects of CP may 
be largely nonspecifically mediated, presumably by such 
an activated macrophage system. The in vivo antitumor 
activity of CP is operative in T-cell-deprived (7, 14) 
and antilymphocyte serum-treated mice (15). It is also 
radioresistant (4) and effective in mice genetically se-
lected for low antibody responses (16). Under some cir-
cumstances, augmentation of specific antitumor re-
sponses may also be a component of CP's mode of 
antitumor activity as suggested by the recent findings 
that mice whose tumors had completely regressed after 
CP was given intralesionally (3, 8) were highly and spe-
cifically immune to subsequent tumor challenge. 
This paper describes the strong, specifi c, cell-mediated 
immunity that results from the sc injection of CP mixed 
with irradiated tumor cells into mice, and the failure to 
achieve such immunity with systemic injections. The op· 
timal immunizing conditions are described, and the 
efficacy of such immunity in a therapy model is demon-
strated. 
MATERIALS AND METHODS 
Animals.-Adult male (C57BL / fiXDBA/ 2)F, (B6D2F,) 
mice were used. 
T-cell-dejJrived mice.-Thymectomized, irradiated, 
bone-marrow-reconstituted mice were prepared as in 
(7). 
CP.- A formal-killed suspension of CP (7 mgf ml) 
was obtained from Burroughs Wellcome Co., Research 
Triangle Park, North Carolina. Subsequent dilutions 
were made with saline. 
Tumm·.-Mastocytoma P815 (MA) was originally in-
duced in a DBA/ 2 mouse by 3-methylcholanthrene. 
The experimental use and characteristics of MA in 
B6D2F, mice were described in (7, 8). The tumor was 
maintained in ascites form by weekly passage, and var-
ious numbers of tumor cells in H anks' balanced salt so-
lution (HBSS) containing 20 U heparin per ml were in-
jected sc either into the footpad (0.05 ml with a 
30-gauge needle) or the thigh (0.1 ml with a 26-gauge 
needle) . Tumor growth in the footpad was measured as 
footpad thickness by a dial gauge caliper (Schnelltaster, 
H. C. Kroplin GMBH, Hessen, West Germany). Tumor 
growth in the thigh was measured as two diameters at 
right angles, the size being expressed as the multipli-
cand. Once the tumor became necrotic, the measure-
ments were discontinued and the mice scored for sur-
vival only. Mean tumor sizes at various time points were 
compared by the Student's /- test, and relevant differences 
were noted. 
Irradiation of tumor cells.-Tumor cells (107 f ml) to 
be irradiated were suspended in Eagle's minimum essen-
tia l medium (Grand Island Biological Co., Grand Is-
land, N.Y.) containing 10% fetal calf serum (Flow Lab-
oratories, R ockville, Md.). Six thousand rads of 
y-irradiation were delivered from a 13'Cs source at a 
dose rate of 32 rads per minute. After irradiation, the 
cells were resuspended in HBSS (20 U beparinfml) be-
fore injection. 
RESULTS 
Tumor Immunity Resulting From Local Injection of CP-Irradiated 
Tumor Cell Mixtures 
Mice were given a mixture of 107 irradiated MA cells 
and 175 p.g CP sc in the left hind footpad. They were 
challenged 7 days later with 10° live MA cells injected 
into the contralateral footpad, and the growth of this 
tumor was monitored. Control groups were either un-
treated or pretreated with irradiated MA or CP alone 
(text-fig. 1). The growth of 106 MA cells in the foot· 
pads of normal mice conformed to that described pre-
viously (or this tumor model and no survivors were re-
corded (7, 8). Injection of CP alone did not influence 
tumor growth as evidenced by tumor size and mean sur· 
vival data. I njection of irradiated MA alone also did 
not significantly modify tumor growth. The mean sur-
vival time of these animals was marginally less than for 
normal mice (P<O.l) in the experiment shown; how· 
ever, repeat experiments showed no overall statistical1y 
significant difference in survival time for these two 
groups. I njection of CP-irradiated MA mixtures mark-
edly inhibited tumor growth (in some cases, com-
pletely) and increased survival times. The systemic na-
1 Received October 23, 1974; accepted March 21, 1975. 
2 This work was performed during the tenure of a fellowship 
from the Cancer Research Institute, Inc., 1225 Park Ave., New York, 
:'\.Y .. and was supported by Public Health Service contract 2NOI -
CP·23221 £rom the Division of Cancer Cause and Prevention, Na-
t ional Cancer Institute. 
3 Trudeau Institute, Inc., Saranac Lake, N. Y. 12983. Present 
address: Department of Experimental Immunobiology, Wellcome 
Research Laboratories, Beckenham, Kent BR3 3BS, England. 
1 The excellent ·technical assistance of Sandra L. Warner is grate· 
fully acknowledged. 
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ture of the tumor immunity after InJection of 
CP-irradiated MA mixtures was further demonstrated in 
experiments where the challenge MA cells (104 ) were 
injected iv and survival data recorded. Normal mice all 
succumbed to the iv challenge, with a mean survival 
time of 20.5 ± 1.6 (sE) days, whereas only 3 of the 10 mice 
pretreated with CP-irradiated MA mixtures died during 
a 60-day period. 
Dose of CP in the Mixtures 
The effect o£ varying the amount of CP in the 
CP-irradiated MA mixture~ was investigated. Groups 
of mice received 107 irradiated MA cells mixed with dif-
ferent amounts of CP sc into the hind footpad. Tumor 
was challenged 7 days later in the contralateral footpad 
(text-fig. 2). The lowest dose of CP (3.5 p.g) was most 
effective at producing tumor immunity; it caused four 
complete inhibitions of tumor compared with only one 
in mice given 175 /Lg CP. The difference in tumor size 
between these two groups was also significant (P<0.05) 
from day 14 onward. Accumulated results from repeated 
experiments showed cure rates for 175-p.g and 3.5-p.g 
groups of 20.0 ± 3.1 (sE) and 45.8 ± 4%, respectively. 
There was no significant difference in tumor size be-
tween the 3.5-/Lg and the 17.5-/Lg groups throughout the 
experiment, and the 35-/Lg group appeared intermediate 
between the 175-/Lg and lower-dose group, as judged by 
tumor size and number of complete inhibitions. 
Dose of Irradiated MA Cells in Mixtures 
Between 1-2X 107 irradiated MA cells was the highest 
number practical to include in the mixtures because of 
the small injection volumes required for footpad inocu-
lation. Less than this number of irradiated MA cells 
(106, 10~. 104) mixed with CP gave significantly less im-
munity to the tumor challenge, as judged by tumor 
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T.EXT·FIGVRE I.-Tumor immunity arising from sc injection of CP-
irradiated MA mixtures. Mice were inoculated sc in the left hind 
footpad with 175 pg CP (0--0), 107 irradiated MA (.&--.&), 
or a mixture of 107 irradiated MA and 175 pg CP (e ---e ). 
Controls were untreated (x-- x). Seven days later, all mice 
received 106 live MA cells in the contralateral footpad and 
growth of this tumor was measured. Vertical bars represent ±sE. 
Numbers are: mean survival time ±SE of those mice that died, 
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T EXT-FIGURE 2.-Effect of different doses of CP in CP-irradiated 
MA mixtures. Various doses of CP were mixed with 107 irradi-
ated MA and injected sc into the left hind footpad. Seven days 
later, '1()6 live MA cells were injected into the contralateral foot-
pad and growth of this tumor was measured. Numbers are as in 
text-figure I. 
Duration and Specificity of Tumor Immunity 
Duration of the immunity was ascertained by the re-
challenge of mice whose previous challenge tumors had 
completely regressed. A group of 7 such mice from var-
ious experiments were rechallenged between 99 and 160 
days after their initial tumor challenge. Transient 
tumor growth was evident in 5 of these mice but the 
tumor subsequently regressed, which left all the mice 
tumor free by day 30. Controls all died with large tu-
mors; their mean survival time was 27.2 days. Specificity 
of the immunity arising from the injection of CP-irra-
diaied MA mixtures was tested by challenge of MA-im-
mune mice with 106 live cells from an antigenically 
unrelated, benzpyrene-induced fibrosarcoma Kl (8). 
Growth of the fibrosarcoma in the footpad of MA-im-
mune mice was no different from that in normal mice. 
Effect of Varying the Site of Injection of Irradiated MA Cells 
and CP 
To determine whether CP and tumor antigen need to 
interact at the same site to produce tumor immunity, 
the following experiment was designed to effect differing 
degrees of lymph node mediation between the MA cells 
and CP. All mice received irradiated MA cells sc in the 
left hind footpad. In the first group, the irradiated MA 
cells were mixed with CP; other groups received CP as 
follows: sc below the knee of the left leg, sc into the 
thigh of the left leg, or sc into the neck region. Controls 
received only irradiated MA in the left footpad. Seven 
days later, all groups were challenged with live MA in 
the right hind footpad and the growth of this tumor 
was monitored (text-fig. 3) . The combination of CP 
into the neck and irradiated MA in the footpad caused 
no tumor immunity as evidenced by the lack of influ-
ence on the challenge tumor. CP injected into the thigh 
was expected to involve the popliteal node draining the 
site of immunization with MA (at least to some extent) . 
CP at this site did significantly inhibit tumor growth 
and prolong survival time; but inhibition of tumor 
growth was less than that seen after injection of CP and 
irradiated MA into the same site. The difference in 
tumor size between 'these groups was significant 
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(P<0.05) from day 19 onward. CP injected into the leg 
below the knee would be likely to fully engage the node 
receiving the stimulus from the irradiated MA and, as 
expected, inhibition of tumor growth in this instance 
was not significantly different [rom that in mice receiv-
ing CP mixed with irradiated MA in the footpad. In 
the latter group, however, there was one instance of 
complete tumor inhibition. 
l ymph Node Cell Transfer Studies 
To determine whether the CP-induced tumor immu-
nity was cell mediated, lymph node cell suspensions 
were prepared from the popliteal lymph nodes of mice 
that had received footpad injections of CP-irradiated 
MA mixtures 8 days previously. The lymph node cells 
were mixed with live MA cells at a ratio of 200: I 
(2x 107 lymph ·node cells:l05 live MA cells per injec-
tion) and injected sc into the thighs of mice which had 
been sublethally irradiated (400 rads) 24 hours before. 
Two controls were the growth of MA cells mixed with 
normal lymph node cells (mesenteric) or cells from pop-
liteal lymph nodes which had been stim ulated by CP 
injection alone (text-fig. 4A). Lymph node cells stimu-
lated with CP-irradiated MA mixtures totally inhibited 
tumor cell growth, the experiment being terminated at 
54 days. Except for the transient inhibition of tumor 
growth seen around day 12 with lymph node cells stimu-
lated by CP alone, there was no overall difference be-
tween the tumor growth and mean survival times of the 
groups receiving MA mixed with either CP-stimulated 
cells or normal cells. 
Serum Transfer Studies 
Serum transfer experiments were done to determine 
whether the CP-induced tumor immunity was entirely 
cell mediated. Serum was prepared from mice given CP-
irradiated MA mixtures in both hind footpads 10 days 
before. Normal mice were bled for control serum. Mice 
sublethally irradiated (400 rads) 24 hours previously re-
ceived 0.4 ml undiluted serum iv followed by 10~ live 
/ MA liP •- • 
CPn•ck + o- o 
CPthigh + •-- - • 
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T.,;xT·FICURE 3.-EITect of CP and irradiated MA cells injected at 
different sites. All mice recei,·ed 101 inadiated MA sc in the lefl 
hind footpad. C P (175 pg) was then injected sc into the same 
site (X - - - X), below the knee of the left teg (.._.), in the 
left thigh (A- - A), or into the neck (0--0). Controls received 
only irradiated MA (X - -X). Seven days later all groups were 
challenged wi.th 106 li\'e MA in the right hind footpad and 
growth of th1s tumor was measured. Numbers are as in text· 
figure l. 
~ 
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TEXT-FIGURE 4A.- Transfer of tumor immunity by lymph node cells. 
Mesenteric lymph node cells (107) from normal m1ce (...._.....), 
or popliteal node cells from mice given either 175 pg C P plus 
101 irradiated MA (0--0) or only 175 11g CP (X--X) sc into 
both hind footpads 7 days bc£ore were mixed with 105 live MA 
cells and injected sc into the thighs of sublethally it;radiated 
recipients. Growth of the tumor in the thigh was measured. 
Nrtmbers are as in text-figure I. B. Serum transfers. Live MA 
cells (1().';) were injected into the thighs of subl'ethally irradiated 
recipient mice. Immediately after tumor injection, the mice re-
cei\'ed 0.4 ml undiluted serum iv from mice either inoculated in 
both hind footpads with 175 11g CP plus 107 irradiated MA 
(~--8) 10 days be£ore or untreated <• ---e). Controls re-
ceived no serum ( X- -X). Numbers are as in text-figure I. 
MA cells sc into the thigh. Growth of the tumor in the 
thigh is shown in text-figure 4B. Both normal and "im-
mune" sera were without effect. A modification of these 
experiments was to mix the live MA cells with undi-
luted serum and inject the mixture sc into the thigh; 
here again no serum-mediated antitumor immunity or 
enhanced tumor growth was found. 
T-cell Dependence of Tumor Immunity 
The apparent noninvolvement of serum, along with 
the ability of the author to transfer the effect with cells, 
indicated cell-mediated immunity. This prompted an in-
vestigation into the T-cell dependence of the phenome-
non. T-cell-deprived mice were given CP-irradiated MA 
cell mixtures sc into the hind footpad, and 7 days later, 
challenged with 106 live MA in the contralateral foot-
pad. Control T -cell-deprived mice were untreated (text-
fig. 5). The kinetics of growth of MA in deprived mice 
was like that in intact mice, but survival times were con-
siderably shorter (7, 8) . The survival of deprived mice 
pretreated with the mixture was prolonged (P<O.Ol) 
compared with untreated deprived mice, but the usual 
marked inhibition of growth of the solid tumor seen in 
intact mice (text-figs. I, 2) was absent; there was no 
significant difference in tumor size between the groups 
at any point. 
Role of Immune Response to CP in Development of Tumor 
Immunity 
A previous study with B6D2F1 mice detailed how an 
iv injection of a large dose (700 J.l.g) of CP 4 days be-
fore a footpad inoculation of CP makes the popliteal 
(draining) lymph node speci fically unable to proliferate 
in response to the footpad CP injection (8). With the 
use of this technique, the specific immune response to 
CP was demonstrated to underlie part of the antitumor 
activity of an intratumor injection of CP (8). This de-
vice of "preempting" the local immune response was 
used here to determine whether the immune response to 
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TEXT-FIGURE 5.-Tumor immunity in T-cell-deprived mice. T-ecH-
deprived mice were inoculated in the left hind footpad with 101 
irradiated MA plus 175 ,ug CP (~ -0) or untreated (X--X). 
Seven days later they were challenged with 1()6 live MA cells in 
the contralateral footpad and growth of this tumor was meas-
ured. Nttmbers are as for text-figure I. 
cific antitumor immunity under the present conditions. 
The failure of the preempted nodes to respond to CP in 
the following experiments was evident from their failure 
to grow after footpad inoculation compared with nor-
mally responding nodes. 
A group of mice received an iv injection of 700 p.g CP 
and, 4 days later, an immunizing dose of CP-irradiated 
MA mixture into both hind footpads. Controls were un-
treated or received only the immunizing mixture. Eight 
days Jater lymph node cell suspensions were prepared 
(rom the popliteal nodes of immunized mice and mesen-
teric nodes of normal mice. Lymph node cells were 
mixed with live MA cells at ratios of 5'0: 1, 20: I, and 
10: l and injected into the thighs of mice given 400 rads 
l day before. Each mouse received 105 live MA cells. 
The results of the 10:1 transfer are in text-figure 6. 
Growth of MA cells mixed with normal cells was evi-
dent at 7 days and all mice were dead within 20 days. 
No tumor growth was obvious until day 14 in the 
groups receiving either immune cells or preempted-im-
mune cells, and then only 2 of the preemptea group 
and 3 of the unpreempted group developed tumors. A 
similar relationship was found with cell ratios of 50:1 
and 20:1: Only I mouse in each group given un-
preempted immune cells developed tumors and none ap-
peared in mice receiving preempted cells. The fact that 
CP-irradiated MA mixtures were fully capable of gener-
ating tumor immunity in lymph nodes that bad been 
preempted against responding to CP suggests that im-
munity to CP was not involved in its mediation of the 
tumor immune-response. 
Tumor Immunity Arising From Systemic Injection of 
CP-lrradiated MA Mixtures 
Various considerations, outlined in the "Discussion," 
Jed to the speculation that tumor immunity may not re-
sult from CP-irradiated MA mixtures injected systemi-
cally. To test this, mice were inoculated ip with 5x l07 
irradiatecJ MA cells mixed with 350 fJ.g CP. Control 
groups received either no treatment, CP, or irradiated 
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TEXT-FIGUI\E 6.-Mesenteric lymph node cells (106) from normal 
mice (X--X), 106 popliteal node cells from mice given either 
a mixture of 3.5 ,ug CP and 107 irradiated MA sc in both hind 
footpads 8 days previously (e ---e ), or, in addition, a pre· 
empting dose of 700 ,ug CP iv 4 days before the mixture (e--e) 
were mixed with 105 live MA cells and injected sc into the 
thighs of sublethally inadiated recipients. Growth of the tumor 
in the thigh was measured. Thir1 li11es represent tumor growth 
in individual animals (see text). Num.be1·s are as in text-figure l. 
MA alone. Seven days later, all mice were challenged in 
a hind footpad with 106 live MA cells and the growth of 
this tumor was monitored (text-fig. 7) . CP alone was 
marginally but not significantly inh ibitory. Injections ip 
of irradiated MA cells alone enhanced growth of the 
challenged tumor. This increase in tumor size was 
highly sign ificant (P<0.001) at day 16, as was the re-
duced overall mean survival time (P<0.005). Although 
the injection of CP-irradiated MA mixtures was no 
more inhibitory than CP alone, the presence of CP com-
pletely abolished the enhancing effect of the irradiated 
cells. The experiment was repeated by the iv injection 
route (text-fig. 7B) . The dose of irradiated MA cells 
was reduced to 107 , since higher numbers caused some 
immediate deaths due to cell clumping in the inoculum. 
Again, CP alone did not significantly inhibit tumor 
growth, and irradiated MA cells alone caused significant 
tumor enhancement; the difference in tumor size at day 
16 and the overall mean survival times between normal 
and enhanced animals were P<0.005 and P<0.001, re-
spectively. Injection of CP-irradiated MA mixtures again 
significantly abolished the enhancing effect of the irra-
diated MA cells but was 'no more inhibitory than CP 
alone. A similar protocol was used in a further experi-
ment where the effect of varying the dose of CP in the 
mixtures was studied. Irradiated MA cells (107 ) were 
mixed with either 700, 350, 70, or 7 p.g CP. At no dose 
of CP was the tumor inhibition caused by the mixtures 
greater than that r(:!sulting from CP inject ion alone. 
Spleen Cell Transfers 
Systemic injection of CP-irradiated MA mixtures thus 
failed to confer any overall protection against subse-
quent tumor challenge, which suggested no development 
o£ tumor immunity. A possibility remained, however, 
that the significant abrogation of the enhancing action 
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TExT-FtCURE 7 A.- Mice received an ip injection of 5 X I O• irradiated 
MA plus 350 p.g CP (A--A}, irradiated MA (0----0), CP 
<• ---e) alone, or no. treaune!tt (X- _-X). ~even days later 
they were challenged with I ~ h ve MA 111 a hmd footp_ad and 
the growth of this tumor was measured. Numbers arc as 111 texL-
Iigu•·e l. B. Croups are the same as in. A, ~xcept pretreatment 
was by the iv injection route and the trradtatcd MA dose was 
reduced to 10•. 
of irradiated MA alone indicated the development of 
tumor immunity. To detect any such immu~1ity, sple~n 
cell transfer experiments were performed. M!ce were In-
oculated iv with either CP-irradiatecl MA mtxtures, CP, 
or irradiated MA cells alone as above. Seven days later 
spleens were removed and sing_le cell_ suspensions pre-
pared. The spleen cells were mtxed With hve MA cells 
at a ratio of ~00: I (2 X l()r spleen cells: I 05 ~IA c_ells pe1· 
injection) and i njccted sc into the th1ghs of mtce that 
had received 400 rads 24 hours before. Growth of the 
tumor in the thigh was followed for _sigt_ls_ of im~unity 
(text-fig. 8) . Tumor growth was n_ot mlubned wtth any 
spleen cell group, nor were any cltfferences between the 
groups statistica lly significant. 
Therapeutic Use of CP-Irradiated MA Mixtures 
Tumors were established in the right hind footpads of 
mice by sc injection of 106 live MA ~el !s. Three _days 
later, CP-irradiated MA mixtures were 111Jected sc etther 
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TEXT-FJCURF. 8.- Spleen cells, 2xl07, from normal mic~ (X--X), 
mice g iven 10 irradiated MA cells plus 350 pg CP IV (....___.), 
irradiated MA (~--A), or CP (0---0) al0!1c. 7 days pre-
viously were mixed wilh 10 live MA _cells and llljected sc 1111.0 
the t.highs o{ sublethally Jl'radtated m tce. Growt~ of the tumor 
in the thigh was then measured. Numbers are as 111 text-figure I. 
tumor-bearino- leg. Controls received injections of CP 
b ' I 1 alone at the same sites. Text-figure 9 shows t_1e resu _ts 
of the experiment with a CP dose of 175 p.g wt th 107 u·-
racliated MA cells. CP alone in the contralateral footpad 
was without effect; however, tumor resistance after CP-
irracliatecl MA' mixtures was evident from the plateau in 
tumor growth between days 12 and 17: Followi~1g this 
transient inhibition, tumor o-rowth contmuecl at 1ts nor-
mal rate. The increased t~ean survival time of this 
group compared to m_ice. treated with CP a l<?ne was s!g· 
nificant (?<.05). lnJecuon o~ C_P. ~lone uno a s~te 
near the wmor caused marked mhibltiOn of growth, Ill· 
creased su rvival times, and one complete regression. 
Tumor growth after injection of CP-ir~adiated MA mix-
ture at this site was not significa ntly dtfferent from that 
following CP injection alone at any P?i nt i~ the g1·owth 
curve, nor were the overall mean survtval tunes of those 
animals that died. There were, however, two complete 
regressions in the inst_ance of_ the mixture i~ject_ion . 
Since from the prevention studtes (text-fig. 2) 1t nll_ght 
be predicted that stronger immun ity wo~lld result 1f a 
lower dose of CP were used, the expenment was ~·e­
peated with 3.5 p.g CP in the CP-irradiated MA mtx-
tures. The results were like those with the 175-p.g dose 
with re<rard to tumor growth and overall survival times. 
The relationship between the groups was also similar, 
and the ultimate cure rates were the same. 
70 SCOTT 
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DAYS AFTER TUMOR 
TEXT·FICURE 9.-Three days after establishment of a tumor in the 
right hind footpad by injection of 106 live MA cells, mice were 
treat~d w~th an injection of 175 p.g CP (e --- e ), 175 l"g CP plus 
101 trrad•ated MA (0--0) mto the left footpad, 175 pg CP 
(A -:--- A) or 175 l"g CP plus 101 irradiated MA cells (8--11) 
sc JUSt below the knee of the tumor-bearing leg. Controls were 
untreated (X--X). Numbers are as in text-figure l. 
DISCUSSION 
These data show that when CP is mixed with irra-
diat~d tumor cells and injected sc, strong, specific, sys-
~em1c ~ell-~ediated antitumor immunity results. This 
1m~un1ty ts ?e_mo~strable and effective in a therapy sit-
uauon; the_ IOJ_ectl<:~n of such mixtures is consistently 
n~ore effecttve m etther terms of prolongation of sur-
VIval or number of tumor regressions than injection of 
CP alone. These findings are in accord .with recent stud-
ies des_cr!bi~g the successful, _specific, therapeutic use of 
local mJecuons of CP-irradtated tumor cell mixtures 
against a mouse 3-methylcholanthrene-induced fibrosar-
com~ (Bo~ford .~: Manuscript in preparation). That 
the 1mmumty ansmg from the inte-raction of CP with 
tumor cells is cell mediated is also evidenced by the re-
cent demonstration that cells from the tumor-draining 
lymph node exhibited increased cytolytic antitumor ac-
tivity in vitro after intratumor CP therapy of a mouse 
mammary carcinoma (17). 
The CP-mediated anti-MA immunity in this study 
was reduced in T-cell-deprived mice, which suggests the 
phenomenon to be at least partially T-cell dependent. 
Bomford (Manuscript in preparation) also finds that 
the therapeutic effects of CP-irradiated tumor cell mix-
tures are considerably reduced in T-cell-deprived mice, 
and subsequent experiments in this laboratory indicate 
that the in vit_ro. tumor inhibitory capacity of lymph 
node cells. dram1~g ~he site of mixture injection in 
T-cell-depnved m1ce IS less than that of intact mice 
(Scott' MT: Unpublished data). Considerable data have 
accumulated showing that the effect of CP on various 
manifestations of T-cell-mediated immunity is one of de-
pression rather than augmentation (18-22). In such re-
ports, however, CP was used systemically, and some 
recent observations concerning the CP-mediated de-
pression of delayed hypersensitivity to sheep red cells 
show that no depression occurs if CP is injected locally 
rath~r th~n sys~emically .. The impairment of cell-
medtated tmmumty by CP 1s apparently centered in the 
-spl~en (22) _. ~here are data _from nontumor systems 
whtch also mdtcate augmentation of cell-mediated im-
munity by a local effect of CP. C. granulosum, which is 
similar ~o CP in its ret~culoendothelial stimulatory (23) 
and a~tttumor properttes (24), has been shown to have 
an adJuvant effect on the purely T-cell response to azo-
benzenearsenate-N-acetyl·L·tyrosine when mixed with an-
tigen and injected locally (25). 
. The _present study failed to demonstrate any tumor 
unmumty after the systemic administration of CP and 
irradiated MA cells either iv or ip. The combination of 
CP iv ~nd ir~adiated MA sc similarly failed to evoke 
tumor 1mm_untty (7) :. Some other data support the idea 
t~at sy~temic CP does not augtnent specific tumor immu-
mty. Btweekly therapeutic ip injections of CP and killed 
mammary adenocarcinoma cells are no more tumor inhi· 
bitory than ip injections of CP alone (26). Another 
st_udy showed that CP given ip did not augment the in 
vitro cytotoxicity of tumor-draining lymph node cells, 
whereas local CP injection did (17). At variance with 
these results are those reported for a mouse leukemia 
model in which cytolytic activity of lymph node cells 
from a tumor-bearing mouse was both enhanced and 
pr_olonged_ by CP g_iven ip (!). In keeping with the neg-
ative find111gs, vanous studies have shown that the in 
vivo protec~ive effects of systemic CP, against both solid 
and system1c tumors, are resistant to various immuno-
suppressive procedures and are therefore probably 
largely nonspecific and macrophage mediated (4, 7, 
14-16). 
The present ~lata give no insight into the reasons for 
the apparent £allure of development or lack of involve-
ment of specific tumor immunity in systemic CP-MA sys-
te'_lls; however, some considerations are apparent. The 
fatlure to achieve immunity in the instance of systemic 
CP an? periph:rally localized tumor antigen (7) may 
be attnbutable 111 part to the demonstrated requirement 
for lymph node-mediated contact between CP and 
tumor antigen. Such reasoning does not seem to apply, 
however, to systemic administr~tion of both tumor anti-
gen and CP, since contact between the two would be ex-
pected to occur at various lymphoid levels, especially in 
~he spleen. An?ther consideration is that immunity aris-
~~g from splemc and lymph node processing of antigens 
dttfers qualitatively (27). This is apparently true for the 
MA sy~tem, because the sc injection of irradiated MA 
was Without effect, whereas systemic injection consist-
ently caused tumor enhancement. It may then be that 
~urth~r manipula_tion of dosage and timing of CP and 
uTa~tated !VfA might meet the exacting requirement for 
the m~lucuon of effective antitumor immunity via the 
system1c route. Another point of interest is the reported 
depression of cell-mediated immunity by CP. Thus far, 
all reported cases of depression have followed the sys-
temic injection of CP (18-22), but not after local injec-
tion (22, 25) . 
Clearly the local injection of CP-irradiated MA tumor 
cell mixtur~s i_s a~~logous to an intratumor injection of 
CP. Some Similanues between the present findings and 
previous results obtained with intratumor injection of 
C_P into an e_stablished MA suggest that the CP-me-
dlated generation of tumor immunity may be responsi-
ble in part for the local inhibition or destruction of 
tumor after intratumor injection of CP (8) . Both phe-
nome?a are T-cell dependent. The degree of immunity 
resultmg from CI?-irradiated MA mixtures is shown here 
to be maximal if both CP and irradiated MA interact at 
the same site. 1t is reduced but still considerable if con-
tact between the two is mediated by a common draining 
lymph node, and nonexistent if the two are injected at 
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distant sites. The same is true for the effects of an sc 
injection of CP on an established MA: Intratumor injec-
tion was the most effective; reduced but marked tumor 
inhibition occurred if the tumor-draining node was stim-
ulated with CP, but distant injections were without ef-
fect (8). The present studies show that systemic tumor 
immunity is reduced with high doses of CP and the 
same is also true for tumor inhibition after intratumor 
injection of CP (8). The local antitumor effects associ-
ated with intratumor injection of CP are, however, 
clearly not all attributable to specific antitumor immu-
nity. Previous studies indicate a component of them to 
depend on the development of a specific immune re-
sponse to CP (8), whereas the present CP-mediated gen-
eration of tumor immunity is not. Another discrepancy 
is that, whereas both processes are reduced with high 
doses of CP, the overall dose responses are differen t: 
The optimal inhibiting dose of intratumor CP injected 
into an established MA was 70 J.Lg, with lower doses con-
siderably less effective (8), whereas extremely low doses 
of CP (3.5 J.Lg) mixed with irradiateq cells produced 
maximal tumor immunity. It seems then that the local 
antitumor effects of an intratumor injection of CP may 
be a ttributed to at least two sources. In addition to the 
previously described nonspecific "innocent bystander" ef-
fect arising from a specific immune response to CP (8), 
there is also the specific immune destruction of tumor 
resulting from the interaction of CP with tumor anti-
gen. 
A cause for concern with any immunostimulation reg-
imen in cancer therapy is the possibility of stimulating 
undesirable aspects of tumor immunity, i.e., enhancing 
tumor growth. To date there have been no published re-
ports of enhancement concerning CP and the present 
findings are similarly encouraging. No enhancing activ-
ity was detected in the serum of mice immunized with 
CP-irradiated MA mixtures sc. Further, the enhancing 
activity of system ic injection of irradiated l\ £A cells alone 
was abolished by the simultaneous injection of CP. The 
spleen cell transfer experiments suggest tha t this effect is 
not due to a counteracting development of tumor im-
munity but is more likely attributable to a nonspecific 
mechanism, possibly clearance of blocking complexes 
from the circulation by the activated reticuloendothelial 
system. These findings agree with those of Proctor et a!. 
(28) who also demonstrated abolition of the enhancing 
effect of irradiated rat hepatoma cells by injection of CP 
and also suggested that it may be attributable to the 
nonspecific activity of reticuloendothelial system. 
The production of specific, systemic antitumor immu-
nity by local injection of CP-tumor cell vaccine mix-
tures may be an additional clinical approach to the use 
of CP. The clinical feasibility of such tumor cell vac-
cines in combination with BCG has been established 
(29). The therapy experi ments described in this paper 
have been empirical, and further manipulation of the 
many variables involved, e.g., multiple injections, tim-
ing, and alternate means of tumor cell inactivation, may 
significantly increase the effectiveness of such mixed vac-
cines. 
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Brief Communication: Failure of Corynebacterium parvum Presensitization To Modify the 
Antitumor Effects of Systemic and Local Therapeutic lniections of C. parvum in Mice t. 2 
Martin T. Scott 3, •· s 
SUMMARY-The therapeutic effects of iv and intralesional 
injection of Corynebacterium parvum against mastocytoma 
P815 in mice, presensitized and showing marked delayed 
hypersensitivity to C. parvum, were no different from those in 
unimmunized controls.-J Natl Cancer lnst 56: 675-677, 1976. 
Evidence is accumulating that a component of the 
antitumor activity of Cm-ynebacterium pamum (CP) may 
be the cell-mediated immune response to CP itself (J-3). 
A similar dependence has been described to underlie 
the antitumor effects of two other nonspecific bacterial 
vaccines, BCG (1, 5) and Listeria monocytogenes (6). It 
was decided, therefore, to investigate whether presensiti-
zation of mice to give delayed hypersensitivity (DTH) 
reactivity <1gai nst CP would augment the efiecti veness of 
subsequent therapeutic injections of CP against an 
established tumor. The mouse tumor model, mastocytomil 
P815 (M A), was used extensively in previous studies 
(1, 7-9) to elucidate the antitumor effects of CP. 
MATERIALS AND METHODS 
Mice.-Adult (C57BLf 6 X DBA/ 2)Fl (B6D2F,) males 
were used. T cell-deprived mice were prepared by thy-
mectomy, irradiation, and bone marrow reconstitution, as 
described in (7). 
CP was provided by Burroughs ' t\Tellcome Co., Research 
Triangle Park, North Carolina. 
DTH to CP.- Mice were scnsiti;:ed by sc inj ections o( 
70 p.g CP into a hind footpad. DTH was eli cited at 
various times after sensiti:t.ation by a 70-p.g sc injection 
inlO the contralateral footpad and recorded as (ootpad 
thickness, measured with a dial gauge caliper, 2'1 hours 
after the eliciting injection. Results are expressed as the 
difference in footpad th ickncss between sensiti :t.ed mice 
and normal mi ce receiving only the eliciting injection o( 
CP. Characteristics of DTH reactivity to CP in B6D2F1 
mice were descr ibed in (1). 
Tu.mor.- The characteristics of MA and its growth 
in B6D2F, mice were described in (1, 7, 9). Solid wmors 
were established in the hind footpad by an sc injection 
of I 0° live MA cells. The footpad size was measured 
with a dial gauge caliper. Differences in mean tumor size 
between experimental groups for each time point were 
compared with the use o( a Student's t-test. 
RESULTS 
DTH to CP 
Mice were sensitized by an sc injection of CP as 
described, and DTH was el icited at the times shown in 
text-figure I. Significant levels of DTH were detected in 
intact mice 4 days after CP sensiti;:ation and were maxi-
mal by day 6. No significant DTH reactivity was detect· 
able in T cell -deprived mi ce 6 days after sensitization. 
Effect of CP Presensitization on Intravenous CP Therapy 
These experiments were arrang·ed so that the thera-
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DAYS AFTER C. PARVUM 
TEXT·F I GUR~: 1.- DTH to CP: At the times shown, an eliciting dose 
o[ CP (70 _ug) was injected into the contralatera l footpad. and 
footpad thickness measured at 24 hours (X--X). Results are 
expressed as the difference in footpad thickness between sensitized 
mice and IIII$Cnsitizcd mice receiving only eliciting Cl'. Histogram 
sho\\·s DT II reactivit y in T cell -deprived mice, 6 days after 
sen s iti ~a tion. 
·when mi ce showed marked DTH reactivity to CP. Both 
normal mice and those presensit ized wi th 70 p.g C.P sc 
into a hind footpad 4 days previously received 106 live 
MA cells sc into rhe conu·alateraJ footpad. Two days 
later mice from both groups were given either 700 p.g 
CP iv or no treatment (text-fig. 2). Presensitization 
alone had no effect on tumor growth, and CP given iv 
caused a marked but transient growth inhibition, which 
was refiected in a significantly increased mean survival 
t ime. Presensitization d id not modify the effects of CP 
given iv, as judged by both tumor growth and survival 
time. This lack of effect was confirmed in a repeat experi-
ment. 
Effect of CP Presensitization on lntratumor CP Therapy 
Mice were given sc injections of 106 live MA cells into 
a h ind footpad and, 1 hour later, received an sc sensitiz-
ing injection of 70 p.g CP into the contrala teral footpad 
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DAYS AFTER TUMOR 
TEXT·FtGURE 2.- Effect of CP prcsensitization on in tra,·enous CP 
therapy. GrO\\"th of 106 MA cells in the footpads of normal mice 
(X--X), and mice presensitized 4 days earlier by sc; injection 
of 70 J.Lg CP into lhe coutralateral footpad (0---0). CP (700 
J.lg) was injected iv 2 days after wmor es tablishment in add itional 
groups of both uormal (A. -- - A.) and scusitizcd (......_.) mice. 
Numbers in fJarentheses represent mean surviva l tim<· ± sF., num-
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T~:xT-FtGURE 3.-Effcct of CP presensitization on intratumor CP 
therapy. Growth of lOs MA cells in the footpads of normal mice 
(X--X) and mice sensitized on the same day by sc injection of 
70 pg CP into the contralateral footpad (0---0 ). CP (70 J.lg) 
was injected into the tumor, 6 days after tnmor establishment in 
additional groups of both normal (A. - -- A.) and scnsi tized mice 
~). Numbers in parentheses represent mean survival 
tirne± st:, number of survivorsJnumber in experimental group. 
or no treatment. Six days later, mice from both groups 
received 70 1-tg CP directly into the growing tumor or 
were untreated (text-fig. 3). Presensitization alone 
again did not affect tumor growth. In the experiment 
(text-fig. 3), an intratumor injection of CP in normal 
mice markedly inhibited tumor growth and prolonged 
survival time. The immune state of the presensitized 
mice was apparent from the increased swelling at the 
tumor site, 1 day after inu·atumor injection of CP. Pre-
sensitization did not modify the inhibition of tumor 
growth, and the mean survival time of those mice that 
died was significantly reduced (P<O.OOl). Two complete 
regressions did, however, occur. In a repeat experiment, 
the regression was reversed, i.e., 1/ 8 regression in the 
normal mice and 0/8 in the presensitized group. In this 
case, no significant differences were noted in either 
growth inhibition or mean survival times. 
DISCUSSION 
It is apparent that the in vivo antitumor effects of 
CP may be both specifically and nonspecifically mediated 
[reviewed in (10)]. The effects of systemic CP are 
extremely rapid in onset (11) and resistan t to various 
immunosuppressive procedures (10, 11); this implies a 
nonspecific, macrophage-mediated mechanism. Such non-
specific CP-activated macrophage activity is considered 
the predominant effect of CP given iv against MA (7). 
Recent work (2, 3) has shown that, in addi tion to a direct 
activation of macrophages by CP, there is an immuno-
logic pathway dependent on T-cell immunity to CP. 
Activation of macrophages by CP in vitro required the 
presence of CP-immune spleen cells (2), and the onset 
of macrophage activation by CP in vivo was more rapid 
in CP-sensitized mice (3). The present therapy studies 
with MA showed, however, no increased effectiveness of 
CP given iv to mice presensitized and showing DTH 
reactivity to CP. Two considerations are apparent: a) 
The direct pathway of activation may predominate in 
vivo, and b) any such u·ansient increased reactivity of 
CP-activated macrophages in CP-sensitized mice, as 
detected in vitro (3), may be insufficient to influence the 
outcome of a relatively prolonged in vivo situation. 
The failure of presensitization to modify the effect 
ot an intratumor injection of CP in the MA system is 
more impressive, since DTH reactivity to CP occurs 
directly at the tumor site. Concurrent studies (12) in 
these laboratories with fibrosarcoma Meth-A in a semi-
syngeneic system similar to the present MA model, clearly 
show that the local destruction of tumor cells by CP in 
injected mixtures of CP and live tumor cells completely 
depends on the local inflammatory response mediated 
by a DTH response to CP. Regression of such mixtures 
was enhanced in mice presensitized to CP and, in the 
case of an intratumor injection into an established solid 
Meth-A, LUmor inhibi tion occurred only in presensitized 
mice. The difference between these findings and those 
with the MA system may be reconciled by the apparent 
differences in susceptibility of the tumors to the various 
antitumor components of CP. Unlike Meth-A, local 
destruction of MA cells only partially depends on the 
nonspecific activity arising from a local immune reaction 
to CP (/). The remaining activity has been attributed 
to the CP-mediated generation of specific tumor-immune 
cells, a process apparently independent of CP immunity 
for MA (9). The fai lure of CP presensitization to aug-
ment the overall effects of an intratumor injection of 
CP against MA suggests this latter mechanism may be 
dominant. Additional experiments in the present series 
(data not included) showed that the specific tumor 
immunity arising frorn sc injection of CP-irradiated 
MA mixtures (9) is not modified in mice presensitized 
to CP. 
Clearly, some components of the in vivo antitumor 
activity of CP arise from the generation and expression 
o£ immunity to CP (1 - 3, 13), and the possible modifica-
tion o£ the antitumor activity of CP by preexisting 
immunity to CP may be a relevant consideration in pro-
tocols with the use of multiple CP injections. The present 
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data indicate, however, that, at least for the local destruc-
tion of tumor by CP, any such modification may depend 
on which components of CP-mediated antitumor activity 
the particular tumor is susceptible to. 
A recent study of the local destruction of various 
tumor cells by BCG in rats similarly concludes that 
tumors may differ widely in their sensitivity to host 
reactions aroused by BCG (13). Also, two earlier reports 
describing the mediation of the local antitumor effects 
of BCG by DTH to BCG in both mice (5) and guine·a 
pigs (4) failed to detect augmemed antitumor activity 
in animals presensitized to BCG. 
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Short Communication 
C. parvum in Germ-Free Mice* 
M. T. Scotti, T. T. MacDonald\ and P. B. Carter3 
Trudeau Institute, lnc., 
Saranac Lake, N.Y. 12983, U.S.A. 
Summary. The effect of previous sensitization to C. par-
vum, by cross-reacting antigens from other bacteria, on 
the immunostimulatory effects of C. parvum treatment 
were studied in germ-free and conventional mice. It was 
found that the development of splenomegaly and specific 
delayed hypersensitivity following C. parvum injection 
were similar in both germ-free mice and conventional 
mice. 
Introduction 
There are data indicating that both the in vitro and in 
vivo stimulatory and antitumor effects of C. parvum de-
pend, at least in part, on the specific immune response to 
C. parvum (Scott, 1974; Christie and Bornford, 1975; 
Bomford and Christie, 1975; Tuttle and North, 1976). 
The onset of splenomegaly and macrophage activation 
has been found to be more rapid in mice presensitized to 
C. parvum (Bomford and Christie, 1975) and, in a 
particular mouse fibrosarcoma model, the expression of 
the local antitumor effect of C. parvum occurred only in 
presensitized mice (Tuttle and North, 197 5). 
Preexisting immunity to C. parvum is thus likely to 
modify the effects of a subsequent injection of C. par-
vum. Recent studies (Woodruff et al., 1974; James et al., 
1975; Wolberg et al., 1977) have demonstrated that sig-
nificant levels of anti-C. parvum antibody are present in 
both normal mouse and human serum, and it has been 
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postulated that these resulted from prior interaction with 
cross-reacting bacterial antigens. We therefore decided 
to compare the effect of C. parvum in germ-free and 
conventional mice, in order to determine the role of pre-
vious sensitization, from other bacteria, on the immuno-
potentiating effects of C. parvum treatment. 
Materials and Methods 
Animals. Non-inbred Tru : ICR mice aged 5- 8 weeks were used in 
all experiments. Conventional animals were housed 10 to a cage and 
maintained on a sterilized diet and acidified water. Sera from these 
mice all showed positive agglutinating reactivity with C. parvum. 
Germ-free mice were kept in Trexler-type flexibile isolators (Trexler 
et al., 1957) on sterile hardwood chip bedding and given sterile water 
and diet RMH 3500 (Agway Inc., Syracuse, N.Y.) and libitum. The 
gnotobiotic status of the mice was checked regularly during the ex-
periments by following accepted procedures for microbial monitor-
ing (Wagner, 1959). In all cases the mice remained axenic through-
out the experiments. 
C.parvum. Strain CN 6134 (Wellcome Research Labs. Beckenham, 
Kent, UK) was diluted to the appropriate concentration in sterile 
saline. 
Delayed Type Hypersensitivity (DTH) to C. parvum. Mice were sen-
sitized by s.c. injection of 700 ~g C. parvum into the nape of the neck 
and 10 days later DTH was elicited in a hind footpad by s.c. injec-
tion of 10 11& C. parvum (0.04 m1 volume). Nonsensitized control 
mice were similarly injected in a hind footpad. 24 h later the thick-
ness of the injected and contralateral footpads were measured using 
dial gauge calipers (Schnelltaster, H. C. Kroplin, GMBH, Hasson, 
West Germany). The development and characteristics of DTH to C. 
parvum in mice have been described previously (Scott, 1974; Tuttle 
and North, 1975). 
Splenomegaly . 350 ~g C. parvum was injected i.v. and spleens and 
body weights were measured at the times shown. Results are ex-
pressed as a spleen index: 
Spleen weight (mg) 
Body weight (g) 
0340-7004/78/0004/ 0135/$ 01.00 
136 
Results 
Splenomegaly (Fig. I). The spleens of unimmunized 
germ-free mice were significantly smaller than conven-
tional mice (P < 0.01), but neither the kinetics nor mag-
nitude of the spleen index resulting from i.v. C. parvum 
were significantly different between the germ-free and 
conventional mice. 
DTH to C. parvum (Fig. 2). The nonspecific inflamma-
tory swellings caused by the eliciting dose of C. parvum 
in nonsensitized germ-free and conventional mice were 
not significantly different, nor were the levels of DTH 
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Fig. I. Effect of an injection of 350 )lg C. parvum i.v. on the spleen 
index in germ-free and conventional mice (5 mice per point). 
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Fig. 2. The DTH response to C. parvum in conventional and germ-
free mice (5 mice per group). 0 C. parvum sensitized, ml non-sensi-
tized 
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Discussion 
As outlined in the Introduction, it seems that a true pri-
mary immune response to C. parvum may be unobtain-
able in conventional mice due to pre-existing immunity 
resulting from prior interaction with cross-reacting 
bacteria (Walberg et al. , 1977). We therefore chose to 
examine the responsiveness of germ-free mice to C. par-
vum reasoning that, since a component(s) of the stimula-
tory effe.cts of C. parvum is considered to result from 
specific immunity to C. parvum (Scott, 1974; Christie 
and Bamford, 1975; Bamford and Christie, 1975; Tutt-
le and North, 1975), these effects may be reduced in 
germ-free animals. C. parvum has, however, been found 
to be fully capable of lymphoreticular stimulation in 
germ-free mice as evidenced by splenomegaly. The in-
crease in spleen weight following systemic C. parvum 
injection has correlated with antitumor (McBride et al., 
1975; Riveros-Moreno et al., 1978) and other potentiat-
ing effects (Adlam and Scott, 1973; O'Neill et al., 
1973). 
The development of cell-mediated immunity to C . 
parvum in germ-free mice was similarly unimpaired, and 
it is this aspect of C. parvum immunity which has been 
implicated as a basis for its antitumor activity (Christie 
and Bamford, 1975; Bamford and Christie, 1975; Tuttle 
and North, 1975). The present data do not of course 
exclude an immune basis for the stimulatory effects of 
C. parvum, but show that they may be fully established 
in the absence of previous sensitization. 
A further implication of the fmding that C. parvum is 
active in germ-free mice concerns the current interest in 
the application of gnotobiotic techniques in cancer ther-
apy. Germ-fre.e animals will tolerate more cancer che-
motherapy than conventional animals (Srivastava et al., 
1976), and the effects of chemotherapy can be poten-
tiated by combination with C. parvum (Fisher et al., 
1976; Purnell et al., 1977). It may therefore be possible 
to exaggerate such drug-C. parvum interactions using 
gnotobiotic conditions. 
Since completion of these studies, a report describ-
ing the in vitro tumor inhibitory capacity of C. parvum-
activated peritoneal cells from germ-free mice as similar 
to that of C. parvum-activated cells from conventional 
mice has appeared (Fray et al., 1978). 
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Comparison of the Potentiation of Specific Tumor Immunity in Mice by Corynebacterium parvum or 
BCG1• 2 
Martin T . Scott3· 4 and Robert Bomford5 • 6 
ABSTRACT- Two independent studies have compared killed C. 
parvum (CP) vaccine with viable BCG (Pasteur) and BCG (Giaxo) 
vaccines, respectively, for potentiation of antitumor immunity 
when Injected with irradiated tumor ce lls into B6D2F, and 
CBA·Ts Ts mice. Both studies concurred that, for a given number 
of irradiated tumor cells, larger amounts (dry weight equivalent) 
of BCG than CP were required to produce similar degrees of 
tumor Immunity. Evidence also showed that stronger and more 
protracted immunity was mediated by CP than by BCG.-J Natl 
Cancerlnst57: 555- 559,1976. 
The modes of antitum or activity of the two bacte rial 
vaccines BCG and C P, currently under cl inical investiga-
tion as immunotherape utic an tica ncer agents, may be 
simila r; each probabl y pote miates no nspecific mano-
phage- rn ed ia te d (/ , 2) a nd s peci£ic lymphocyte-me-
diated (3-5) a ntitumor immunit y. The distinctio n be-
tween these '"'0 types o f a ntitu mor resistance has been 
p articu la rly dea rly delineated in the case of C P. Sys-
te mic (iv or ip) injection o f C P produces a predomi-
nantly no nspeci fi e antitumor resistance that is still de-
monstrable in mice immunosuppres eel by T-cell d e ple-
tion (6-8) or irradiation (9). Therefore, it probably d oes 
not involve a host immune respo nse to tu mor antigens 
and m ay be mediated by activated macrophages . wh ich 
appear after C P injection in normal and T-cell d epleted 
mice (1 0, II ). In contrast , the injectio n o f C P directl y 
imo a tumor or ad mixed with tumor ce lls produces 
hig hly specific antitumo r resistance o nl y in immuno logi-
call y intact mice (4, 12. I}) and probably invo lves the 
promotion o f ccll-mcdi<Hcd im mun ity lO tumor-specific 
tran splantation antigens (3, 4). 
Direct co mparative data C'once rning C P and BCG arc 
clearly required . T his paper d escribes two independ ent 
in vestigatio ns in which the s pecific immunity that resu lts 
from local int e ractio n of e ithe r BCG o r C P with irradi-
ated tumo r cells are compa red. MA , the tumor model 
u sed in one of th e swdics (M .T.S.) . in B6D2F1 mire . 
~eemed particula r ly appropriate for comparative work , 
masmur h as results of exte nsive inde pendent studies in 
the same laboratory revealed t hat interactio n of irrad i-
a ted MA ce lls with C P (J) or BC G (5) result in specific 
cell-media ted a ntitumor immu n ity. The second tumor 
mode l studied was ~14. and a similar type o f immunity 
was observed fro m interaction of irradiated l\14 cells and 
C P (4). 
MATERIALS AND METHODS 
Mice.-Adult male (C57 BL/6 x DBA/2)F1 (B6D2F1) 
and CBA -T11T1; mice \\'ere used for the mastocytoma and 
~brosarcoma sllldics . respective ly. MA \\·as origina ll y 
tnduced by 3-methylcho lanthre ne in a DBA/2 mou se 
and has been used exte nsive ly in B6D2F1 mice fo r 3 
yea rs. Its ma int enance, h (lrvesting, and growth charac-
te ristics as a solid tumor in these min .: have been d e-
VOL. 57 , NO. !I, SE f>TEMIII·:t{ 1!176 555 
scribed in (8). T echniques for the maintenance and 
harvest o f M4 , o rigin a lly induced by 3-methylcholan-
th re nc in a CBA-T 6T 6 mo use a nd subseque ml>' main-
ta ined in tissue cultu re, were descr ibed in (4). 
Statistics.-ln t hose tests in which P was less than 0.05 
with Student's /-test , results \\'ere considered s ignificant. 
BCC (PastPur).-Used throu gho ut the MA stud ies, 
Pasteur stra in BC G (TMC 1011) from the Trudeau My-
cobacteri<tl Collection was grown as dispersed cultures in 
Middlebroo k 7 H9 medium containing Tween 80 (Difco, 
P .O. 13ox 1058A , Detroit, Mich.). After7daysof incuba-
tion , cu lt ures we re frozen slowly in 1-ml vials to - 70° C 
and stored a t t his te mperature (14) . In some repeat 
experim ents, the sa me stra in o f BCG was grown in 
d ispe rsed cultures in Proskau er-Beck medium (Difco) 
comaining 0.05% Tween 80. Afte r 6 days of culture, the 
organ isms we re used witho ut frozen storage. Absolute 
counts were made with a Petro ff-Ha user chambe r a nd 
phase contrast m ic roscopy. The cultures were plated on 
Middlebroo k 7H 10 medium, and viable counts were 
performed. 13CG sus pensions were concentrated by our 
a llowing th em to settle ovemig ht at 37° C and by re-
moval of the supernatant. Total and viable counts were 
again recorded. We ki lled appro priate BCG suspe nsions 
by heating them in a waterbath at 60° C for I hour; 
viable count s " ·ere pe rformed to ensure complete kill-
ing. 
BCC (G/axo).-Batch P658H of "Dried BCG Vaccine 
(Pe rcutan eous)" (Giaxo Labo rato ries Ltd. , Greenford, 
England) was used throug ho ut the M4 stud ies and \''as 
resuspended in saline for injection. Mr. T. Va r ley o f 
We lkome Resea rch Laboratories d id the viable counts 
by p lat ing the wlturcs o n Dubos' T.B. medium . 
CP .-ln both studies , killed s uspensio ns o f C P (Co-
parvax , We llco me Research Labo rato ries) pre pared as 
previo usly d escri bed (15 ) were used. 
Tumor CPII irradiatiou. - M A cell suspe nsion s were ex-
posed to 6.000 rads fro m a 137Cs source as descr ibed in 
(3). M4 cell sus pensio ns were ex posed to 10,000 rads 
from a '«>Co so urce ( 4). 
AnnRFVtA tiO:-IS us~c.o: CP=Cm)lltbacterium pan•um; ~lA= mastoC)'toma 
PSI:>; ~14= fihro~arcoma. 
1 Reteiv<·d lo,•emba II. 1975; accepwd February 20, 1976. 
• Supported b) the Canu~r Research Institute. Inc .. 1225 Park Ave .. 
:'\e" Yml... 1'\.Y.; and Publit Health Sen·ice contract 2~01 CP23221 
from the Di"ision of Can<cr Cause and Prc ,·e rHio n . :'\ational Cancel 
Institut e. 
3 Trudeau I n~titulc I m .. Saranac Lake. ~. Y. 12983. 
• Pre1mt addrrn: Dc·parum:nt of Expcrimerllal ln11n unobiolog>. 
Wcllcomc Re~carch Laboratories. Bccken h<tm , Kent BR3 3 BS. Eng-
lane!. 
'' DepartnH.: nl of F.xpai111ental Immunobio logy. Wellromc Rc-
scan h l .ahorawric~ . 
6 The lt't hnical assbtam t' uf Sandr:~ L. Warn<T and Susan \\'i5han 
is gr:nd'ull) arkno"·ledgcd. 
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RESULTS 
Comparison of CP and BCG (Pasteur) by Use of MA 
The principle of the experiments with MA was immu-
nization of mice by sc injection into a hind footpad of 
mixtures of irrad iated MA cells and either BCG (Pas-
teur) or CP. Immunity was assessed by monitoring the 
growth of a subsequent live MA cell challenge in the 
contralateral foot. In the .first series of experiments, a 
previously determined (3) optimally immunizing dose 
(3.5 J.l..g) ofCP was compared with an equ ivalent amount 
of BCG. Mice received 3 .5 J.l..g of e ither live (2x 106 viable 
organisms) or heat-killed BCG mixed with 107 irradiated 
MA. CP-treated mice received 3.5 J.l..g CP mixed with 107 
irrad iated M A, and controls were untreated. After 7 
days, a ll animals were challenged with 106 live MA cells 
(text-fig. lA) . CP-treated mice were markedly immune 
as evidenced by reduced tumor growth, prolonged sur-
vival time, and 50% tumor-free animals. With both live 
and dead BCG, tumor growth was no different from 
that of untreated controls. A repeat experiment con-
firmed this lack of effect. Other controls (data not 
shown) had no reactions from injections of CP, BCG, or 
untreated MA alone (3). 
For the second series of experiments, BCG was con-
centrated as described, and again equ ivalent dry weights 
of BCG and CP were compared. Mice were immunized 
with 107 irradiated M A cells mixed with 17.5 J.l..g either 
live (9X 106 viable o rganisms) or heat-killed BCG. CP-
treated an imals received 17.5 J.l..g of the vaccine mixed 
with 107 irradiated MA cells, and controls were un-
treated. Live tumor challenge was g iven 7 days later 
(text-fig. lB). Mixtures containing killed BCG caused 
slight enhancement of tumor growth, with the mean 
tumor size being significantly larger than in control 
animals from day 6 onward. However, survival time was 
not significantly modified. Live BCG was considerably 
more effective; tumor size was significantly less than 
both killed BCG and control groups from day 4. Sur-
vival time was prolonged, and tumor growth was com-
pletely inhibited in 1 animal. CP caused a similar inhibi-
tion of tumor growth, there being no significant differ-
e 10 
~ 
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• - • dead BCG 
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ence between the overall survival time and number of 
complete inhibitions of the CP- and live BCG-treated 
groups. The result suggested, however, that CP-me-
diated tumor inhibition might be longer lasting than li ve 
BCG inasmuch as mean tumor sizes in the BCG group 
were significantly larger from day 8 onward. The same 
significam difference in tumor size was observed in a 
repeat experimem. Throughout these studies, and in 
keeping with previous recent data accumu lated with the 
MA model (3), 17.5 /-1-g was consistently less e ffective at 
immunizing than was 3 .5 JLg CP (12.5 % and 50% com-
plete tumor inhibitions, respectively). 
To prove that the immunity resulting from CP may be 
longer lasting than from BCG, we did other tests by 
challenging mice at various times after immunization. 
Here, however, BCG immunization was further optim-
ized. Previous studies in our (M.T.S.) laboratories have 
shown that o ptimal immunization against live MA chal-
lenge resulted from the injection of irradiated MA into a 
site prepared by BCG 10 days previously , rather than 
from the injection of mixtures of BCG and irradiated 
MA (16). This method of BCG immunization was com-
pared with the optimal CP-irradiated MA cell mixture as 
follows: Live BCG (5X 106 viable organisms) was injected 
sc into a hind footpad, and 10 days later 107 irradiated 
MA cells were injected into the same site. On the same 
day , another group received 107 irradiated MA cells 
mixed with 3.5 J.l..g CP into a hind footpad, and mice 
from both groups were challenged with 106 live MA cells 
in the contralateral footpad at the times shown (text-fig. 
2). Control mice received only tumor challenge . Seven 
days after immunization, both CP- and BCG-treated 
mice were equally resistant to tumor cha llenge, there 
being no significant differences benveen mean tumor 
sizes, survival times, and occurrence of complete tumor 
inhibition. The same was true for mice challe nged 14 
(data not shown) and 21 days (text-fig. 2B) after immu-
nization . At day 28, however, BCG was considerably less 
effective than CP and only significa ntly different from 
control at day 9 (text-fig. 2C). By day 35, no immunity 
was detectable in BCG-treated mice , whereas CP-treated 
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Tt::xT-FIGURE 2 .-Tumor immunity at 
various times afte•· injenion of CP-irra-
diated wmor cell mixw•·es or in·adi-
atcd tumor cells into BCG pre pared 
sites. Mice were given sc injections of 
3.5 f.Lg CP mixed with 107 irradiated 
MA cells into a hind footpad (• .... · • ) 
or 107 irradiated MA cells into a foot-
pad pre pared 10 days previously by sc 
injection o f 5X 106 viable BCG (A- .t.} . 
Control .miee- were unu·eated (x- x) . 
After 7'{1\.). 21 (B), 28 (C). and 35 (D) 
da)•S they were challenged with 10" live 
MA cells in the contralatera l footpad , 
and turno•· growth was mon itored. 
Numbas are as in text-figure l legencl. 
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Comparison of CP and BCG (Giaxo) With the M4 Model 
The principle of the studies with fibrosarcoma M4 was 
essentially the same as forMA except that mixtures were 
given the rapeutically, i.e. , after tumor establishme nt, 
and viable Glaxo BCG was used. Live M4 cells (104 ) were 
injected sc into a hind footpad , and 2 days later mice 
were treated in the opposite footpads with 106 irradiated 
M4 cells, with 6 , 30, or 150 J.Lg of either CP or BCG (the 
BCG containing 5X 106 viable organisms at the 150-J.Lg 
dose) or with mixtures of irradiated M4 and bacte ria 
(table I). M4 cells or bacte ria given alone did not prevent 
tumor outgrowth. With CP-M4 mixtures, the low doses 
of CP (6 and 30 J.Lg) were equally inhibiting to tumor 
growth and more so than the highest d ose ( 150 J.Lg). This 
confirms our earlie r observation (4). The opposite re-
sult was obtained with BCG-M4 mixtures, in which the 
lowest dose (6 J.Lg) was relativel y ineffective, but the two 
higher doses (30 and 150 J.Lg) were almost equal to the 
low doses of CP. 
The effect of a high dose ofBCG and a low dos~ o fCP 
on increasing tumor burdens was also tested . Mice re-
ceived 10\ 4X 10\ or 16X 104 live M4 cells sc in a hind 
footpad and were treated 2 days later in the contralat-
eral footpad with 106 irradiated M4 mixed with either 6 
J.Lg CP or 150 J.Lg BCG. Controls we re untreated (text-
fig. 3). CP and BCG were equall y effective against 104 
live tumor cells. Against 4x 104 cells, on ly CP treatment 
slowed the rate of tumor growl h and resulted in lesion-
free animals. CP was sti ll inhibitory against L6X 104 cells, 
mean tumor sizes be ing significantly smaller from day 
10 onward, but BCG was again without effect. 
DISCUSSION 
Using different mo use systems, we have shown in two 
indepencle m stud ies that local injection of whole orga-
nisms of eith er viable BC:G or killed CP, mixecl with 
VOL. 57, NO. 3, SEF'TJ::MBER 1976 
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TABLE !.-Proportion of mice developing fibrosarcomas after treat-
ment with various amounts of either CP or BCG (Glaxo) with or 

























irradiated tumor cells, potentia te tumor immunity. 
Other workers reported that with BCG (5) and CP (3, 4) 
the immunity is cell med iated and specific. H ere, with 
M A, heat-killed BCG was ineffective ; however, this loss 
of activity may be a function of the method of killing 
rather than being indicative of a requireme nt for living 
organ isms , since recent work established that tumor-
specific immunity results from rejection ~f tumor cell_s 
with radiation-killed BCG (17) and BCG cell wall-otl 
droplets (18). . . 
It was apparent from the present stud tes that for a 
given numbe r of irradiated tumor cells, larger ~tmounts 
(dry weight eq uivalem) of viable BCG than ktlled CP 
were required to produce similar d egrees of antitumor 
immunity. BCG showed no activity at the low-dose levels 
at which CP was effective. These a nd previous studies 
(3, 4) concur that CP inhibiteclLUmor growth max imall y 
at these low doses and, for a constant amount of tumor 
amigen, was less effective at highe r closes . Why C~ 
produces less antitumor immunity is not known. Posst-
ble reasons include 1) interfere nce with the function of 
J NATL CANCER I NST 
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TExT-FIGURE 3.-Therapeutic effect of BCG- or GP-irradiated tumor 
cell mixtures against increasing tumor burde ns. Mice received 10". 
4X 10'. or 16X LO'Iive M4 cells sc in a hind footpad and were treated 
2 days later in the contralateral footpad wi1h lOS irradiated M4 
mixed with either 150 1-Lg BCG (•--• ) or 6 1-Lg CP (• · ·· .. e). 
Controls were untreated (x--x). Numbers represem No. of ani-
mals tumo1· free/ o. in experimental group. 
the draining lymph node due to intense histiocytic infil-
tration , 2) the local generation of suppressor macro-
phages (19, 20), or 3) the trapping and retention of 
responding lymphocytes within the draining node (21, 
22). With BCG, however, higher amounts were increas-
ingly effective for the dose range stud ies. When high 
and low doses of BCG and CP, respectively, were com-
pared in the fibrosarcoma model, CP-mediated immu-
nity was capable of inhibiting larger tumor burdens than 
was BCG. This may represent a more potent , or more 
rapid onset of, immunity with CP. That the effects of 
BCG may be more slowly established is supponed by 
previous findings that tumor immunity arising from 
BCG-ir radiated cell mixtures was less than when the 
tumor cells were injected into a site prepared by BCG 10 
days previously (16). This optimal method of BeG-
irradiated tumor cell immunjzation was compared with 
low doses of CP mixed directly with irradiated tumor 
cells . Immunity in both groups was similar for 3 weeks 
after im mun ization, whereafter BCG-induced immu-
nity was lost but that of CP persisted. Hawrylko and 
Mackaness (16) observed a gradual loss of BCG ami-MA 
immunity 10 clays after imm unization. 
There have been other reports concerning the use of 
CP and BCG in the same experimental animal tumor 
systems but without attempts to compare the activity of 
equivalent amounts of the vaccines (23-29). In some of 
these stud ies, the vaccines were used alone and most 
likely nonspecific immunity mediated by activated mac-
rophages was assessed (23-26) . With regard to potentia-
tion of specific tumor immunity, mixtures of either CP 
or BCG with irradiated tumor cells given as multiple 
local and systemic injections had sim ilar therapeutic ef-
fects against lung metastases in rats (27). Fishe r et al. 
(28) found that 14 clays after intralesional injection of 
1.4 mg CP into an established mouse mammary carci-
noma the cytotoxic activity of regional lymph node cells 
was potentiated, but not after 0.7 rng BCG (IQ1 viable 
organ isms). Specific tumor immunity results from 
J NATL CANCER INST 
regression of tumors after intralesional injection of CP 
(1) or BCG (30) and may be responsible in part for the 
local inhibition of tumor growth. lntralesional injection 
of 2 mg C. granulosum, which is similar to CP (15, 31), 
caused comple te regression of hamster melanomas, 
whereas BCG (5-6 X 106 viable organisms) only sligh tly 
inhibited tumor growth (29). 
We do not know what determines the relative effica-
cies of the CP and BCG vaccines used in these studies. 
The differe nce may merely represent the relative clilu-
tjon of active principle(s) by "irrelevant" material, which 
studies of active fractions, such as have been described 
for BCG (18, 32), should resolve . However, the present 
direct comparison between killed CP and viable BCG 
whole vaccines is a practical one because it is in these 
forms that both are currently undergoing clinical evalu-
ation (33-36). 
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The Accumulated Effects of Repeated Systemic or Local 
Injections of Low Doses of Corynebacterium parvum 
in Mice 
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SUMMARY 
The effects of 14 weekly injections, s.c. or i.v. , of '' human 
equivalent" doses (5.25 mg/sq m) of Corynebacterium par-
vum (CP) in mice have been compared. Both s.c. and i.v. CP 
caused significant splenomegaly and antibody to CP, but 
stimu lation was considerably greater after i.v. CP. Delayed 
hypersensitivity levels to CP were similar after s.c. and i.v. 
injection. T-cell competence, as judged by phytohemagg lu-
tinin reactivity and delayed hypersensitivity to sheep cells, 
was unimpaired after s.c. CP and augmented by i.v. CP. 
Activated peritoneal macrophages capable of nonspecifi-
cally inhibiting tumo r growth in vitro were detected only 
after i.v. CP, and in vivo resistance to tumor cell challenge 
was greater after CP administered i.v. than s.c. 
INTRODUCTION 
Most of the data with regard to CPt injection in an imals 
have been obtained with high and sing le doses of CP, as 
compared with lower but repeated doses used clinical ly. 
The currently acceptable dose in humans is around 5 mg/sq 
m (8, 9, 14), whereas an average dose range for mouse 
studies has been around 75 to 100 mg/sq m (6) (reviewed in 
Ref. 19). The present study was undertaken to see whether 
repeated low (human equivalent) doses of CP resulted in 
functional alterations in immunity similar to those reported 
previously for single high doses. The effects of systemic and 
local CP injections have also been compared, since both 
routes are used c linically (8, 9, 14). 
MATERIALS AND· METHODS 
Mice. Adu lt female CBATuT1; mice were used throughout 
except for the carcinogen studies, in which C57BL/6 x 
DBA/ 2 F1 (hereafter cal led B6D2F1) mice were substituted. 
The react ivities of both strains to CP were simi lar as judged 
by natural and acquired, humoral , and cell-mediated re-
sponses. 
Immunization. Mice rece ived injections once a week for 
14 weeks, either i.v. or s.c., of 35 f..tg CP (5.25 mg/sq m) 
• To whom requests tor reprints should be addressed. 
1 The abbreviations used are: CP. Corynebacterium parvum; DTH. delayed 
hypersensitivity; SRBC. sheep red blood cells; PHA. phytohemagglutin in ; T· 
cell, t hymus·derived lymphocyte. 
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(Coparvax; Wellcome Research Laborato ries, Beckenham, 
Kent, England). The i.v. injections were via the lateral tai l 
vein. The site of s.c. injection was varied because of skin 
th ickening at the site of previous injections, but avoided the 
right footpad and thigh which were to be the sites of subse-
quent tumor and carcinogen challenge, respectively. Con-
trol mice received no CP. 
CP Agglutination. Sera, doubly diluted in isoton ic borate-
buffered saline, pH 7.2, were dispensed into p lastic microti-
ter trays (Scientific Suppl ies, Vine Hi ll, London , England). 
Where appropriate, mercaptoethanol was then added (0.1 M 
to a final dilution of 10%), and trays were al lowed to stand at 
room temperature for 30 min. To each well was then added 
an equal volume of a 1:10 dilution of washed CP. Fol lowing 
brief agitation, trays were incubated for 30 min at 56° and 
then overnight at 4°. End points were recorded as the recip-
rocal of the f inal serum di lution causing agg lutination. Du-
plicate determinations were made on each serum. 
DTH to CP. Characteristics of DTH to CP in mice have 
been described previously (18). Seventy ~-t9 CP were in-
jected s.c. into a hind footpad and footpad thickness was 
measured 24 hr later. Results are expressed as percentage 
increase in footpad thickness over uninjected feet. 
DTH to SRBC. Mice were sensitized by injecting 108 SRBC 
into a hind footpad, and 5 days later DTH was elicited in the 
ear by s.c. injection of 0.01 ml 50% SRBC. Ear th ickness was 
measured 24 hr later, using the electrical modification of a 
micrometer screw gauge, as described in Ref. 4. 
PHA Response. Spleen cells were prepared and their 
responsiveness to PHA was assayed as described previously 
(15). Results are expressed as stimulation indices, (cpm/ 
stimulated culture)/(cpm/contro l culture). 
In Vitro Assay for Nonspecific Inhibition of Tumor 
Growth. The techn ique was as described in Ref. 17. Perito-
neal cells were mixed in vitro at a rat io of 10:1 with CBA-RI 
leukemia cells (13). Tritiated thymidine was added after 24 
hr of culture, and its uptake by tumor cells was assessed 24 
hr later. 
Tumor Cha.,llenge. Mice received s.c. injections into the 
right hind footpad either s.c. with 2 x 104 syngeneic M4 
f ibrosarcoma cells (2) or i.p. with 1 Ot Rl leukemia cells (13). 
Tumor growth and su rvival t imes, respectively, were mon i-
tored. 
Carcinogen Challenge. Both 3-methylcholanthrene and 
benzo(a) pyrene were suspended in trioctanoin (Eastman 
Organic Chemicals, Rochester, N. Y.); 1 mg of carcinogen 
was injected s.c. into the right thigh. 
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most prominent difference between the 2 injection regi-
mens. It is interesting to note that the present finding of 
unimpaired and augmented T-cell responsiveness to mite-
gens, after repeated doses of CP s.c . and i.v., respect ively, 
accords with the preliminary clinical data from patients 
receiving repeated equivalent doses of CP by these routes 
(14). T-cell competence is clearly an important considera-
tion in CP therapy, since recent animal data show that a 
component of the antitumor activity of CP is mediated by 
potentiating specific cell-med iated antitumor immunity (2, 
20). 
With regard to the choice of route of injection of CP; 
although it is apparent from recent animal studies that, 
under some conditions, local injections of CP may be highly 
effective therapeutically, e.g. , intralesional injection (18) or 
injection near to the tumor site (18, 20), and specific immu-
notherapy by s.c. injection of CP mixed with irradiated 
tumo r cells (2, 20), g iven an inaccessib le or widely dissemi-
nated cancer, the present study suggests that systemic CP 
may be more effective. The degree of systemic stimulation, 
especially macrophage activation, achieved by repeated 
system ic injections of CP was considerably greater than the 
same doses given locally. Current studies using '2"1-labeled 
CP (M. T. Scott, in preparation) also show a wider distribu-
tion of the organisms after systemic injection increasing the 
probability of CP reaching the vicinity of the tumor and 
initiating local CP-mediated antitumor effects mentioned 
above. 
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CONDITIONS FAVOURI NG THE SELECTION 
OF ELTI-IER SPECIFIC OR NON SPECIFIC C. PARVUM-MEDIATED , 
SYSTEM IC ANTITUMOUR IMMUNITY I N MICE 
M. T. Scott 
ABSTRACT 
Accumulated data suggest that one of two an ti tumour mechanisms of C. par-
wm may predominate depending on the route of injection of C. porvum and its dis-
tribu tion in rela tion lO the tumour. Afte r sy>temic C. pnrvum the mechanism is 
considered to be immunologically non specific ( i. e . not requiring tumour specific 
antig~ns) and mediated by C. pan·um ac tiva ted macrophagcs. After local injection 
of C. parvum the inte ractio n (di rect or lymph node mediated) between C. parvum 
and tumou r specific antigens has resulted in the generation o r immunologically 
specific T lymphocytes wi th an titumour activity. 
Considera tion of the accumulated data concerning C. parvum (CP) treatment 
of various experime ntal tumours indicates that different effector mechanisms may 
predo minate dependi ng o n the ro ute o f injection of CP and its distribution in 
rela tio n to the tumo ur. 
Th at th e a mitumo ur effects of systemically injected (i.v. or i.p.) CP are 
arge ly im munologically no n specific (i.e. not amplifying a specific antitumour 
response) is suggested by their resista nce to subsequent whole body irra-
diation (5, 18), and the fact that they are still appa rent in athymic mice (32) and 
mice de pleted of T lymphocytes by thymectomy, irradiation a nd bone marrow 
reconstitution (23, 31), or antilymphocyte serum (9). Splenectomy, a procedure 
likely to im pa ir antibody production, did not impa ir the effects of a subsequent 
system ic C P injection (6, 14), a nd system ic C P is a lso effective in mice genetically· 
selected for low a ntibody responses (2). 
The above cha racteristics are compatible with macrophage mediated 
efrects a nd perito nea l macrophages from normal mice injected systemically with 
C P kill ( I, 20). o r inh ibit the growth and DNA synthesis of a wide ra nge of tumo ur 
cells in vitro (8, II , 2 1 ), whereas a local injectio n (s. c.) of CP is considera bly less 
effective (Fig. 1). In additio n to peritoneal mac rophages, alveola r (21) 
and spleen (I I, 23) macrophages, a nd, as yet, undefined peripheral blood cells (7) 
are a lso effect ive. 
Wha t is the evidence that a no n s pecific destructio n of tumour cells by CP 
activated rnacrophages occurs in vivo ? Mac ro phages are fully activated by CP in 
both conventio nally T cell deprived (4) and nude mice (8), and are also radio-
resista nt (23). These a re all characteristics already described for the in vivo anti-
tumo ur effects of systemic CP. 
Further implications are that the in uivo C P effects are abrogated by macro-












M. T. Scott 
Fig. 1. Percentage inhibition of in vitro growth of mouse 
mastocytoma (P815) 'Cells (sec ref 25 for details) by 
mixing with peritoneal cel ls from normal mice (N), or 
mice that had received 700 /IS C. parvum (CP) either 
i.v. or s.c. 4 days earlier. 
from CP stimulated mice to tumour cells has resulted in the suppression of tumour 
cell growth when the mixture was injected into syngeneic recipients (Peters et al., 
this volume). Also, mouse tumours regressing following i.v. CP treatment have 
been shown to be heavily infiltrated with macro phages ( 16, 17). 
Studies using local injec tio n of CP have revealed a further mode of action 
which is immunologically specific, i. e. potentiating the host's immune response 
to tumour specific antigens. 
S. c. injection of mixtures of CP and live tumour cells, or direct injection 
of CP into established tumours has frequently resulted in tumour regressions, 
and animals whose tumours had reg ressed were subsequently found to be speci-
fically immune to t umour rechallenge ( 12, 13, 22). These results suggested that, 
under conditions of close contact between C P and tumour cells, CP was augmenting 
a specific antitumour response. Potentiation of specific tumour immunity is also 
evident from experiment s in which subcutaneous injections of CP mixed with 
irradiated tumour cells have specifically protected mice against both subsequent 
lllmour challenge (24) and established tumours (3, 24), whereas injections of 
either CP or irradiated tumour cells alone were ineffective. The injection sites of 
CP and irradiated tumour cells did not need to be coincident for immunity to 
result, but did require a common lymphoid drainage (24). The immunity arising 
from loca l interaction of CP and tumour ant igen is cell mediated in that it is 
reduced in T cell deprived mice (24, 3), and can be transferred by lymph node cells 
but not serum (24, 27, 29). It may be a relatively short-lived T lymphocyte which 
probably does not require macrophages or other lymphocytes to effect its anti-
tumour activity (29). That such a cell mediated immune mechanism may operate 
in t he local destruction of tumour cells following direct injection of CP into a 
tumour site is supported by reports of the T cell dependence of this fo rm of the-
rapy (22, 30). A component of this T cell dependence may, however, also reflect 
the non specific antitumour activity of macrophages activated locally as a result 
of an ongoing local T cell dependent immune reaction to CP (28). 
The potentiation of specific tumour immunity is not exclusive to locally 
inj ected CP, and may be apparent following systemic CP treatment of tumours (33). 
This ·seems logical , since systemic CP is widely distributed throughout t he lympho-
reticu lar elements of the body following systemic injection (Scott, this volume), 
and some direct, or lymphoid mediated, CP-tumour antigen interaction is li kely 
to occu r. 
C. pt1rvum-mediated, systemic antitumour immunity 275 
The ultimate goal of immunotherapy sho uld be the establishment of systemic 
antitumour immunity since it is metastases persisting, or appearing after successful 
t'reatment of the primary tumour that a re ofte n the ultimate cause of death. The 
fact that with CP therapy eit her specific o r no n specific systemic immunity may 
be preferentially selected under different circumstances is a relevant consideration 
in deciding how it sho uld be used. The intensity a nd durability of the specific cell 
media ted antitumour immunity that has resulted from local interaction of CP and 
tumo ur a ntigen in mice (26) suggests this may be a desirable situation to achieve 
c linically. Optimal immunity may, however, be restricted to situations where either 
direct intralesiona l injection, o r st imula tio n of tumour dra ining nodes is practical, 
o r specific active immune therapy using CP mixed with attenuated tumour cells 
when these are obtainable. A reasonably st rong tumo ur associated antigen and 
high degree of patient immunocompetence wo uld both be p redicted to facilitate 
specific immunization . 
The immunologica lly no n specific, mac rophage mediated , systemic anti-
tumo ur activity that seems to predominate after systemic injectio ns of CP does 
not require close contact between CP and tumo ur, and is like ly to be independent 
of tumo ur a ntigenicity and patient immunocompetence. Theoretically, therefore, 
tumours a t inaccessible sites, those of low a ntigenicity, and patients with poor 
immunocompetence are situations where no n specific therapy may be appropriate. 
A further consid eratio n in the selection o f specific o r non specific CP anti-
tumour effects is the susceptibility of the tumour in questio n. There are recent 
a nimal data showi ng systemic C P trea tment to be rela tively ineffec tive in T cell 
deprived mice ( 19), and ineffect ive in nude mice ( 10). Mac ro phages seem to be 
full y activated in such mice (4, 8) a nd it thus seems that particula r tumours may 
be insensitive to this fo rm of attack. 
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General discussion 
McBride: You have nicely shown that intratumoural injection of C. parvum 
gives rise to regression and leads on to a state of specific immunity. Do you know 
wha t the level of immunity is in your no rma l mice not treated with C. parvum? 
What 1 am really asking is whether you are increasing T-cell immunity or whether 
you are increasing the expression ofT-cell immunity within the tumour. 
Scott: We have not examined specific immunity in non-C. parvum treated , 
tumour-beari ng mice. 
McBride: You haven't tried any transfer experiments? 
Scott: o. 
Chare: I think that for the sake of completeness we may also mention the 
work of Fischer in Pittsburgh who has shown that systemic administ ration of 
C. parnrm to tumour-bearing animals does lead to the product ion of macrophages 
specifically cytotoxic to the immunising tumours. 
Sco11: Other workers too have reported potentiation of specific immunity 
following systemic C. parcum. 
Gautltier- Rai1111G11: I wam to comment on the experi ment suggested by 
Dr. S<.:ott wh ich has a parallel in what we have done with simple protein antigens. 
The results are very similar. ln both cases there is a marked effect due to the route 
by which you administer C. paruum. We fou nd the strongest immunisation was 
obtained when C. part'l/111 is mixed loca lly with antigen. We used the guinea pig 
and also did transfer experiments in cell mediated immunity induced by local 
inject ion of tumour with C. pcrrvum against a tumour specific a ntigen. 
(CANCER RESEARCH 37. 1673- 1679. June 1977] 
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SUMMARY 
Killed Corynebacterium parvum was labeled with fluores-
cein isothiocyanate or ' 251, and both preparations we re 
shown to retain lymphoreticular stimulatory and antitumor 
activity. Large amounts of C. parvum injected i.v. were 
found in the liver , spleen, and lungs with less in bone 
marrow and lymph nodes. Apart from a rapid loss from the 
lungs w ithin 24 hr, the pers'istence of killed C. parvum was 
striking, and some intact bacteria were still detectable in the 
liver and spleen at 15 days. (By contrast, the breakdown of 
an inactive C. parvum strain in the liver was considerably 
faster.) The blood clearance of ' 251-labeled C. parvum in-
jected i.v. into tumor-bearing mice was more rapid than in 
normal mice, and the absolute , but not the unit , amounts of 
C. parvum taken up by the spleen and tumor-draining node 
were increased. 1251-labeled C. parvum was found within the 
body of establ ished solid tumors, but there was no correla-
tion between the amount of C. parvum taken up by various 
mouse solid tumors after i.v. injection and their susceptibil-
ity to i.v. C. parvum therapy . The d istribution and persist-
ence of C. parvum injected into a tumor lesion was similar 
to that after s.c. injection. The bulk of the inoculum was 
retained at the injection site and draining lymph node. 
Contralateral nodes were unlabeled , and uptake in the liver 
and spleen was considerably less than after i.v. injection. 
Although no C. parvum was found in peritoneal cells after 
i .v . injection , the macro phages in this population became 
activated and were capable of nonspecifically inhibiting 
tumor cell growth in vitro . 
INTRODUCTION 
The bacterial vaccine Corynebacterium parvum is an ef-
fective antitumor agent in animals (reviewed in Ref. 23) and 
is currently undergoing clinical investigation (12, 20). The 
present studies using labeled C. parvum preparations were 
undertaken to delineate the distribution of injected C. par-
vum, which might provide a guideline in selecting the route 
and site of injection for given tumor situations and further 
information as to underlying antitumor mechanisms. This 
paper describes the preparation of both 1251- and fluores-
cein-labeled C. parvum and their distribution after either 
local or systemic injection in normal and tumor-bearing 
mice. 
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MATERIALS AND METHODS 
Mice. Adult female CBAT6T6 and DBA/2 mice were main-
tained at Wellcome Research Laboratories, Beckenham, 
England. Adult female C3Hf/Bu mice were from t he specific 
pathogen-free breeding colony at the Section of Radiother-
apy, M.D. Anderson Hospital, Houston, Tex. 
C. parvum. A formol-killed suspension , Coparvax (Well-
come Reagents Ltd ., Beckenham, Kent , England), Batch 
Px401 (7 mg/ml) was used. In some experiments an inactive 
strain of C. parvum, CNS888, was used. It was grown and a 
formol-killed suspension was prepared as described in Ref. 
1 . 
'
2 sl-labeled C. parvum. C. parvum (5 ml) was washed 2 to 
3 t imes in 0.9% NaCI solution and resuspended in 0.4 ml 
phosphate-buffered saline (8.01 g NaCI, 1.42 g Na2HPO~, 
0.41 g KH 2PO ,. and distilled water to 1.0 liter). 1251 (2 mCr) 
(Radiochemical Centre , Amersham, Eng land) was added , 
followed immediately by 0.4 ml chloramine T (S mg/ ml) . 
After s min, 0.4 ml sodium bisulfite (25 mg/ ml) was added , 
followed immediately by 0.4 ml sodium iodide (10 mg/ ml) . 
The suspension was washed once by centrifugation in 0.9% 
NaCI solution and resuspended to its original volume . It was 
dialyzed for 5 days against daily changes of 2 liters of 0.9% 
NaCI solution at 4°, by which t ime the rad ioactivity in the 
d ialysate had stabil ized. In different batches only 0.~1 to 
0.02% of iodine remained unbound, and no apprecrable 
amount was released after incubating the labeled C. parvum 
for 24 hr at 37°. One-tenth ml of 10% thiomersalate preserv-
ative per 10 ml suspension was added. Suspensions were 
stored at 4°. Concentration was determined by optical com-
parison with di lutions of unlabeled C. parvum vaccine of 
known concentration . Unless otherwise specrfred. Injec-
tions were of 300JA.Q . 
Gamma Counting. Organs or blood samples (SO JA.I) taken 
from ' 251-labeled C. parvum-injected mice were placed di-
rectly into plastic tubes and counted using a Packard Tri 
Garb Automatic gamma counter. Results are expressed as 
percentage of total isotope injected . Means and standard 
errors were calculated for all experimental groups, and 
d ifferences where p < 0 .05 (Student's t test) were consid-
ered significant. 
Phagocytic Index (K). Mice received i.v. injections of ' 251-
labeled C. parvum and were bled repeatedly (50-JA.I samples) 
at recorded times over a 10-min period . The radioactivity of 
the samples was determined , and the phagocytic index was 
calculated as described previously (3). 
FITC-CP.3 C. parvum was washed 3 times by centrifuga-
>The abbreviations used are: FITC-CP, fluorescein-labeled Corynebacte· 
rium parvum: FITC. fluorescein isothiocyanate. 
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t ion in 0.85% NaCI solution and resuspended to its orig inal 
volume. Buffer was prepared by mixing Na2C0:1 (53 mg/100 
ml) with NaHC03 (4.2 mg/100 ml) to pH 9.0. One volume of 
buffer was then added to 9 volumes of washed C. parvum. 
The suspension was set up on a stirrer, and FITC, 1 mg/ml 
suspension , was added very slowly while stirring at room 
temperature, and stirring continued for 1.5 hr. The suspen-
sion was washed 4 to 5 times in 0.85% NaCI solution to 
remove unbound FITC and resuspended to its original vol-
ume in 0.85% NaCI solution. FITC-CP was stored in the dark 
at 4o with no noticeable loss of fluorescein into the superna-
tant during a 1-year period. Un less otherwise specified in-
jections were of 300 J.l.g. 
Fluorescent Microscopy. Organs removed from FITC-CP-
injected mice were immediately frozen using Polar Spray 
BPC (dichlorodifluoromethane; Aerosol Marketing and 
Chemical Co. Ltd. , London, England). Cryostat sections 
were cut at - 20°, f ixed in methanol for 10 min , and mounted 
in Polarfluor B (Polaron Experiment Ltd., Watford , Eng-
land). Blood smears were air dried before fixing and mount-
ing. Peritoneal and bone marrow cells were washed and 
resuspended at 2 x 106/ml in Eagle's minimum essential 
medium. Aliquots (0.1 ml) were placed on coverslips, and 
the cells were allowed to settle for 1.5 hr at 3r in a 5% C02 
atmosphere. The monolayers were then fixed and mounted 
as above. Slides cou ld be stored in the dark at 4° for up to 2 
weeks without marked loss of fluorescence. They were ex-
amined using a Leitz Ortholux II phase contrast/fluores-
cence microscope. 
Tumors. CBA, methylcholanthrene-induced fibrosarcoma 
cells (M4) were maintained in vitro and prepared as de-
scribed in Ref. 5. Similar details have been given for CBA T3 
fibrosarcoma (7) and CBA AI leukemia cells (18). DBA/2 
mastocytoma P185 (MA) was obtained in frozen form from 
Dr. A . C. Allison , Clinical Research Centre, Harrow, Middle-
sex, England. Cells were maintained by serial ascitic pas-
sage and obtained for injection by peritoneal lavage. C3Hf/ 
Bu fibrosarcoma cells (Fsa) were maintained and prepared 
for injection as described in Ref. 16. Solid tumors were 
established by s.c. injection of cel ls into either the hind 
footpad or flank . Tumors growing in the flank were meas-
ured as 2 diameters at right angles , the size being ex-
pressed as the multiplicand. 
In Vitro Assay for Nonspecific Inhibition of Tumor 
Growth. The technique has been described before (24). 
Peritoneal cells were mixed in vitro at a ratio of 10:1 with AI 
leukemia cells. [3H]Thymidine was added after 24 hr of 
culture , and its uptake by tumor cells was assessed 24 hr 
later. 
RESULTS 
lmmunostimulatory and Antitumor Activity of Labeled C. 
parvum Preparations. Experiments were performed to con-
firm that both the FITC-CP and 1251-labeled C. parvum prep-
arations retained their lymphoreticular stimulatory and anti-
tumor activity. CBA mice received i.v. injections of FITC-CP, 
'
251-labeled C. parvum, or unlabeled C. parvum (Table 1), 
and , after 14 days, there were no significant differences 
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Table 1 
Comparison of the splenomegaly and tumor-inhibitory effects of 
unlabeled, FITC-Iabeled, and ' 251-labeled C. parvum, after i.v. and 
intra tumor injection , respectively 
Spleen Wt at Day + 14 
Injection i.v. at Day 0 (g ± S.E.; n = 4) 
C. parvum (300)• 
FITC-CP (300) 
1251-labeled C. parvum (300) 
0.08 ± O.Q1 
0.40 ± 0 .06b 
0.48 ± 0 .06b 
0.39 ± 0.02b 
lntratumor injection at Day + 3• 
Proportion of mice tumor 
free at Day + 40 
C. parvum (70) 
FITC-CP (70) 





• Numbers in parentheses, dose in p.g . 
b Not significantly different from similarly designated results (p > 
0.05). 
< M4 fibrosarcoma cells (106) were injected s.c. into a hind foot-
pad. and 3 days later C. parvum was injected s.c. into the tumor 
site. 
among the splenomegalies induced by any of the C. parvum 
preparations (Table 1). They were also equally effective 
when injected into a tumor lesion, all treated tumors com-
pletely regressing with no regrowth during a 40-day period. 
By this t ime untreated mice were dying with large tumors 
(Table 1) . 
The Use of FITC-CP. FITC-CP preparations were highly 
fluorescent (Fig. 1 a). After injection, f luorescence was 
clearly visible in tissue sections under x 20 magnification, 
and , using x 1000 magnification , individual bacteria could 
be resolved (Fig . 1b). Results obtained with FITC-CP pro-
vide unequivocal evidence of the presence of C. parvum 
organisms , but it is not possible to quantitate the amount of 
C. parvum in a tissue sample. For quantitative studies of the 
distribution and persistence of C. parvum in organs and 
other solid tissues , we have used 1251-labeled C. parvum, but 
all experiments were repeated using FITC-CP to confirm the 
presence or absence and the relative distribution of C. 
parvum. FITC-CP was particularly useful with cel l popula-
tions (e.g. , bone marrow, peritoneal) when FITC-CP-con-
taining cells were readily identified and quantified. 
Blood Clearance of 1251-labeled C. parvum and FITC-CP 
in Normal and Tumor-bearing Mice. M4 cel ls (106) were 
injected s.c. into the hind footpad of CBA mice; 3 weeks 
later, when the footpad thickness was 7 to 8 mm. the mice 
received i.v. injections of 1251-labeled C. parvum , and the 
phagocytic index (K) was determined. The clearance of 1251-
labeled C. parvum from the blood of tumor-bearing mice 
was significantly faster than normal; K = 0.25 ± 0.009 and 
0.14 ± 0.007 , respectively . Twenty-four hr after i.v. 1251-
labeled C. parvum treatment in both normal and tumor-
bearing mice , there was no detectable difference between 
the radioactivity of whole-blood samples and t hose in which 
cell and bacteria had been removed by high-speed centrifu-
gation (10 ,000 x g for 15 min). This suggested that C. 
parvum had been completely cleared from the blood within 
24 hr. It was confirmed by the complete absence of FITC-CP 
in blood smears taken 24 hr after i.v . FITC-CP treatment , 
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whereas after 1 hr some smears still contained FITC-CP-
containing cells. 
Distribution and Persistence of Labeled C. parvum In-
jected i.v. into Normal and Tumor-bearing Mice. ' 251-la-
beled C. parvum was injected i .v. into normal and tumor-
bearing CBA mice as above (Chart 1). At the time of injec-
tion, spleen weights in tumor-bearing mice (0.19 ± 0.2 g) 
were significantly larger than normal (0 .10 ± 0.004 g) , as 
were tumor-draining lymph nodes: 15.7 ± 0.5 and 1.4 ± 0.3 
mg, respectively . There were no significant differences in 
lung and liver weights. 
In normal mice large amounts of radioactivity (80.8% in-
jected) were present in the liver after 1 hr. The levels then 
declined gradually with 10% still being detected after 15 
days. The presence of the tumor did not modify the uptake 
or persistence of radiaoctivity in the liver. Radioactivity 
(2.8%) was present in normal spleen after 1 hr and persisted 
similarly to that in the liver. Significantly more radioactivity 
(4.8%) was found in tumor spleens after 1 hr; however, the 
uptake per g spleen was not significantly different: 30.4 ± 
4.3% and 30.0 ± 3.0%/g for normal and tumor spleens, 
respectively. Normal lungs contained 3.8% radiaoctivity at 1 
hr. and this declined rapidly over the next 24 hr (0.2%) , but 
more gradually thereafter. lungs from tumor-bearing mice 
were not significantly different. Significant levels of ra-
diaoctivity were detectable in normal popliteal nodes only 
after 1 hr but persisted in tumor-draining nodes for 3 days. 
Despite the larger amounts of radioactivity in tumor-drain-
ing nodes at 1 hr (0.56 ± 0.003% compared with 0.009 ± 
0 .004%) , compensating for their increased mass , the unit 
uptake (0.004 ± 0.001%/g) , was significantly less than in 
normal and tumor-bearing mice. As noted in the previous 
section , radiaoctivity in the blood after 24 hr is in soluble 
form and most probably reflects the breakdown of ' 251-
labeled C. parvum in the various organs. 
Parallel studies using i .v. FITC-CP confirmed the pres-
ence of intact FITC-CP in the various organs and their 
relative distribution (sem i-quantitative estimate of numbers 
of FITC-CP per unit section). A correlation between the 
amounts of FITC-CP and radiaoctivity was particularly ap-
parent from the marked loss of FITC-CP from the lungs 
between 1 and 24 hr. FITC-CP detected in the liver and 
spleen after 15 days appeared intact and was similar to that 
seen after only 1 hr (Fig. 1b). Intact FITC-CP have been 
100 
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Chart 1. Amounts of "'!·labeled C. parvum ({125/]CP) in various organs 
and SO·J.LI blood samples at various times after i.v. injection into normal mice 
or mice bearing a solid M4 tumor in a hind footpad (10' M4 cells s.c. 3 weeks 
earlier) . Pop. node. popliteal node. 
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detected in liver sections up to 28 days after injection. 
Distribution and Persistence of Labeled C. parvum In-
jected s.c. into Normal Mice or lntralesionally into Tumor-
bearing mice. Injection s.c. of C. parvum has been com-
pared with injection of C. parvum directly into tumor tissue . 
The latter has been a particularly effective form of C. par-
vum therapy in many animal tumor models (13, 19 , 23 , 26) 
including the present M4 (see Table 1 ). Normal CBA mice 
received ' 251-labeled C. parvum s.c. into a hind footpad. 
Another group of mice bearing a 3- to 4-mm M4 tumor in the 
hind footpad received 1251-labeled C. parvum s.c. directly 
into the tumor lesion (Chart 2). The bulk of the radioactivity 
(75%) was found at the injection site after both s.c. and 
intralesional injection. It persisted as shown with 0.4 and 
0.6%, respectively , remaining at 15 days. The amounts of 
radioactivity and their persistence in liver and spleen were 
simi lar after both injections and were considerably less than 
after system ic injection (Chart 1). The radioactivity levels in 
the draining popliteal nodes after both injections were simi-
lar to each other and to those found in the spleen . No 
significant activity was detected in contralateral nodes. A 
consistent difference in the distribution of radiaoctivity after 
either s.c . or intralesional injection was found after 1 hr; 
with s.c. injection , peak levels in the liver, spleen , and 
draining node were delayed until 24 hr . In both cases these 
levels paralleled those in the blood. The presence or ab-
sence of C. parvum in the various organs at different times 
after both s.c. and intralesional injection was confirmed 
using FITC-CP. 
Localization of i.v .-injected C. parvum within a Solid Tu-
mor. Solid tumors were estalished in the flanks of CBA mice 
by s.c. injection of 106 M4 cells; 7 days later, when the 
tumors were 25 to 30 sq mm and still responsive to i .v. C. 
parvum (see Chart 3) , FITC-CP was injected i.v. Twenty-four 
hr later the tumors were dissected out and carefully cleared 
of nontumorous tissue. Cryostat sections were prepared 
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Chart 2. Amounts of •••l·labeled C. parvum ({"'IJCP in various organs and 
50-J.LI blood samples at various t imes after s.c. injection into a hind footpad of 
normal mice or intralesional injection into mice with a solid M4 tumor 
growing in a hind footpad (106 M4 cells s.c. 1 week earlier). Pop . . popliteal 
Contra ..• contralateral. 
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Chart 3. The relative sensitivities of various mouse solid tumors to i.v. C. 
parvum therapy. M4 or MA cells (1 01) were injected s.c. into the flank of CBA 
or DBA/2 mice, respectively. Fsa cells (5 x 106 were similarly injected into 
C3Hf/Bu mice. Seven days later, 700 1-'g C. parvum (CP) were injected i.v. 
Control mice (Nor) were untreated. Tumor size was measured as 2 diameters 
at right angles and expressed as the multiplicand. 
and examined for the presence of FITC-CP. Intact FITC-CP 
were visble in all sections. The experiments were repeated 
using i.v. 1251-labeled C. parvum, and 0.007 ::!: 0.001% of 
injected radioactivity was found per mg of tumor tissue. 
Relationship between Localization of C. parvum within a 
Solid Tumor after i.v. Injection and Ultimate Response to 
i.v. C. parvum Therapy . To determine whether the suscepti-
b ility of various solid tumors to i.v. C. parvum therapy was 
related to the amount o f C. parvum that localized within the 
tumor, 3 different mouse tumor models were used. The 
relative sensitivities of these tumors to i .v. C. parvum are 
shown in Chart 3. M4 or MA cells (106 ) were injected s.c. 
into the flanks of CBA or DBA/2 mice , respectively . Fsa cells 
(5 x 1 06 ) were injected at the same site in C3Hf/Bu mice. C. 
parvum (700 JLg) was injected i .v. 7 days later. Growth of MA 
was completely unaffected by i .v. C. parvum, but with M4 
there was transient growth inhibit ion with no complete 
regressions. In accordance with previous findings (15), after 
a short period of growth Fsa tumors underwent complete 
regression. In parallel experiments 1251-labeled C. parvum 
was injected i.v. 7 days after tumor establishment. The 
tumors were removed 1 and 2 days later. cleared of sur-
rounding tissue, weighed , and counted for rad ioactivity 
(Chart 4). Tlie amounts of ' 251-labeled C. parvum taken up 
per mg of MA and Fsa were not significantly different and 
were significantly less than that taken up by M4. Th us there 
was no correlation between the amount of C. parvum that 
localized within the solid tumo rs after i .v. injection and the 
ultimate outcome of i .v. C. parvum therapy. 
Uptake of FITC-CP by Peritoneal and Bone Marrow 
Cells. Normal CBA mice received FITC-CP i.v. , i.p., or s.c., 
and the numbers of FITC-CP-containing cells in bone mar-
row and peritoneal cell preparations were co unted (Chart 
5). Of bone marrow cells, 10% contained FITC-CP 1 hr after 
i.v. injection , dropping to 2% after 10 days. A few (approxi-
mately 0.1%) FITC-CP-containing bone marrow cells were 
found in occasional preparations after s.c. and i .p. injec-
tion. No FITC-CP-containing peritoneal cells were found at 
any t ime after i.v. or s.c. injection. That the peritoneal cells 
were , however, capable of taking up FITC-CP was apparent 
from the large number (50%) of FITC-CP-containing cells 
found after i .p. injection. Despite the presence or absence 
of FITC-CP in peritoneal cel ls after i.p. or i .v. injection , 
respectively, 2 days after injection both cell populations 
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Chart 4. Relative amounts of "'Habeled C. parvum ({' .. 1/CP taken up by 
various mouse solid tumors after i.v. injection . Mice bearing 7-day sol id 
tumors in the flank (see Chart 4) received i.v. injections of •••!-labeled C. 
parvum, and the tumors were removed 1 and 2 days later for radioactive 
assay. 
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Chart 5. The percentage of FITC-CP (CP)-containing cells in the perito-
neum and bone marrow at vaf'ious times after i.v., i.p., or s.c. inject ion. 
Table 2 
In vitro inhibition of AI leukemia cell growth by peritoneal cells 
from mice pretreated either i.v. or i.p . with FITC-CP 
Cells 
Rl alone 
Normal peritoneal cells + Rl 
(10:1) 
i.v. FITC-CP peritoneal cellsb 
+ Rl (10:1) 
i .p. FITC-CP peritoneal 
cells'1 + Rl (10:1) 
(3H)Thymidine in- cpm/cul-
corporat ion (cpm/ ture (% Rl 
culture• ::!: S.E.) alone) 
32,996 ::!; 300 100.0 
39,902 ::!; 3,759 120.9 
734 ::!; 96" 2.2 
860 ::!; 76< 2.6 
• Cultures of normal or FITC-CP-stimulated peritoneal cells 
alone incorporated insignificant amounts of (3 H]thymidine. 
b Peritoneal cells from mice that had rece ived 300 ,ug FITC-CP 
i. v. 4 days earlier. 
< Not significantly different from simi larly designated resu lts (p > 
0.05) . 
d Peritoneal cells from mice that had received 300 ,ug FITC-CP 
i.p. 4 days earlier. 
showed simi lar degrees of macrophage activation as evi-
denced by degree of spreading and vacuolation (19). Four 
days after injection the cell popu lations were compared for 
their ability to inhibit nonspecifically the growth of synge-
neic leukemia cells in vitro , and both were found to be 
highly active (Table 2) , with 97 .8 and 97.4% inhibition after 
i.v . or i .p. FITC-CP, respectively. 
Failure of an Inactive Strain of C. parvum to Persist in 
Vivo . Throughout these studies we were impressed with the 
relative resistance of C. parvum to degradation in vivo, 
some intact FITC-CP still being detectable more than a 
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month after injection. To determine whether the property 
may be related to the antitumor activity of C. parvum, the in 
vivo persistence of either 1251- or FITC-Iabeled inactive C. 
parvum (CN5888) was studied. This organism has no lym-
phoreticular stimulatory or antitumor effects (1) and did not 
acquire any after labeling. The results of i.v. injection of 
equivalent amounts of active and inactive 1251-labeled C. 
parvum into CBA mice are shown in Table 3. Considerably 
more rad ioactivity was lost from the liver and spleen during 
the 1st 24 hr after injection of inactive 1251-labeled C. parvum 
than with active 1 251-labeled C. parvum. Studies using inac-
tive FITC-CP again suggested a rapid breakdown of this 
organism in vivo: 24 hr after i.v . injection no intact bacteria 
could be resolved in spleen and liver sections, the only 
f luorescent material resembl ing debris (Fig. 1, c and d). 
DISCUSSION 
1251- or FITC-Iabeled C. parvum, injected i.v. into normal 
mice , was found in high concentrations in the liver, spleen. 
and lung, and in lesser amounts in the lymph nodes and 
bone marrow cells. After s.c. administration , however, most 
of the bacteria were restr icted to the site of injection. with 
high concentrations in the draining lymph nodes and none 
in the contralateral nodes. Amounts in the spleen , liver, and 
bone marrow were far less than after i.v. injection . Although 
C. parvum was rapidly lost from the lungs after i.v. injection. 
it was remarkably persistent elsewhere ; this will be dis-
cussed later. The presence of C. parvum in the various 
tissues corresponds with reported biological modifications 
in them after injection of C. parvum, e.g. , hepatomegaly, 
splenomegaly and lung weight increase (1), increased 
lymph node weights (8} , augmented proliferative response 
of lymph nodes to mitogens (14) and antigens (25), and 
increased colony-forming capacity of bone marrow cells 
(30). 
The restricted distribution of C. parvum after s.c. injec-
tion results in intense stimu lation of the draining lymph 
nodes with only minimal splenomegaly and hepatomegaly 
compared with the i.v. route . This suggests that the degree 
of regional stimulation caused by C. parvum may be directly 
proportional to the amount of C. parvum reaching the tis-
sue. The relative distributions of C. parvum after these 
routes of injection also parallel the in vivo antitumor activi-
ties induced. Whereas systemic C. parvum is capable of 
inhibiting the growth of tumors at various sites in the body 
(reviewed in Ref. 23) . s.c. C. parvum is usually on ly effective 
when injected either di rectly into the tumor or so that it 
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stimulates the tumor-draining nodes (13, 26) . The same 
relationship holds for the generation of specific cell-me-
diated tumor immunity after local injections of C. parvum 
and irradiated tumor cells (5. 27) . The immunity resulting 
from injecting irradiated tumor cells and C. parvum at sepa-
rate sites having the same draining lymph node is as strong 
as when they are injected as a mixture , but is reduced by 
wide spatial separation of the injections (27). 
The presence of a solid fibrosarcoma growing in the 
footpad increased the rate of clearance of i .v. C. parvum 
from the blood . and this elevated phagocytic activity of 
tumor-bearing mice has been noted previously (17) . The 
amounts of C. parvum taken up by the spleen and tumor-
draining node were also increased , but liver and lung up-
take were not modified. That the increased splenic uptake 
was proportional to the tumor-induced splenomegaly sug-
gests an increased nonspecific trapping of C. parvum rather 
than any selective uptake attributable to the tumor. This 
also applies to the increased uptake by the tumor-draining 
node where the unit uptake was actually decreased . How-
ever , the increased total amount of C. parvum in the tumor-
draining node may contribute to the efficacy of i .v. C. par-
vum therapy , since stimulation of a tumor-draining node by 
C. parvum is known to result in specific cell -mediated anti-
tumor immunity . whereas distant injections are ineffective 
(27). 
The distribution of C. parvum after intralesional injection 
resembled that after s.c . injection into normal animals . 
However, the systemic spread of C. parvum was more rapid 
after intralesional than after s.c . injection, peak radioactiv-
ity being detected in the blood liver and spleen after 1 and 
24 hr. respectively. This difference most probably reflects a 
better vascularization of the tumor bed compared with nor-
mal tissue. 
The persistence of C. parvum at the tumor site after 
intralesional injection may be a factor contributing to the 
efficacy of this form of C. parvum therapy against solid 
tumors (13, 19, 26). Recent studies by Tuttle and North (29) 
indicate that a major component of the mechanism of anti-
tumor activity of intralesional C. parvum is dependent on 
the generation of systemic immunity to C. parvum antigens 
which allows an immune-mediated inflammatory response 
to be focused at the site of C. parvum antigens (i.e. , the 
tumor site) . This local inflammation was shown to exert a 
powerful antitumor effect. The prolonged presence of intact 
C. parvum (C. parvum antigen) after intralesional injection 
would be expected to prolong such local reactivity within 
the tumor site. 
Table 3 
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The relative in vivo persistence of active and inactive strains of ' 251-/abe/ed C. parvum 
during 24 hr after i.v. injection 
1 hr 
24 hr 
% radioactivity lost 
during 24 hr 
" CP , C. parvum. 
Liver 
Act ive CP" Inactive CP 
62.3 :t 3.8& 
40.2 :t 3.2 
35.5 
40.0 :!: 1.6 
7.5 :t 0.4 
81 .2 
'' cpm/organ as a percentage of radioactivity injected . 
Spleen 
Active CP 
2.8 :t 0.02 
1.1 ± 0.02 
60.7 
Inactive CP 
3 .7 :t 0.2 
0.43 :t 0.02 
88.4 
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The in vivo antitumor effects of systemic C. parvum are 
considered to be predominantly nonspecific and med iated 
by activated macrophages (reviewed in Ref. 23). Recent 
studies on the mechanism of macrophage activation by C. 
parvum implied that 2 activation pathways may operate in 
vivo: direct activation after the ingestion of C. parvum by the 
macrophage, and an indirect activation resu lting from the 
interaction of C. parvum-sensitized lymphocytes with C. 
parvum antigen (6 , 9) . The present find ing that peritoneal 
macrophages are fully activated 4 days after i .v. C. parvum 
treatment in the total absence of C. parvum-containing cells 
in the peritoneum supports the viewpoint that uptake of C. 
parvum by a macrophage is not a prerequisite for its activa-
tion. The data do not exclude the possibility that peritoneal 
macrophages expressing in vitro anti tumor activity may be 
the progeny of cells that had taken up C. parvum elsewhere 
and digested it before migrating into the peritoneal cavity.lt 
is likely that the source of such cells may be the bone 
marrow, si nee we have shown here that C. parvum is taken 
up by bone marrow cells , and others have shown that C. 
parvum stimulates macrophage production in the bone 
marrow (11, 30). 
Mouse sol id tumors have been shown to contain varying 
numbers of macrophages (10), and the amount of C. par-
vum that localizes within a solid tumor after i.v. injection is 
most probably a function of the number of these tumor 
macrophages and the degree of vascularization of the tu-
mor. Overall, the strongest antitumor effects against solid 
tumors have been achieved by injecting the C. parvum 
directly in the tumor lesion (13 , 19, 23 , 26), and , on finding 
that some i.v. injected C. parvum localized within a solid 
tumor, it was considered that a component of the effects of 
i .v . C. parvum may be analogous to an intralesionsl injec-
tion. However, the amounts of i.v.-injected C. parvum that 
localized within different solid tumors did not correlate with 
their sensitivities to i.v. C. parvum therapy. It would then 
seem that the amount of intratumor C. parvum found after 
i .v. injection does not make a critical or sign ificant contri-
bution to the overall antitumor effects of i.v. C. parvum 
therapy. A relevant consideration is our finding that C. 
parvum-activated macrophages, which have been consid-
ered to be the predominant effector cell after systemic C. 
parvum (reviewed in Ref. 23) , need not contain C. parvum. 
The in vivo degradati on of killed C. parvum after both i.v. 
and s.c. injection is a gradual process , and intact FITC-CP 
were found consistently 2 weeks and more after injection. 
Interestingly , this resistance to d igestion mirrors the 
chronic stimulation of hyperplasia in the spleen and liver 
which is detectable 2 to 3 days after i .v. C. parvum treatment 
and gradually increases, peaking around 14 to 16 days (1). 
Persistence of C. parvum has also been noted by Tuttle and 
North (29), who reported that 6 days after local C. parvum 
injection phagocytic cells at the injection site were still 
replete with intact bacteria . The data presented here show 
that " inactive" C. parvum (CN5888) was digested far more 
rapidly than " active" C. parvum. Rapid degradation of other 
inactive bacteria have been reported. Killed 131 !-labeled Sal-
monella enteritidis were completely eliminated from the 
mouse liver within 24 hr of i.v. injection (4). Roberts (21) 
found that most of the heat-killed S. typhi phagocytosed by 
1678 
rabbit macrophages were completely digested within 6 hr, 
and Topley (28) showed that within 24 hr of being taken up 
by rabbit splenic histiocytes , S. paratyphi N was rendered 
nonantigen ic. In contrast to these is a study with a yeast cell 
wall extract , zymosan , which is also a reticuloendothelial 
stimulant (2) with antitumor activity (17). [ ' 4 C]Zymosan in-
jected i.v . into mice and taken up by the liver persisted in 
relatively high amounts for a period of several weeks (22). 
Considering these points , it is interesting to specu late that 
the relative resistance of naturally occurring ret icu loendo-
thelial stimulants to intracellular degradation may contrib-
ute to their antitumor activity , and this is now under experi-
mental consideration. 
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Fig. 1. Fluorescence photomicrographs. a, FITC-CP smear; b , FITC-CP in spleen section 1 day after i.v. injection; c, FITC-CP (CN 588\l) smear; d , FITC-CP 
(CN 5888) in spleen section 1 day after i.v. injection. x 1000. 
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STUDIES USING LABELLED C. PARVUM PREPARATIONS 
IN .MICE 
M. T. Sco11 
ABSTRACT 
The in vit•o distribution of a:) I and fluorescein labelled C. parvum, after local 
and sys temic injection mice has been studied. After i. v. injection large amounts were 
found in the liver, spleen and lung.~. with less in the lymph nodes. The distribution 
after s. c. injection was more restricted; the bulk of inoculum was retained at the 
injection site and draining lymph node, and only small amounts were found in the 
liver and spleen. C. parvum was found in bone marrow, but not peritoneal cells after 
i. v. injection. It was, however, possible to recruit C. parvum-containing cells into 
the peritoneal cavity by i. p. injection of thioglycollate, and to a lesser extent, i. p. 
injection of syngeneic tumour cells. 
The present st udies using labelled C. parvum preparations were undertaken 
to determine its in vivo distribution after systemic or local injection and provide 
further information as to its mode of antitumour action. 
Fluorescein and 12 5 Iodine labelled C. p a r v u m ( CP) 
F luorescent preparations of CP were prepared by mtxtng CP vacci ne 
(Wellcome) with fluorescein isothiocyanate (FITC) as detailed in (6). At various 
times after injection of FITC-CP into mice, organs were removed, cryostat 
sectioned, and exami ned using phase contrast-fluorescence microscopy. CP was . 
labelled with 1251 using a chloramine-T conjugation method described in (6). 
After injection of 1251-CP organs were removed and counted in an automatic 
y counter. Both FITC-CP and 1251-CP retained lymphoreticular stimulatory and 
antitumour activity (6). 
l n v ivo distrib111ion of FITC-CP 
300 Jtg of FITC-CP were injected i. v. into normal CBA mice and I and 
24 h later various organs, and peritoneal and bone marrow cells were examined 
for FITC-CP (Table 1). After I h large amounts were present in the liver, spleen 
and lungs, with less in the kidneys. Some, but only small amounts, were detected 
in all lymph node sections (popliteal, inguinal) but only a few organisms were 
fo und in occasional thymus sections. Brain sections were negative. All organs 
were similarly labelled after 24 h except for a drastic loss of F JTC-CP from the 
lungs. Some bone marrow cells contained FITC-CP but none was found in peri-
toneal cells after i. v . injection (Table 1). 
20 
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Tnhll' I. Distribution of FITC-C. twrtmm following i. v. injection. tScmi-quantitativc estimate 
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Recruilmenl of FJTC-CP containing cells into the peritoneal cavity 
Mice were injected i. v. with FITC-CP and 4 days later (when no FITC-CP 
containing cells were detectable in either the peritoneal cavity or blood) were 
given 0.5 ml thioglycol late i. p. (Difco Laboratories, Inc., Detroit, Michigan, 
U.S.A.). Peritoneal cells were subseq uently screened for FITC-CP contain-
ing ce lls (Fig. 1) and these appeared within I day and persisted throughout the 
next 4 days' studies. To determine whether an i. p. injection of syngeneic tumour 
cells would similarly recruit FITC-CP contain ing cells, mice were injected i. v. 
with FITC-C P and 3 days later 105 syngeneic R I leukemia cells (4) were 
injected i. p. Control mice received only i. v. FlTC-CP and 2 days later peritoneal 
cell samples were screened for FITC-CP containing cells. None was found 
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Fig. I . Recruitment of FITC-CP contain-
ing cells into the peritoneum by thio-
glycollate. Mice were injected i. v. wi th 
FITC-CP and 4 days later were injected 
i. p. with 0.5 ml thioglycollate (Thio. ) or 
were untreated (N). The percentage of 
peritoneal cells containing FITC-CP at 
various times after thioglycollate was 
assayed. 
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Correia! ion of FITC-CP with 12 5 1-CP 
. Microscopic detection of FJTC-CP provides unequivocal evidence 
of the presence of CP organisms, but the results are difficult to quantitate. 
To determine whether the amount of radioactivity detected in 1251-CP experi-
ments correlated with the presence of FITC-CP detected by fluorescence 
microscopy, advantage was taken of the rapid loss of CP from the lungs 
described above. Mice were injected i. v. with 300 )1g of either 1251-CP or 
FJTC-CP and the lungs removed I, 24 and 48 h later. The number of FITC-CP 
per unit area (20 microscope fields) .of lung sections was counted. 1251-CP 
containi ng lungs were weighed and the cpm/unit weight of lung determined. The 
I h results were assigned the value of 100% and the result plotted as % CP/ 
unit lung (F ig. 2). The correlation between the loss of F ITC-CP and 1251-CP 
suggests that the amount of radioactivity is representative of the amount of C P 
present. 
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Fig. 2. Correlation of the amounts of 'Uf-CP and FITC-CP 
present in the lung at various times afte r i. v. injection. 
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Distribution of 125 1-CP injected either i. v. or s. c. into normal mice 
1251-CP was injected either i. v. or s. c. into a hind footpad. Twenty-
four hr later organs were removed for y counting (Fig. 3). In keeping with the 
F lTC-CP data (Table I) the highest activity was found in the liver and spleen, 
with intermediate amounts in the lungs, and on ly small amounts in lymph nodes 
(popliteal). After s. c. injection the bulk of the inoculum was retained at the 
injection site. The d irect draining node (popliteal) was heavily labelled with 
100 liYer 
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Fig. 3. Relative amounts of ... 1-CP in various 
organs 24 h after i. v. or s. c. (hind footpad) 
injection (300 Jig) into normal CBA mice. The 
lymph nodes assayed were popliteal; after s. c. 
injection these were either draining or contralateral 
(contra) to the injection site. 
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successively dista l nodes (lumbar, inguinal) less so (data not included in 
Fig. 3). Contralateral nodes were unlabelled and uptake in the liver and spleen 
was considerably less than after i. v. injection. 
DISCUSSION 
The presence of CP in the various tissues corresponds with reported 
biologica l modifications in them following injection of CP: hepatomegaly, 
splenomegaly and increased lung weight ( I) increased lymph node weight (2), 
increased lymph node mitogen (3) and antigen (5) responsiveness, decreased 
thymus mass (2) and increased bone marrow colony forming capacity (8). 
That the degree of stimulation ca used by CP may be directly proportional 
to the amount of CP reaching the tissues is suggested by the fact that the 
restricted dist ribution of CP after s. c. injection causes intense stimulation of the 
draining lym ph nodes with only minimal splenomegaly and hepatomegaly 
compared with i. v. C P. 
The recruitment of cells containing intact CP into the peritoneum 
following thioglycollate and, to a lesser extent , tumour cell injection is inte-
resting in that it suggests that a tumour, or tumour associated infla mmation may 
serve to focus CP ant igen at a tumour site, thereby initiating, or intensifying 
immune mediated local anti-tumour activity (7). 
Both FITC-CP and 125 f-CP ha ve proved useful reagents in further 
studies using tumour bearing animals and these data are report ed elsewhere (6). 
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General discussion 
Chare: What is the distribution of labelled o rganisms which possess no 
anti-tumour act ivity? 
Scolt: The o rgan distribution of labelled preparations of an active strain of 
C. parvum (one tha t does not have lymphoreticular or anti-tumour activity) 
is simi lar to the act ive strain. The persistence is much less, nearly a ll of the 
label having disappeared in 24 hours. 
Dimitrov: There is a substantial difference in the residual activity in the 
kidney when i. v. and subcutaneous routes of administration of the radioactive 
vaccine arc compared . It appears that the radioactivity persists longer aft er sub-
cutaneous administ ration. 
S cott : I have not looked at persistence of labelled C. parvum in the 
kidney after subcutaneous administration. 
Labelled C. paruum preparations in mice 127 
Gauthier-Rahman: r should like to make a comment. You found that the 
peritoneal macrophages had very little C. parvum after i. v. administration to 
rats. But at the times you looked at them, at I and 24 hours, you took the 
resident macrophages. 
Scott: We have looked right through to 21 days after administration 
and we never find any C. parvum in the peritoneum. 
Gauthier- Rahman: The resident macrophages are not provoked macro-
phages? Macro phages activated by C. parvum are largely of bone-marrow 
origin and could be studied wit h a provoked peritoneal exudate. 
Scott: In mice, pre-treated i. v. with labelled C. parvum, we are able to 
recruit cells containing C. parvum into the peritoneal cavity by a subsequent 
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of Intrapleural Corynebacterium parvum in Mice 
A Comparison with Intravenous Corynebacterium parvum 
M. T. Scott1 and J. Decker2 
Department of Experimental Immunobiology, The Wellcome Research Laboratories, 
Beckenham, Kent BR3 3BS, U.K. 
Summary. After intrapleural (I PI) injection of 125 I or 
fluorescein labelled C. parvum, most was confined to the 
pleural and mediastinal spaces. The pleural phagocytes 
and mediastinal lymph nodes were heavily labelled, but 
very little was found in the lung. The amounts of C. 
parvum taken up by the liver and spleen were less than 
after IV injection and splenomegaly was also less after 
!Pi than IV injection. A large proportion (> 90%) of 
1 M.T.S. is a member of the Ludwig Lung Cancer Study Group. The 
present work arose out of discussions with other members of the 
group and is presented on their behalf. The study group is: M. Kauf-
mann, J. Stjernswiird (Ludwig Institut for Cancer Research, Lau-
sanne Branch, Switzerland), M. Zelen, K. Stanley (Frontier Science 
and Technology Research Foundation, Inc. Amherst, New York, 
USA), D. S. Freestone, R. Bomford, M. T. Scott, T. Priestman (The 
Wellcome Research Laboratories, Beckenham, England), C. Mourit-
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Aarhus Kommunehospital, Aarhus, Denmark), N. Konietzko, D. 
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Benedik, B. Hrabar (Clinical Center, Dept. of Thoracic Surgery, 
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cells in pleural washouts following IPl C. parvum was 
activated macrophages which inhibited, nonspecifically, 
the growth of tumor cells in vitro. No similar activity 
was detected after IV C. parvum. !Pl injection of C. 
parvum mixed with irradiated tumor cells conferred 
strong, specific systemic immunity against tumor chal-
lenge, and this immunity was also demonstrable using 
mediastina/lymph node cells in a Winn assay. The im-
munity resulting from IV C. parvum and IPl irradiated 
tumor cells was significantly lower. 
!PI C. parvum has been compared with IV C. par-
vum for its effect against tumors growing either in the 
lung or pleural cavity. Tumors growing in the pleural 
cavity were inhibited more effectively by /PI than IV C. 
parvum. With tumors growing in the lung (caused by 
tumor cells injected IV), although IV C. parvum was 
more effective at reducing the number of lung nodules 
during the first two weeks, the mice consistently survived 
longer after !PI C. parvum. 
Introductio n 
McKneaJly et al. (1976, 1977) have reported encourag-
ing data concerning the treatment of stage I lung cancer 
patients with post resection injection of BCG into the 
pleural space. It was apparent from animal studies that 
the mechanisms underlying the antitumor activity of C. 
parvum were similar to those of BCG (Scott and Born-
ford, 1976) and in 1977 the Ludwig Lung Cancer 
Group started a multicentre clinical trial using post re-
section intrapleural (I PI) C. parvum (Ludwig, 1978). The 
animal studies described here were undertaken in con-
junction with this trial with the purposes of defining the 
distribution of C. parvum following IPI injection, the an-
titumor mechanism(s) engaged, and any effects on ex-
perimental lung-associated tumors. These effects have 
been compared with those resulting from C. parvum in-
0340-7004/78/0005/0085/ S 01.40 
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jected IV since this was considered by the Group as a 
future additional, or alternative, treatment. 
Materials and Methods 
Mice. Adult CBA/ H mice were used throughout. 
C. parvum. A killed suspension of C. parvum (Wellcome strain 
CN6 I 34) was provided by Wellcome Reagents Ltd., Becken ham, 
Kent, England. Dilutions were made with saline. 
' 25Iodine and Fluorescein Isothiocyanate (FITC) Labelled C. par-
vum. The preparation and characteristics of these reagents, and also 
the fluorescence microscopy and p-counting techniques for monitor-
ing their in vivo distribution have been described previously (Scott 
and Milas, 1977). 
lmrapleural (!PO lll}ection Technique. This was based on that de-
scribed by Chu and Lin (1976). Mice were anesthetized with Avertin 
(Winthrop Laboratories, Surbiton-upon-Thames, Surrey, England), 
and a small incision made in the left lateral side of the chest; 0.1 ml 
volumes were injected carefully through an intercostal space using a 
27 gauge needle. The incision was closed with autoclips (Clay 
Adams, Parsippany, New Jersey, USA). 
Collection of Pleural Cells. Mice were killed by C02 asphyxiation 
and a ventral mid-line incision made over the chest. Dulbecco's me-
dium (20 ml) containing 5% heparin/ml was injected with a 27 gauge 
needle into the pleural cavity. The chest wall was gently massaged 
for a few minutes. A small vertical incision was made with fine 
pointed scissors and the fluid collected using a Pasteur pipette. 
Tumors. The origins, characteristics and maintenance of syngeneic 
CBA M4 fibrosarcoma (Bomford, 1975), T3 fibrosarcoma (Bomford 
and Olivotto, 1974) and RI leukemia (Olivotto and Bomford, 1974) 
have been described previously. 
Tumor Cell Irradiation. M4 fibrosarcoma cells were exposed to 
10,000 rads from a ll7Cs source. 
ln vivo Tumor Measurement. M4 fibrosarcoma cells were injected 
SC (0.05 m1) into a hind footpad, where they grew as a solid tumor. 
Tumor growth was measured as footpad thickness using a dial gauge 
caliper. 
In vitro Assay for Nonspecific Tumor Inhibition. This technique has 
been described before (Scott, 1974). Washed peritoneal or pleural 
cells were mixed in vitro at a ratio of 10: l with RI leukemia cells. 
3H thymidine was added after 24 h of culture, and its uptake by RI 
cells assayed 24 h later. Neither normal nor C. parvum stimulated 
pleural or peritoneal cells incorporated significant amounts of thymi-
dine when cultured alone and the results are expressed as per cent 
tumor inhibition, calculated as follows: 
cpm/culture RI alone - cpm/ culture Rl+effector cells x 
100
. 
cpm/culture RI alone 
Lung Nodule Inhibition Assay. The number of nodules present in the 
lungs of mice at various times after IV injection of live T3 fibrosarco-
ma cells was assayed as described by Bomford and Olivotto 
(1974). 
Winn Assay for Tumor Inhibition. Washed lymph node cells were 
mixed (IO: I) with live M4 fibrosarcoma cells. The mixtures were 
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injected SC into a hind footpad of mice which had received sublethal 
whole body irradiation (500 rads) I day earlier. The growth of the 
tumor in the footpad was then monitored. 
Statistics. Results were compared using a Student t-iest and differ-
ences where P < 0.05 were taken as significant. 
Results 
Distribution of Labelled C. parvum Preparations 
Following IPI or IV Injection 
In mice the right and left pleural cavities are continuous 
(unlike in humans where they are separate), and FITC-
labelled C. parvum injected into one side appeared im-
mediately in samples taken from the other side. The up-
take of FITC-labelled C. parvum by pleural, peritoneal 
and bone marrow cells after IPl or IV injection is shown 
in Table I. One hour after IPl injection there were still 
large amounts of C. parvum free in the pleural cavity. 
After 24 h these had been completely phagocytosed and 
many pleural cells contained C. parvum. In contrast, 
very few C. parvum-containing cells were found after IV 
injection. The uptake of C. parvum by bone marrow 
cells following IPl injection was much less than after IV 
injection, and no uptake by peritoneal cells occurred 
after either IPl or IV injection. 
Previous studies using labelled C. parvum prepara-
tions have shown that after 24 h all C. parvum has been 
removed from the blood (Scott and Milas, 1977). 
Table 2 shows the amounts of radioactivity associated 
with various organs 24 h after either IV or IPl injection 
of r25I-labelled C. parvum. The relative amounts found 
after IV injection accord with those described previously 
(Scott and Milas, 1977). For the spleen and liver these 
were significantly larger than after IPl injection, whereas 
uptake by the lungs and mediastinal lymph nodes was 
larger after IPl injection. Axillary lymph nodes were 
similarly labelled after either IV or IPl injection. 
To confirm the presence of morphologically recog-
nizable C. parvum in the various tissues, the experiments 
were repeated substituting FITC-labelled for 1251-la-
Table I. Uptake of FITC-C. parvum by pleural, peritoneal and bone 
marrow cells after either IPI or IV injection 
Cells I h I day 
IPI IV IPI IV 
Pleural free orgs < 0.5• 54.8 ± 5.8 <0.5 
Peritoneal 0.0 0.0 0.0 0.0 
Bone marrow < 0.5 10.3 ± 1.2 < 0.5 7.I ± 0.3 
• % cells containing FITC-C. parvum 
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Table 2. Organ distribution of 1251-C. parvum 24 h after IV or IPI injection 
Injection Liver Spleen Lung Axillary Mediastinal 
route node node 
IV 35.0• (8.4) 1.1 (0.2) 0.2 (0.002) 0.003 (0.0003) 0.005 (0.001) 
IPI 7.2 (2.0) 0.4 (0.3) 6.3 (3.1) 0.006 (0.001) 0.8 (0.3) 
• Radioactivity - cpm % injected (standard error) 
Fig. 1. FITC-Iabelled C.parvum 
24 h after IPI inje.ction. No nuorescent 
organism are within the lung 
tiss11e (upper right); they are 
restricted to cellular aggregates 
ndhering to the lung surface 
(lower left) 
belled C. parvum and examining cryostat tissue sections. 
In all cases, except for the lungs after IPl injection, the 
fluorescence data confrrmed the presence of intact C. 
parvum directly within the tissues and also their relative 
distribution. After IPl injection only occasional C. par-
vum organisms were seen within the lung tissue but large 
amounts were contained in aggregates of pleural cells 
closely associated with the lung surface (Fig. 1). It is 
known that after IV injection of FITC-labelled C. par-
vum the largest amounts are found in the lung after only 
1 h (Scott and Milas, 1977). Further studies in the pres-
ent series have, however, failed to show significant 
amounts of C. parvum actually within the lung from 1 h 
up to 7 days after IPl injection. 
Splenomegaly After IV or !PI C. parvum 
Splenomegaly is a convenient measure of the degree of 
systemic stimulation resulting from C. parvum injection 
(Adlam and Scott, 1973) which has correlated with anti-
tumor effects (McBride et al., 1975; Riveros-Moreno et 
al., 1978). Mice were injected either IV or IPl with 350 
1-1-g C. parvum; 14 days later their spleens were removed 
and weighed. Control spleen from uninjected mice 
weighed 0.08 ± 0.02 (SE) g, and those from IV and IPl 
C. parvum injected mice 0.55 ± 0.03 and 0.20 ± 0.08 g 
respectively (P < 0.005). 
Nonspecific, in vitro Antitumor Activity of Pleural and 
Peritoneal Cells After IV or IPI C. parvum 
Mice were injected either IV or IPl with 350 1-1-g C. par-
vum and 4 days later their peritoneal and pleural cells 
assayed for in vitro tumor inhibitory activity against 
syngeneic target RI leukemic cells. These cells are sus-
ceptible to in vitro inhibition by activated macrophages 
(Olivotto and Bomford, 1974). Both pleural and perito-
neal cells from untreated mice were either without effect, 
or slightly promoted target cell thymidine uptake 
(Table 3). After IV C. parvum, inhibitory activity was 
restricted to the peritoneal cells. After IPl C. parvum, 
both pleural and peritoneal cells were significantly inhib-
itory but the activity of peritoneal cells was considerably 
less than that of pleural cells. The activity of pleural cells 
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Table 3. Nonspecific, in vitro, tumor inhibitory activity of pleural 
and peritoneal cells 4 days after either IV or 1Pl C. parvum 
C.parvum Effector cells 
None Pleural 
Peritoneal 
350 1-!g IPl Pleural 
Pleural ( 1000 rads)b 
Peritoneal 
350 )Lg IV Pleural 
Peritoneal 
% Tumor inhibition• ± SE 
- 7.1 ± 1.10 
- 4.9 ± 1.8 
75.0 ± 2.4 
73.4 ± 0.6 
22.7 ± 3.5 
1.93 ± 0.9 
82.8 ± 1.3 
• See Materials and Methods for assay details 
b Mice irradiated (1000 rads) immediately before removal of cells 
irrad. M4 i.pl. 0/6 
5 untreated 0/6 
CP i.pl. 0/6 
~ CP~ ~ ! 3 £~~+ CP l.v. + lr rad. 1141.pl. 2/6 
~ 2 ~~::::~--<> CP l.pl. + irrad. M41.pl. 6/6 ... 
9 13 17 21 
DAYS AFTER TUMOUR 
Fig. 2. Groups of 12 mice were injected with 100 fig C. parvum (CP) 
either IV, IPI, or were untreated. Immediately afterwards six mice 
from each group received 106 irradiated M4 tumor cells (irrad. M4) 
IPI; the remainder were untreated. Seven days later all mice were 
challenged in a hind footpad with 106 live M4 cells and growth of 
tumor in the foot is shown. Numbers represent the proportion of 
mice tumor-free at the end of the experiment 
stimulated by IPl C. parvum was resistant to 1000 rads 
irradiation delivered to the mice immediately prior to 
their sacrifice for cell harvest. Pleural cell yields were 
consistently increased 2-3 fold following IPl C. parvum 
and were composed of > 90% activated macrophages as 
characterized previously (Bomford and Olivotto, 
1974). 
Potentiation of Tumor Specific Immunity Following 
Either IV or !PI C. parvum 
Mice were pretreated with either IV or IPl C. parvum in 
combination with IPl irradiated M4 cells. Seven days 
later they were challenged in a hind footpad with 106 live 
M4 cells and the growth of this tumor was monitored 
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Table 4. Tumor immunity (Winn assay) expressed in the mediastinal 
lymph node 6 days after intrapleural injection of C. parvum-irra-
diated tumor cell mixtures 
Immunization 
IPI cp• + irrad. M4b 
IPlCP 
IPI irrad. M4 
None 
• CP: 100 ~1g C. pan>um 
Effector cells 
Med. lymph node 
Med. lymph node 
Med. lymph node 
Med. lymph node 
Proportion of 
mice developing 






b Irrad. M4: 106 irradiated M4 fibrosarcoma cells 
(Fig. 2). Control pretreatments were IV or IPl C. par-
vum, or irradiated M4 cells alone. The IPl injection of 
irradiated M4 cells alone did not modify growth of the 
challenge tumor compared with untreated controls. In-
hibition oftumor growth after IPl C.parvum was signifi-
cant after 13 days but less than that observed after IV 
C. parvum. The combination of IPl irradiated M4 with 
IV C. parvum was more inhibitory than IV C. parvum 
alone, but the strongest inhibition (all mice tumor free) 
was achieved when both C. parvum and irradiated M4 
were injected I PI. The specificity of this immunity result-
ing from IPl C. parvum-irradiated M4 mixtures was dem-
onstrated in further experiments where mice received IPl 
C. parvum mixed with either irradiated M4 cells, or irra-
diated, antigenically unrelated, RI leukemia cells. Only 
the latter combination provided significant protection 
against subsequent live RI cell challenge. 
Cell-mediated Expression of Specific Tumor Immunity 
Following !Pl C. parvum 
Groups of mice were untreated or injected IPl with 
100 fA-g C. parvum, 106 irradiated M4 tumor cells, or a 
mixture of C. parvum and irradiated M4. Six days later 
the mediastinal lymph nodes were removed (these were 
significantly enlarged following injections containing C. 
parvum), washed cell suspensions prepared and assayed 
for antitumor activity in a Winn assay (Table 4). Tumor 
immunity was only expressed in the mediastinal lymph 
nodes foliowing injection of C. parvum-irradiated M4 
mixtures. 
Experimental Lung-Associated Tumors 
T3 fibrosarcoma cells injected IPI into mice grow as 
solid deposits restricted to the pleural cavity and shortly 
after signs of respiratory distress are apparent the mice 
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Table 5. The effect of either IV or IPI C. parvum (350 ~g) I day before lPI injection of 




Survival in days (mean ± SE) 
IV 14, 14, 14, 15, 15, 15, 15, 15, 15, 16 ( 14.8 ± 0.2)" 
IPI II , 14, 18, 19, 22, 26, 27,27,31 (21.7 ± 2.2)• 
None J I, II, II, 12, 12, 12, 12, 12, 13 (11.8 ± 0.2)1 
• Result significantly different from other groups 
Table 6. The effect of 350 ~g C. parvum injected either IPI or IV I day before 5 x 104 T3 
fibrosarcoma cells IV 
C.parvum No. of lung nodules ± SE Mean survival time 
injection days ± SE 
route Day + 7 Day + 14 
lV 2.0 ± 1.0 22.6 ± 8.5 19.2 ± 0.9 
IPI 22.6 ± 8.5 56.2 ± 4.9 35.3 ± 4.7 
45.0 ± II > 100 15.0 ± 0.5 
die. Increased numbers ofT3 cells in the inocula shorten 
the survival times for such mice. T3 cells injected IV 
grow as discrete nodules in the lung, again eventually 
killing the mice (Bomford and Olivotto, 1974). 
The Effects of Either !PI or IV C. parvum 
Against Malignant Pleural Deposits 
Groups of mice were either untreated, or injected IPl 
or IV with 350 )lg C. parvum. The following day all mice 
were challenged IPl with 5 x 104 T3 cells and then 
monitored for survival (Table 5). IPl C. parvum 
prolonged survival significantly more than IV C. 
parvum. 
The Effect of Either IPl or IV C. parvum 
Against Tumor Nodules Growing on the Lung 
Groups of mice were injected with 350 1-Lg C. parvum 
either IPI or IV, or were untreated. Seven days later 
5 x 104 live T3 fibrosarcoma cells were injected IV. Five 
mice from each group were assayed for lung nodules 7 
and 14 days after tumor challenge and the remainder 
scored for survival (Table 6). At both times lung nodule 
inhibition after IV C. parvum was greater than after IPI 
C. parvum, however, the ultimate survival of !PI-treated 





mice was significantly greater and included one survivor 
(experiment terminated at 60 days). Similar significant 
differences between the effects of IPl and IV C. parvum 
on both nodule inhibition and survival were obtained 
when C. pan1um was given either 7 days before, or up to 
8 h after IV tumor cells. Neither IPl nor IV C. parvum 
given more than 8 h after tumor cells consistently 
caused significant nodule inhibition. In all experiments, 
survivors occurred only after IPl C. parvum -
accumulated total 26.7 ± 6. 7%. Those killed for lung 
examinations had no characteristic, well defined white 
nodules but showed occasional diffuse patches of white 
pathology. 
Discussion 
These studies, aimed at characterizing the IPI route of 
C. parvum injection in mice, were carried out in con-
junction with the ongoing clinical trial of IPl injection of 
C. parvum into man following surgical resection of lung 
cancer (Ludwig, 1978). This, in turn, was stimulated by 
the encouraging clinical data concerning the similar IPl 
injection of BCG into man (McKneally, 1976, 1977). 
The local, as opposed to the systemic nature of the 
IPI C. parvum injection, was apparent from the distribu-
tion studies. After IPI injection the bulk of the inoculum 
was restricted to the injection site (within the pleural 
phagocytes) and the draining mediastinal lymph nodes. 
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The amounts of C. parvum found in the liver, spleen and 
bone marrow were considerably less than after IV C. 
parvum injection and this overall distribution is similar 
to that previously described for C. parvum injected SC 
(Scott and Milas, 1977). It is interesting that between 
1 h and 7 days after IPl injection very little C. parvum 
was found within the lung, whereas 1 h after IV injection 
large amounts were present in the lung (Scott and Milas, 
1977). This difference may have a bearing on the rela-
tive effects of IV and IPl C. parvum against lung and 
pleural tumors as discussed below. 
The antitumor effector systems stimulated by C. 
parvum in mice may be either immunologically specific 
or nonspecific (reviewed by Milas and Scott, 1978; 
Scott, 1978). The immunologically nonspecific effects 
(i.e., independent of specific tumor antigens) seem to 
predominate after systemic C. parvum and are mediated 
by C. parvum-activated macrophages. The local interac-
tion of C. parvum and tumor antigen (e.g., after intrale-
sional injection of C. parvum, or SC injection of C. par-
vum-irradiated tumor cell mixtures) results in poten-
tiated specific T lymphocyte mediated antitumor immu-
nity. It is apparent that both mechanisms may be en-
gaged by IPl C. parvum: nonspecific antitumor activity 
was expressed in vitro by both pleural and peritoneal 
cells following IPl injection of C. parvum into normal 
mice, and the local interaction of C. parvum and tumor 
antigen in the pleural cavity resulted in strong, specific 
cell mediated immunity. 
Since recurrence in operable lung cancer may be at a 
distant site, the degree of systemic antitumor activity 
resulting from IPl injection of C. parvum is an important 
consideration. The systemic nature of the specific immu-
nity arising from C. parvum-tumor antigen interaction in 
the pleural cavity was evident from the resistance of 
mice to a distant (footpad) tumor cell challenge. The 
source of tumor antigen in man might be expected to be 
that remaining within the pleural cavity or draining 
lymph nodes after either lobectomy or pneumonectomy. 
Previous animal studies have shown that for specific im-
munity to result C. parvum and tumor antigen do not 
have to mix directly as long as the lymphoid drainage of 
both is common (Scott, 1975). 
The nonspecific tumor resistance to a footpad tumor 
challenge following IPl injection of C. parvum alone was 
significantly less than after IV C. parvum. The degree of 
splenomegaly, which has been correlated with the anti-
tumor effects of systemic C. parvum (McBride et al., 
1975; Riveros-Moreno et a!., 1978) was also less after 
IPl than IV injection. These facts, along with the obser-
vation that after IPl C. parvum pleural cells showed 
greater nonspecific antitumor activity in vitro than did 
peritoneal cells, suggests that the systemic expression of 
nonspecific tumor immunity may be more restricted 
after IPl than IV C. parvum. 
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The ability of IPl C. parvum to inhibit the growth of 
solid tumor deposits growing in the pleural cavity in 
mice accords with similar findings for the rat where IPl 
C. parvum has reduced both solid tumors and pleural 
effusions (Pimrn and Baldwin, 1977). Pleural macro-
phages were both increased in number and highly acti-
vated after IPI C. parvum and it is likely that these were 
responsible for local tumor destruction within the pleu-
ral cavity. Pleural macrophage activation after IV C. 
parvum was insignificant and this may be the basis for 
its inferior effect against pleural tumor. Since IV C. par-
vum does not enter the peritoneal cavity it has been rea-
soned that peritoneal macrophages become activated as 
macrophage precursors (Scott and Milas, 1977). Should 
this be the case then the minimal amount of pleural mac-
rophage activation detected after IV C. parvum sug-
gests that these bone marrow precursors may not enter 
the pleural cavity as readily as they enter the peritoneal 
cavity. 
Tumor deposits growing within the lung were inhib-
ited more strongly by IV than IPI C. parvum, as judged 
by the numbers of lung nodules present up to 14 days 
after IV tumor cells. These relative effects are in keeping 
with the relative amounts of C. parvum reaching the 
lung after either IV or IPl injection and suggest that C. 
parvum within the lung may be triggering a local antitu-
mor effect. Despite the early inferiority of IPI C. par-
vum, however, !PI-treated mice survived longer and long 
term survivors had very few, and nontypical (regress-
ing?) nodules. Assuming that lung tumor growth is ulti-
mately responsible for death in this model (death consis-
tently follows shortly after the onset of signs of respira-
tory distress), then these results indicate a delayed, but 
potent, antitumor effect after IPl C. parvum. The nature 
of this effect is not yet understood. However, prelimi-
nary results indicate that it may not operate in T cell 
deprived mice. Thus our working hypothesis is that 
whereas the early lung nodule inhibitory effects of C. 
parvum seem to be mediated by immunologically non-
specific means (Bomford and Olivotto, 1974), the de-
layed effect may be the result of specific T cell mediated 
immunity arising from C. parvum-tumor antigen interac-
tion. Such an interaction would be facilitated if the lungs 
and pleural cavity had a common lymphoid (medias-
tinal?) drainage. 
Whatever mechanism(s) prove to be operating, it 
may be stated that, in the present CBA T3 fibrosarcoma 
model, the IPl route of C. parvum injection has been 
consistently more effective than the IV route against 
both tumors growing in the pleural cavity and within the 
lung tissue. 
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Sear~h 'for the Possible Role of 'Immunotherapy' 
in O~erable Bronchial Non-small Cell Carcinoma (Stage I and II): 
A Phase I Study with Corynebacterium parvu1n Intrapleurally 
The Ludwig Lung Cancer Study Group 1 
Summary. The possibility of giving C. parvum intrapleu-
ral/y (i.p.) was investigated. C. parvum was gil•en post· 
operatively either i.p. only or i.p. and illlravenous~y (i.v.) 
simultaneously. The dose varied from O.J - 10 mg i.p. All 
patients had been operated for a bronchial carcinoma. 
Results: (J) Subjective complaints of either dyspnoea, 
thoracic pain, chills or nausea occured in 31 of 63 pa-
tients. No clear dose relation was found. A feeling of 
discomfon and fever could occur for another 3-4 days 
after the above more acwe symptoms had disappeared. 
The study group is: M. Kaufmann, J. Stjernswiird (Ludwig lnsti· 
. tut for Canc.:r Resea rch. Lausanne Branch, Switzerland), M. Z.elcn, 
K. Stanley (Frontier Science and Technology Research Foundation, 
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stein, Germany), J. Orcl, M. Benedik, B. Hrabar (Clinical Center, 
Dept. of Thoracic Surgery, Ljubljana, Yugoslavia), S. Plesnicar (The 
Institute of Oncology, Ljubljana, Yugoslavia), H. A. Rostad, J. R. 
Vale (Rikshospital, Oslo, Norway), S. Hagen, S. Birkeland, (UIIcval 
Hospital, Oslo, Norway), T. Harbitz, R. Nisscn-Meyer (Aker Hospi· 
tal, Oslo, Norway), L. Rodriguez, V. 0. Bjork, K. Book (Karolinska 
Sjukhusct, Thoracic Clinic, Stockholm, Sweden), E. Gradel, J. 
Hasse, P. Holbro (Kantonsspital, Thoraxchimrgische Klinik, Basel, 
Switz.c rlantl), L. Eckmann (Ticfenauspital, Chir. Univ.-Klinik, Bern, 
Switzerland), B. Nachbur, T. Liechti (Inselspital, Dept. of Thoracic 
and Cardiovascular Surgery, Bern, Switzerland), H. Cottier ( lnst. of 
Pathology, lnsclspital, Bern, Switzerland), W. Maurer, M. Kauf-
mann, P. Froelicher (Biirgerspital, Surgical Dept., Solothurn, 
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Research, University of Vienna, Austria) · 
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(2) increased fever (0.5° C) occurred in 71 % of rhe pa-
tients injected i.p. only. (3) No anaphylactic reaction 
was observed. (4) Increased to/a{ ll"hire blood cell t OtllliS 
( < 20%) occurred in 38 patients. The WBC increase 
was mai11~y due to higher number of neutrocytes and 
granulocytes. Total lymphocyte, monocyte, eosi11ophilic. 
and basophilic granulocytes 1·alues per Jl/1113 circulating 
blood remained unchanged, except at the dose of 7 111g 
C. parvum i.p. when monocyte \'Glues were increased 
significantly from 576 ± 247 to 1100 ± 578/nun3. (5) 
Moderate to severe effusions were obsen·ed radiologicai-
ly in three patients after C. parvum imrapleurally. 
Introduction 
C01ynebacterium parvum (CP) is known to be a potent 
stimulator of the immune system (Halpern et al., 1963: 
Scott, 1974; Woodruff and Dunbar. 1973). In view of 
its inhibitory effect on tumour growth in a variety of 
animal models (Bomforcl and Olivet to. 1974; Cheng et 
al., 1976: Halpern et at., 1966) it has been suggested 
that CP may be of value in human cancer (Fisher et al., 
1976; Hirshaut et al., 1976; [srael , 1973, 1976). ln car-
cinoma of the bronchus the survival is unacceptably low 
even in operable cases and the addition of radiotherapy 
and chemotherapy has failed to improve the prognosis. 
The role of immunotherapy remains to be confirmed but 
it has been indicated that a relationship exists between 
histological signs of immunoreactivity in regional lymph 
nodes and prognosis in squamous cell bronchogenic car-
cinoma (Kaufmann et al., 1977). This observation is 
consistent with other indirect data demonstrating a rela-
tionship between immuno-competence and prognosis in 
lung cancer. Some current randomised. clinical trials are 
exploring the role of immunotherapy in lung cancer. In 
one BCG is given intrapleurally and the results indicate 
that local recurrence rates may be reduced in patients 
with early disease (McKneally et al., 1976). Another 




study uses levamisole and has indicated that distant me-
tastases may be affected (Amery, I 976). An effect by 
BCG subcutaneously both to inoperable lung cancer 
(Pines, 1976) and operable (Pouillart et al., 1976) has in 
two studies with a relative small number of patients been 
claimed to have a therapeutic positive effect, as has CP 
given subcutaneously to disseminated epidermoid bron-
chogenic carcinoma (Israel, 1976). In a recent review, 
however, it )vas stated that no single trial to date has 
conclusively demonstrated a positive role for immuno-
therapy in malignant disease (Mastrangelo ct ·a!., 
1976). 
The purpose of this study was to investigate the fea-
sibility of giving intrapleural CP post-operatively to pa-
tients who had a carcinoma of the lung resected . CP was 
chosen in preference to BCG for the following rea-
sons: 
I. CP su ... pension contains on\; killed organisms and 
there is no need for subsequent neutralisation with other 
agents. 1 
2. CP is ' table for at least I year and thus more 
reliably stanaardised than BCG (an important factor 
within a 1nulticentre trial). 
3. CP is at least as efTective as BCG in its tumour 
inhibiting efTect in animal models (Likhite, 1976; Scott 
and Bomford, 1976). 
Materials 
Patients. Sixty-three patients were entered into this study from eight 
of the European clinics within the Ludwig Lung Cancer Study 
G roup. All patients had a bronchogenic carcinoma and the majority 
of these were Stage I and II (53/63). All but one pmient were treated 
either by lobectomy (45/ 63) or pneumonectomy ( 17/ 63), one patient 
with mediastinal node involvement had an exploratory thoracotomy 
only. 
C. parvum. C P was supplied by Burroughs Wellcome (Batch No. BA 
3974) and consisted of a suspension of washed formalin-killed organ-
isms in physiologic pyrogen-free saline conta ining 0.0 1% thiomcrsal 
as preservative, each ampoule containing 7 mg dry weight organisms 
in I mi. CP was given either intrapleurally (i.p.) (46 patients) or 
intraplcurally and intravenously (i.p. and i.v.) simultaneously ( 17 pa-
tients). The i.p. dose of CP varied from 0.1-10 mg. when given i.p. 
and i.v. a total dose of 7 mg CP was used, 3.5 mg being given by 
each route. C P was administered following removal of the thoracic 
drainage tubes between the sixth and tenth post-operative day. When 
given i.p., C P was dilu ted in 5- 10 ml of physiological saline and 
administered via a catheter placed at the time of the operation with 
its tip at the tracheal bifurcation, a t the side of the bronchial resec· 
tion line. The posi tion of the catheter was ensured with a catgut 
suture. CP was injected slowly through the ca theter which was after-
wards Oushed with an equivalent volume of saline prior to removal. 
When CP was given i.p. and i.v. for the i.v. route 3.5 mg C P was 
diluted in 100 m! of physiological saline and was given by i.v. infu· 
sion over I h. 
Local and systemic effects of CP administration were monitored 
as follows. Total and differential white blood cell counts (WBC) were 
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performed immediately before and on the first. second, and third day 
nftcr CP injection. The erythrocyte sedimentation rate (ESR) was 
measured before and 3 days after CP administration. Temperature 
and blood pressure were recorded every 12 h. respiration :md pulse 
every 4 h. following CP. Chest X-ray was performed I or 2 days 
before and 3 days after CP. Subjecti ve complaints following C P. 
such as dyspnoea. chcast pain, chi lls, and nausea, were no ted in 
rclatton to time of onset and duration. 
Results 
Table I summarises the data on individual patients. 
listed according to dose of CP given. The individual 
complications observed, the effect on white blood differ-
entials. eryth rocyte sedimentation rate, temperatu re. 
pulse rate, blood pressure, are listed. 
Subjectil•e Complaints. Subjective complaints of either 
chest pain, pleuritic pain, chills, and/ or fe ver. occurred 
in 3 I of the 63 patients and 32 patients had no com-
plaints whatsoever (Table I , last column). No clear rela· 
tionship between dose of CP and incidence of subjective 
complaints was observed. Subjective complaints were 
more frequent among patients receiving CP i.v. and i.p. 
(Fig. l). 
Orher Changes. Moderate to severe pleural effusions 
were observed in three patients and minor radiological 
changes were seen in fi ve patients (Table 1). There was 
no correlation to dose of CP administrated. 
Changes in blood pressure showed no correlation 
with dose. Four patients receiving i.p. C P experienced 
an increase of systolic blood pressure greater than 30 
mm Hg at doses of2.5, 4.0, 5.0, and 10.0 CP respective-
ly. Three patients receiving i.p. and i.v. CP experienced 
similar changes. One patient receiving i.v. and i.p. CP 
experienced severe hypotension (BP 60/50) accompa· 
nied by supraventricular tachycardia 60 h after adminis· 
tration. The paresis of the recurrence nerve observed in 
one patient happened immediately after CP injection. 
The paresis disappeared gradually and completely 
(Table 1). 
Temperarure Changes. An elevation of temperature 
greater than 0.5° C following CP administration was 
considered a febrile response. After i.p. C P, 71 % of pa· 
tients had a febrile response (70% of lobectomy paticntl> 
and 769& of those who had pneumonectomy). After i.v. 
and i.p. CP, 88% of patients suffered a febrile response 
and the maximum temperature elevations were recorded 
in this group (Figs. 2 and 3). The maximum temperature 
elevation occurred earlier in lobectomy patients com-
pared to pneumonectomy patients (Fig. 2). There was a 
tendency of increased temperature with an increased 
The Ludwig Lung Cancer Study Group : C. parvwn lntrapleurally 
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Fig. 2. Maximum temperature after C. parvum injection. Intrapleural 
C. parvuuz: 0 Lobectomy, A Pneumonectomy; Intrapleural and in· 
travenous C. pan•um: • Lobectomy, A Pneumonectomy 
dose ofCP, with a clear increase when i.v. and i.p. injec· 
tions of CP were given simultaneously (Fig. 3). 
Changes in Blood Differentials. Venous blood cell dif-
ferentials were done immediately before CP administra-
tion and thereafter during the first, second, and third 
day. The maximum values which occurred are given in 
Table l and Figure 4. 
An increase in the total WBC of more than 20% was 
observed in 38 patients following CP administration. 
The increase in WBC is not related to the amount of CP 
given and is principally accounted for by an increase in 
the neutrophil compartment although monocytes are 
also increased at higher doses (Table 2). Table 2 gives a 
. "'* 
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Fig. 4. Increase of white blood cell (WBC) count in relation to dose 
of C. parvum: e rncrease of WBC after C. parvum injection s 20%. 
0 Increase of WBC after C. parvum injection > 20%; • All but one 
patient received the 7 mg dose as 3.5 mg i.v. and 3.5 mg i.p. simulta· 
ncously 
summary of the changes occurring before and after C P 
injection in relation to dose given. Independently of the 
dose given, there is after intrapleural C P an increase in 
the rota! number of W BC per mm3 venous blood. Thus 
a change from 8,940 ± 2,994 to 13,940 ± 6.299 with o 
dose betwen 0.1 and 2.2 mg and from 9,320 ± 2,776 to 
15,520 ± 6,383 when 7- 10 mg were given intrapleu-
rally was observed. The increase in total number of 
WBC is mainly due to a neutrocytosis. There is no 
change seen for the eosinophiles, basophiles, nor do 
lymphocytes or monocytes change in total number ex-
cept for the higher dose of 7-10 mg of CP when a 
doubling of the monocyte number per mm3 was ob-
served, from 576 ± 247 to 1100 ± 578. 
.I 
' o# 
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Table I. Reactions to C. parvum inirapleurally 
StQut•"<.e P.st ;tnts 'fur of Clinic ty~ o f Oou9~ of Postop. d•y lt"d;olo,k •l 11$({., J W8C./tto3 P\u . Pft"CMt49t 
Ito. 'nhhh bi rt~ s .. (I) oof rn ion ( ,l)fi"VUftl of C .p~,.,.\111'!1 t h•ngt fn btfo~ lhtl" tncrtut in 
("'ll injft t lon p1et~r.s1 tH,n ton C.pfrv.- c . ~ .......... tot. 1 wac • fttr •'t•,. c.,..,. ... \dl J) C.parve,r~ C) 
h C.. ptnu. K.G. 1906 0. 1 6 . 6600 8500 (l) 19 
I .A. 1915 0. 1 I. 9)01) 11600 (I) IS 
~ W,(. 1915 0 . 1 I . "00 18500 PI so 
Oougt l.S "'l· • H,k, 1911 0 .1 10. 4900 6<00 fnstg s G.A. 1910 1. 0 8. 14700 HJOO ( I ) instg. 
6 Z.R . 19?6 1.0 I . 9600 14100 (l) 1'-6 
I B.A . 19>8 1. 0 8 . 
8 F . A. . I~IJ 1,0 6 . 1600 11900 (I) IO 
9 a.u . 1914 1.0 10 . 
10 1. s. 191l 1 . 0 s. 1800 66;>0 (1) ins fg 
II G.H . 19J9 1 . 0 8. 11600 11500 (l ) <I 
12 P,P, 1911 2.0 I. 6800 9100 (1) )0 
IJ . U. A. 1900 2 .1 10, 9l00 n•oo (II •6 
14 v.s. 191 6 2. 1 I, 13900 11800 (1) i t'!S i q 
IS J . C. 1919 1 .1 8. 16800 1<000 (1) .. 
16 8.L 19!8 2.1 I 1100 10100 (1) )I 
II J . H, 1916 1.1 6. 6100 11100 (3) 181 
18 H.S. m• 1 .1 s. 9000 11600 ( I ) 19 
19 l.R. 1909 3.0 10. IIJOO 11<00 (3) lnsig 
10 A. O. 1911 ).1 I. 15300 18600 (1) 11 
21 A.H. 1911 3 .1 6 . 7100 11100 (1) lo• 
11 l.C. 19) 0 3. 1 II . 11600 11100 ( 2) rn .. ig 
2l S.K. 1909 l .S 11. 1100 6800 (1) ht\ ( 9 
1< k . lt. 190< 3 .1 10 1900 16800 (1) Ill 
IO t. p•rvUit 21 U.'l4. 1917 <. 0 6 . 8800 18)00 (1) 108 
16 1.0. 1921 • 0 6 . lotO() 10600 PI tnr.t9 
~ v S.'ll. 1911 •.o 13. 11JOO ISJOO (I) 2• 
Oougt 3.5 "'l· 18 H. [ . 1915 4 , 0 II 10200 12100 (1) ?l 
19 P.J. 1901 4 , 0 8. 8300 10000 (l) intig 
JO O.t. 1911 4.0 1. 1000 1000 ( 2) 40 
)I H.l. 1916 •.o '· 8900 8600 (l) inslg 3Z 1 .8. 1918 4 . 0 6. 11100 11100 (I) lAS I~ 
Jl S.H, 1931 5 . 0 8. 5<00 11600 (I) n' 34 A. A. 1902 5 . 0 8. 1000 I nDO (1) IGO 
35 C.J. 1917 5 .0 s. 1100 
36 c.s. 191• 5 . 0 s. 9l00 
J7 v.o. 1916 1.0 II . 1/00 16900 (I ) 199 
38 C.R , 1911 10.0 II . 11100 IJ900 (1) H\$19 
39 H.[. 1918 10.0 II. 13300 16100 (l) 11 
40 LH . 19) 4 10. 0 6 . 11400 11000 (I ) IJI 
" (.A, 1912 10. 0 1. " 00 11400 (I) n <1 5.r. 190• 10. 0 9. 107000 11200 61 
43 A.H , 1911 10.0 10. 6800 8900 (I) J l .. H. A • 1914 10. 0 10. 11100 1<900 (1) 100 
<I R.f, 1905 10.1 "- 1100 1900 (I) 1t1\1 9 46 Y.l. 1901 IO. S 14 . 1800 11000 (I) <I 
11 C. p•nvr~ 41 P.A. 1911 3.5 • 3.5 6 . 0 1100 /COO (II ln\1 9 
3.5 !9 L p. i n.d 
48 <.0. 1911 J.S • J , S, ], 0 8600 JC600 (I) 151 
49 tc. H. 1906 3.1 • J.l 10. 0 11600 23900 (I) 100 
.!.:L~ so P. O. 19!1 l.S • J.S 6. 0 10900 I 3800 (3) 1' Sl P. A. 1913 l.l • l . S 8. 0 18100 11600 (I) '"''9 
51 S. C. 1911 l.S • l.S 8 . 0 1300 11600 (I) 13 
13 J .S. 1914 J .S • J.S 1. 0 111 00 13300 (I) 1nstg 
14 !.( , 1916 J.l • l.l 10, 0 11900 13900 (I ) ft~st~ 
II A. R. 1905 l.S • 3.1 ' · 0 11400 1<900 (II fn~ t<; 16 C. 8. 19ZO 3.1 • l.S I. 0 6900 9100 (I I •o 
II S.J, 1911 J.S • l . S s. 0 9000 11100 m 39 
58 A. IC . 1911 l.S • l. S I . 0 11100 9900 (2 ) ha 1g 
19 J.l, 191 9 l. S • l.S 1, 0 1000 11100 (I) " 60 I .J . 1914 J.l • 3. 1 8. 0 8)00 10000 (3) 11 
61 C, A. 19)1 J . l • J.S e. 9100 11800 ( l) ft~s1g 
61 S.Y . 1921 l .S • J.S B. 10900 11400 (3) if~) tg 
6) P. C. 1918 J.S • l.S 8. 16100 2(600 (I) 31 
(l} Cli nt< tn ..t~''"' P~tt ltnU wtr'f tnvutfg<Hed: I • A~rhus , l • euel , ) • 6~rn {IMtl) 
4 • hun , S • Lj ubiJ•n• , 6 • lMn\tt fn , 1 • Sol othvrn, 8 • Stodho1•. 
(2) Ri diologiul (hinge in Qltu··• l tff~o~sion aft~r C.e>ar-vua: 0 • ~o~nchan.q~. • • Hut ~ 
•• IIOd~ratt .... \evert. 
(3) Oay on lllfl fch naxf""-111 chatl.1}e occur!N h l)htn lA parent~J.h . 
( 4) P~rc~nhgts 20t are t,~Jiute-4 by · lnstg• ( IM igncncant). 
( !.) Ct1an.9U of 0 .$0 .sr~ tMiuted u i 1u tgnificant. 
6) lttl'!f Interval (hr) C. parv~,tl'll aO'Ifnh trat ion INA . change of t~raturt , pulu r.tt t , 
blOOd pf'tssure f'tspect ively h givu In parrnthU h . 
7) CI\.)"9U o f 20 tl-taU'~In art lnd le~trd u lnslgn1f in nt . 
8 ) Changt1- II"! systolic &~rtuure o f JO t'ti'IHg o'rt in41 cu td u Insignif icant. 
9) Ko sl~nHtcant co-p1• 11"1U, re.tctlo.ns rupec t f'II'C' l )' art lndlu t td by •o· . 
'· 
Discuss.on 
This study was designed as a pilot investigation to ex-
plore the feasibility of intrapleural CP administration 
with a view to carrying out randomised clinical trials 
using this technique. The results reported indicate that 
intrapleural CP therapy is possible without undue toxi-
city, although subjective side effects are increased when 
CP is given i.v. and i.p. simultaneously. 
... 
For future studies we intend to adopt a dose of 7 mg 
C P i.p. as the standard. This decision is based on the 
observation that a dose of 7 mg combines a measurable 
systemic effect (increased neutrophil and monocyte 
counts) with acceptable toxicity. 
The observation that pyrexia is seen earlier in pa-
tients after lobectomy than after pneumonectomy may 
have one of two explanations. Either the greater quan-
tity of pleural fluid post-pneumonectomy has a diluting 
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eiTect on the CP and delays its action or the residual 
lung tissue present in lobectomy patients leads to a more 
rapid absorption of CP. 
One patient had paroxysmal tachycardia with blood 
pressure fall to 60/50 mm Hg. It occurred 60 h after CP 
injection i.p. It is uncertain whether the hypotension ob-
served relates to the CP given earlier. However we have 
I agreed th<.t our patients in the , uture will have their CP 
in the morning. Furthermore, the contra-indications for 
! 
giving CP ought to be respected. They are: patients with 
any severe allergic disorder or history of endotoxic 
shock, significant hypertension (e.g., resting diastolic 
blood pressure of more than 100 mm Hg), current preg· 
nancy, patients with disturbance in blood clothing mech-
anisms, gross impairment of liver or renal function , 
long-term steroid administration, primary or secondary 
cerebral neoplasms, patients with known thiomersal sen-
sitivity, coexisting major untreated infection and per-
•I 
, 
Table 2. While blood cel ls (WBC) and WBC subpopulations before and after C. pammr 
Dose (mg) 0. 1- 2.2" 2.5-3.5" 4.0- 5.0" 
----------
No. of patients 13 II 12 
- -- ---
C. pan·um Defore After Before After Before 
WBC tota.l 8,940 ± 2,994' 13,940 ± 6.299' 10.590 ± 3.695 I 4,363 ± 4, 739 8.602 ± 2, 717' 
(X ± SO) 
Gr~nulocytes 
Unsegmented 230 ± 282 221 ± 38 1 555 ± 685 737 ± 983 425 ± 533 
Segmented 5,5 79 ± 1,992· 9,528 ± 4,893• 7,034 ± 3,25 I 10.344 ± 4.699 5J56 ± 2.229. 
Eosinophils 207 ± 182 149 ± 106 352±210 230 ± 253 2!!<1 ± 173 
Basophils 39 ± 87 29 ±so 61 ±57 29 ±53 60 ±56 
Lymphocytes 1,948 ± 892 2,814 ± 1,536 1,908 ± 794 1.513 ± 505 1,559 ± 583 
Monocytes 529 ± 257 920 ± 615 681 ± 140 730 ± 365 580 ± 260 
• C. parvum given intrapleurally 
•• C. parvum given as 3.5 mg intravenous and 3.5 mg inuapleural simultaneously 
Statistically the following levels of difference were obtained: 
• t ·= 2.56 (P < 0.05) I t = 2.20 (P < 0.05) 
b t = 2.34 (P < 0.05) h t = 2.81 (P < 0.05) 
c t = 2.46 (P < 0.05) I t = 2.60 (P < 0.05) 
d t = 2.22 (P < 0.05) J t = 2.63 (P < 0.05) 
' t = 2.09 (P < 0.05) • t = 2.63 (P < 0.05) 
r t = 1.94 (P < 0.05) 
1.o•• 7.0- 10.5" 
17 10 
-
After Before After Before 
I 2,380 ± 3,590' 10.881 ± 3,228' 13,143 ± 5,898' 9,320 ± 2,776~ 
356 ± 533 246 ± 312 723 ± 1,167 560 ± 3771 
8,847 ± 3,469' 7,199 ± 3,255' 10,565 ± S,l 19' 6,319 ± 2,6321 
299 ± 207 419 ± 239' 168 ± 165' 277 ± 198 
130 ± 366 41 ± 49 16 ± 32 60± 85 
1.664 ± 646 2,068 ± 1,088 1,793 ± 1,498 1,503 ± 476 
734 ± 422 527 ± 245 582 ± 396 576 ± 247° 
- · -- ::: - -· . =- ' . 
After 
I 5,520 ± 6,383• 
1,483 ± 1,0531 
I 1,064 ± 5,049' 
233 ± 377 
64 ± 88 
1,655 ± 527 
































The Ludwig Lung Cancer Study Group: C. pnrvwn lntrapleurally 
haps also patients with coexisting auto-immune disord-
er, e.g., collagen disease. 
The search for the possible role of immunotherapy 
in human~ by immunomodulators known to have a 
tumor-inhibiting effect in experimental animal systems is 
still in a very crude primary stage. The present study 
· shows how difficult it is to transfer a simple question 
such as optimal dose from mouse to man and explore a 
new route of administration. 'Unspecific immunother-
apy' in the close vicinity of the tumor at the site for 
recurrence is proven to be efficient for different human 
tumours Jncalised in the skin l~tjernsward and Levin, 
1971; Klein and Holterman, 1972) and is more likely to 
give an effect than e.g. unspecific ' immunotherapy' far 
I away from the areas of tumour recurrence. 
The' hig . number of patients with bronchogenic car-
cinqma the early tumour recurrence after 'radical' re-
section (minimal tumour burden realistic for immuno-
therapy) and the inefficiency of present treatment mo-
dalities such as radiotherapy and chemotherapy (Second 
Nat!. Cancer Inst. Conf. on Lung Cancer, Airlie House, 
Virginia, USA, in press, 1977) otTers a realistic opportu-
nity to analyse conclusively and in a short time whether 
the proposed immunotherapy could improve prognosis. 
The i.p. route is an attempt to bring CP in proximity to 
the micro metastases and for recurrences known to 
occur intrathoracically in a very high frequency even in 
operable lung cancer. CP given i.p. certainly also has a 
systemic effect, as revealed by e.g. increase in total num-
ber of circulating WBC. 
The present study shows for the first time that it is 
feasible to give CP intrapleuraUy and indicates which 
dose can be used clinically. This is nmy being done in a 
clinical trial with 7 mg of C P intraplcurally in the search 
of the possible role of C. parvum 'immunotherapy' 
postoperatively in operable bronchial carcinoma. 
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Antitumor Activity of Purified Cell Walls From Corynebacterium parvum 1 
V. Riveros-Moreno, 2 R. Bamford, 3 and M. T. Scott 3 • 4 
ABSTRACT -Cell walls (CW), containing peptidoglycan and car· 
bohydrate, were prepared from Corynebacterium parvum and 
tested for lymphoretlcular stimulation and antitumor effects in 
CBA·T6T6 mice. CW did not Induce splenomegaly. Peritoneal 
macrophages became cytostatic to Rl leukemia cells in vitro 
after ip Injection of CW or of peptidoglycan but not of carbohy-
drate; however, on a dry-weight basis the activity was low (< 10%) 
compared with that of C. parvum . Tumor outgrowth was signifi· 
cantly suppressed after sc Injection of mixtures of M4 flbrosar· 
coma cells and CW, but again the activity of CW was less than 
10% of that of C. parvum . In contrast to Injection of C. parvum, 
lntratumor Injection of CW failed to retard tumor growth In normal 
mice, although a suppressive effect was found In mice presensl· 
tized to C. parvum. Again , unlike C. parvum, CW did not act as 
an adjuvant for tumor-specific transplantation antigen, as judged 
by a lack of enhanced resistance to tumor challenge after 
Injection of mixtures of CW and Irradiated M4 cells. The distribu-
tion and persistence of 1251-labeled C. parvum and CW after sc or 
lp injection were similar. CW activity was not restored by attach-
ment to oil droplets or emulsification in Freund's Incomplete 
adjuvant.-J Natl Cancer lnst 60: 653-658, 1978. 
Corynebactnium /Hli1JUIII is a potent stimulator of the 
lymphoreticular sy tern (1), an immunologic adjuvant 
(2), and an antitumor agent {3). 
The cornponent(s) of C. parvum responsible for these 
effects is not yet known. Bacterial fractions containing 
CW of C. fJarvltm (in so me cases, of other anaerobic 
coryneform bacteria or propionibacteria) retain lym-
phoreticular stimu latory (4), adjuvam (5~). and anti-
lUmor properties (9-11} . 
We therefore examined the lymphoreticular stimu la-
tory activity a nd both nonspecific and specific antitumor 
activities of purified CW of C. fJarvwn. A drastic loss of 
aCLivit.y in CW was found, and some possible causes of 
this were investigated . 
MATERIALS AND METHODS 
All studies reported here were performed with CW 
or fractions obtained from chemica lly untreated, bro-
ken bacteria. Cultures of C. parvum (Wellcome strain 
C~ 6134) were supplied by the Department of Bacteri-
ology, The Wellcome Research Laboratories. Fresh cul-
tUJ·es of baCLeria, grown in I% glucose broth, were 
centrifuged at 5° C in a Sorvall KSB continuous flow 
system at 12,000 xg. The cell pellet was washed similarly 
with cold saline and tored as a cell paste at - 20° C 
until used. 
Preparation of CW .-The bacteria were broken in a 
1ovotny cell disruptor {12) with a modified pestle of 
monocast nylon (Polypenco, CM901; Imperial Chemical 
Industries Ltd., Millbank , London, England). The cells 
were resuspended in 0 .1 ~~ tris buffer, pH 7.6. Ballot.ini 
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beads No. 12 were added, and the mixture was pre-
pared at 10,000 rpm for Jt/z minutes on ice+ NaCI in a 
Silverson homogenizer (Silverson Machine Ltd., Water-
side, Chesham, Bucks, England). The homogenate was 
filtered through an ice-cold sintered glass funnel, and 
the glass beads were washed with four times the original 
volume of the same ice-cold buffer. After spinning at 
l ,OOO xg for 20 minutes at 4° C in a Sorvall RC5 centri-
fuge, the pellet contained mainly com plete cells and 
was routinel y disca rded. The supernatant was treated 
as detailed in tex t-figure l. After SDS, trypsin, DNase, 
and R Nase (B. D. H . Chemical Ltd., Poole , Dorset, Eng-
land) treatments, the CW were extensively washed and 
fina lly freeze-dried. 
Analytic methods.-Protein was determined by the 
method of Lowry et al. (13); hexose , by the phenoi-
H2S04 method of Dubois et al. (14); and phosphate, by 
the method of Ames and Dublin (15). Amino acids 
were determined automatically by use of a Beckman 
model 120C amino acid analyzer. 
Hydrolysis.-For amino acid and amino sugar analyses 
the CW and fractions were hydrolyzed in 4 N HCI fo r 4 
hours at 108° C in Pierce vacuum hrdrolysis tubes 
(Pierce Chemical Co., Rockford, Ill.). After hyd rolysis, 
amples were dried in vacuo in the presence of P20s 
and NaO H pellets. For the analysis of sugars and amino 
sugars, samples were hydrolyzed in 2 N H2S0 4 by being 
heated in a boiling water bath for 2 hours. eutraliza-
tion was achieved by the addition of solid BaC03 and, 
after centrifugation and washing of the pellet, the 
combined su pernatants were evaporated lO dryness un-
der P20 5 • 
ChmmatogTfLjJhy. - Sugars were analyzed qualitatively 
by descending chromatography on Whaunan #1 paper. 
The solvent used was ethyl acetate:pyridine:wat.er 
(8:2: 1) , and the chromatogr ams were run for 24 hours 
a t room temperature. Compounds were detected by 
use oft he silver nit rate method of T revelyan et al. {16). 
Preparation of CW carbohydrate and peptidoglycan frac-
tions.-Purified CW, as described above, were mildly 
hydrol yzed in 0. 1 M acetic acid for 1 hour in a boiling 
water bath . The mixture was centrifuged, and the 
A6BR£VIATIONS ust:o: CW = cell wall (s); SDS = sodium dodeC)'I 
sulfate; ~ = normal; DHR = dela)•ed h)·persensitivity reaction. 
1 Received june 8, 1977: accepted September 22, 1977. 
" Depanmem o f Immunochemistry, The Wellcome Research Lab-
oratories, Becken ham , Ke111 BR3 3BS, England. 
3 Department of Experimental lmmunobiology. The Wellcome 
Research Laboratories. 
• We ackno,~ ledge the skillful technical assistance of Anne Niblock, 
Susan Wishart , lain Jaundreii-Thompson, anci Anthony Ford . 
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supernatant contamtng the carboh ydrate was freeze-
dried in the presence of solid laOH. The peptidogly-
can-containi ng pellet was reh ydrolyzed and, after cen-
tri fugation , similar!)' freeze-dried. 
Preparation of CW associated with oil droplets.-The 
technique used was exaclly as described for BCG by 
Zbar et al. (17), except that CW were substituted for 
mycobacterial components. Phase comrast microscopic 
examination of preparations confirmed the association 
of some of the CW with oil d roplets. 
Assa'y for C. parvum serum agglutinins.-This test was 
as described previously (18). 
Absorption of sera.-Sera diluted with saline (1/8, vol/ 
vol) were absorbed with concentrated CW at room 
temperature for 18 hours with rotary mixing; CW were 
removed by centrifugation. 
Assay for DHR.-DHR to C. parvum and CW was 
assayed as described in (19). 
Electron mict·oscopy.-The CW prepa rations were rou-
tinely checked by negative staining with phosphotungs-
tic acid and examined in a Philips 800 electron micro-
scope. 
125
/ labeling of C. parvum and CW.-Tyramine was 
coupled to C. parvurn and CW by the technique de-
scribed in (20). C. parvum and CW were then dialyzed 
against saline and water, respecti vely. The tyramine 
incorporated into CW was estimated by the Folin assay 
(13). The pmtein contents of CW before and after 
tyramine coupling were 3 .1 and 18%, respectively. Of 
the tyramine-coupled C. parvurn and CW suspensions 
(7 mg/ml) , 5 ml was washed 2-3 times in saline and 
finall y r esuspended in 0.4 ml phosphate-buffered sa-
line; 2 mCi of 1251 (Radiochemical Centre , Amersham, 
Buckinghamshire, England) was added, and addition 
of 0.4 ml chloramine T (5 mg/ml) then followed imme-
diately. After 5 minutes, 0.4 ml sodium bisulfite (25 
mg/m l) and, immediately thereafter, 0.4 ml sodium 
iodide (10 mg/ ml) were added. The suspension was 
washed once by centrifugation in saline and resus-
pended to its original volume. lt was dialyzed for 5 
days against daily changes of 2 liters of saline at 4° C, 
by which time the radioactivity in the dialysate had 
stabilized. In different batches only 0.01-0.02% iodine 
rem ained unbound , and no appreciable amount was 
released after incubation of the labeled C. parvurn for 
24 hours at 37° C . A total of 0.1 ml 10% thiomersalate 
preservative/ 10 ml suspension was added. Suspensions 
were stored at 4° C . 
Gamma counting.-Organs taken from mice given in -
jections of 1251-labeled C. pm"um were placed directl y 
into plastic tubes, an d the radioactivity was measured 
wi th a Packard automatic y-counter. 
Mice.-Male or female CBA-T6T6 mice , 8-12 weeks 
of age, were used. 
Tumm·s.-The origins and techn iques for mainte-
nance and harvest of syngeneic M4 fibrosarcoma and 
RI leukemia were described in (21) a nd (22), respec-
tively. 
Measw·ement of /umors.-Appropriate dilutions of M4 
cells were injected sc into a hind footpad by means of a 
27-gauge needle. Subsequent rumor growth in the foot-
J NATL CANCER I NST 
pad was meas ured as footpad thickness in 0. 1-m m units 
with a Schnelltester dial gauge ca liper A0 2T (H. C. 
Kroplin, Schli.ichtern, Hasse, Federal Republic of Ger-
many). 
!nadia/ion of tumor cells. - M4 cells were irrad iated 
(10,000 racls) with the use of a 13iCs source. 
Cytostatic macrophage assay.-Peritoneal macrophages 
were prepared a nd assayed for their ability to inhibit 
the DNA synthesis of Rl leukemia cells in vitro as 
described in (22). 
Statistics.-The results were expressed as means 
(± sE). Means were com pared by Student's t-test, and 
values of P<0.05 were considered significant. 
RESULTS 
Composition of CW, Peptidoglycan , and 
Carbohydrate 
The CW, prepared as summarized in text-figure 1, 
were routinely checked for contamination by complete 
cells. CW did not take up gram stain , whereas complete 
C. PARVUM CELLS IN 
BUFFER . HOMOG. W/ BALLOTINl 
BEADS FOR ll MIN. AT 4°C AT 
10,000 RPM. FlL TERED AT 4°C, 
SPUN AT l,OOOG 20MIN., 4°C 
SUPERNATANT SPUN~COMPL ETE CELLS 
AT27,WM\C 
SUPERNATANT PELLET WASHED JX 







WITH D . D.W. AT l~C 
! 
200 I,.Lg /ml TRYPSIN 
200 I,.Lg/rnl DNASE 
200 I,.Lg/ml RNASE 
37°C OVERNIGHT 
! 
2X WASHED W /BUFFER 




TEXT-FIGUR£ I.-Scheme of preparation of C. parvum CW. 
Homog. = hornogenized; W/= wi th; O.O.W.= double-dislilled water. 
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TABLE l.~hemical composition ofCW and fractions 
Total Hexosa-







Complete CW 2.5 14.5 29 3 24.8 0.25 
Peptidoglycan 0.0 7.5 17.8 31.4 0.0 
Polysaccha- 0.0 20.0 24.3 0.8 0.0 
ride 
cells were positive. CW stained with phosphotungstic 
acid and examined under the electron microscope ap-
peared transparent and maintained the cell shape with 
only a few hole:.. Preparations that contained either 
complete cells or s ha ttered CW were discarded . The 
chemica l a nal ysis of the complete CW is shown in table 
1. The CW contained virtua lly no phosphate and litlie 
protein. Hexose , galactOse, glucose, and man nose were 
idemified by pa per chroma1ogra ph y as components of 
CW. Uronic and aminohexuronic acids were also de-
tected , but they were not qua mified ; these m ay be ex-
pected to influence the overa ll composition of the CW 
presented in table 1. 
The two major components of the CW (peptidoglycan 
a nd carbohydrate) can be separated by treatment with 
dilute acetic acid , which produces a soluble polysaccha-
TABLE 2.- Amino acids and amino sugars in CW and fractions 




amino J.Lmoles/ Molar ra- J.Lmoles/ Molar ra- J.Lmoles/ sugars mg tio mg tio mg 
Glutamic 0.48 1 0.69 1 0.004 
acid 
Muramic 0.57 1.18 0.80 1.16 0.004 
acid 
Glycine 0.43 0.90 0.52 0.75 0.008 
Alanine 0.62 1.29 0.76 1.10 0.008 
Diamino 0.47 0.98 0.55 0.80 0.005 
pimelic 
acid 
Glucos- 0.19 0.40 0.31 0.45 0.028 
amine 
Galactos- Modified Modified 0.019 
amine 
ride (mol wt, = 30,000 daltons) and a peptidoglycan 
shell that retains the cell shape and is resistant , like C. 
pmv u:m and CW, to lysozyme (data not included). Table 
1 shows the composition of the peptidoglycan and poly-
saccharide fractions. The polysaccharide had negligible 
amounts of am ino acids. The peptidoglycan fraction 
still contained some sugars . Since peptidoglycans do not 
usually comain sugar (23) , possibly some sugars from 
the polysaccharide were still bound tO iL Repeated 
acetic acid hydrolysis removed the sugars but also hy-
drol yzed part of the peptidoglycan, inasmuch as dia-
mino pimelic and alanine were also released. 
The amino acid and amino sugar compositions of 
CW, peptidogl ycan, and polysaccharide are shown in 
table 2 . The galactosamine had a slightly different 
retention time from that of the standard galactosamine 
used to calibrate the amino acid analyzer. It may there-
fore be modified, but this has not been investigated 
further. 
Assays for Lymphoreticular Stimulatory and 
Antitumor Activities 
Splenomegaly.-Mice were given ip injections of 400 
JLg CW or various doses of C. panmm. Spleens were 
weighed 14 days later at about the peak of the res ponse 
to C . fJar-uum. (24 ) . Normal spleens weighed 0.087±0.005 
g. C. jJanmrn markedly increased spleen weight 
(0.48±0.03 g), but CW were not active (0.091 ±0.004 g). 
Growth of mixture of M4 cells with C. parvum or CW. -
Mice were inoculated sc in t he foot pad with 106 M4 cells 
alone or mixed with 10 or 100 JLg of C. parvu.m or CW 
(table 3). C. parvum suppressed tumor outgrowth at all 
tested concentrations . (The significant footpad swelling 
at day 20 following injection of M4 and 100 JLg C. parvum 
was attributable LO the C. jJarvum; it subsequently sub-
sided.) CW was significanrly suppressive at only the 100-
J.tg dose and even then prevented wmor outgrowth in 
only 2/6 animals . 
lntratumor injection of C. parvum or CW.-Mice were 
inoculated with 105 M4 cells in the footpad and l day 
la ter recei ved 10 or 100 JLg of C. jJarvum or CW in the 
inoculated footpad (table 3). CW failed to inhibit tumor 











Tumor outgrowth from C. par- Intratumor injection of C. par-
vum-CW plus t umor cell mix- vum-CW, mm 
tures, mm mean:!:SE < 
mean :!:SE • 
Immunization with C. par-
vum-CW irradiated tumor 




2. 7::!:0.07 (0/6) 
2.1::!:0.02 (4/6) 




6.9 ::!:0.6 (5/5) 
6.6::!: 1.1 (5/5) 




5.5 :!:0.4 (5/5) 
4.9:!: 0.4 (5/5) 
" Measurements were taken 20 days after M4 injections. Numbers in parentheses: No. mice with tumors/ No. in experimental groups. 
& Mice were inoculated sc in the footpad with JOG live M4 cells alone (control) or mixed with 10 or 100 J.Lg C. parvum or CW. 
' Mice received sc injections in the footpad with 10~ live M4 cells and 1 day later received 10 or 100 J.Lg C. parvum or CW in the inoculated 
foot pad. Control mice received no treatment. 
11 Mice were inoculated sc in the footpad wi th 5><10$ irradiated M4 cells admixed with 10 or 100 J.Lg C. parvum or CW; 7 days later, 1Q$Jive 
M4 cells were injected sc into the contralateral footpad. 
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TExT-FI GU RE 2.-lncorporation of tritiated thymidine (3H-TdR) by 
R1 leukemia ce lls growing alone or on mooolayers of normal 
macrophages, or by macrophages from mice given injections of 
various doses of C. parvum (CP), CW, peptidoglycan (PEPT.), or 
carbohydrate (CARS.); cpm = counts per minute. 
growth, whereas both doses of C. parvum were full y 
effective. 
Immunization with irradiated M4 cells.- To test whether 
CW can stimulate specific cell-mediated immunity to 
tumor-specific transplantation antigen, mice were im-
munized with 5 x 105 irradiated M4 cells adm ixed with 
CW or C. parvum and challenged 7 days later in the 
contralateral footpad with 105 living M4 cells. Neither 
M4 cells nor C. parvum alone protected against tumor 
challenge, but, as expected (25, 21), the addition of C. 
parvum prevented tumor take (table 3). On the contrary, 
the addition of 10 or 100 J,tg of CW failed to suppress 
tumor outgrowth or inhibit tumor growth rate. 
Cytostatic macrophages.-Mice were inoculated ip with 
different doses of C. parvum or CW or 400 mg of pepti-
doglycan or carbohydrate. Peritoneal macrophages 
were tested for cytostasis of RI leukemia cells 5 days 
later (text-fig. 2). Macrophages activated by C. parvum 
totally suppressed DNA synthesis of RI cells, but mac-
rophages from mice given injections of CW were only 
partially inhibitory, in a dose-dependent manner. Of 
the two separated CW components, only the peptidogly-
can was active. 
Retention of C. parvum su.rface antigen by CW.-The 
CW preparations were shown to retain C. parvum sur-
face antigens for both humoral and cellular immunity. 
The activity of hyperimmune mouse anti-C. parvum 
serum (agglutinat ion titers, l /2 ,000) was completely re-
moved by adsorption with CW. CW were also capable of 
eliciting DHR in C. pm-uum-sensitized mice: Six days 
after a sensitizing sc injection of 70 J,tg C. parvum into a 
hind footpad, 70 J,tg of CW injected into the contralat-
eral footpad elicited a 24-hour DHR footpad swelling of 
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DAYS AFTER TUMOR 
TExT-FIGURE 3.-Growth of 106 M4. cells injected sc in to a hind 
footpad of either 12 normal mice <-•> or 12 mice sensitized 4 
days earlier by sc inject ion of C. parvum into the contralateral foot 
(• --• ). After 2 days of tumor growth, 6 normal (x-x) and 6 
sensitized ( ><--><) mice were given injections of 70 J.Lg CW d irectly 
into the tumor site . 
0 .3±0.03 mm but was without effect in unsensitized 
controls. 
Antitumor activity of CW in mice sensitized to C. 
parvum.-A component of the antitumor activity of 
intratumor C. parvum is mediated through a local im-
mune DHR to C. parvum itself (26). In light of this and 
the ability of CW to elicit DHR reactivity to C. parvum, 
CW were injected intratumorally in mice previously 
sensitized and showing DHR to C. parvum. Mice were 
sensitized by sc injection of 70 J,tg C. parvum into a hind 
footpad. Four days later, 106 live M4 cells were injected 
into the contralateral footpad; intratumor CW were 
given 2 days later {text-fig. 3). Sensitization alone did 
not affect tumor growth , and in tratumor CW were 
ineffective in nonsensitized mice. T umor growth was, 
however, significantly inhibited by intratumor CW in 
sensitized mice. No complete regression occurred, and 
this contrasts with the 100% complete regression rou-
tinely achieved by equivalent amounts of intratumor C. 
parvum in the system (see table 3). 
In vivo distribution and persistence of 1251-labeled C. par-
vum and CW.-T he in vivo fates of t 25I-Iabeled C. 
pa1-uum and 1251-labeled CW were compared to see 
whether the relative inactivity of the CW could be 
attributed to an altered distribution or persistence pat-
tern. After ip injection of 300 J,tg of either 1251-labeled 
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DAYS AFTER CP/CW INJECTION 
TExT-FIGURE 4.-Dislribtllion of 1251-labeled C. parw m (CP) o1· CW 
injected either ip or sc into •• hind foo1pacl; cpm=coun1s per 
minute: pop.= popli1eal. 
TABLE 4.-E((ect of inlratumor injection of'CW attached to oil 
droplets 
Intratumor injection " 
Untreated control 
Oil alone 
C. paruwn (10 J.tg) 
cw (10 J.tg) 
Oii+CW (10 J.'g) 
Oii + CW (70 J.'g ) 
Tumor growth, mm 
mean::!:SE" 
6.2::!:0.4 (5/5) 
5. 7::!:0.4 (5/5) 




"Mic.e were inoculated with 10" live M4 cells sc into the footpad, 
and 1 day later test substances (0.05 ml) were injected in to the same 
s ite. 
1
' Measurements taken 20 days after M4 injections. Numbers in 
parentheses: No. of mice with tumors/No. in experimental groups. 
C. paTv um or 1251-labelecl CW no overa ll difference in 
the upta ke or persistence was observed in the liver, 
spleen , or lung (text-fig. 4A ) . Similarly, fo llowing sc 
injection intO a hind footpad , the radioactivity profiles 
of both C. j)([rtJUm and CW at the injection site and in 
the draining popliteal lymph node were not different 
(text-fig. 4B). 
lntratumor injection o/ CW associated with oil dTOjJlets or 
emuL~i/ied in Freund's incomjJlele adjuvant.-M4 ce lls ( 105 ) 
were injected sc into the footpad; 1 day later CW 
attached to oi l droplets , or appropria te control mix-
tures, were injected into the same site (table 4) . The 
performance of CW- oi l droplets was not significantl y 
different from that of CW a lone. Similar experiments 
with CW emu lsified in Freund's incomplete adjuva nt 
were a lso negative. 
DISCUSSION 
The characteristic lyrnphoreticular stimulatory and 
antitumo•- propert ies of C. jJaTv tml were not present or 
were drastically reduced in CW preparations. Our data 
on CW composition ma y he compared with those on the 
composit ion of other stra ins of "active" anaerobic cory-
VOL. 60 , NO. 3 , ~lARCH 19i8 
neform bacteria analrzed previously (27-29) . The qual-
itative composition of CW is sim ilar , and close resem-
blances ex ist in amounts of CW amino acids and am ino 
sugars . 
The antitu mor effects of C. jJarvum can conven iently 
be classified into the nonspecific, in the sense of not 
requirin g an immune response tO tumor antigens, and 
the specific , or adjuvant effect on rurnor antigens (3). 
The residual antitumor effects of CW were nonspecific, 
be ing confined to macrophage acti vation and suppres-
sion of tumor outgrowth after injection of mixtures of 
M4 cells and CW. Th is latter effect is independent of a 
host immune response in that it is demonstrable in 
nude mice (30) , in contrast to the antitu mor effect of 
intratumor C. parv um, which is not expressed in T -cell 
depleted mice (31, 32). The low macrophage-activating 
capacity of CW prep;;u-ations that we observed was 
attributable to the peptidoglycan moiety and cou ld be 
sufficient to account for the variable antitumor effects 
of simila rl y prepared C. jJa1<Jtlln CW reponed in (9). 
Our resu lts a lso agree with the report that C. j}(trvum 
CW preparat ions failed to stimulate cell-mediated im -
mun it y to tumor a ntigen s (28). 
The in vivo distribution and persistence of C. parvum 
and CW were not different ; manipulations designed tO 
vary these parameters , i.e. , emulsification in Freund's 
incomplete adjuvant and association with oil droplets, 
did not result in restored CW activity. 
The a lmost total loss of act ivity of CW did not 
correlate with an y detectable loss of amigen icity o r 
immunogenicit}'. The role that immuniry to C. parvwn 
plays in t he stimulatory and antiwmor effects of C. 
/Xlrvum is equivoca l. Specific C. j}([rvum preimmuniza-
tion has been shown to facilit a le, bu t not be essentia l 
for, in vivo macrophage activation br C. parvwn (33). 
Sim ila rly, preimmunization has enhanced (26 ) , or been 
without effect (19) on , in vivo antitumor effects in 
different experimental S)'Stems. Our present finding 
that CW retain C. jJa·rvum antigens but lack stimu latory 
and antitumor activity indicates that the stimu lation 
res ulting from immunit y to C. jJam um represented a 
minor contributi on to the overa ll detected effects of C. 
pm<Jwn. T hat intratumor CW were detectably tumor-
suppressive in mice presensitived to C. /Jm<Jwn is analo-
gous to the reponed local antitumor effects at the site 
of ongoing DHR reactions tO other antigens that simi-
larly lack any intrinsic stimu lator y activity (34). 
Clearl y, CW are not solely responsible for the an tit u-
mo r effect of C. parvum. Some iimited activity has been 
attributed to a C. jJa.Tvum carbohydrate fraction isolated 
from culture medium (35), and C. parvum phospholipid 
preparations are chemotactic for macrophages (36). 
The only fractions of C. fJa m wn that have so far been 
shown to retain fu ll antitumor activity are phenol-
treated unbroken cells, which contain CW as well as an 
undefined amount of non-CW components (10 , 11). lt 
thus seems that complete antitumor activity is not asso-
c ia ted with a sing le molecu lar component capable of 
bein g isolarecl in pure form: Synergism between, or 
molecular association of, CW and non-CW components 
may be required. 
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Brief Communication: In Vivo Cortisone Sensitivity of Nonspecific Antitumor 
Activity of Corynebacterium parvum-Activated Mouse Peritoneal Macrophages 1•2 
Martin T. Scott 3• 4 
SUMMARY-The nonspecif ic antitumor activity of Coryne· 
bacterium parvum-activated mouse peritoneal macrophages 
in vitro was inhibited by their prior treatment with cortisone 
acetate i n vivo. Inhi bit ion was marked (60% ) 24 hours after 
cortisone injection and was still significant at 7 days, but 
anti t umor activity was completely recovered by 9 days. 
This transient inhibition was sufficient to abolish the non-
specif ic protection afforded by C. parvum in an in vivo 
pretreatment modei.- J Natl Cancer lnst 54: 789-792, 
1975. 
THE IN VIVO ANTITUMOR EFFECTS of 
Corynebacterium parvum (CP) are in some ways non-
specific and macrophage mediated (I). This paper 
describes the in vivo sensitivity to cortisone of the non-
specific antitumor activity of CP-activated macro-
phages. The antitumor activity of macrophages 
activated by CP is similar to that of those activated 
by protozoan infection (2-5), and my investigation 
was prompted by the recent description that the anti-
tumor effects of macrophages activated by Toxoplasma 
gondii were abolished by in vitro treatment with 
hydrocortisone (5). Corticosteroid drugs figure in 
some cancer chemotherapy regimens, and a promising 
approach to the use of CP as an anticancer agent 
seems to be its use in either simultaneous or sequential 
combination with chemotherapeutic agents (6-10). 
A previous study with the present mastocytoma 
tumor model demonstrated that the cell type among 
CP-stimulated peritoneal cells expressing nonspecific 
antitumor activity in vitro is the activated macro-
phage (11). Thjs has been confirmed by two inde-
pendent studies with other tumor models (12, 13). 
MATERIALS AND METHODS 
Mice.-Adult (C57BL/6XDBA/2)F1 B6D2F1 males 
were used throughout. 
CP.- PX 374 was kindly provided by Burroughs-
Wellcomc and Co., Research Triangle Park, North 
Carolina. 
Drugs.-Cortisone acetate (Sigma, St. Louis, Mo.), 
vinblastine sulfate (Eli Lilly and Co., Indianapolis, 
Ind.), and cyclophosphamide (Mead J ohnson & Co., 
Evansville, Ind.) were used . 
Tumor.- Mastocytoma P815 (MA), originally in-
duced by 3-methylcholanthrene in a DBA/2 mouse, 
has been maintained in ascites form by weekly 
passage in B6D2F1 mice for 2 years. Cells were har-
vested by peritoneal lavage with Hanks' balanced 
salt solution (HBSS) containing 10 U heparin/ml. 
In vitro tumor inhibition assay.- Peritoneal cells were 
obtained by peritoneal lavage with HBSS containing 
10 U heparin/mi. They were washed and resuspended 
in Eagle's minimum essential medium (l\lEl\1) 
(Grand Island Biological Co., Grand Island, X.Y.) 
containing 10% fetal calf serum (FCS) (Flow Labora-
tories Inc., Rockville, Md.). Target tumor cells were 
obtained as described above and resuspended in 
M EM I 0% FCS. One ml peritoneal cells (l 06/ml) 
was added to 1 ml ( 1 05) MA cells in 16 X 125-mm 
tissue culture tubes (Falcon Plastics, Oxnard, Calif.). 
Cultures were incubated at 37° C in a 5% C02 
atmosphere. After 24 hours of culture, 1 ~Ci tritiated 
thymidine (New England Nuclear Corp., Boston, 
Mass.) was added to each tube; 16 hours later, isotope 
incorporation into the acid-precipitable material 
was assayed as described in (14), except that What-
man glass fiber papers (2.5 em GF/B) (H. Reeve 
Angel and Co. Ltd., London, England) were used. 
RESULTS 
Development of CP-Mediated In Vitro Tumor Inhibitory 
Activity 
Groups of 5 mice were given 700 ~g CP intra-
peritoneally (ip) I, 2, or 4 days before removal 
of their peritoneal cells for assay of tumor inhibitory 
activity as described. Control cultures contained MA 
cells alone or MA plus peritoneal cells from normal 
mice (text-fig. I). Normal peritoneal cells did not 
significantly modify the growth of MA cells in vitro. 
CP-stimulated peritoneal cells were significantly 
inhibitory 24 hours after CP injection (51 % inhibi-
tion) and, after 4 days, inhibition of MA growth 
was almost total (97% inhibition). Cultures of either 
normal or CP-activated peritoneal cells alone were 
always less than 500 counts per minute (cpm) and 
not significantly different. 
Cortisone Sensitivity of Antitumor Activity 
Mice received 700 J.Lg CP ip and, 4 days later, 2.5 
mg cortisone acetate subcutaneously (sc) in the 
neck. At various times after cortisone treatment, 
peritoneal exudates were harvested and assayed for 
inhibition of tumor growth in vitro (text-fig. 2) . 
The results are expressed as percent tumor inhibition 
calculated as follows: 
cpm/culture MA alone-cpm/culture 
MA+peritoneal cells X lOO. 
cpmfculture MA alone 
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INTERVA l BETWEEN CP AND P.Ex . COLLECTION (DAYS ) 
TEXT-FIGURE I.-In vitro growth inhibition of MA cells by 
CP-activated peritoneal cells. Thymidine uptake, expressed 
as cpm/culture of J05 MA cells cultured with 106 peritoneal 
cells from normal mice (O ) or mice that had received 700 pg 
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DAYS AFTER CORTISONE 
TEXT-FIGURE 2.-Cortisone sensitivity of in vitro antitumor 
activity, expressed as percent tumor inhibition (see text). 
105 MA cells were cultured with 106 peritoneal cells harvested 
at various times from mice given either 700 pg CP ip (Q--0 ), 
or 700 pg CP ip and 2.5 mg cortisone acetate sc in the neck 4 
days later (0---0 ). Included arc two groups of mice given 
700 pg CP ip and, 4 days later, either 4 m~ cyclophosphamide 
(• ) or I mg vinblastine sulfate (e ) mtravenously (iv ). 
Vertical bars represent ± SE. 
(Since the amount of isotope incorporated by the 
peritoneal cells relative to the tumor cells was negli-
gible, total radioactive counts were used in calculating 
tumor inhibition.) 
CP pretreatment alone produced the expected 
marked inhibition of tumor growth which persisted 
throughout the 9 days of the experiment, and cortisone 
treatment of these mice transiently reduced the anti-
tumor effect. One day after cortisone injection it was 
reduced by 60%, still significantly reduced at 7 days 
(5%), but completely recovered by day 9. Cultures of 
peritoneal cells from non-CP-treated animals given 
injections of cortisone behaved as normal cells and 
did not modify MA growth. Included in text-figure 2 
are the results from CP-treated mice that, instead of 
receiving cortisone, were given l mg vinblastine sul-
fate or 4 mg cyclophosphamide iv. Peritoneal cells 
were harvested 24 hours later. Inhibition of the CP 
antitumor effect by these t\vo agents, though statisti-
cally significant, was considerably less than that of 
cortisone. All three drugs at their respective doses 
were equally able to reduce the number of cells during 
a 24-hour period, as measured by decrease in spleen 
weight: cortisone acetate, 50% reduction; vinblastine 
sulfate, 51 %; cyclophosphamide, 43.8%. 
Histologic Studies 
Aliquots of peritoneal cell suspensions prepared as 
for culture were allowed to settle onto glass cover 
slips for l hour at 37° C. The overlying fluid was then 
pipetted off and the adherent monolayer fixed for lO 
minutes in ice-cold methanol and stained with Giemsa. 
The number of peritoneal cells obtained from OF-
treated or CP-cortisone-treated mice 24 hours after 
cortisone was given did not differ significantly, and 
the proportion of adherent cells in both these groups 
was greater than 90% macrophages. During the !-hour 
incubation period, CP-activated macrophages spread 
out and were highly vacuolated, whereas normal 
macrophages remained rounded up. These changes 
are indicative of the activated state ( 12). CP-activated 
macrophages were apparently still activated 24 hours 
after cortisone treatment as judged by their rapid 
spreading and degree of vacuolation. 
I n Vivo Demonstration of Cortisone Sensitivity 
To ascertain whether the magnitude of the transient 
inhibitory effect of cortisone was sufficient to be 
significant in vivo, the following experiment was 
performed. A group of 10 mice was given 700 J.tg CP 
ip; 4 days later they received 2.5 mg cortisone acetate 
sc in the neck, and the following day, l 05 live MA cells 
ip. Control groups received only CP or cortisone or 
were untreated before challenge. Survival of the mice 
is shown in text-figure 3. Cortisone treatment did not 
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TExT-FIGURE 3.-Survival of groups of mice challenged with 
105 MA cells ip. Pretreatment for the groups was 700 pg CP 
ip 5 days before challenge(---) or, in addition, 2.5 mg 
cortisone acetate sc I day before challenge(- --). Control 
groups received either cortisone acetate alone ( . .. . .. ) or 
were untreated (--- -). 
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modify growth of the tumor in untreated mice; the 
mean survival times of control and treated groups 
were 22.8±0.7 (sE) and 21.2±1.2 days, respectively. 
CP significantly prolonged survival time (mean survi-
val time, 29.7±1 day) but this effect was completely 
abolished by subsequent cortisone treatment (mean 
survival time, 21.6±0.8 days). 
DISCUSSION 
Macrophages activated by CP nonspecifically in-
hibit tumor cell growth in vitro (1 1-13). That such a 
nonspecific system is operative in vivo is suggested by 
the observation that the in vivo antitumor effects of 
CP are in large part resistant to various immunosup-
pressive procedures- T cell deprivation (J 1, 15), 
antilymphocyte serum and splenectomy (16), and 
irradiation {17). T he present data show that this non-
specific antitumor activity of the CP-activated macro-
phage is sensitive to in vivo treatment with cortisone. 
The effect was transitory but sufficient to abolish the 
protective effect of CP in an in vivo pretreatment 
model. Preliminary results suggest that the antitumor 
activity may not be equally sensitive to two other 
commonly used cytostatic agents-cyclophosphamide 
and vinblastine sulfate. 
That the cortisone was administered when the 
nonspecific antitumor activity was fully developed, 
and no histologic differences were apparent between 
the peritoneal exudates of cortisone-treated or non-
treated, CP-stimulated mice, indicates the cortisone 
acted at the effector cell level- the activated macro-
phage. The data do not, however, exclude the possi-
bility that cortisone also may affect other cell types or 
interactions. The cytostatic activity of cortisone may 
be excluded, since the exprer.sion of tumor inhibition 
by CP-activated macrophages is highly radioresistant 
(11); further, both vinblastine sulfate and cyclophos-
phamide are also cytostatic. Insight into the mode of 
action of cortisone may be gained from recent work of 
Hibbs (5). Using macrophages activated by T. gondii 
infection, he demonstrated that their nonspecific 
tumor inhibitory activity was effected by direct 
contact between the activated macrophage and the 
target tumor cell. Lysosomes from the activated 
macrophage were secreted directly into the cyto-
plasm of the tumor cell, which subsequently lysed. 
Corticosteroid drugs prevented exocytosis of macro-
phage lysosomal enzymes, most probably through 
stabilization of the macrophage cell membrane (18-
20), and treatment of T. gondii-activatcd macro-
phages in vitro with hydrocortisone inhibited their 
expression of antitumor activity (5). The present 
findings suggest that activated macrophages arc 
similarly sensitive to cortisone treatmenl in vivo. 
Such a mechanism would also explain the relative 
lack of activity of cyclophosphamide and vinblastine 
sulfate, neither of which is a membrane-stabilizing 
drug. 
The impetus for the present cortisone studies 
came from the predicted in vivo incompatibility 
between cortisone and CP-activated macrophages 
based on Hibbs' work; also, both clinical (9, 10) 
and experimental (6-8) results with CP in combina-
tion with various chemotherapeutic agents suggest 
this to be a promising approach to its clinical use. 
Despite the transitory nature of the inhibitory effect 
of cortisone, it significantly impaired the performance 
of CP in vivo. Further studies to evaluate the potential 
cytostatic effect of corticosteroids as opposed to their 
possible inhibition of macrophage effector functions 
are recommended. I t may prove possible, through 
manipulation of the corticosteroid therapy and non-
specific immunotherapy, to maximize the antitumor 
effect of each while minimizing the antagonistic 
effect of corticosteroids on macrophage activity. 
Since other cytostatic agents without membrane-
stabilizing properties may prove less antagonistic, 
another consideration may be substitution of these 
drugs for corticosteroids if these are equally effective 
in the given tumor situation. The nonspecific anti-
tumor effects of macrophages activated by BCG (21) 
are similar to those activated by CP (J 1, 12) or 
protozoan infection (2-5), and the same drug 
sensitivity may be predicted. 
In vitro models of the nonspecific antitumor activity 
of activated macrophages such as that described 
would seem to provide a ready screen for possible 
future drug incompatibilities. Such incompatibilities 
may be particularly important in advanced cancer 
patients, since these are most likely to be relatively 
anergic and depend on the nonspecific component 
of the antitumor activity of CP rather than any 
augmentation of specific tumor immunity; further, 
they arc most likely to require continuous main-
tenance chemotherapy. 
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CHEMO-IMMUNOTHERAPY OF MO USE TUMOURS 
USING CYCLOPHOSPHAMIDE AND C. PARVUM 
M. T. Scott 
ABSTRACT 
Treatment of a chemically induced mouse solid fibrosarcoma using either 
non-specific (C. parvum 350 J1 i.v.), or specific active (s.c. C. parvum mixed with 
5 . I~ irradiated tumour cel ls) immunotherapy, 4 days after a single dose of cyclo-
phosphamide (200 mgfkg) was synergist ically more effective than either C. parvum 
or drug trea tment alone. A contributory factor may be that cyclophosphamide pre-
treatment has been shown to potentiate the specific antitumour immunity that 
arises from C. pan·um interaction with tumour antigen. 
Systemic C. partllllll before cyclophosphamide will potentiate the antitumour 
cnccts of the drug- previously ineffective low doses becoming effective. No similar 
polenl ialion of lin: elrecls of another alkylating agent, Melphalan, was evident. 
Despite th e immunosuppressive nature of most cancer chemotherapy 
drugs, animal studies show that immunostimulation using C. parvum (CP) can 
be successfully combined with drug therapy, often with add itive, or even synergistic 
elrects (2-6). This report desc ribes some preliminary experiments aimed at analysing 
the pri nciples involved in such chemo-immunotherapy situations. 
MATERIALS AND M ETHODS 
IO•Iive M4 tumour cells tl) were injected s.c. into a hind footpad of syngeneic CBA mice, 
and the resulting solid tumour was measured as footpad thickness us ing a dial gauge caliper. 
Foo1pads > 10.0 mm became necrotic and measuremcn1s were disconlinued. CP (Wellcome) 
was diluled in saline, and cyclophosphamide (CY -Koch Light Labs. Lid.) was .dissolved in · 
dislilled wa1er and 4 mg (200 mg/ kg) injected i.p. 
RESULTS 
Experiment 1 
Tumours we re established and 6 days later CY was injected i.p. and CP 
(350 11g) was given i.v. I, 4, 8 o r I 2 days after CY (Table 1). CP at these times 
in non CY -treated mice was ineffective. The inhibitory effects of CY alone were 
transient, all tumours being > 10.0 mm and necrotic by day 20. Only CP I or 
4 days after CY was effective a nd , of ·these, CP 4 days after CY was significantly 
better. 
Experiment 2 
After 4 days, tumours were CY treated, and 4 days later C P (70 J.lg) was 
injected direct ly into the tumo ur lesion (Table U). Neither CY, nor CP a lone, 
25 
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Table l. Antitumour effects of i.v. C P at various times after CY. 
• p < 0.05 between results (Student 1 test) 
Tumour si ze at day 20 
Treatment 
(footpad thickness nvn t s.e.) 
Tumour alone day 0 >10.0 
4 mg i. p . CY + 6 >10 .0 
350 t•9 CP i.v. + 7/ 1 0/14/1~ >10 .0 
CY + 6 , CP i.v. +7 7.8 ± 0 . 38* 
+ 10 6.4 ! 0.40* 
t 14 9. 5 • 0 . 37 
.. 18 > 10 .0 
Table !1. Antitumour effects of intralesional (i.l.) CP . 
after CY treatment 
Treatment 
Tumour al one day 0 
4 mg CY i. p. + 4 
70 o9 i. 1. CP + 8 
CY + 4 , CP + 8 






caused tumour regressions, but 5/6 tumours regressed completely when CP follo-
wed CY. 
Experiment 3 
To study the effect of CY in the antitumour activity of CP it was necessary 
to eliminate the direct antitumour effects of CY itself. This was achieved by 
injecting CY 4 days before tumour cells since the in vivo half-life ofCY is consider-
ably shorter. CP (350 pg) was given i.v. I day after tumour cells (Table HI). 
CY pretreatment was without effect. CP 1 day after tumour cells inhibited tumour 
growth but was significantly more effective in CY pretreated animals. 
Table Ill. Antitumour etrects of i.v. CP in CY pretreated mice. 
•p < 0.005 between results (Student 1 test) 
Treatment 
Tuw~ur alone day 0 
4 mg CY i.p. - 4 
350 ~9 CP i .v. +1 
·cv -4. cr + 1 
Tumour size at day 20 
( footpad thickness nun± s. e . ) 
8 . 8 ± 0 .41 
8 . 3 ± 0.56 
5.8 t 0 . 23* 
4. 2 I 0 . 34* 
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Experiment 4 
CP (350 Jlg) was injected i. v. 2 days after tumour cells and 4 days later a 
ttnnour inhibitory dose (4 mg), or an ineffective dose (I mg) of CY was given 
(Table IV). The individual atHitumour effects of CP and 4 mg CY were additive. 
The 1 mg dose of CY, ineffective in normal mice, was significantly inhibitory 
after CP treatment. 
Table I V. Eft'ect of i.v. CP pretreatment on the antitumour efrects of CY. 
•p < 0.005 between results (Student t test) 
Tr·ea tmen t 
Tumour size a t day 20 
( footpad th ickness mm! s . e. ) 
Tumour alone day 0 
350 ug CP i . v . + 2 
4 mg CY i. p. + 6 
I mg CY i. p. + 6 
CP i . v. + 2, 4 mg CY + 6 
CP i . v. • 2, 1 mg CY + 6 
DfSCUSSION 
>10 .0 
8 .9 ~ 0. 37 
6.8 :! 0. 42• 
>10.0 
4. 9 ' 0 . 35 
6.9 • 0. 37 
The find ings from the preliminary experiments accord with previous stu-
dies (2-6) in showing that stimulatory CP immunotherapy in combination with 
immunosuppressive drug th erapy can produce additive, and even synergistic 
antitumou r effects, in mice. They also affirm the idea that the timing between the 
two agents is a critical factor, and this parameter is under further investigation. 
Thus far it would seem that the basis of successfu l CP-CY combinations may 
include both a potentiation of CP effects by CY, a nd of CY etTects by CP. 
REFERENCES 
I. Bomford. R. (1975). Br. J. Cancer 32. 551. 
2. Currie, G. A. & Dagshawe, K. D. (1970). Br. med. J·. I , 541. 
3. Fisher, B., Rubin, H., San·er, E. & Wolmark, N. (1976). Cancer Res. 36, 3714. 
4. Fisher, B., Wolmark, N . , Rubin, H. & JaiTer , E. (1975). J. Nat. Cancer Jnsr. 55, 1147. 
5. Hattori, T. & Yamagata, S. (1975). Gam1 66, 711. 
6. Houchens, D.P., Johnson, R. K., Ovcjcra, A. , Gaston, M. R. & Goldin, A. (1976). Cancer 
Treatm. Rep. 60, 823. 
General discussion 
Woodruff: lt 's very important in the design of c linical trials to have some 
advance information about the sort of order in which to employ your vario us 
therapies; and the sort of thing that Dr Scott reports I think is very important 
for that reason. But r do think that one needs to look at quite a lot of tumours 
before you can extrapolate too confidently. I think I' m right in sayi ng that when 
C urrie and Bagshawe first described the synergistic effect of C. parvum and cyclo-
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phosphamide they found an interval of 12 days between administration of agents 
was optimal. . With a CBA/ methylcholan trene induced sarcoma we found about 
8 or 9 days was optimal. These figures vary somewhat from the 4 days Dr Scott 
found was optimal. 
Scott: I think our 4 day interval here agrees with 1 he Fisher data. The Currie 
and Bagshawe data was using intradermal C. parvum and so was probably very 
different. This does c heck out with a no ther mouse system-we used the CBA 
radiation induced leukaemia syste m, a nd found the same answer. We are well 
aware that 4 days in a mo use is really not very meaningful when you are talk ing 
about patients. We therefore correlate it with measurable parameters, and although 
we talk about 4 days in a mo use as p resented here, we have been following the 
cfTects of cyclophosphamide o n such things as reduction of spleen weight and 
periphe ra l le ucocyte count , a nd so far the 4 days in our system correlates with 
j ust immediately prior to the escape fro m the suppressive effects of cyclophospha-
mide as measured by peri phe ra l leucocyte count... whereas 8 days would correlate 
with the over-shoot. 
Salomon: I wou ld like to ask if you have considered the possibility of 
lnoking at th e d ilution o f C. partl lllll susceptibility in tumo urs which a re made 
resistant by cyclophosphamide. 
Scolf: No, we haven't. What we're looking at now is resistant to adriamycin 
a nd vinblastine and so we a re having a look at the effect of cyclophosphamide to 
:;ee whether yo u can get any sensitising effect in that respec t. We don't have a 
tumour a t th e moment wh ich is insensitive to cyclophosphamide. 
There's just o ne other point which r didn't make, but in the light of Dr Fos-
ter's data 1 his morn ing concerning inc reased toxicity of C. parvum, we find that 
intraveno us C. parvum treatme nt will increase the susceptibility .to toxic effects 
of cyclo phosphamide. We also find tha t cyclophosphamide pretreatment will 
increase the s uscept ibility of mice to the toxic effec ts of very high doses of intra-
venous C. parvum. 
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Analysis of the Principles Underlying Chemo-Immunotherapy 
of Mouse Tumours 
I. Treatment with Cyclophosphamide Followed by Corynebacterium parvum 
M. T. Scott 
Department of Experimental Jmmunobiology. The Wellcome Research Laboratories, 
Beckenham, Kent BR3 3BS, England 
Summary. A CBA mouse fibrosarcoma (M4) growing 
as a solid tumour was treated with a single high dose 
(200 mg/kg) of cyclophosphamide (CY) followed by C. 
parvum (CP) immunotherapy. The optimal timefor the 
administration of both nonspecific (CP IV) and active 
specific (SC CP-irradiated tumour cell mixtures) immu-
notherapy after CY was 4 days, compared with 1, 8, or 
12 days. Optimal combinations ofCY and CP were 'syn-
ergistic' in that they provided a stronger antitumour ef-
fect than the sum of the individual effects of the two 
agents. In keeping with the finding that a 4-day interval 
between CY and CP was better than only 1 day, studies 
in normal mice show that when CP is given early during 
the suppressive phase of CY the onset of both specific 
and nonspecific antitumour effects are delayed. CY in-
creased the susceptibility of mice to the toxic effects of a 
subsequent high systemic dose of CP. 
Introduction 
Animal studies indicate that the combination of chemo-
therapy with bacterial immunostimulants such as BCG 
or CP may be a promising form of cancer treatment, the 
individual antitumour effects being additive or even syn-
ergistic1 (Fisher et al., 1976; Hattori and Yamagata, 
1977; Pearson et a!., 197 5; Purnell et aJ., 1977; Sansing 
et al., 1977; Tagliabue et al., 1977). These studies have 
shown that the time interval between treatment with the 
chemotherapeutic agent and with the immunostimulant 
is important. This paper is concerned with the analysis 
of the principles underlying chemo-immunotherapy with 
The terms synergistic/synergism have been used in this paper to 
describe (a) situation(s) where the antitumour effects of a combina-
tion of two treatments are apparently greater than the sum of each 
treatment alone. The complexities of a true definition of synergism 
have been critically reviewed by Berenbaum. Clin. Exp. Immunol. 
28, J (1977) 
cyclophosphamide (CY) given before CP. The reverse 
combination, CY after CP, is the subject of the accom-
panying paper (Scott, 1979). CY was chosen because its 
marked immunosuppressive properties were likely to ac-
centuate any antagonism between immunostimulation 
and drug therapy, and because previous workers have 
shown synergistic effects when CP was combined with 
CY in mouse tumour models (Currie and Bagshawe, 
1970; Fisher et al. , 1975; Pearson et al., 1975; Purnell et 
al., 1977). Two forms of CP therapy have been used: 
CP injected systemically (IV) and specific active immu-
notherapy by SC injection of CP mjxed with irradiated 
tumour ce!Js. The mode of action of systemic CP is con-
sidered to be predominantly nonspecific (i.e., unrelated 
to tumour antigens) and mediated by CP-activated ma-
crophages, whereas local interaction of CP with tumour 
antigen generates strong, specific T cell-mediated antitu-
mour immunity (reviewed in Milas and Scott, 1978; 
Scott, 1978). 
Materials and Methods 
Mice. Adult CBA T6T6 were used throughout. 
Cyclophosphamide Monohydrate (CY). CY (Koch Light Laborato-
ries, Colnbrook, Buckinghamshire, England) was dissolved in sterile 
distilled water for injection. Unless otherwise stated. injections were 
of 200 mg/kg. 
C. parvum. A formalin-ki lled suspension, strain CN6 I 34 (Wellcome 
Research Laboratories, Beckenham, Kent, England). was diluted 
with sterile saline for injection. 
Tumour. The origins and techniques for maintenance and harvesting 
of syngeneic M4 fibrosarcoma and RI leukaemia cells have been 
described elsewhere (Bomford, 1975; Olivotto and Bomford, 
1974). 
Tumour Measurement. A 27 g needle was used to inoculate groups 
of 6-8 mice SC in a hind footpad with live M4 cells. Subsequent 




ness in O.l-mm units. with the aid of a Schnelltaster dial gauge cali-
per A02T (H. C. Kroplin , Schluchtern. Hessen. West Germany). 
Irradiation of Tumour Cells. M4 cel ls were irradiated (10.000 rads) 
with a 137Cs source. · 
In vivo Neutralisation Assay (Winn). Popliteal lymph node cells were 
gently homogenised in Hank's Balanced Salt Solution by means of a 
ground glass homogeniser. Viable (trypan blue exclusion) cells were 
mixed in a ratio of 10: I with viable M4 cells and the mixture in-
jected SC into the flanks of mice that had received 400 rads whole-
body irradiation 24 h earlier. These mice were then monitored for 
tumour growth. 
In vitro Cytostatic Assay. The technique was as described by Scott 
( 1974). Peritoneal cells were mixed in vitro in a ratio of 5 : l with Rl 
leukaemic cells. After 24 h of culture 3 H-thymidine was added and 
its uptake by Rl cells was assessed 24 h later. Limitations to this 
form of cytostatic assay are apparent from the work of Stadecker et 
al. ( 1977). 
Statistics. Means and standard errors were calculated for all experi-
mental groups and differences where P < 0.05 (Student's /-test) were 
considered significant. 
Results 
Optimal Timing for CY 
and Specific Active CP Therapy 
We injected 105 live M4 cells into a hind footpad and 
4 days later when the tumours were macroscopically 
visible, CY, 200 mg/kg (the previously determined 
highest, nontoxic dose maximally inhibiting tumour 
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Fig. I. M4 tumours were established in mice, which then received 
CY, 200 mg/kg IP (CY) 4 days later (e - --e ) or were untreated 
(controls) (e -e). Individual groups ofCY-treated mice were then 
given CP-irradiated M4 mixtures SC (Imm) I (x-- x), 4 
(T - T ), 8 (• ), or 12 (0--0) days later 
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mixture of 3.5 1-1-g CP and 5 x 10 irradiated M4 cells 
(previously determined doses and ratio for optimal ther-
apy) was injected into the contralateral footpad (Fig. I). 
CY alone produced a marked but transient inhibition of 
tumour growth and CP-irradiated M4 mixtures 1, 8, or 
12 days after CY were without further significant effect. 
Mixtures injected 4 days afte.r ·cv, however, were 
significantly more inhibitory than CY alone and in the 
experiment shown resulted in one complete tumour re-
gression in the six mice. Mixtures given at the same 
times in nan-CY-treated mice were without effect (data 
not included); however, when given earUer, within 0- 2 
days after tumour cells, they were inhibitory (see 
Fig. 3b). 
Optimal Timing for CY and IV CP Therapy 
We injected 106 live M4 cells into a hind footpad and 4 
days later CY, 200 mg/kg, was injected IP. One, 4, 8, or 
12 days later CP (350 ~tg- previously determined opti-
mal therapeutic nontoxic dose) was injected IV (Fig. 2). 
CY alone caused a transient inhibition of tumour growth 
4-9 days after injection, after which a growth rate simi-
lar to that in controls was resumed. IV CP given 8 or 12 
days after CY (i.e., at the time of, or after. the escape of 
the tumour from the inhibitory effect of CY) was with-
out effect. Tumours treated with IV CP 1 day after CY 
grew more slowly than those treated with CY alone, 
although this effect was not always statistically signifi-
cant in repeated experiments. IV CP 4 days after CY 
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Fig. 2. M4 tumours were established in mice. which then received 
CY, 200 mg/kg 1P (CY) 4 days later (-.-- ... ) or were untreated 
(controls) (e-e). Individual groups of CY-treated mice were then 
given CP IV I (x- x), 4 (T-~). 8 (• - • ). or 12 (D--0) 
days later 
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CP 1 day after CY. CP given IV at the same times in 
nan-CY-treated mice was without effect (data not in-
cluded), but as with CP-irradiated tumour cell mixtures, 
they were effective against smaller tumour masses (see 
Fig. 3a). 
Potentiation of CP-Mediated Antitumour Effects 
by CY Pretreatment 
It seemed possible that CY pretreatment was modifying 
the host in such a way that the antitumour effects of CP 
given 4 days later were potentiated. To determine this it 
was necessary to eliminate the effects of CY on the tu-
mour itself, and this was achieved by giving CY 4 days 
before injection of tumour cells, since the in vivo half-life 
ofCY is only a few hours (Bach, 1975). We injected 106 
live M4 cells into a hind footpad of normal mice or mice 
that had received CY 4 days earlier. One day later these 
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Fig. 3. a M4 tumors were established in either normal mice (controls) 
(+- --+) or mice treated with CY. 200 mg/kg IP 4 days earlier. One 
day after tumour establishment mice from both groups received 350 
~~g CP IV or no further treatment. --.. CY and CP [V: +--+. 
CY only; e---e, IV CP only 
b In the same scheme as a , SC immunization with 3.5 f.l& CP mixed 
with 5 x 105 irradiated M4 cells (fmm) was substituted for IV CP. 
._. , CY only; • ---• , controls; • ---e, Tmm only ; e-e, 
CY and Imm 
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treated (Fig. 3a). CY pretreatment alone was without 
effect or, in some experiments, enhanced tumour growth 
(e.g., Fig. 3b). Growth in nan-CY-treated mice was in-
hibited by CP, but the effect was significantly greater 
after CY pretreatment. The same protocol was used in 
further experiments where SC CP-irradiated tumour cell 
mixtures were substituted for IV CP (Fig. 3b). Again, 
therapy was considerably more effective in CY -pre-
treated animaJs. 
Kinetics of the Suppressive Effects of CY 
in Normal Mice 
The finding that the antitumour effects of CP given 
I day after CY were less good than those of CP given 
after 4 days (see Figs. I and 2) suggested that the stimu-
latory effects of CP given shortly after CY may be 
suppressed. Figure 4 shows the suppressive effects of a 
single IP injection of CY in normal mice, as judged by 
spleen weight and peripheral blood leucocyte count. The 
effects'on both parameters were roughly parallel: within 
24 h both were significantly depressed, recovering after 
4- 5 days. By day 8 leucocyte counts were again nor-
mal, whereas spleen weights were above normal, return-
ing to normal between 12 and 18 days after CY. 
Effects of CY Pretreatment on CP-Mediated Specific 
and Nonspecific Antitumour Effects 
The nonspecific assay was based on the accumulated 
reports that, after systemic CP, peritoneal cells acquire 
the capacity for, significant inhibition of the growth of 
various tumour cells in vitro, the phenomenon being at-
tributable exclusively to CP-activated macrophages 
(Oiivotto and Bamford, 1974; Scott, 1974). In the ex-
periment shown in Table 1, mice were injected IP with 
CY and 1 or 4 days later received 350 f.Lg CP IP. Fur-
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Fig. 4. Kinetics of the modification of peripheral blood leucocyte 
(PBL) count and spleen weight by a single IP injection of 200 
mg CY/ kg 
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Table I. In vitro, nonspecific tumour inhibitory activity of peritoneal cells 
from mice treated with systemic CP after CY 
Effector cells: Inhibition assay at days 
Peritoneal cells from 
mice treated at days 
-4 -I 0 + 4 + II 
CYb 
118,156 ± 6,302• 
l 18,532 ± 420 
224 ± 48d 
3,762 ± 420d 
198 ± 60 
244.620 ± 48,309' 
180,724 ± 30,039 
CP< 1,049 ± 198 
CY CP 756± 121 
CY CP 
• Results expressed as 3H-thymidine incorporation cpm/ culture. Incorporation by 
peritoneal cells alone was insignificant 
b CY, 200 mg/kg IP 
e CP, 350 J.tg !P 
d Result significantly different from similarly designated results (P < 0.0005) 
Table 2. Specific cell-mediated immunity arising from SC injection of 
CP-irradiated tumour cell mixtures after cyclophosphamide 
Effector cells: 
Popliteal lymph node cells 









Winn assay at days 








• ResuJts expressed as proportion of recipient mice developing tu-
mours 
b Imm, SC 3.5 1-'g CP mi!ted \vith 5 x 105 irradiated M4 cells 
e CY, 200 mg/ kg IP 
ther · groups received either CY or CP alone, or were 
untreated. Peritoneal cells from the various groups were 
assayed for in vitro tumour inhibitory capacity 4 and 
11 days after CP. No inhibition resulted from CY treat-
ment alone. In non-CY -treated mice marked inhibition 
was apparent both 4 and 11 days after CP, whereas if 
CY was given 1 day before CP activity was significantly 
impaired at day 4 but had fully recovered by day 11. No 
similar impairment was apparent when CP was delayed 
until 4 days after CY. 
Strong, specific, T cell-mediated antitumour immu-
nlty results from SC injections of CP mixed with irra-
diated M4 (Bomford, 1975) and other tumour cells 
(Scott, 197 5), and is detectable in a Winn neutralisation 
assay when cells from the node draining the site of mix-
ture injection are used as effector cells (Scott, 1975). In 
the experiment shown in Table 2, CP-irradiated M4 
mixtures were injected SC into a hind footpad of normal 
mice or of mice treated with CY either 1 or 4 days ear-
lier. Six and 12 days after immunisation, draining popli-
teal lymph node cells from the various groups were as-
sayed for tumour inhibitory capacity by the Winn assay. 
Cells from normal immunized mice were fully inhibitory 
at both 6 and 12 days. CY 1 day before immunisation 
inhibited the 6- but not the 12-day effects, whereas CY 
4 days before CP had no effect. Further control groups 
showed that no immunity developed after injection of 
either CP or CY alone. 
Increased CP Toxicity Following CY Pretreatment 
Mice injected with 350 1-Lg CP IV 4 days after 200 mg 
CY/ mg IP showed no overt signs of toxicity: however, 
an increased susceptibility to the effects of a higher IV 
CP dose ( 1.4 mg) was evident. Normal mice tolerated 
this CP dose without apparent ill effects, whereas rnlce 
pretreated with CY 4 days earlier lost weight and seven 
of ten died. 
Discussion 
The finding that CP can be combined with CY in the 
treatment of a mouse fibrosarcoma to give more pro-
nounced effects than are obtained with either agent 
alone accords with the findings of other workers using 
various multiple- or single-dose regimens in different 
mouse tumour models (Currie and Bagshawe, 1970; Fi-
M. T. Scott: Cyclophosphamide-C. parvum Tumour Treatment 
sher et al., 1975; Pearson et al., 1975; Purnell et a!., 
1977). To facilitate analysis of the interaction between 
CP and CY I have restricted the present study to treat-
ment with a single injection of CY followed by a single 
injection of CP. 
In the present model, the optimal timing of CP im-
munotherapy, both systemic and specific active, was 
4 days after CY, compared with 1, 8, or 12 days. With 
specific CP therapy the 4-day interval was critical to 
obtain potentiated antitumour effects, but with systemic 
CP, although a 4-day interval was optimal, potentiated 
effects were also apparent with a 1-day interval. CP 8 
and 12 days after CY, i.e., at a time when the tumour 
was escaping, or had escaped, from the inhibitory in-
fluence of the drug, was ineffective. Similar data have 
been reported for a mouse leukaemia where the optimal 
timing for systemic CP after CY was during remission, 
and CP given immediately before relapse was ineffective 
(Pearson et al., 197 5). 
When CP was injected 1 day after CY the expres-
sion of its stimulatory effects was delayed compared 
with CP given 4 days after CY. The relative sensitivities 
of macrophage activation and generation of specific im-
munity to the suppressive effects of CY, partial and total 
respectively, correlated with the partial and total loss of 
potentiated antitumour effects in vivo following either 
systemic or specific active CP therapy l day after CY 
compared with 4 days. CP is relatively resistant to de-
gradation in vivo (Scott and Milas, 1977), and it may be 
presumed that the stimulatory effects of CP 'recovered' 
once the suppressive effects of CY had worn off because 
of persisting CP. Intact fluorescein-labelled CP is still 
present in the spleen and draining lymph node 4- 5 days 
after IV and SC injection respectively (Scott and Milas, 
1977). 
A basis for the reduced effectiveness of CP given 
very shortly after CY is then postulated to be a delay in 
onset of the stimulatory effects of CP due to the persist-
ing suppressive effects of CY. It is interesting that two 
recent studies where multiple weekly injections of CY 
and systemic CP have been used to treat two different 
mouse solid mammary adenosarcomata (Fisher et al., 
1976; Purnell et al., 1977), the optimal CY -CP intervals 
were defined as 3 and 4 days, respectively. both inter-
vals producing significantly better results than when CY 
and CP were given on the same day. At variance with 
these data are those of Currie and Bagshawe ( 1970), 
who in the treatment of a mouse solid fibrosarcoma, 
found a CY -CP interval of I 2 days to be considerably 
better than 3, 6, lO, or 16 days. The CP was given TD, 
however, and this may be a determining factor. 
A further factors contributing to the optimal CY -CP 
interval of 4 days with the M4 fibrosarcoma model is 
likely to be the demonstrated CY -mediated potentiation 
of the effect of both subsequent systemic and specific 
Ill 
active CP therapy. The fact that the optimal timing for 
CP after CY coincided with the period immediately be-
fore recovery from the suppressive effects of CY sug-
gests a possible basis for the potentiated CP effects, 
namely, that the cells contributing to the recovery after 
CY may, through modified metabolism, for example, be 
hyper-responsive to CP. 
Overt toxicity was apparent only when very high 
doses of systemic CP were given after CY. However, the 
stimulatory effects of repeated low doses of CP are 
known to be cumulative (Scott and Warner. 1976), and 
the possibility of toxic effects should be a consideration 
in any repetitive dose regimens. 
CY was chosen for the present study because its 
potent immunosuppressive effects were predicted to ac-
centuate any antagonism between immunostimulant and 
immunosuppressive therapy. The findings seem to af-
firm what might have been previously presumed, i.e., 
that the best time for immunotherapy is likely to be after 
the drug toxicity for cells has worn ofT and before the 
tumour growth has gone out of control. Additive and 
synergistic antitumour effects in mice have been re-
ported for a range of cancer therapy drugs when given 
in combination with CP (Fisher et at., 1976; Hattori and 
Yamagata, 1977; Pearson et al., 1975: Purnell et al., 
1977; Sansing et al., 1977; Tagliabue et aL, 1977). Since 
drugs used in cancer treatment differ in their immuno-
suppressive activities it will be interesting to see whether 
the same principles described here for CY apply to other 
drugs, particularly those of low or negligible immuno-
suppressive activity. 
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Summary. The nonspecific macrophage-mediated anti-
tumour effects resulting from IV C. parvum (CP) in 
mice were resistant to cyclophosphamide (CY), whereas 
the specific T cell-mediated immunity resulting from S C 
injection ofCP-irradiated tumour cell mixtures was sen-
sitive for up to 8 days after immunisation, and resistant 
thereafter. Mice with solid fibrosarcoma (M4) were 
treated by I V CP followed by CY and, with intervals 
between CP and CY of 1- 4 and 15- 18 days, the antitu-
mour effects of the CY were potentiated in a 'synergistic' 
manner. This did not happen with 8- or 12-day intervals. 
The most potent antitumour effects (39% complete re-
gressions) occurred with the 15- 18 day interval. (The 
antitumour activity of another alkylating agent, mel-
phalan, was similarly potentiated when given 12- 18 
days after IV CP, but not after 4 days.) No potentiated 
antitumour effects were found when specific active im-
munotherapy with CP-irradiated tumour cell mixtures 
preceded CY by 1, 4, 8, 12, or 18 days. CP given IV 
increased the susceptibility of mice to subsequent high 
doses of CY, the peak sensitivity being around 10 days 
after CP. 
Introduction 
In the preceding paper the optimal conditions for giving 
Corynebacterium parvum (CP) immunotherapy after 
CY were defined for the treatment of an experimental 
mouse solid fibrosarcoma (Scott, 1979). This paper con-
siders the situation where the order of the two agents is 
reversed, i.e., CY after CP in the treatment of the same 
tumour. 
Materials and Methods 
The mice, tumours, assay system. CP, and CY were as described in 
the previous paper (Scott, 1979). Unless otherwise specified the CY 
injections were 200 mg/kg. Melphalan (Wellcome Research Labora-
tories. Beckenham. Kent, UK) was dissolved in the acid diluent pro· 
vided. 
Results 
CY Resistance of CP-Activated Macrophages 
The in vivo mediator of the immunologically nonspecific 
antitumour effects of CP is considered to be the CP-
activated macrophage (reviewed in Milas and Scott, 
1978; Scott, 1978). T he nonspecific inhibition of tumour 
cell proliferation in vitro by CP-activated peritoneal cells 
is attributable exclusively to sucb activated macro-
phages (Olivotto and Bornford, 1974; Scott, 1974), and 
the CY sensitivity of this effector mechanism was exam-
ined (Table 1). At day 0 mice were injected with 350 1-l-g 
IP, followed by CY IV at day + 4. (By this time the 
nonspecific antitumour activity of C P-activated macro-
phages is fully established (Olivotto and Bomford, 1974; 
Scott, 1974). Four days later peritoneal cells were re-
moved and assayed for their ability to inhibit the incor-
poration of 3H-thymidine into syngeneic RJ leukaemic 
Table I. Failure of CY to inhibit the nonspecific tumour-inhibitory 
activity of peritoneal cells stimulated by a previous injection of C. 
parvum 
Effector cells: 
Peritoneal cells from mice 









11 3.467 ± 2.977"· d 
112,983 ± 1.082d 
4.085 ± 842• 
2,587 ± 342• 
• Results expressed as (3H) thymidine incorporation cpm/ culture. 
Incorporation by peritoneal cells alone was insignificant 
b CY. 200 mg/kg IP 
< CP, C. pa111um 350 ~tg IV 
d . • Results not significantly different from similarly designated re-
sults 
0340-7004/ 79/ 0006/0 113/S 01.40 
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cells in vitro. CP-activated cells were markedly inhibi-
tory, whereas inhibition after CY alone was slight and 
inconsistent. The inhibitory activity of CP-activated 
cells was undiminished following CY treatment. 
CY Sensitivity of CP-Mediated Specific Antitumour 
Immunity 
As described in the previous paper (Scott, 1979), the SC 
injection of CP mixed with irradiated tumour cells gen-
erates specific cell mediated antitumour immunity, 
which is detectable in a Winn assay performed with cells 
from the lymph node draining the injection site. To de-
termine the CY sensitivity of this immunity, mice were 
immunised SC in both hind footpads with 3.5 ,_,.,g CP 
mixed with 5 x 105 irradiated M4 tumour cells. Differ-
ent groups of these mice then received CY IP I, 4, 8, 15, 
or 22 days later, and the activities of the various popli-
teal lymph node cell populations were determined in a 
Winn assay 4 days after CY. For each time point the 
appropriate nonimmunised and immunised non-CY-
treated controls were included; the results are set out in 
Table 2. CY 1 and 4 days after immunisation com-
pletely abolished immunity, but by day 8 immunity was 
becoming CY-resistant and it was completely so at 
days 15 and 22. 
Recovery of CP-Mediated Specific Antitumour 
Immunity from the Inhibitory Effects of CY 
Although, as described above (Table 2), CY given 
4 days after immunisation abolished immunity in the 
draining lymph node 4 days later, this was demonstrated 
to have recovered fully 12 days later (Table 3). 
Optimal Timing for CY after IV CP Therapy 
Mice were injected with 106 live M4 cells SC into a hind 
footpad and 2 days later received 350 1-lg CP IV or were 
untreated. Groups of six mice, both CP-treated and con-
trol, received CY IP or no treatment I, 4, 8, 12, or 
18 days later. The size of the M4 tumour growing in the 
footpad was monitored throughout (Fig. la- d). CP IV 
at day +2 (tumour established day 0) caused a charac-
teristic temporary inhibition of tumour growth (Scott, 
1979). Inhibition of tumour growth by CY at day +6 in 
non-CP-treated mice was similar to the effects of CP at 
day + 2, and the combination of the two was apparently 
additive (Fig. l a). (The results with CY I day after CP 
were similar; the data have not been included.) CY at 
day + 10 in non-CP-treated mice caused no detectable 
inhibition of tumour growth and when it was given in 
M. T. Scott: C. pan>U/11-Cyclophosphamidc Tumour Treatment 
Table 2. CY sensitivity of specific antitumour immunity resulting 
from SC injection of C. parvwn-treated tumour cell mixtures 
Treatment Proportion of Winn assay 
mice tumour-free 
lmm• day 0 8/8 } 
lmm day 0 CYb day + I 0/ 8 assay day + 5 
0/ 8 
lmm day 0 8/ 8 } 
lmm day 0 CY day + 4 0/ 8 assay day +8 
0/ 8 . 
lmm day 0 7/ 8 } 
lmm day 0 CY day + 8 5/ 8 assay day + 12 
0/ 8 
Imm day 0 6/ 8 } 
lmm day 0 CY day + 15 8/ 8 assay day + 19 
0/ 8 
lmm day 0 
5/ 8} lmm day 0 CY day +22 8/ 8 assay day +26 
0/8 
• Tmm, SC injection of 3.5 ftg C. parvum mixed with 5 x 10s irra-
diated M4 cells 
b CY, 200 mg/kg IP 
Table 3. Recovery of C. parvwn-mediated specific antitumour 
immunity from the inhibitory effects of CY 
Effector cells: Winn assay 
Popliteal lymph node cells at days: 
from mice treated at days 
0 + 4 + 8 + 16 
Immb 0/8" 0/8" 
lmm eye 8/8 0/ 8 
CY 8/8 8/8 
8/8 8/ 8 
• Results expressed as proportion of mice developing tumours 
b Imm. SC injection of 3.5 ~-!& C. parvum mixed with 5 x 10s irra-
diated M4 cells 
c CY, 200 mg/kg IP 
combination with CP no added effect was apparent 
(Fig. I b). CY alone at day + 14 was ineffective; how-
ever, a slight, but significant, effect occurred in CP-pre-
treated mice (Fig. I c). CY alone at day +20 was ineffec-
tive, but when it was given in combination with CP at 
this point a marked inhibition of tumour growth oc-
curred, with two complete regressions in the group of six 
mice (Fig. ld). In repeat experiments the results were 
similar, the most potent antitumour effects and the only 
complete regressions (accumulated total 38.9 ± 5,6%) 
occurring when CY was given 15- 18 days after IV 
CP. 
M. T. Scott: C. parvum-Cyclophosphamide Tumour Treatment 
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Fig. la- d. Optimal timing for CY after IV C. parvum therapy: M4 
tumours were established in mice at day 0. At day +2 they received 
IV C. parvwn (CP) or no treatment (controls). The two groups then 
received CY or no further treatment at days + 6 (i.e., 4 days after 
C P) (a), + I 0 (i .e., 18 days after CP) (b), + 14 (i.e., 12 days after C P) 
(c), or +20 (i.e. , 18 days after CP) (d) . .-. CP: • - • . CP 
followed by CY; • ---• , CY; A ---A. controls 
Optimal Timing for Melphalan after IV CP Therapy 
For reasons discussed later, the experiments were re-
peated with another alkylating agent, melphalan, instead 
of CY. Melphalan was injected IP in a dose of 10 mg/kg 
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Fig. 2a- d. Optimal timing for melphalan after IV C. parvwn: M4 
tumours were established in mice at day 0. At day + 2 they received 
IV CP or no treatment (controls). The two groups then received 
melphalan (Melph) or no further treatment at days + 6 (i.e., 4 days 
after C. parvum) (a), + 10 (i.e., 8 days after CP) (b), + 14 (i.e .. 12 
days after CP) (c), or +20 (i.e., 18 days after CP) (d). e-e, CP; 
-.. CP followed by Melph: • ---• . Melph: A ---A , con-
trols 
alone at day +6 (tumour day 0, CP IV day +2) caused 
a temporary inhibition of tumour growth similar to that 
caused by CY (cf. Fig. I a). The combined effects of CP 
and melphalan were also additive (Fig. 2a). Melphalan 
alone at day + 10 was ineffective, and no additive effects 
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Fig. Ja and b. M4 tumours were established in mice at day 0. At day 
+ 2 they received IV CP or no treatment (control). At day + 6 control 
and CP-treated mice were either not treated or given CY. 50 mg/kg 
IP (a) or Melph Smg/ kg IP (b). e-e CP followed by CY (a) or 
Melph (b); e ---e , CP; x- x CY (a) or Melph (b); x --- x, 
controls 
phalan alone at day + 14 was ineffective, but in CP-
treated mice a marked inhibition of tumour growth oc-
curred. This inhibition was, however, temporary and all 
tumours regrew (Fig. 2c). Melphalan alone at day +20 
was ineffective, but in CP-treated mice its strongest anti-
tumour effects (decrease in tumour size) were recorded 
at this time (Fig. 2d). All tumours eventually regrew, but 
in a repeat experiment one of six regressed completely in 
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Fig. 4. Failure of active specific CP therapy to potentiate the effects 
of CY: M4 tumours were established in mice at day 0. At day +2 
they were immuniscd by a single SC injection of 3.5 J.Lg CP mixed 
with 5 x 105 irradiated M4 cells (Imm) or received no treatment 
(control). Control and immunised mice then received CY or no fur-
ther treatment at days + 6 (i.e., 4 days after Imm) (a) or + 20 (i .e., 18 
days after lmm) (b). e-e Imm followed by CY: • ---e . lmm: 
x- x, CY: x --- x, controls 
Potentiation of Subeflective CY and Melphalan Doses 
by IV CP Pretreatment 
Low doses of CY ( < 50 mg/kg) caused no measurable 
inhibition of tumour growth in the M4 model, but such 
doses were effective following IV CP. As seen in Fig. 3a, 
tumours were established by SC injection of 106 live M4 
cells in the hind footpad , and 2 days later 350 1-Lg CP 
was injected IV. Four days after CP, 50 mg CY/ kg was 
injected IP. Control mice either received CP or CY 
M. T. Scott: C. parvwn-Cyclophosphamide Tumour Treatment 
Table 4. Increased susceptibility to the toxic effects of CY on mice 
pre-treated with IV C. parvum 
Cyclophosphamide C. parvum pretreated (350 1-Lg IV) 
day 0 lP 














alone, or were untreated. Similar results were obtained 
with 25 mg CY/kg. Fig. 3b shows the same experimen-
tal protocol but with a subeffective dose of melphalan (5 
mg/kg i.e., only half the effective dose; see Fig. 2) in-
stead of CY. No CP-mediated potentiation was ob-
served. 
Failure of Specific Immunization 
with CP-Irradiated Tumour Cell Mixtures 
to Potentiate the Effects of CY 
Experiments identical in design with those shown in 
Fig. 1 except that specific active immunotherapy (SC 
injection of 3.5 1-Lg CP mixed with 5 x 1 os irradiated M4 
cells) was substituted for IV CP were performed. No 
additive or synergistic1 antitumour effects were obtained 
when this form of CP therapy preceded CY by 1, 4, 8, 
12, or 18 days. The data for the 4- and 18-day time 
intervals are shown in Figs. 4a and b. With the 4-day 
interval the individual antitumour effects of immunisa-
tion and CY were not even additive. 
Increased Susceptibility to the Toxic Effects 
of CY following IV CP Pretreatment 
One, 4, 10, and 21 days after 350 1-Lg CP IV, groups of 
mice were given either 300 or 400 mg/kg CY IP 
(Table 4). Increased sensitivity to CY was apparent be-
tween I and 10 days after CP, peaking at lO days. Be-
tween 14 and 21 days it returned to normal. 
Discussion 
The predominant antitumour activity following systemic 
injection of CP is considered to be immunologically 
I The terms synergistic/ synergism have been used in this paper to 
describe (a) situation(s) where the antitumour effects of a combina-
tion of two treatments are apparently greater than the sum of each 
treatment alone. The complexities of a true definition of synergism 
have been critically reviewed by Berenbaum, Clio. Exp. lmmunol. 
28, I (1977) 
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nonspecific and effected by CP-activated macrophages, 
whereas after local interaction of CP with tumour anti-
gen (e.g., SC injection of CP-mediated tumour cell mix-
tures) tumour destruction is mediated by specific T lym-
phocytes (reviewed in Milas and Scott, 1978; Scott, 
1978). The preceding paper (Scott, 1979) has described 
how both these forms of CP therapy may be given after 
CY in the treatment of a mouse solid fibrosarcoma to 
achieve additive and even synergistic antitumour effects. 
In the present study the reverse situation, where CP pre-
ceded CY in the treatment of the same tumour, has been 
analysed. 
CY given 4 days after IV CP did not modify the 
nonspecific tumour inhibitory activity of peritoneal ma-
crophages, whereas the specific cell-mediated immunity 
expressed in the draining lymph node following SC in-
jection of CP-irradiated tumour cell mixtures was abol-
ished. CP-mediated specific antitumour immunity was 
CY -sensitive until about 8 days after immunisation, 
after which it became CY -resistant. These kinetics most 
probably reflect the transition of the lymphocytes ex-
pressing specific tumour immunity from a proliferating 
to a nonproliferating population. Using a different 
mouse model, Tuttle and North (1976) similarly found 
that 7 days after local injection of CP mixed with live 
tumour cells, the specific T ceU-mediated immunity ex-
pressed in the draining lymph node was sensitive to the 
antimitotic drug vinblastine sulphate. The abolition of 
tumour-specific immunity by CY given 4 days after im-
munisation was not permanent, and the immunity had 
spontaneously and fully recovered by 12 days after CY. 
This may be attributed to the recovery of a residual 
population of specific immune cells, or a restimulation 
resulting from persisting CP and tumour antigen, as dis-
cussed in the preceding paper (Scott, 1979). 
Potentiated antitumour effects were obtained when 
the M4 solid fibrosarcoma was treated with IV CP fol-
lowed by CY. The appearance of these effects was bi-
phasic, occurring when CY was given 1 or 4 days and 
15-18 days after CP. During the early period tumours 
were sufficiently small to be measurably affected by the 
usual high dose of CY, and the effects of CP and CY 
were apparently additive. However, the fact that low, 
subeffective doses of CY were effective after CP allows 
the CP-CY interaction to be defined operationally as 
synergistic. This also applies to the later period, when 
the larger tumours were apparently unaffected by high-
dose CY. Here the effect was not just due to the smaller 
tumours in CP-treated mice being susceptible to CY, 
since tumours of similar size in non-CP-treated mice 
were too large to be measurably affected by CY (cf. 
Fig. lc and ld). 
To investigate a possible basis for these CY-CP in-
teractions, the drug melphalan was substituted for CY. 
There are data showing that C P pretreatment of mice 
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with systemic CP inhibits the microsomal enzyme activ-
ity of the liver (Macnee and Nimmo-Smith, 1978; Soyka 
et al., 1976). CY requires microsomal enzyme activation 
to effect its antitumour activity, and its metabolism has 
been shown to be modified by systemic CP pretreatment 
(Fisher et al., 1976b), suggesting a basis for the observed 
potentiation effects. Melphalan is an alkylating agent 
that has an inhibitory effect on M4 similar to that of CY 
but is intrinsically active, i.e., does not require liver acti-
vation. The biphasic nature of the combined antitumour 
effects when melphalan followed IV CP resembled those 
seen with CY. Unlike the situation with CY, however, 
during the early phase the combined effects of CP and 
melphalan were not synergistic, but only additive, since 
IV CP did not allow the use of subeffective doses of 
melphalan. This suggests that a CP-mediated modifica-
tion of liver enzyme activation of CY may contribute to 
the observed potentiation of CY given shortly after IV 
CP. With regard to the observed difference between mel-
phalan and CY, it is interesting that in the treatment of a 
mouse solid mammary carcinoma with repeated combi-
nations of either CY or melphalan 3 days after systemic 
CP, Fisher et al. (l976a) reported significantly greater 
antitumour effects with CY. 
In the present study, with the longer time interval 
between IV CP and drug treatment, the effects of both 
CY and melphalan were similarly potentiated, suggest-
ing that a non-drug-specific mechanism was operating. 
An hypothesis under experimental consideration is that 
drug-mediated damage to the tumour, particularly the 
necrosis and ensuing inflammation, whilst themselves in-
sufficient to produce an observable decrease in tumour 
size, may serve to focus antitumour-active macrophages 
concentrating their activity at the tumour site. Certainly 
the biphasic occurrence of the IV CP-mediated potentia-
tion of the antitumour activity of CY is in keeping with 
different mechanisms operating during the different peri-
ods. 
No potentiated antitumour effects occurred when 
specific active immunotherapy with SC injection of CP-
mediated tumour cell mixtures preceded CY by I, 4, 8, 
12, or 18 days. The early stages of the development of 
specific tumour immunity have been shown to be inhib-
ited by CY, and this would account for the fact that 
during this period the antitumour effects of immunisa-
tion and CY were not even additive. With a longer CP-
CY interval, however, the generation of specific immu-
nity was resistant to CY but there were stiU no poten-
tiated antitumour effects resulting from combined treat-
ment. Differences between the characteristics of the an-
titumour activity resulting from systemic and local CP 
therapy have been detailed elsewhere (Milas and Scott, 
1978; Scott, 1978) and the in vivo interaction with CY 
may now be added to these. 
The strongest antitumour activity, with an accumu-
M. T. Scott: C. parvum-Cyclophosphamide Tumour Treatment 
lated total of 38.9% complete regression, occurred when 
CY was given 15- 18 days after IV CP. The previous 
study showed that when CY preceded CP the time inter-
val for optimal therapy was only 4 days (Scott, 1979), 
and these differences should be a consideration in the 
design of clinical chemo-immunotherapy protocols 
where the two agents are likely to be administered 
asynchronously and repeatedly, i.e., involving both 
chemo-immunotherapy and immuno-chemotherapy in-
tervals. 
Clinical findings have suggested that CP may reduce 
drug toxicity (Israel and Edelstein, 1975), but here mor-
tality resulting from very high doses of CY was in-
creased by CP pretreatment. It may be significant that 
the optimal CP-CY interval for tumour therapy did not 
coincide with this period of increased CY sensitivity. 
Systemic CP has also been reported to increase the sus-
ceptibility of mice to a range of other cancer chemother-
apy agents - 5-FU, melphalan, and methotrexate 
(Fisher et al., 1976a; Foster, 1978). 
In addition to alkylating agents, additive or synergis-
tic antitumour effects have been demonstrated when CP 
has been combined with nonalkylating antitumour drugs 
(Fisher et al., 1976a; Hattori and Yamagata, 1977; Tag-
liabue et al., 1977) and it will be interesting to see wheth-
er similar principles will apply to these combinations as 
have been described here for CP combined with CY. 
Acknowledgemems: The author thanks Mr. I. Jaundrell-Thompson 
for excellent technical assistance throughout the study and the art-
work contained in the paper. 
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Corynebacterium parvum as an Immunotherapeutic Anticancer Agent 
Martin T. Scott 
I MMUNOLOGIC INTEREST in the gram-posi-tive anaerobe Corynebacterium parvum was 
aroused following the demonstration of its re-
markable stimulatory effect on the reticuloendo-
thelial system when administered as a killed 
vaccine.' Subsequent work describing its antitumor 
properties in animals has led to the current clinical 
interest in the organism as a potential anticancer 
agent in humans. This article reviews the accumu-
lating data on animal tumor therapy and also the 
preliminary clinical studies. An intelligent appraisal 
of the anti tumor properties of C. parvum, how-
ever, first requires some review of its stimulatory 
effects reported in nontumor systems, and these 
are discussed first. 
EXPERIMENTAL PROPERTIES 
Macrophage Activation 
Following i.v. injection of killed C. parvum, the 
organisms are taken up by the cells of the 
reticuloendothelial system, resulting in a prolonged 
hyperphagocytic response due to the emergence of 
large numbers of highly activated macrophages. 1 
Manifestations of this stimulation are spleno-
megaly, hepatomegaly, increased lung weight, and 
augmented clearance of particulate matter from 
the bloodstream. 1- 4 Macrophages activated by C. 
parvum respond in a manner similar to those 
activated by other means (see below) in that they 
show accelerated adherence to glass, vacuolation, 
and increased lysosomal enzyme activity.6 •7 The 
augmented (Jhagocytic capability and lysosomal 
enzyme content contribute to their increased bac-
tericidal capacity, which has been demonstrated in 
vitro,8 and it is this nonspecific mechanism that is 
most probably responsible for the resistance against 
various bacterial and protozoal infections in 
vivo.9,IO 
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Humoral Immunity 
C. parvum has been shown to be an adjuvant in 
the classical sense that it boosts antibody response 
to a variety of antigens. 11 - 18 Both IgM and IgG 
antibody levels are augmented, 18 and relative 
binding affinities are enhanced. 11 • 16 A change in 
the class of antibody following C. parvum, the 
production of lgE, has been reported;19 but 
interestingly the only strain of C. parvum to do 
this was inactive as a reticuloendothelial stimulant. 
Many commonly used adjuvants, e .g., Freund's 
complete adjuvant and Borde tel/a pertussis, require 
thymus-processed lymphocytes (T cells) to effect 
their activity,20- 23 whereas C. parvum is capable 
of boosting antibody levels to T-cell-independent 
antigens. 15• 17•18 Investigations into the cellular 
basis for the adjuvant effects of C. panntm 15 •18 and 
other adjuvants24 indicate that it is the activated 
macrophage that provides the added proliferative 
stimulus to the antigen-sensitive, and, ultimately, 
antibody-producing, B lymphocyte. A further role 
for macrophages activated by C. parvwn and other 
adjuvants is considered to be that they cause 
chronic retention of lymphocytes within lymphoid 
organs, thereby facil.itating extended contact be-
tween the antigen-charged phagocytes and lympho-
cytes, effectively magnifying the antigenic stimu-
lus.25 ,26 
Cellular Immunity 
Systemic injection of C. parvum has been shown 
to depress various T-cell-mediated immune phe-
nomena. Thus far, delayed hypersensitivity ,1°·27- 30 
phytohemagglutinin (PHA), mixed lymphocyte, 
graft-vs.-host,3 1 and homograft32 reactivities have 
been reported impaired. An immunosuppressive 
effect on Trichinella spiralis infection has also been 
attributed to depression of T-cell immunity by 
C. parvum. 33 Since antitumor immunity is recog-
nized as being predominantly cell-mediated, the 
finding ofT-cell depression by an antitumor agent 
seems anomalous and deserves consideration. In-
sight into a possible underlying cellular mechanism 
and yet another role for the C. parvum-activated 
macrophage came from in vitro studies of the 
T-lymphocyte response to the mitogen PHA.34 It 




lated animals were refractory to stimulation with 
PHA; however, after removal of macrophages the 
T lymphocytes were again fully responsive. 
The conclusion was that T-cell activity was 
being inhibited by C. parvum-activated splenic 
macrophages. In contrast, cells from lymph node 
that had been directly stimulated with local injec-
tions of C. parvum were still capable of responding 
to optimal amounts of PHA,34 indicating that T-
cell inhibition does not occur in the lymph node. 
These findings have their parallel in some recent in 
vivo work describing depression of delayed-type 
hypersensitivity (DTH) by pretreatment with C. 
parvum. 30 DTH resulting from a subcutaneous in-
jection of sheep red blood cells was only depressed 
by C. parvum pretreatment if the C. parvum was 
injected intravenously (i.e., stimulating the spleen); 
subcutaneous C. parvum (stimulating the lymph 
nodes) was without effect even when injected into 
the same region as the subsequent injection of 
sheep red blood cells. The apparently unique role 
of the C. panntm-stimulated spleen in mediating 
the depression phenomenon was confirmed by 
splenectomy experiments, the mechanism being 
interpreted as being attributable to an effective 
depletion of DTH-reactive T cells due to their 
sequestration and possible destruction in the C. 
parvum-stimulated spleen.30 The apparent non-
involvement of the lymph node in depression of 
cell-mediated immunity is important to the con-
sideration of C. parvum as an antitumor agent, 
since strategic local injections of C. parvum will 
be described to be effective in tumor therapy. 
Another relevant finding was that systemic C 
parvum needed to precede antigen sensitization to 
effect its DTH-depressive activity, 30 and since 
treatment of established tumors means that sensi-
tization with tumor antigens must in large part 
precede C. parvum, some depression of cell-
mediated immunity may thereby be circumvented. 
While it is not the intent of this section to be 
comprehensive, some other effects reported for 
C. parvum are listed: protection against viral 
infection35 and graft-vs.-host disease,36 induction 
of autoimmunity evidenced by hemolytic 
anemia,37- 39 fetal resorption,40 an increased 
sensitivity to endotoxin43 and histamine.44 
Species of Corynebacteria 
The antitumor and other effects of several 
species of anaerobic corynebacteria other than C. 
parvum appear in the literature. Two things should 
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be borne in mind: first, the taxonomy of the 
corynebacteria remains a matter of considerable 
controversy;3 •4 5- 4 7 second, several species have 
been demonstrated to stimulate the reticuloendo-
thelial system to greater or lesser degrees, while 
others are inactive.3 •4 •48 The two strains figuring 
most prominently in current tumor work are C. 
parvum and C. granulosum, and these are appar-
antly similar in their reticuloendothelial-stimulating 
and antitumor effects. There are specific refer-
ences comparing the antitumor activities of dif-
ferent strains.12 •35 •48 •49 
ANIMAL TUMOR THERAPY STUDIES 
The purpose of Table I is to provide a source of 
references as to where C. parvum has been used, 
and under what circumstances in the various ani-
mal tumor models to date. Until recently the ma-
jority of animal investigators have restricted them-
selves to prophylaxis with C parvum, i.e., 
stimulation of the animal prior to tumor challenge, 
or they have taken only a relatively cursory look 
at therapy situations. Prophylactic models have 
been invaluable in elucidating the possible modes 
of antitumor action of C. parvum; however, this 
review restricts consideration of the animal data 
primarily to therapy models using either syngeneic 
or semisyngeneic tumors. 
Therapy Using Systemic C. parvum 
The first demonstration that a systemic injection 
of C parvum was effective against an established 
syngeneic tumor was in 1966 by Woodruff and 
Boak.50 They demonstrated delayed appearance of 
a subcutaneously injected spontaneous mammary 
adenocarcinoma by a single i.v. injection of C. 
parvum 8 or 12 days after tumor injection. Once 
the tumor became palpable, however, the subse-
quent growth rate was unaffected. 50 Later studies 
by the same group showed that a single i.p. injec-
tion of C. parvwn 3 days after tumor establishment 
inhibited the actual growth of the same adenocar-
cinoma and two unrelated methylcholanthrene-
induced sarcomata,5 1 and also that the vaccine 
was equally effective in T-cell-deprived mice.48 •52 
Another spontaneous mammary carcinoma, grow-
ing as a solid tumor, was inhibited by biweekly 
i.p. injections commencing either at the time of 
tumor injection 53 or 14 days after tumor estab-
lishment. 54 Studies in this laboratory have shown 
a marked but transitory inhibition of growth of 
a solid mastocytoma (P-815) in the mouse foot-
Table 1. References to the Various Uses of C. parvum in Animal Models 
Prophylaxis Therapyt 
Tumor Designation Host • Systemic Local Systemic Local 
Mammary carcinoma A·stra in (s) 50,49,69 69 50,69,51, 
48,52 
Mammary carcinoma C3H/ He (s) 57 :t 
Mammary carcinoma DBA/ 2 (s) 53,54 
Sarcoma (methylcholanthrenel CBA X A (s) 50 
Sarcoma (methylcholanthrene) C57BL/ 6J (s) 59 59 
Sarcoma (methylcholanthrene) CBA (s) 51,48 60 
Sarcoma ( methylcholanthrene) A/ HeJ (s) 51,48 
Sarcoma ( methylcholanthrene) C57BL (s) 62 62 
Sarcoma (methylcholanthrene) C3H (sl 57 :t.67 57:t 57 :t 
Sarcoma (meth A) BALB/c (s) 73 
Sarcoma J Allogeneic mice 84 84,35 
CBAT-3 Fibrosarcoma CBA (s) 80 
ICIGCI 1 (dimethylbenzanthracene) DBA/ 2 X C57BU6 (ss) 12:t 12:t 
Leukemia AKR AKA (s) or F 1 (ss) 58,74 58 
Leukemia L-121 0 C57Bll6 X DBA/ 2 (ss) 12:t 12t 56 
Leukemia Moloney CD F1 64 :t 
Leukemia YC8 BALB/c (sl 85 
Leukemia L-5178 BALB/ c X DBA/ 2 (ss) 80 
Leukemia Rl (radiation) DBA (s) 80 
Leukemia Ed G2 DBA/2 X C57BL(s) 66,87 65,66.87 
Leukemia (myeloblastic, chloroma) Outbred rats 53 53 
Hepatoma H-129 A llogeneic mice 80 
Hepatoma (ethioninel Hooded rats (s) 68 68 
Plasmacytoma PC6 BALB/c (s) 80 
Adenovirus-12 CBA (s) 86 
Lewis lung tumor DBA/ 2 X G57BL/6 (ss) 12t 12t: 
Melanoma- Fortner's Hamster, allogeneic 63 
Mastocytoma P-815 C57BL X DBA/ 2 (ss) 55 55 61 
Ehrlich asci tes Allogeneic mice 72 j,84 84,35 
• Refers to inbred mouse strains unless shown otherwise; s = syngeneic, ss s semisyngeneic. 
tFor the purposes of this table, treatment commenced on the same day as tumor challenge is included under therapy. 
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pad when C. parvum is given i.v. 2 days after tumor 
establishment. 55 
With regard to nonsolid tumors, failure of mul-
tiple i.p. C. parvum injections to influence the 
growth of a mouse leukemia (L-121 0) has been 
reported by Mathe.56 An i.p. injection of C. 
granulosum 2 days after i.v. injection of fibrosar-
coma cells into mice significantly reduced the 
number of metastases in the lungs and prolonged 
survival of the mice . C. granulosum 7 days after 
tumor injection did not affect lung metastases, 
although survival of the mice was still prolonged.57 
Lamensans et al. have shown that i.p. C. parvum 1 
day after i.p. AKR leukemia cells had little effect 
on the ultimate survival of mice. 58 
The systemic effects against established solid 
sarcomas can be achieved either by i.v. or i.p. in-
jection of C. parvum, 51 and the favored use of the 
i.p. route in animal studies is presumed to be be-
cause of its convenience. Doses of C. parvum em-
ployed for systemic injection into mice, whether 
single or multiple, have varied from I 00-1,000 11g 
dry weight of organisms, the most frequent dose 
being around 500 11g per injection. Toxicity in 
mice has been reported for both i.v. and i.p. 
routes of injection for extremely high doses48 and 
for more routinely used doses.55 •57•59 •60 There is 
a paucity of published data on the relative ef-
ficiency of various doses of systemic C. parvum in 
therapeutic models; the author's work using a 
mouse mastocytoma showed the maximum tumor-
inhibiting effect to be with 700 11g i.v., at which 
dose some deaths occurred due to toxicity. Lower 
doses were not toxic but were considerably less 
effective at inhibiting tumor growth. Multiple 
doses of C. parvum were no more effective than a 
single dose and considerably more toxic.55 An in-
crease in toxicity with multiple doses of C. parvum 
has been reported elsewhere ,59 as has the apparent 
lack of increased antitumor effect with multiple 
doses. 56 There is one report, however, that mul-
tiple doses were better than a single injection 
against a mammary carcinoma.5 1 
Despite the undeniable tumor suppression de-
scribed in experiments using systemic C. parvum 
therapy alone, the effects are transient, and no 
complete regressions have been recorded.* This is 
*Some complete and lasting regressions of mouse solid 
tumors following systemic C parvum or C. granulosum 
therapy have since been reported.8 8 
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in contrast to the regressions that have occurred 
after some local injections of C. parvum and C. 
parvum in combination with other forms of 
therapy discussed below. 
Therapy Using Local C. parvum 
No toxicity problems have been encountered 
following the local administration of C. parvum. t 
Injections have been either subcutaneous or intra-
dermal, neither of which results in marked sple-
nomegaly or hepatomegaly, stimulation being re-
stricted to the lymph nodes draining the sites of C. 
parvum injection. Because of this localized effect 
the relationship between the site of C. parvum in-
jection and the tumor site becomes a relevant 
consideration. 
There is a report that an intradermal injection 
of C. parvum into the flank opposite an existing 
solid fibrosarcoma caused significant depression of 
tumor growth.60 Other investigators using a mouse 
mammary adenocarcinoma54 and mastocytoma61 
found that local injection of C. parvum at sites 
distant from the tumor were only minimally effec-
tive, but when injected near to the tumor site 
(i.e., at a site likely to engage the tumor-draining 
node) marked inhibition of growth occurred. In-
terestingly, both studies suggest that local C. par-
vum injection near to the tumor site may be more 
effective than systemic injections. Significant 
growth inhibition of a solid fibrosarcoma following 
ipsilateral s.c. injections of C. parvum has also been 
reported. 59 Subcutaneous injection of C. parvum 
into the inguinal and axillary regions reduces simu-
lated pulmonary metastases resulting from i.v. in-
jection of fibrosarcoma cells, even if delayed up to 
14 days.62 In none of the cases cited have any 
complete tumor regressions been reported. 
C. parvum has also been injected directly into 
the tumor lesion itself. 53 •54 •61 •63 Preliminary ex-
periments injecting mixtures of live mouse mam-
mary carcinoma cells with C. parvum resulted in 
normal tumor growth for 14 days and then a 
rapid and complete regression. 53 Later studies 
employed a intralesional injection of C. parvum 
t While doses of C. parvum under 4 mg are well toler-
ated subcutaneously in mice, even 1.4 mg intradermally 
may cause local granulomata in man or rodents (Dept. of 
Clinical Immunology, Wellcome Research .Labs). The side 
effects from injection of2-10 mg/sq m subcutaneously in 
man have been limited to local discomfort and low grade 
fever.89 
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14 days after tumor establishment, and this caused 
rapid and lasting regressions of both the primary 
tumor and its metastases. 54 Studies in this lab-
oratory using a solid mastocytoma in mice have 
shown that an intra tumor injection of C. parvum 
up to 12 days after tumor establishment causes 
some complete regressions.61 Similarly, regression 
of primary tumors and inhibition of development 
of pulmonary metastases occurs following intra-
lesional injection of C. granulosum into established 
hamster melanomas.63 AJI mice cured by intra-
lesional injection of C. parvum thus far have been 
shown to be highly and specifically immune to 
tumor rechallenge.53•54 •61 
Doses (200-500 11g) for local injection of C. 
parvum into mice, whether single or multiple, have 
been similar to those given systemically. Studies 
with the mouse mastocytoma have shown that an 
intralesional injection of 70 11g was optimal, higher 
and lower doses resulting in fewer complete regres-
sions. 61 This reduced effectiveness of high doses 
of C. parvum may be attributable to overstimula-
tion of the draining·lymph node. 
Combination Therapy 
The combination of immunostimulation using 
corynebacteria with cytoreductive chemotherapeu-
tic agents has produced some interesting and pro· 
mising results. Currie and Bagshawe60 followed 
i.v. cyclophosphamide cytoreductive therapy with 
intradermal C. parvum injection and produced 
dramatic inhibition of growth of established solid 
fibrosarcoma with 70% lasting regressions. Neither 
cyclophosphamide nor C. parvum alone produced 
any regressions. C. parvum prior to cyclophospha-
nlide was without effect, and simultaneous ad-
ministrations were toxk. The time interval, I 2 
days, between cyclophosphamide and C. parvum 
was found to be extremely critical, 6 or 16 days 
producing no regressions. 60 In a similar tumor sys-
tem the results have been more variable , but are 
still in keeping with these findings.48 A murine 
leukemia has been successfully treated with 76% 
complete remissions using a combination of 1 ,3-bis 
(2-chloroethyl)-1-nitrosourea (BCNU) followed 3 
days later by intradermal C. granulosum. 64 Again, 
chemotherapy or C. granulosum alone was con-
siderably less effective, and the 3-day time interval 
between chemotherapy and immunotherapy was 
found to be critical. It would seem from these two 
studies that the time interval may depend on the 
particular chemotherapy employed. Simultaneous 
administration of procarbazine i.p. and C. parvum 
i.v. 10 days after injection of leukemia cells fully 
protected all mice, whereas with procarbazine 
alone there were no survivors .65 •66 
No therapy data are available on combination of 
C. parvum with radiotherapy; however, a pretreat-
ment mouse model shows that the protective ef-
fects of i.p. C. granulosum are resistant to subse-
quent low-dose (600 R) whole-body irradiation. 
Irradiation within 2 days before stimulation abro-
gated the protective effect.67 
Another therapeutic approach has been the com-
bination of immunostimulation with specific active 
immuni.zation against the tumor using inactivated 
tumor cells. Biweekly systemic injections of heat-
or formal-killed tumor cells plus C. parvum were 
found to be no more effective at inhibiting an on-
going solid mammary adenocarcinoma than were 
i.p. C. parvum injections alone.53 Woodruff and 
Dunbar found that simultaneous subcutaneous in-
jection of irradiated neuraminidase-treated tumor 
cells and i.p. C. parvum may cause a more pro-
longed remission than either treatment alone.48 
The author's current studies (in preparation) using 
a mouse mastocytoma model show that s.c. injec-
tion of irradiated tumor cells mixed with C. par-
vum confers strong specific immunity against both 
subcutaneous and i.v. tumor challenge. This im-
munity is also detectable as transient tumor growth 
inhibition in a therapy model. 
The combination of surgical excision of the pri· 
mary tumor and eitJ1er C. parvum or C. parvum 
plus irradiated tumor cells has been studied using 
a rat hepatoma model.68 It was found that im-
munization with a combination of intradermal 
and i.p. C. parvum prior to excision of the primary 
tumor had no effect on the subsequent develop-
ment of lung metastases. Mixtures of C. parvum 
and irradiated cells had an overall therapeutic 
effect, reversing the facilitating e ffect found with 
irradiated cells alone. lf therapy was delayed until 
after excision of the primary tumor, C. parvum 
alone, as well as in combination with irradiated 
cells, reduced both the incidence and number of 
lung metastases. 
A synergistic antitumor effect between C. par-
vum stimulation and tumor cells that had been pre-
incubated in vitro with heterospecific antitumor 
globulin has been described ;5 1 •6 9 however, the 
failure to demonstrate any e ffec t in vivo5 1 would 
seem to eliminate this approach. 
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CLINICAL DATA 
Few definitive clinical data concerning C. par-
vwn have been published. Reports thus far deal 
only with lhe use of C. parvum in simultaneous 
combination with chemotherapy. 70 •71 Clinical 
trials began in France under Professor Israel in 
1967 with a study of patients with advanced 
metastatic visceral cancers. Because of possible 
adverse effects of C. parvum, it was decided not to 
treat good-risk patients .1or to refuse poor-risk 
patients the possible benefits of chemotherapy. 
One group of patients received chemotherapy given 
as a mixture of Cytoxan ( 15 mg/kg), 5-fluorouracil 
(IS mg/kg), methotrexate (0.5 mg/kg) vinblastine 
(0.1 mg/kg), and rufocromomycin (0.003 mg/kg) 
twice a month. A second group received the same 
chemotherapy but in addition received a sub-
cutaneous injection of I ml C. parvum (2 mg) in 
each arm once a week. To counteract local pain at 
the injection site, the C. parvum was mixed with 
either 2% xylocaine 70 or I% lignocaine. 71 In both 
groups therapy was continued throughout the life-
time of the patient, except for discontinuation of 
chemotherapy during periods of low white cell or 
platelet counts. Subcutaneous C. parvum is ap· 
paren tly tolerated well without allergic reactions, 
many patients having now received weekly injec-
tions for more than 3 yr without adverse effects. 
Local pain and swelling are occasionally encoun-
tered, and thermic reactions up to 39°C with 
chills lasting many hours are reported to have 
occurred. 71 
In the trials the only parameters compared be-
tween the groups were survival times from the be-
ginning of treatment. A preliminary report70 shows 
that of 141 patients with various metastatic visceral 
cancers divided into two randomized groups, those 
treated with chemotherapy alone survived a sig-
nificantly shorter time (mean survival time = 6.1 
mo) than those receiving combination therapy 
(I 0.5 mo). Similar data were later presented for 
various subgroups of human cancers-71 The mean 
survival times of "treated" and control groups with 
disseminated carcinoma of epidermoid broncho-
genic origin were 9.8 mo and 5.6 mo respectively. 
The comparable mean survival times for oat-cell 
bronchogenic carcinoma were 9. I mo and S.O mo. 
In both cases there was also an apparent difference 
in lesion size between the two groups. Significant 
differences in survival data at 12 mo are also docu-
mented for patients with advanced lymphoid sar-
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comas and breast carcinomas. Preliminary data for 
advanced melanoma with visceral metastases show 
twice as many survivors at 12 mo if C. parvum is 
combined with the chemotherapy_71 
Patients with good cell-mediated immune status, 
as judged by positive reactivity to a range of skin· 
test antigens, responded better to C. parvum treat-
ment than did those of poor status. There was also 
an apparent overall trend of conversion to posi-
tivity during the course of C. parvum treatment.71 
This correlation of C. parvum activity with the 
patient's immune status is interesting in light of 
the idea that at least some of the antitumor effects 
of C. parvum have an immune basis. This concept 
is discussed under Modes of Antitumor Action 
below. 
Another interesting observation arising from the 
C. parvum clinical studies is that the combination 
of C. parvum with chemotherapy increases the 
hematopoietic tolerance to the chemotherapy, the 
number of chemotherapeutic interruptions due to 
low white cell or platelet counts being twice as 
great in the control groups.71 
From the animal data it is apparent that the re-
ported clinical studies have been crude in their ap-
proach, their empirical nature having been dictated 
by ethics and currently available knowledge. The 
results are encouraging in that they indicate that 
repeated local injections of C. parvum are appar-
ently well tolerated in humans and are capable of 
enhancing the therapeutic effect of chemotherapy 
against massive tumor burdens. The optimal sched-
ule and doses for such combination therapy remain 
to be determined: subsequent animal experi-
ments60•64 have stressed the critical importance of 
the timing between chemotherapy and immuno-
stimulation, and it may well be that sequential 
courses of chemotherapy and immunostimulation 
will be more advantageous than the simultaneous 
therapy described. 
MODES OF ANTITUMOR ACTION 
Nonspecific Activity 
Various results indicate that systemically ad-
ministered C. parvum may be largely nonspecific 
in its action, i.e. , not amplifying a specific anti-
tumor response. Its overall effects are not abro-
gated in T-cell-deprived mice,52•55 and are also 
resistant to antilymphocyte serum.72• 73 Any modi· 
fication of tumor immunity by C. parvum would 
be expected to be apparent following combined 
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administration of C parvum and inactivated tumor 
cells; however, injection of i.v. C parvum 1 day 
after a subcutaneous injection of irradiated masto-
cytoma cells afforded only as much protection 
against tumor challenge as did C parvum injection 
alone.55 Also, in a therapy model, biweekly in-
jections of i.p. C parvum alone have been shown 
to be as effective as similar injections of mixtures 
of C parvum with killed tumor cells. 5 3 The cumu-
lative evidence of suppression ofT-cell activity fol-
lowing systemic C. parvum seems to argue ·against 
boosted cell-mediated immunity determining in-
creased tumor resistance. That antibody may not 
be involved is suggested by the efficacy of C. par-
vum against tumors in mice selected for low anti-
body responses,74 and also by the fact that sple-
nectomy is without effect.73 
The nonspecific antitumor act ivi ty of C. parvum 
is most probably mediated by · the C. parvum-
activated macrophage. Peritoneal and lung macro-
phages from mice stimulated systemically with 
C. parvum have been shown to inhibit nonspe-
cifically the in vitro proliferation of tumor cells. 
6
•
55 Similar activity has been described for macro-
phages activated nonspecifically by other means, 
e.g., BCG or Toxoplasma infection, where the 
mechanism is apparently nonphagocytic and in-
volves the secretion of lysosomal enzymes directly 
into the cytoplasm of the target tumor cell.75 It is 
likely that the same mechanism is operative fol-
lowing C. parvum activation, and the recent find-
ings of Wilkinson et al. are therefore extremely 
interesting. They demonstrated that many strains 
of C. parvum produce a chemotactic factor that 
specifically attracts macrophages,76 and they fur-
ther implicate tllis facto r in the activation of lyso-
somal enzymes in these macrophages.7 That such 
macrophage antitumor activity is operative in vivo 
is supported by the finding that the effects of sys-
temic C. parvum pretreatment against simulated 
metastases are radioresistant- a characteristic of 
macro phages. 
Specific Activity 
In addition to the macrophage-mediated non-
specific antitumor mechanism, C. parvum is capa-
ble of boosting specific antitumor responses. The 
clinical data describing the conversion of skin-test 
reactivity in cancer patients undergoing C. parvum 
therapy 71 are indicative of augmented or restored 
cell-mediated immunity by C. parvum. In vitro 
evidence for elevated cell-mediated immunity has 
been presented by Halpern et al.35 Using a mouse 
leukemia model they report that lymph node cells 
from mice that had received an s.c. injection of 
tumor cells were only minimally cytolytic for tu-
mor cells in vitro; however, the cytolytic activity 
of lymph node cells from animals that also re-
ceived an i.p. injection of C parvum was both en-
hanced and prolonged. Current work in tllis labora-
tory (in preparation) shows that subcutaneous 
injection of C parvum mixed with irradiated mouse 
mastocytoma cells results in strong speci fie systemic 
immunity to subsequent tumor challenge at a dis-
tant site. Irradiated tumor cells or C. parvum in-
jected alone are without effect. om transfer 
studies indicate that the tumor immunity is cell-
mediated. Thus C. parvum is capable of boosting, 
or in the case of the mastocytoma apparently 
initiating, immune responses to specific tumor 
antigens. The failure of this to occu r with systemic 
C parvum treatment of solid tumors would suggest 
that development of immunity depends on the 
proximity of the tumor cells to the C. parvum. 
Current experiments, again using the mastocytoma 
model, show that the C. parvum-tumor-cell inter-
action required for immunity does not have to 
occur at the same site; it may also be mediated by 
a common draining lymph node. It might be pre-
sumed that systemic administration of C. parvum 
and tumor cells would result in a similar develop-
ment of immunity, and the in vitro experiments 
cited above35 support this presumption. But a re-
port describing that the therapeutic tumor-suppres-
sive properties of multiple i.p. injections of C. 
parvum alone were just as effective as similar in-
jections of C. parvum plus inactivated tumor 
cells53 suggests this may not always be the case. 
The antitumor effects of an intralesional injec-
tion of C. parvum are reduced i.n mice that have 
been rendered specifically unable to mount an im-
mune response to C. parvum. 6 1 It is likely that the 
antitumor activity of an intralesional C. parvum 
injection is effected by both local nonspecific 
macrophage activation and augmented speci fie tu-
mor immunity. Thus either or both of these ac-
tivities may be triggered in part by "fallout" from 
the specific immune response to C. parvum. The 
same phenomenon is known to occur with intra-
lesional injections of either BCG77•78 or Listeria 
monocytogenes, 79 and such a mechanism would 
certainly explain the better clinical performance of 
C parvum in patients with better immune 
status. 70• 71 
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CONSIDERATIONS FOR FUTURE 
IMMUNOTHERAPY 
The accumulated animal data are impressive, and 
the initial human data are encouraging for the con-
sideration of C. parvum as a potential clinical 
therapeutic anticancer agent. Its ultimate evalua-
tion must await the results of the increasing num-
ber of clinical investigations that are now either 
underway or porposed. In this final section I shall 
venture to consider some of the clinical implica-
tions of the available data. 
As with any form of immunotherapy, the effects 
of C. parvum are likely to be more pronounced 
against minimal amounts of tumor. Clinically these 
situations are currently represented by reasonably 
good-risk patients with minimal residual disease 
achieved by previous surgical therapy, radiother-
apy, or chemotherapy. These ·cases would not re-
quire the continuous maintenance therapy typical 
of advanced cancers, and thus the effects of C. par-
vum would be more readily evaluated. Considering 
our current knowledge of the mode of action of 
C. parvum, it is not only the reduced tumor load 
that may contribute to an expected increased ef-
fectiveness of C. parvum in such cases. The later 
stages of cancer are often accompanied by a re-
duced competence of the patient's immune system, 
and it is presumably the nonspecific component of 
C. parvum that is primarily effective in such cases. 
Other components of the antitumor activity of 
C. parvum involves immunity to both C. parvum 
and the tumor, and these would be expected to be 
facilitated by a maximum degree of patient im-
munocompetence. 
Various negative considerations concerning the 
injection of C. parvum systemically have accumu-
lated from the animal data. Toxicity in animals has 
been encountered, especially with the high doses 
that seem to be required to e.ffect maximum anti-
tumor activity against solid tumors. If, as indi-
cated, specific antitumor immunity may not result 
from the use of systemic C. parvum injections 
against solid tumors, this might prove to be critical 
in cases of possible "escapes" following only par-
tially successful treatment. Relatively little is 
known, however, about the effects of systemic 
C. parvum in therapy situations against "systemic" 
tumors, e.g., leukemias. Also, i.v. C. parvum would 
be expected to localize in the liver and lungs and 
may prove to be highly effective against tumors or 
metastases in these organs and result in systemic 
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immunity. One further consideration is that the 
phenomenon of depressed cell-mediated immunity 
following C. parvum may be peculiar to the sys-
temic route of injection.30 
Local injection of C. parvum, subcutaneous or 
intradermal, is not toxic and may be highly effec-
tive if used strategically. A situation in which it 
may be expected to have a pronounced effect is 
when injected directly into the tumor lesion, as for 
example with cutaneous neoplasms and other 
readily accessible lesions. It should be noted that 
too high a dose of C. parvum may "overstimulate" 
draining lymph nodes and impair their efficiency. 61 
If intralesional injection is not practical, the in-
jection as near to the lesion as is practical ( cer-
tainly, if possible , engaging the tumor-draining 
lymph node) should be advantageous. In the case 
of widely disseminated disease, it follows that in· 
jections of C. parvum at many different sites, 
rather than restricting C. parvum to a single site, 
may be more effective. If conditions necessitate a 
local injection of C. parvum at <1 site distant from 
the tumor, then a case is made for mixing in· 
activated tumor cells with C. parvum. This would 
seem at least to assure the augmentation or de-
velopment of systemic antitumor immunity. Any 
such procedure that augments the immune re-
sponse to tumor antigens is open to the risk of 
selectively boosting the "wrong" component of the 
response, in this case blocking antibodies. On this 
point, thus far, the author is unaware of any pub-
lished reports of enhanced tumor growth following 
therapy with either C. parvum alone or C. parvum 
combined with either inactivated tumor cells or 
chemotherapy. C. parvwn in combination with 
irradiated rat tumor cells is reported to reverse the 
facilitating effect that large doses of irradiated 
tumor cells alone have on tumor growth.68 A 
report that in a pretreatment model i.v. C. parvum 
prior to i.p. injection of irradiated leukemia cells 
compromized the protective effect of irradiated 
cells alone is not compatible with blocking anti-
body,80 but is in keeping with the depression of 
cell-mediated immunity known to result from i.v. 
C. parvum prior to antigen,30 as discussed above. 
These results are encouraging, but the possibility 
of tumor enhancement under certain conditions 
cannot be ruled out. 
The importance of timing in any therapeutic ap-
proach involving combination of C. parvum and 
chemotherapy has been stressed and elaborated 
upon in both the animal- and clinical-data sections. 
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A point from the animal data that deserves reitera-
tion is that these parameters may well be different 
for different cytostatic agents. Mathe "has reported 
that in both animals and humans the intensity of 
chemotherapy, whe ther administered as mainten-
ance or preimmunotherapy, influences the effect 
of subsequent immunotherapy.81 Animal and hu-
man data concur, however, that chemotherapy is 
certainly not incompatible with immunostimula-
tion using C. parvum, and given the right conditions 
the two antitumor effects may synergize. No simi-
lar data are available for combination of irradiation 
with C. parvum in therapy situations. The effects 
of systemic C. parvum in mice are resistant to the 
effects of whole-body low-dose irradiation (600 
rads), but irradiation shortly before C. parvum 
administration abrogated its effect.67 This latter 
phenomenon may be expected to fade if C. parvum 
administration is delayed sufficiently, and the 
situation may even be analogous to that described 
for combination with chemotherapy where a criti-
cal time interval for potentiation of the C. parvum 
effect exists. Tt has been reasoned that the effects 
of systemic C. parvum may be largely nonspecific 
and macrophage-mediated, in which case the radio-
resistance of the C. parvum effect is not surprising. 
That certain administrations of C. parvum do in-
volve specific antitumor immune responses com-
plicates the picture, since these would be expected 
to be relatively sensitive to subsequent whole-body 
irradiation. 
Attention to the use or" bacterial vaccines as non-
specific stimulants in cancer therapy has been 
largely focused on BCG, with a resultant relative 
wealth of experimen tal and clinical data. I t is ap-
parent that BCG and C. parvum may be similar 
with respect to their modes of antitumor activity. 
Macrophages activated by either vaccine demon· 
strate nonspecific antitumor activity in vitro; in 
addition, in vivo antitumor effects of both ap-
parently result in part from the "fallout " from an 
immune response to the organisms themselves. 
Again, augmentation o f specific antitumor immune 
responses is common to the ways in which their 
antitumor activities are effected. There is a practi-
cal difference between the two organisms ; whereas 
C. parvum is fully effective when administered in 
the form of a killed vaccine, killed BCG is ap ·· 
parently ineffective.77 The requirement for live 
BCG subjects it to variability arising from loss of 
viability during storage or transportation and 
further allows only a retrospective knowledge of 
the actual dose administered. C. parvum is readily 
administered in standard doses with no such prob-
lems of deterioration and, more important, no dan-
ger of any resulting systemic infection. These prac-
tical advantages of C. parvum are only relevant 
should the two vaccines prove to be equally effec-
tive in given situations. No valid comparative data 
as to this point are available, studies thus far 
having lacked experimental compensation for dose, 
timing, and other discrepancies arising from tl1e re-
quirement of living BCG. Subject to these qualifi· 
cations, C. parvum has been described to be as 
effective as BCG in reducing rat lung metastases,68 
considerably more effective against a mouse mam-
mary carcinoma48 and hamster melanoma,63 and 
less effective against two mouse leukemias.56•66 
Comprehensive comparative studies may reveal 
differences in modes of action or patterns of ac-
tivity that are sufficient to form the basis for pos-
sible future combination therapy using both vac-
cines. 
Data are now accumulating on the antitumor 
activity of various fractions of BCG, which may be 
as effective as viable organisms.82•83 It is expected 
that material fractiona ted from C. parvum will 
become available, and i t will be interesting to see 
the relationship between the nature and activity of 
both the C. parvum and BCG antitumor fractions. 
It is evident from the animal studies that tumors 
seem to vary in their response to treatment with 
C. parvum; however, no characteristics related to 
the various susceptibilities are thus far apparent. 
One report correlated the response with the rela-
tive immunogenicity of the tumors,80 but consid-
eration of subsequent work suggests the situation 
to be more complex- some poorly immunogenic 
tumors responding well to treatment. Mathe has 
noticed that variations in the durations of remis-
sion and of survival of human leukemias induced 
by chemoimmunotherapy are related to the 
cytological variety of the leukemia.81 Stiffel et at? 
have shown that the degrees of stimulation in-
duced by both C. parvum and BCG are different 
for inbred strains of mice; thus, genetic constitu-
tion may be another intrinsic source of variability 
in any future protocol using these agents. 
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I. Introduction 
Inte rest in the bacterium Cory nebacterium parvum (CP) as an im-
munostimulant was first aroused a fte r the d emonsh·ation by Halpern 
and colleagues (1964) that injection of killed organism s into mice 
caused intense stimulation of the lymphore ticuloendothe lial system . 
This was at a time when other bio logical re ticuloendothelial stim u-
lants, e.g., zymosan (yeast cell walls) and Bacillus Ca lme tte -G uerin 
(BCG) organisms we re being found to be capable of inhibiting the 
g rowth of transp lantable tumors in mice (Oid et al. , 1960, 1961 ). CP was 
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shown to be similarly effective in 1966 (Halpern et al., 1966; WoodtUff 
and Boak, 1966), and preliminary clinical trials were initiated in 1967 
(I srael and Halpern, 1972). 
The antitumor properties of CP in animals and p re limina1y clinical 
data were reviewed by Scott in 1974 (1974d), and the amount of data, 
concerning both its mode of action in an imals and clinical experiences, 
that have accumulated during the past 2 years reflects the current level 
of inte rest in CP as a potential immunotherapeutic anticancer agent. 
Th is review considers first the immunological modifications resulting 
from CP administered in non-tumor-bearing animals. Animal tumor 
data and finally the clinical data are then considered. Throughout the 
reported studies the bacteria used have been in the form of ei the r heat-
or formalin-killed vaccines . 
II. Terminology and Definitions 
A number of anaerobic corynefonns known by the general designa-
tion Corynebacter-ium parvum possess lymphoreticular stimulating ac-
tivity (Adlam and Scott, 1973; O'Neill et al., 1973; McBride et al., 
1975a). However, until recently the taxonomic classification of these 
organisms has been confused and, in some instances, it has been dif-
ficult to establish the taxonomic identity or re lationship between the 
dilferent organisms used by various workers. Throughout this review 
the taxonomic descrip tions of the original authors have been re ta ined, 
this most often being CP. An a lte rnative stra in that has figured promi-
nently in animal tumor studies is Corynebacterium granulosum (CG). 
Johnson and Cummins (1972) and Cummins and Johnson (1974) 
have attempted to clarify the taxonomy of the anaerob ic corynefonn s 
using serology, cep wall composition, and D NA homology. Their con-
clusions were that they shou ld be called Propionibacteria, since they 
produce propionic acid by feiment:'ltion , and shou ld be divided into 
three groups-P. acnes, P. granulosum, and P. avidum. According to 
this scheme, the Burroughs Wellcome C. parv·um vaccine strain 6134 
is classified as P. acnes type I (C. Adlam, personal communication ), 
and the lnstitut Merieux vaccine 1M 1585 asP. avidum (Roumiantzeff 
et al., 1975b). It is apparent that another group of anaerobic 
corynefonns, isolated main ly from dairy products and referred to as 
the "classical" Propionibacteria of van Niel (1928) are different from P. 
acne$, P. gmnulosum, an d P. avidum (Johnson and C ummin s, 1972). 
The "classical" Propionibacteria have thus far been unifo1mly nega-
tive in stimulato1y activity (O'Neill et al., 1973; McBride et al., 1975a). 
There have been studies to determine whether lymphoreticu lar 
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stimulatory activity correlate with particular species. O'Neill et al. 
(1973) found activity among representative organisms from P. acnes, P. 
granulosum, and P. avidum with no single species showing outright 
superiority. McBride et al. (1975a) confirmed activity in organisms 
belonging to P. acnes and P. avidum and described a soluble cross-
reacting antigen produced only by these strains. 
Ill. Stimulation of the Lymphoreticuloendothe lial System 
A. CHANGES IN ORGAN WEIGHT AND HISTOLOGY 
A single intravenous injection of CP into mice produces prolifera-
tion oflymphohistiocytic e lements in the li ver and spleen, resulting in 
a marked enlargement of these organs. The increase in organ weight is 
evident within a few days of CP injection, peaks in the second week, 
and then gradually returns to n01mal (Halpern et al., 1964; Adlam and 
Scott, 1973). The degree of splenomegaly and hepatomegaly depends 
directly on the amount ofCP injected, but the kinetics of the responses 
are relatively dose-independent (Adlam and Scott, 1973). Repeated 
injections provoke more intense, longer-lasting reactions (Halpern et 
al., 1964). 
I n addition to the splenomegaly (Halpern et al., 1964; Howard et al. , 
1967; Adlam and Scott, 1973; O'Nei ll et al., 1973; WoodmfF and Dun-
bar, 1973; Bomford and Olivotto, 1974; Casb·o, 1974a; McBride et al., 
1974; Milas et al., 1974a, 1975c) and hepatomegaly (Halpern et al., 
1964; Adlam and Scott, 1973; O'Neill et al., 1973; Bomford and 
Olivotto, 1974; McBride et al., 1974; Milas et al., 1974a) that result 
from systemic injection of CP into mice, lung (Adla_m and Scott, 1973) 
and lymph node (Castro, 1974a; McBride et al, 1974; Milas et al., 
1975c) weights are also increased. High doses of systemic CP may lead 
to tl1ymic atrophy (Castro, 1974a; McBride et al., 1974). The changes 
in spleen and liver weights following single subcutaneous injections 
of CP are minimal, but there is marked proliferation in, and enlarge-
ment of, the lymph node draining the injection site (Scott, 1974c; 
Tuttle and North, 1975). 
Similar organ weight changes have been reported for other species: 
splenomegaly and hepatomegaly in the rat (Stiffe l et al., 1966; 
Brozovic et al., 1975), rabbit (Pinc kard et al., 1968), and guinea pig 
(Stiftel et al., 1966), and lung weight increase and splenomegaly in the 
rabbit (Collet, 1971) and an amphibi an (Turner et al., 1974), 
respectively. 
260 L. MILAS AND M. T. SCOTT 
Histol ogic changes in the spleen have commonly consisted of exten-
sive proliferation of histiocytes; macrophages, lymphocytes, and 
hematopoie tic cells : e1y throid and myeloid cells and megaka1yocytes 
(H alpern et al., 1964; Collet, 1971; Brozovic et al. , 1975; Milas et al., 
1975c). Prolife ration occurre d predominantly in the red pu lp, whereas 
the white pulp of mice treated with CG has been repoJted to undergo 
lymphocyte depletion (Milas et al., 1975c). 
Extensive proliferation of lymphocytes and histiocytes was found in 
the lymph nodes (Colle t, 1971; O'Neill et al., 1973; Scott, 1974c; Tut-
tl e and North , 1975) and in the lung (Colle t, 1971; Pinckard et al., 
1968). 
Hepatomegaly is usually associated with mononuclear cell infil-
tJ·ates (Halpern et al., 1964; Milas et al., 1974a; Brozovic et al., 1975). 
The cells are predominantly histiocytes, and they form granulomas or 
diffusely infiltrate liver parenchyma (Milas et al., l974a). CP induces 
proliferation of liver macrophages and also increases the influx of ex-
trahepatic macrophages (Warr and Sljivic, l974c). 
B. HEMATOPOIETIC I NFLUENCE 
CP increases hematopoie tic activity in the spleen. In addition to the 
hi stological evidence already mentione d, an increased number of 
colony-fo1ming units (CFU) has been de monstrated. A similar increase 
in CFU occurred in the bone manow, although the total number of 
nucleated cells remained unchanged or was slightly reduced (Toujas 
et al. , 1972, 1974, 1975). CP has also increased the number of CFU in 
the peripheral blood of mice (Basic et al., 1975b). 
Shortly after administration of CP, a transient le ukopenia, affecting 
either lymphocytes alone (Milas et al., 1975c; Brozovic et al., 1975) or 
both lymphocytes and polymorphs (Woodruff and Dunbar, 1973), was 
found in the peripheral blood of mice. This may be re lated to the 
observation by Castro (1974a) that CP caused an absolute decrease in 
the number of 8-positive lymphocytes in the thymus, and a reduced 
percentage in the spleen and lymph nodes. The reason for this reduc-
tion in T cells is not known; a direct effect ofCP on lymphocytes, or an 
increased secretion of adrenal steroids due to stress have been sug-
gested (Castro, 1974a). 
Ane mia may follow CP injection (Halpern and Fray, 1969; McCrac-
ken et al., 1971; Cox and Keast, 1974; McBride et al., 1974) and is 
accompanied by increased erythropoiesis in the spleen and a rise in 
reticulocyte count (Brozovic et al., 1975). The basis for this anemia is 
considered to be the enhanced phagocytosis and d estruction of e1yth-
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rocytes by the CP-stimulated reticuloendothelial system (Cox and 
Keast, 1974; McBride et al., 1974). Soluble antigens from CP become 
attached to red cells in vitro, and any such attachment occuringin vivo 
would be expected to facilitate the phagocytic removal of the cells by 
virtue of their becoming opsonized by the anti-CP antibodies present 
in CP-treated mice (Cox and Keast, 1974; McBride et al., 1974). An 
autoantibody directed against syngeneic red cell antigens has also 
been found after CP treatment (McCracken et al., 1971). 
C. MACROPHAGE ACTIVATION 
More macrophage colonies are formed hom bone marrow cells from 
mice which received CP either subcutaneously (Wolmark and Fisher, 
1974; Wolmark et al., 1974) or systemically (Dimitrov et o.l., 1975a; 
Baum and Breese, 1976). CP increases not only the number of mac-
rophage precursors, but also their rate of proliferation (Baum and 
Breese 1976). The number of peritoneal (Basic et al., 1974; Yuhas and 
Ullrich, 1976) and alveolar (Collet, 1971) macrophages is also 
significantly increased after CP. 
CP-activated macrophages show more rapid adherence to glass in 
vitro and increased spreading and vacuolation compared with n01mal 
macrophages (Olivotto and Bomford, 1974) . Electron microscope 
studies have shown modifications in surface structure and distribution 
of lysosomes (Puvion et al., 1976). Cytochemical analyses have d e-
tected increased (Wilkinson et al., 1973a,b; McBride et al., 1974) or 
modified (Puvion et al., 1976) lysozomal enzyme activity and activa-
tion of phospholipase A (Munder and Modelell, 1974). 
A fUlther characteristic of the CP-activated macrophage is its ac-
quired ability to kill, or inhibit the growth of: malignant cells in vitro, 
and this process will be described in detail in Section VII,G. 
0. PHAGOCYTIC ACTIVITY 
The increased phagocytic capabilities of CP-activated macrophages 
are reflected in vivo by increased clearance of .pa1ticulate material 
from the blood: colloidal carbon (H alpern et al., 1964; Prevot and Van 
Phi, 1964; Stiffel et al., 1966; Raynaud et al., 1972; Adlam and Scott, 
1973; O'Neill et al. , 1973; McBride et al., 1974; Wan and Sljivic, 
1974b), bovine serum albumin (BSA) (McBride et al., 1974), and 5 1Cr-
labeled sheep red blood cells (SRBC) (Warr and Sljivic, 1974b). 
Studies by Stiffel et al. (1970, 1971) have shown that the degree of 
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phagocytic stimulation achieved with CP in mice depends on the 
strain of mice used. 
The liver and spleen are the major organs responsible for the in-
creased uptake of injected material (McBride et al., 1974; WaiT and 
Sljivic, 1974b), and the ability of different c01yneforms to stimulate 
phagocytic clearance seems to correlate with the ir ability to cause 
splenomegaly and hepatomegaly (Adlam and Scott, 1973; O'Neill et 
al., 1973). The in vivo antitumor activity of various strains has, how-
ever, con·elated better with splenomegaly than with stimulation of 
phagocytic index (McBride et al., 1975a). 
IV. Immune Modulation 
A. H UMORAL IMMUNITY 
CP is a potent immunogen: specific anti-CP antibodies have been 
de tected following injection of organisms into mice (Woodruff et al., 
1974; Scott and Wamer, 1976), rabbits (Dawes and McBride, 1975), 
and man (James et al., 1975; Minton et al., 1976). 
Systemic pretreatment of mice with CP amplifies the antibody re-
sponse to various systemically injected, thymus-dependent antigens: 
SRBC (Biozzi et al., 1968; Howard et al., 1973a; James et al., 1974; 
Wan and Sljivic, 1974a), rat erythrocytes (Howard et al., 1973a), 
keyhole limpet hemocyanin (KLH) {Wiener and Bandieri, 1975), and 
BSA (James et al., 1974). Both lgM and l gG responses are affected. 
The exclusively IgM responses of mice to thymus-independent 
antigens-dinih·ophenol hapten coupled to a levan canier (del Guer-
cio, 1972) and pneumococcal polysaccharide Sill (Howard et al., 
1973b; James et al., 1974; Warr and Sljivic, 1974a)- are also boosted. 
Pinckard et al. (1967a,b, 1968) have studied the effects of a non-
reticuloendothelial stimulating strain of CP on antibody production 
against BSA in rabbits. They found that systemic CP pretreatment 
increased the magnitude of primary and secondary responses and the 
relative binding affinities of the antibodies (Pinckard et al., 1967a,b). 
Tolerance induction was also blocked (Pinckard et al., 1968). The "in-
active" strain of CP also increased homocytoh·opic antibody produc-
tion whereas strains of CP with reticuloendothelial stimulating activ-
ity did not (Pinckard and Halonen, 1971). In mice, "active" sh·ains of 
CP have increased the relative binding affinities of anti-BSA an-
tibodies, but only when the mice had tumors (James et al., 1974). The 
induction of tole rance by injection of large amounts of Sill 
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polysaccharide was not affected by CP pretreatment (Howard et al., 
1973b). 
Reports of adjuvant activity ofCP in gu inea pigs have concerned its 
injection mixed with antigen either in F reund's incomplete adjuvant 
(Neveu et al., 1964) or as a water-in-oil emulsion (O'Neill et al., 1973). 
CP injected systemicall y a few days before systemic injection of 
optimally immunizing doses of antigen has usually resulted in in-
creased antibody production; however, the modification of antibody 
responses by CP may depend on the dose of antigen, as well as the 
time of its administration in relation to CP. In mice immunized with a 
high dose of SRBC (lOS), CP given between 7 days and 1 day before 
antigen produced a marked increase in plaque-forming cells (PFC), 
days -7 and - 4 having maximum effect. If the mice were immunized 
with 10n SRBC, CP given 7 days before only slightly increased PFC, 
and from 4 days before to 1 day after antigen, the PFC response was 
depressed. A similar dose-time dependence for CP adjuvant effects 
against Sill polysaccharide was also found (Wan and Sljivic, 1974a). 
Published studies on the adjuvant activity of CP in mice have thus 
far been restricted to systemic injection ofCP; however, subcu taneous 
injection of CP mixed with SRBC into the footpads of mice increased 
the number of IgM (direct) plaque-fonning cells in the draining pop-
liteal lymph node (R. Bamford, to be published). CP boosts antibody 
responses in guinea pigs when injected locally as a substitute for 
mycobacteria in Freund's incomplete adjuvant (Neveu et al., 1964). 
The stimulatOiy effects of CP on antibody p roduction are most prob-
ably mediated via CP-activated macrophages. Wiener (1975) showed 
that macrophages from CP-h·eated mice were more effective than 
normal macrophages at promoting an in v·itro primary response to 
SRBC by macrophage-depleted spleen cells. Watson and Sljivic (1976) 
confirmed these data and further demonsb·ated that antibody re-
sponses to a macrophage-independent antigen (D NP-POL) were not 
affected by CP. CP-activated macrophages retain large amounts of 
antigen on their surfaces, and this intensified presentation of antigen 
to lymphocytes may be a causal factor in the adjuvant activity of CP 
(Wiener and Bandieri, 1975). The interaction between antigen-laden 
macrophages and lymphocytes may be further intensified and pro-
longed in lymphoid organs as a result of the chronic trapping of lym-
phocytes that occurs in CP-b·eated mice {Frost and Lance, 1973). 
The predominantl y T-cell-dependent IgG response to SRBC in 
mice is amplified by CP in T-cell-deprived mice (Howard et al., 
1973a). This suggests that CP may be operating as a T-cell bypass 
mechanism, possibly through direct stimulation ofB cells. Zola (1975) 
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found that CP was mitogenic for B lymphocytes in. vitro; however, 
another organism with no in. vivo adjuvant properties was similarly 
active. 
B. CELLULAR I MMUNITY 
In addition to the anti-CP antibodies found after CP injection, mice 
also develop cell-mediated immunity to CP antigens . Delayed hyper-
sensitivity (DTH) has resulted from subcutaneous injection of a wide 
range of CP doses (Scott, 1974c, 1976; Tuttle and No1th, 1975). No 
DTH was detected after intravenous injection of a single high dose of 
CP (Scott, 1974c), but multiple intravenous injections of low doses 
were effective (Scott and Warner, 1976). 
CP treatment has been associated with depression of ce ll-mediated 
immune response to unrelated antigens. The DTH resulting from re-
gional injections of picryl chloride or oxazolone (Asherson and 
Allwood, 1971; Allwood and Asherson, 1972) and SRBC (Scott, 1974a) 
was markedly depressed in mice preh·eated systemically with CP. CP 
given after SRBC sensitization did not affect DTH reactivity (Scott, 
1974a). Systemic CP pretreatment has also prolonged the survival of 
skin allografts. Skin grafts from A or CaH mice survived several days 
longer when transplanted onto CBA mice which had received CP 1 
day before or after grafting (Castro, 1974a). A similar prolongation of 
survival of BALB/c skin grafts was observed in C3H.f/Bu mice treated 
intravenously with CG, 2-28 days before, but not 2 or 7 days after, skin 
grafting. CG pretreatment did not affect the rejection time of second-
set skin grafts (Milas et al., 1975c). Skin grafting across the H-Y barrier 
(C57B1 o ~ C57B1 s> ), Colapinto (1975) gave a more rapid rejection 
of skin grafts if CP was given before, or w ithin a few days afte r, graft-
ing, but prol ongation occurred if CP was delayed until 10 days after 
grafting. 
Scott (1974a) has attempted to analyze the mechanism(s) that may 
underlie the depressed DTH reactivity that results from a subcutane-
ous injection of SRBC in mice pretreated with intravenous CP. He 
found that anti-SRBC antibodies were not concomitantly increased, 
and that neither antigen sensitization at the draining lymph node level 
nor the subsequent loss of sensitized cells hom the node was impaired 
by CP treatment. An increased uptake of sensitized cells by the CP-
stimulated spleen was demonstrated, and DTH depression did not 
occur in splenectomized mice. These results were interpreted as 
showing that the peripheral expression of DTH was impaired in CP-
stimulated mice owing to an effective depletion of sensitized cells that 
were trapped in the CP-stimulated spleen (Scott, 1974a). 
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Evidence for a fu rther mechanism that may be involved in the CP-
mediated depression of cell-mediated immunity has come from in 
vitro studies of cells from CP-stimulated mice. The perfonnance of 
these cells in in vitro T-ce ll assays is impaired. Responsiveness to the 
T-ce ll mitogen phytohemagglutinin (PHA) of spleen and peripheral 
blood cells, but not lymph node cells, is depressed. The spleen cells 
are also less reactive in an in vitro mixed lymphocyte reaction (Scott, 
1972a). The spleen cell response to the B-cell mitogen lipopolysac-
charide is either unaffected by (Scott, l972a) or less sensitive to (Kir-
chner et al., 1975b) CP. Similar data are repmted for spleen and pe-
ripheral blood cells from CG-stimulated mice by Milas et al. (1975c), 
who also showed that the PHA responsiveness of lymph node cells 
was augmented after very low doses of CG. The PHA reactivity of 
CP-stimulated spleen cells was complete ly restored after removal of 
macrophages by iron magnet techniques (Scott, 1972b; Kirchner et al., 
1975b), rayon adherence columns, and carageenin treatment, but not 
by treatment with anti-8 serum and complement (Kirchner et al., 
l975b). These data suggest a nonspecific inhibition ofT-lymphocyte 
function by CP-activated macrophages, the lack of correlation of mac-
rophage numbers with degree of inhibition indicating a qualitative 
rather than quantitative change in the macrophage population (Scott, 
1972b; Milas et al., 1975c). 
A hnther example of CP-mediated depressed T-cell activity has 
been the protection ofF, recipient mice by intravenous CP against 
the le thal effects of graft versus host resulting from a subsequent injec-
tion of parental spleen cells (Biozzi et al., 1965; Howard et al., 1967). 
Karyotypic analysis revealed a strong inhibition of the proliferation of 
donor cells in the spleen of CP-treated recipients. The effect could not 
be attributed to any augmentation of an immune response against 
hypothetical parental antigens or to lack of space for donor cells in the 
host clue to gross proliferation of lymphoreticu lar tissue (Howard et al., 
1967). The results do, however, seem compatible with a CP-activatecl 
macrophage-mediated inhibition ofT-cell proliferation (Howard et al., 
1973a). 
The depressive effects of CP on cell-mediated immunity have thus 
far been restricted to systemically injected CP. Scott (1974a) was un-
able to depress DTH to SRBC using subcutaneous CP, and the ·in vitro 
PHA response of cells from lymph nodes directly stimulated by re-
gional injection of CP was not depressed (Scott, 1972a). Data are now 
accumulating that local interaction of CP with antigen may potentiate 
cell-mediated immunity. Subcutaneous injection of CP mixed with 
tumor antigens (irradiated tumor cells) results in strong specific cell-
mediated antitumor immunity, whereas injection of CP or an tigen 
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alone are without effect (Bomford, 1975; Scott, 1975b). Subcutaneous 
injection ofCP mixed with SRBC also potentiates DTH to SRBC (M. T. 
Scott, unpublished data). Subcutaneous injections of CP (Neveu et 
al., 1964) or CG (Degrand and Raynaud, 1973), when mixed with 
antigen in Freund's incomplete adjuvant, have produced DTH in 
guinea pigs. 
The fact that systemic CP pretreatment augments lgG antibody re-
sponse to thymus-dependent antigens (see Section IV,A) implies that 
the normal cooperative activity of T cells is not impaired by CP. 
V. Resistance to Infection 
Pretreatment of mice with CP has protected them against sub-
sequent infection with a variety of bacteria: Staphylococcus aureus 
and Bordetella pertttssis (Adlam et al., 1972), Brucella abortus (Adlam 
et al., 1972; Halpern et al., 1973), Salmonella enteritidis (Collins, 
1974; Collins and Scott, 1974), Listeria monocytogenes (Fauve and 
Hevin, 1971; Swartzberg et al., 1975; Ruitenberg and van Noorle 
Jansen, 1975). The effects have been evident both from prolonged 
survival or permanent protection against infection and from decreased 
bacterial counts in the liver and spleen. It is apparent that the CP-
induced bacterial resistance is immunologically nonspecific and 
mediated by the enhanced bactericidal capabilities of the CP-
activated spleen and liver macrophages (Fauve and Hevin, 1971, 
1974; Collins and Scott, 1974; Fauve, 1975). Protection against Sal-
monella enteritidis did not correlate with any augmentation of speci fic 
anti-Salmonella immunity (Collins and Scott, 1974), and protection 
against Listeria monocytogenes still occurred in the athymic nude 
mouse (Ruitenberg and van Noorle Jansen , 1975). CP tJ·eatment after 
bacterial infection has not been protective (Philippon et al., 1972; 
Collins and Scott, 1974). 
CP also protects against protozoal infections. An increased resis-
tance to malaria was caused by CP injected intmvenously 6-19 days 
before intravenous injection ofPlasmodium berghei sporozoites (Nus-
senzweig, 1967). The mice exhibited delay in the onset of detectable 
infection and prolonged survival, and some were completely pro-
tected. A similar protection against P. vinckei and P. chabaudi, but not 
P. berghei, has been reported by Clark et al. (1977). They a lso found 
that systemic CP pretreatment of mice afforded complete and chronic 
protection against infection with Babesia microti or B. rodhaini. In-
b·aerythrocytic death of both Plasmodium and Babesia was eviden t in 
these studies (Clark et al., 1977). Mice injected inb·avenously, but not 
intraperitoneally, with CP have shown increased resistance to the 
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Tulahuen sh·ain of Trypanosoma cruzi, and sign ificant protection still 
occurred ifCP was delayed until 7 days afte r injection (Kierszenbaum, 
1975). A macrophage-mediated mechanism was indicated by the in-
teresting finding that CP protected against infection only with the 
reticulotropic Tulahuen strain, but not with the predominantly myo-
tropic Y strain of T. c-ruzi. CP-preh·eated mice are also resistant to 
Toxoplasma gondii, and peritoneal macrophages fi-om these mice are 
capable in vitro of killing Toxo plasma (Swartzberg et al., 1975). 
In contrast to these protective findings, Bryceson et al. (1972) ob-
served that subcutaneous preh·eatment of guinea pigs with CP emul-
sified in Freund's incomplete adjuvan t increased susceptibility to 
cu taneous infection with Leishmania en-riettii . Treatment with CP did 
not influence delayed hypersensitivity to Leishmania, but caused 
production of anti-leishmania! antibodies. The authors expla ined the ir 
findings by "regional antigenic compe tition" between CP and le ish-
mania! antigen, which may alter the dish·ibution and processing of 
leishmania! anti gen or the traffic of Leishmania-sensiti ve cells within 
drain ing lymph nodes. Intravenous inoculation of CP also depressed 
the resistance of rats to Trichinella spiralis, as expressed in a de lay of 
expulsion of adu lt wom1s from rat intestinal tract. This may be related 
to a depression of the T-cell-mediated immunologic defense against 
Trichinella spimlis (Ruitenberg and Steerenberg, 1973). Depression of 
ce ll-mediated immunity by CP is discussed in Section IV,B. 
The effects of CP against viral infections have also been studied. 
Intraperitoneal and intravenous inoculations of encephalomyocarditis 
virus caused the death of95% of normal Swiss mice, but less th an 50% 
of those treated intraperitoneally with 0.5 mg ofCP 2 or 7 days earlie r. 
Smaller and larger doses of CP were less effective (Cerutti , 1975). 
Peritoneal exudates of CP-h·eated mice con tained a factor that inh i-
bited multiplication of both encephalomyocarditis virus and ves icu lar 
stomatitis virus . The inhibitor was resistant to heating at 56°C for 30 
minutes, but did not requ ire the integrity of ce ll-prote in synthes is, a 
characteristic of the biological activity of interferon. CP was also inca-
pable of inducing interferon in an in vivo model (Ceru tti , 1975). Other 
studies have shown that treatment of mice with C. acnes, an organism 
closely re lated to CP, suppresses the leve l of serum interfe ron induced 
by injection of Newcastle disease virus of Chikungunya virus (Farber 
and Glasgow, 1972; Fischbach and Glasgow, 1975). 
VI. Other Effects 
Systemically injected CP (Adlam et al., 1972; Adlam, 1973; Adlam 
and Scott, 1973) is capable of sensitiz ing mice to histamine, a property 
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previously considered to be i.m ique for Bordetella pertussis. The 
ability of both CP and B. pertussis to sensitize depended on sh·ain of 
mice used, stra ins sensitive to CP treatment being sensitive to B. per-
tussis and vice versa. Contra1y to B. pertussis, CP-mediated histamine 
sensitivity was not associated with anaphylaxis. Anaphylaxis to horse 
serum, or ovalbumin, was not observed in mice receiving CP at vari-
ous times before, after, or in combination with antigen (Adlam, 1973). 
T he histamine-sensitizing activity of CP was not destTOyed by heating 
or by treatment with fom1aldehyde. It was suggested that lysosome-
rich CP-activated macrophages, because of their increased fragility, 
may release into the circulation lru·ge amounts of lysosomal enzymes, 
which then block the ,8-adrenergic receptors and (or) exert a direct 
effect on histamine levels (Adlam, 1973). A similar increase in sensitiv-
ity of CP-treated mice to endotoxin has been associated with a release 
of lysosomal enzymes (Howard, 1968). 
Mice given high doses of intravenous CP have become lethally sen-
sitive to normally safe doses of anesthetics, e.g., pentobarbitone and 
tribromoe thanol, which are catabolized by the liver, but not e ther 
(Mosedale and Smith, 1975). Using mice of a different strain, and 
lower doses of CP, Milas ( 1975) found no increased sen sitivity to pen-
tobarbitone. In rats, pretreahnent with inb·avenous CP has increased 
the pentobarbitone-induced sleeping time by 100%, and this was as-
sociated with impaim1ent of the hepatic microsomal enzyme system 
(Farquharet al., 1975). The anesthetic deaths repo1ted may, therefore, 
be due to interference of detoxification processes in the liver by CP. 
Certain stTains of mice are capable of rejecting incompatible bone 
marrow grafts after lethal irradiation. If, however, these mice are given 
CP prior to irradiation , the bone marrow grafts ru·e accepted (Cud-
kowicz and Benne tt, 197la,b; Lotzova and Cudkowicz, 1972; 
Rauchwerger et al., 1976). The mode of action of CP under these 
circumstances is not understood. 
VII. Effects on Experimental Neoplasia 
A. CARCINOGENESIS 
Baum and Baum (1974) rep01ted that two subcutaneous injections of 
0.7 mg of CP, a week apart, afforded mice protection against the car-
cinogenic effects of methylcholanthrene given at the time of the sec-
ond CP injection. Sarcomas developed later, and their overall inci-
dence was less than in untreated mice. Scott and Warner ( 1976) 
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injected mice once a week for 14 weeks, either inh·avenously or sub-
cutaneously, with 0.035 mg of CP. Eight days after the final injection 
they were challenged with either methylcholanthrene or ben-
zopyrene. The pattern of development and final incidence of 
benzopyrene-induced tumors for both inh·avenous and subcutaneous 
CP-treated groups was similar to the control. Methylcholanthrene in-
duced tumors in all inh·avenous CP-treated and conh·ol mice, but 25% 
of subcutaneous CP-h·eated mice remained tumor fi-ee at the end of the 
experiment. As detailed in later sections, CP-h·eated mice are capable 
of inhibiting the growth of cells transplanted from tumors that have 
been chemically induced in syngeneic mice. It is therefore unclear 
whether the reported protective effects of CP against chemical car-
cinogens represent inhibition of the carcinogenic process, or merely 
inhibition of tumor growth once established. 
There are reports that CP b·eatrnent reduces the incidence of tumors 
following the injection of oncogenic viruses; however, it is again un-
clear to what extent these results may represent neutralization of the 
virus, interference with the oncogenic process or inhibition of estab-
lished tumor growth. In an earlier section CP was described to protect 
against viral infection and a virus inhibitOJy facto r was discussed 
(Cerutti, 1975). CG given systemically 4 days before systemic injec-
tion of Friend leukemia virus markedly increased survival of mice 
(Kouznetzova et al., 1974). CP also inhibits Moloney sarcoma virus 
(MSV) (N. H. Pazmino, M. Yuhas, and L. Milas, unpublished). Mice 
are sensitive to the oncogenic effects of MSV when newborn or aged. 
The final tumor incidence was not affected in newbom mice by CP 
either before or after virus inoculation, but the latent period before 
tumor appearance was significantly prolonged. In senescent mice, 
however, a 50% decrease in tumor incidence was induced by CP. 
Aged DBA/2 mice have a high incidence (70%) of spontaneous 
mammary carcinomas. This incidence is decreased to 3- 6% of the 
mice if, in adult life, they have rejected a subcutaneous h·ansplant of 
syngeneic mammary carcinoma cells mixed with CP (Likhite, 1976). 
These mice are for a long time specifically resistant to tumor rechal-
lenge and the ultimate decreased incidence of tumors may merely 
represent specific immunity to viral or tumor antigens. 
B. IMMUNOPROPHYLAXIS 
The first demonstration that CP pretreatment protected mice against 
challenge with syngeneic tumor cells was by Woodruff and Boak 
(1966). Intravenous CP 2 days before subcutaneous injections of either 
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mammary carcinoma or methylcholanthrene-induced fibrosarcoma 
cells delayed the appearance of tumors and p rolonged survival of the 
mice. Using allogeneic mouse tumor systems, Halpern et al. (1966) 
showed that intravenous CP retarded growth of subcutaneous ly in-
jected Betz sarcoma cells, but only minimally affected the in-
traperitoneal growth of Ehrlich ascites carcinoma. The latter was, 
however, extremely sensitive to intraperitoneal CP pretreatment. 
Numerous reports have since appeared describing the protective 
effects of anaerobic corynebacteria against many syngeneic mouse 
tumors: mammary carcinomas (Woodruff and Inchley, 1971 ; Milas et 
al. , 1974c, 1975b), chemically induced fibrosarcomas (Fisher et al., 
1970; Milas and Mujagic, 1972; Bomford and Olivotto, 1974; Castro, 
1974b; Milas et al., 1974c; Bomford, 1975; McBride et al., 1975b), 
spontaneous fibrosarcomas (Smith and Scott, 1972; Bamford and 
Olivotto, 1974), osteosarcoma (van Putten et al., 1975), chemically 
induced ICIGCI1 tumor (Mathe et al. , 1973), mastocytoma (Scott, 
1974b), plasmacytoma (Smith and Scott, 1972), line 1 lung carcinoma 
(Yuhas et al., 1975), Lewis lung carcinoma (Mathe et al., 1973), 
adenovirus 12-induced tumor (Rees and Potter, 1974), leukemias 
(Lamensans et al., 1968; Amiel et al., 1969; Smith and Scott, 1972; 
Mathe et al., 1973; Kouznetzova et al., 1974; Stiffel et al. , 1974; 
H alpern et al., 1975; Roumiantzeff et al., 1975a), and lymphomas 
(H alpern et al., 1975; Roumiantzeff et al., 1975a) . 
Methylcholanthrene-induced fibrosarcomas have been extensively 
studied. Systemic CP (Bomford and Olivotto, 1974; Milas et al., 1974a) 
or CG (Milas et al., 1974a,c) prevented development of artificial 
metastases in the lung following intravenous injection of fibrosarcoma 
cells . Using stcr-labeled tumor cells, Bomford and Olivotto (1974) 
have shown that the injected tumor cells that settled in the lungs of the 
CP-treated mice were killed more quickly. Subcutaneous preb'eat-
ment with CP also induced resistance to intravenous fibrosarcoma cell 
chall enge (Milas and Mujagic, 1972). Both subcu taneous (Fisher et 
al., 1970) and systemic (Woodmff and Boak, 1966; Milas et al., 
1974a,c) preheatments have been shown to be effective against solid 
tumors arising from subcutaneous fibrosarcoma cell challenge. One 
particular fibrosarcoma was peculiarly sensitive to intraperitoneal CG 
pretreatment. The time of appearance of tumors was not affected, but, 
when they were 6-10 mm in diameter, more than 50% regressed (Milas 
et al., 1974c). Two comparative studies using mouse fibrosarcoma 
models have shown systemic pre treatment to be more effective than 
subcutaneous (Bamford and Olivotto, 1974; Milas et al., 1974a) . 
The p rotective effects of CP preb'eatment against mouse leukemias 
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depends on the relative routes of injection of CP and tumor ce ll chal-
lenge. Intraperitoneal CP pretreatment induced strong resistance 
against the intraperitoneal growth of AKR leukemia cells but was less 
effective against intravenous challenge (Lamensans et al., 1968). Hal-
pern et al. (1975) found that intraperitoneal CP was more effective 
against an intraperitoneal than an intravenous challenge with virus-
induced YC8 leukemia cells. Intraperitoneal and intravenous in-
jections are also more effective than subcutaneous or intrade rmal in-
jections in protecting against intravenous L1210 leukemia (Mathe et 
al., 1973). 
Overall it is apparent that systemic injections have been superior to 
regional injections of CP in protecting against various tumor cell chal-
lenges, and this correlates well with the degree of lymphoreticular 
stimulation resu lting from the two injection rou tes (Bomford and 
Olivotto, 1974; Milas et al., 1974a) . The role of the lymphoreticular 
system in CP-mediated antitumor effects is discussed in Section VII,G 
on modes of action. The stimulating effects of CP are re latively long 
lasti ng, and this is also true for some cases of CP-induced tumor pro-
tection. Although CP given 1-2 weeks before tumor cell challenge 
seems to be most e ffective, sb·ong protection against AKR leukemia 
was still p resent after 35 days (Lamensans et al., 1968). Good protec-
tion against fi brosarcoma cells was present at 25 days, but was los t by 
50 days (Castro, 1974b) and, in another fibrosarcoma mode l, the effect 
ofCG, a lthough reduced, was still detected afte r 130 days (Milas et al., 
1975c). In contrast, the growth of poorly immunogenic line 1 lung 
carcinoma cells was inhibited only if injected within 10 days of CP 
(Yuhas and Ullrich, 1976). Smith and Scott (1972) suggested that the 
reduced susceptib ility of different tumors to the protective effects of 
CP may be re lated to their immunogenicity. They screened several 
mouse tumors and found that better protection was achieved against 
the more immunogenic tumors . 
The anatomical location of tumors may also influence their suscepti-
bility. Yuhas and Ullrich (1976) showed that CP protected mice 
against subsequent intravenous or intraperitoneal injections of line 1 
lung carcinoma, but not against subcutaneous or intramuscular htmor 
cells. Similar da ta have been reported for weekly immunogenic mam-
mary carcinoma cells (Milas et al., 1975b). 
Although CP pretreatment usually protects be tter against low than 
high doses of tumor cells, in some instances it is relatively ineffective 
against very low numbers of tumor cells. Woodtuff and Boak (1966) 
and Fisher et al. ( 1970) reported better protection against 1()4 than 
against 103 fibrosarcoma cells injected subcutaneously. Similarly 102 
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AKR leukemia cells grew better than l(]J cells in mice pretreated with 
CP (Stiffel et al., 1971). 
C. IMMUNOTHERAPY 
1. Systemic 
In the same studies in which they first described the prophylactic 
effects of CP in syngeneic mice, Woodruff and Boak (1966) also first 
described its therapeutic action. A single dose of CP injected in-
travenously 8 or 12 days after subcutaneous injection of syngeneic 
mammary adenocarcinoma cells significantly delayed the appearance 
of the tumors. Once palpable, however, the subsequent growth of the 
tumors was unaffected. In later studies an actual inhibition of the 
growth rate of the same mammary adenocarcinoma, and two unrelated 
fibrosarcomas, was apparent when CP was injected intraperitoneally 3 
days after tumor establishment (Woodruff et al., 1972). Intravenous CP 
treatment also caused a transitoty, but significant, inhibition in the 
growth rate of a solid mastocytoma (Scott, 1974b). The growth of a 
solid mammary carcinoma has also been inhibited by biweekly in-
b·aperitoneal injections of CP statting either at the time of tumor 
injection (Likhite and H alpern, 1973) or 14 days later (Likhite and 
Halpern, 1974). Conflicting results have been reported for Lewis lung 
carcinoma. Intravenous CP given to mice within several days after 
subcutaneous transplantation of tumor cells either caused inhibition of 
tumor growth (Sadler and Casb·o, 1976) or had no effect (Morahan et 
al., 1976). 
In none of the above studies were any tumor regressions observed, 
but, using a methylcholanthrene-induced fibrosarcoma in C3Hf/Bu 
mice, Milas et al. (1974d) obtained complete regressions of sub-
cutaneously growing tumors when CG was injected inb·avenously 3 or 
7 days after tumor cells. This tumor grows rap idl y and by 7 days was 
about 6 mm in diameter. The responses of individual tumors were 
exh·emely variable. Some of them regressed completely and perma-
nently, others regressed pa1tially and regrew, and others grew slightly 
more slowly than in controls (Milas et al., 1974d). A characteristic of 
the regression of these tumors was that the tumor continued to grow at 
the same rate as in control mice for at least 10 clays before the regres-
sion occurred. Systemic injections of CP also caused complete re-
gressions of this tumor (Milas et al., 1974a; Suit et al., 1975, 1976b), its 
effect being equal to that of CG (Milas et al., 1974a). 
In keeping with the pretreatment studies (Smith and Scott, 1972), it 
may also be that the immunogenicity of tumors affects their suscepti-
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bility to systemic CP therapy. Regressions have been achieved using 
intravenous CG against a poorly immunogenic mammary carcinoma, 
but, in contrast to a more immunogenic fibrosarcoma, they were ex-
tremely rare and only temporary (Milas et al., 1975b). The efficiency of 
systemic CP may also depend on the site of tumor growth . Intravenous 
or intraperitoneal CP was more effective against a mouse fibrosarcoma 
growing intradermally or subcutaneously, than inb·amuscularly (Suit 
et al., 1976b), and pulmonary deposits of this tumor were more suscep-
tible than deposits that settled in the brain or heart (Milas et al., 
1974a). 
The therapeutic effects of CP and CG against the artificial lung 
metastases that result from intravenous injection of fibrosarcoma cells 
have been extensively studied (Milas and Mujagic, 1972; Bomford and 
Olivotto, 1974; Milas et al., 1974a; Milas and Withers, 1976). When the 
bacteria were injected systemically within a few days of tumor cell 
injection, they reduced the number of metastatic tumor nodules in the 
lung and completely cured many mice (Milas et al., 1974a; Milas and 
Withers, 1976). 
Variable results have been achieved with therapy of experimental 
leukemias using systemic CP. lnb·aperitoneal CP given as a single 
injection, or 5 times, at 4-day intervals, only minimally affected survi-
val of mice which received subcutaneo usly L1210 le ukemia cells 1 
day prior to CP treabnent (Mathe et al., 1969). In another study using 
the same tumor, a significant e ffect was produced by multiple in-
travenous, or intraperitoneal, treatments of mice with CG; the treat-
ment was started 3 or 4 days after tumor cell inoculation (Kouznetzova 
et al., 1974). Syste mic CP has retarded the growth of Moloney virus-
induced YC 8 lymphoma (H alpern et al., 1975; Roumiantzef:l' et al., 
1975a), but had no effect on Graffi le ukemia (B. Halpern et al., 1975). 
All the above studies have used transplanted tumors. Thus far there 
is only one study conceming the therapeu tic effects of CP on au-
tochthonous tumors. Yuhas and Ullrich (1976) have described that 
three weekly intraperitoneal injections of CP caused temporary re-
gressions of spontaneous mammary tumors growing in old, previously 
inadiated, mice. 
Syste mic CP treatment is most effective against small tumor masses, 
i.e., when injected soon after inocu lation of tumor cells. The e fficacy of 
both intravenous CG (Milas et al., 1974d) and CP (Suit et al., 1976b) 
treatment of C3H fibrosarcomas is substanti all y reduced for tumor 
sizes above 5-6 mm. 
Doses of CP used for systemic injection have varied, but have been 
mostly in the range of 0.1- 1 mg d1y weight of organisms, the most 
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frequent dose being around 0.5 mg. Milas et al. (1974d, 1975a) used 
single injections of 0.25 or 0.5 mg to cause complete tumor regressions 
in their mouse fibrosarcoma model. Suitet al. (1976b) studied the dose 
response of the single injection of inb·avenous CP given 4 days after 
the same tumor. There was a fall in efficacy as the dose was decreased 
from 0.35 to 0.1 mg. Doses of0.7 and 1 mg were no better than 0.35 mg 
but were more toxic. Toxicity of high doses of systemic CP has been 
reported by others (Currie and Bagshawe, 1970; Fisher et al., 1970; 
Milas et al., 1974c; Scott, 1974b). Scott (1974b) observed that the 
highest single intravenous dose of CP that could be tolerated (0.7 mg) 
was most effective in inhibiting the growth of solid murine mas-
tocytoma. Multiple high doses of CP have usually not resulted in 
better antitumor activity (Scott, 1974b; Milas et al., 1975b; Suit et al., 
1976b) but may be more toxic (Fisher et al., 1970). In a fibrosarcoma 
therapy model, Suit et al. (1976b) have shown that multiple doses of 
intravenous CP, individually ineffective, were effective. The same 
finding has been described for a preb·eatment situation (Milas et al., 
1975c). Multiple low doses of systemic CP have been shown to cause 
lymphoreticular stimulation and immunologic modifications similar to 
those of a single high dose (Scott and Warner, 1976), and this mode of 
application of CP may provide a means of avoiding toxicity in clinical 
situations. 
Oral administration of CP has been tested and found to be ineffec-
tive in the therapy of the subcutaneously growing Lewis lung car-
cinoma. This route of injection also failed to cause splenomegaly (Sad-
ler and Castro, 1975). 
2. Local 
D irect injection ofCP into growing solid tumors has been a particu-
larly effective form of therapy, complete and permanent regressions 
being a common observation in many different tumor models. When a 
murine (Likhite and Halpern, 1974) or rat (Likhite, 1974) mammary 
carcinoma growing for 14 and 20 days, respectively, was injected 
with CP they all regressed permanently. Not only did the injected 
tumors regress, but their metastases as well. Sb·ong inhibition of tumor 
growth, or some complete regressions, following inb·alesional CP or 
CG therapy have also been described for mouse fibrosarcomas (Milas 
et al., 1975b; Tuttle and North, 1975; Woodruff and Dunbar, 1975; 
Morahan et al., 1976; Suit et al., 1976b), a mouse mastocytoma (Scott, 
1974c, 1976), and a hamster melanoma (Paslin et al., 1974). Sub-
cutaneous injections ofCP at sites distant from the growing tumor only 
minimally affect its growth, whereas injections into the region of the 
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tumor cause marked inhibition of growth but are less effective than 
intralesional injections (Likhite and Halpern, 1974; Scott, 1974c; 
Woodmff and Dunbar, 1975). 
Animals whose tumors have undergone complete regressions fol-
lowing intralesional CP therapy are specifically res istant to reinocula-
tion of cells from the same tumor (Likhite, 1974; Scott, 1974c; Wood-
ruff and Dunbar, 1975). Mice which have rejected tumors that develop 
from tumor cells admixed with CP ru·e similarly, specifically immune 
(Likhite and Halpem, 1974; Likhite, 1976). The immunity is strong 
and long lasting (at least 20 months), and immune mice ultimately 
develop fewer spontaneous tumors (Likhite, 1976). The nature of this 
immunity is discussed in detail in Section VII,G. 
Doses of intralesional CP that have been used, and found to be 
effective, have varied between 0.02 and 0.7 mg, however, different 
tumor models and sizes of tumor have been studied. Scott (1974c) 
investigated the optimal dose of intralesional CP for a mouse mas-
tocytoma and found that, within the dose range 0.007-0.35 mg, 0.07 
mg was optimal. The reduced effectiveness of higher doses of intrale-
sional CP contrasted with the effects of intravenous CP against this 
tumor where the highest doses were found to be most effective (Scott, 
1974b). 
In keeping with systemic CP therapy, better results are achieved 
with intralesional therapy by sh01tening the time interval between 
tumor cell transplantation and CP. CP injected 6 days after tumor cell 
inoculation caused 4 out of 6 mouse mastocytomas to regress com-
pletely, and on ly 1 out of 6 after 10 days (Scott, 1974c). Similar data 
have been reported for a mouse fibrosarcoma (Woodruff and Dunbar, 
1975). 
Using the C3H fibrosarcoma model, which is extremely sensitive to 
systemic CP, i.e., complete regressions are achieved, Suit et al. 
(1976b) compared the efficacy of intravenous with intralesional CP 
therapy and found more regressions after intravenous treatment. With 
tumors less sensitive to systemic CP, intralesional CP has been found 
to be superior: mouse mammary carcinoma (Likhite and Halpern, 
1974), rat mammary carcinoma (Likhite, 1974), mouse mastocytoma 
(Scott, 1974c), and mouse fibrosarcoma (Woodmff and Dunbar, 1975). 
Milas et al. (1976) reported the two rou tes to be equally effective 
against a mouse mammary carcinoma. Morahan et al. (1976) found that 
intravenous CP had no effect against Lewis lung carcinoma, and re-
sults with intralesional CP were variable, ranging from enhanced 
tumor growth to complete regressions. 
The overall results with intralesional CP in animal tumor models ru·e 
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impressive, but it is again apparent that some tumors are more suscep-
tible than others. This variability may again be re lated to the individ-
ual immunogenicities of the tumors; a component of the local tumor 
destruction caused by CP is considered to be immunologically 
mediated (see Section VII,G). The degree of local tumor destruction 
would also be expected to be re lated to the distribution of CP within 
the tumor, and differences in the individual injection techniques may 
be another source of variation. 
There have been few studies combining systemic and inb·atumor 
the rapy with CP. Scott (1974c) reported that intravenous CP reduced 
the antitumor effects of a subsequent injection of CP against a weakly 
immunogen ic murine mastocytoma. In conb·ast, Suit et al. (1976b) 
demonstrated that a relatively strong immunogenic mouse fibrosar-
coma responded be tte r to the combination of intravenous and intrale-
sional CP, regardless of whether the intravenous inocu lation preceded 
or followed intralesional CP, than to the individual treatments alone. 
D. COMBINATION WITH SPECIFIC ACTIVE IMMUNOTHERAPY 
The local interaction ofCP with live or irradiated tumor cells results 
in strong, specific, long-lasting, cell-mediated tumor immunity (see 
Section VII, G). Specific active immunotherapy using mixtures of CP 
and irradiated tumor cells has been shown to iphibit or prevent the 
growth of mouse mastocytomas (Scott, 1975b) and mouse fib rosar-
comas (Bomford, 1975), respectively. Subcutaneous injection of CP 
mixed with irrad iated fibrosarcoma cells inhibited the growth of live 
tumor cells injected at a distant site 2 or 6 days previously. Therapy 
delayed until 10 days was ineffecti ve. Successful the rapy required a 
minimal number of irradiated tumor cells (> 5 x 1()4), with no upper 
limit being de tected, and only small closes of CP (0.0014- 0.1 mg). 
There was an upper limit for the amount of CP in the mixtures which 
increased with the number of tumor cells. This suggests a necessity for 
a balance between the amount of CP and tumor antigen for optimal 
immunity. The small doses ofCP that, in combination with irradiated 
tumor cells, comple tely inhibited tumor growth, contrasted with the 
larger amounts (0.35 mg) that were considerably less effective after 
intravenous injection (Bomford, 1975). Similar observations on the 
efficacy of very small doses (0.0035 mg) ofCP injected in combination 
with irradiated mastocytoma ce lls are those of Scott (1975b). 
Scott (1975b) was unable to poten tiate tumor specific immunity 
using systemic injections of irradiated mastocytoma cells mixed with 
CP. The CP did, however, abolish the enhancing effect of the ir-
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radiated tumor cells a lone. Likhite and Halpern (1973) using a mouse 
mammary carcinoma and rat Shay chloroma a lso found that biweekly 
therapeutic intmperitoneal injections of CP and killed tumor cells 
were no more inhibitory than intraperitoneal injections of tumor cells 
alone. That tumor immunity may be stimulated using systemic CP 
injections is, however, evident from other studies. Combination ofCP 
and heavily irradiated tumor cells, both given intraperitoneally, pro-
tected mice against viable sarcoma cells inoculated intravenously 
more effectively than the individual treatments (Milas et al., 1975d). 
Yuhas et al. (1975) also reported that combination of intraperitoneal 
injection of CP and intravenous immunization with viable tumor cells 
inhibited the subcutaneous growth of line 1 lung carc inoma more 
effectively than either n·eahnent alone. Combination of systemic CP 
and localized tumor antigen may also result in augmented tumor im-
munity. Woodruff and Dunbar (1973) report strong inhibition of the 
growth of a mouse fibrosarcoma using simultaneous injections of in-
traperitoneal CP and subcutaneous mitomycin C-treated tumor cells, 
which had been further treated with neuraminidase to increase their 
immunogenicity. 
Under some c ircumstances combination ofCP with irradiated tumor 
cells may depress, rather than potentiate, tumor immunity. Smith and 
Scott (1972) have shown that CP given intravenously to mice 7 days 
before intraperitoneal immunization with irradiated leukemia cells 
depressed the protective effects of the immunization. This may be 
related to the depressive effects of systemic CP pretreatment on vari-
ous T-cell-mediated immune phenomena that we have a lready 
discussed. 
E. COMBINATION WITH CONVEN'• lONAL MODALITIES OF 
CANCER TREATMENT 
The foregoing studies have shown that immunothe rapy with CP, in 
keeping with immunotherapy in general, is effective only against rela-
tively small tumor masses. Cl inically, this is likely to represent a min-
imal disease situation, i.e., when the primary tumor burden has been 
reduced by more conventional fo1ms of therapy-radiothe rapy, 
chemothe rapy, or surgery. This section describes the animal data con-
ceming combination of CP with these treatments. 
1. Combination with Radiotherapy 
Tumor response to radiotherapy depends not only on radiobiological 
factors (Withers, 1974), but also on the immune competence of the 
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tumor hosts (for more details, see Milas et al., 1975a). Both CP and CG 
have been combined with local irradiation in the the rapy of exper-
imental tumors (Milas et al. , 1975a,e ; Suit et al., 1975, 1976a,b; 
Moroson and Schechter, 1976). Intravenous CP (0.1- 0.5 mg) reduced 
the radiation dose necessary to achieve local control of a relatively 
strongly immunogenic 8-mm mouse fibrosarcoma in 50% of treated 
animals (TCD 50 values) (Milas et al., 1975a; Suit et al., 1976b). 
Tumors were irradiated with single doses of y-irradiation ranging from 
200 to 4400 rads. CP also significantly augmented radiocurability of 
fractionated irradiation: 500 rads given for 3, 6, or 10 consecutive clays 
(Milas et al., 1975e) or 10 equal doses ranging fi·om 50 to 950 rads with 
2 days between irradiations (Suit et al., 1976b). Tumors that were not 
cured by these combinations grew more slowly, and metastasized less 
frequently than tumors treated with irradiation alone. An interesting 
observation was that CP greatly augmented radiocurability of doses 
between 200 and 2500 racls whereas little improvement occurred 
when tumors were being controlled with about 80% probability. The 
TCD50 value for this tumor in nom1al mice is approximately 3400 rads. 
Higher inadiation doses significantly injure sh·omal tissues including 
blood vessels, and this may result in inaccessibility of surviving tumor 
cells to the immune defense mechanisms. High irradiation doses may 
also inactivate local lymphocytes or macrophages. 
Suit et al. (1976b) studied tl1e effects of several routes of CP admin-
istration, dose levels of CP, and time relationships between treatments 
of CP and irradiation. Intravenous CP regularly potentiated 
radiocurability. Intralesional and subcutaneous CP were, however, 
more effective against tumors if applied alone. When CP was given 
intralesionally and intravenously when tumors were 5 and 8 mm, re-
spectively, followed by 200 rads local irradiation, the effect was less 
than with CP alone. In the reverse situation, i.e., first CP intravenously 
and then intralesionally, augmentation of radiocurability was ob-
served. Single intravenous doses of CP smaller than 0.1 mg were inef· 
fective. The sequence of CP and irradiation was also important. CP 
given to mice 2-4 days before irradiation was more effective than 
when given 2 days after irradiation. 
CP is not as effective in augmenting radiocurability of weakly im-
munogenic murine tumors. In studies by Suitet al. (1976a) tl1e effects 
of the combined treatment were barely evident against a mammary 
carcinoma, but the TCD50 values for two squamous cell carcinomas 
were significantly reduced. Local irradiation of a highly metastasizing 
mammary carcinoma with 6000 rads, single dose, caused complete 
regression of irradiated tumors, but, surprisingly, greatly increased the 
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number of metastases in the lung compared to that in mice whose 
tumors were surgically removed (Milas et al., 1976). Treatment with 
CP before, but not after, irradiation not only prevented this effect, but 
reduced the number of metastases below that in amputated mice. 
Under cettain circumstances radiotherapy may be immunosuppres-
sive and enhance tumor spread (Stje rnsward et al., 1972). CP given 
before inadiation may prevent such de le terious effects. Milas et al. 
(1974b,c) found that enhancement of pulmonary metastases caused by 
whole-body irradiation of mice 1 day before intravenous injection of 
fibrosarcoma cells, can be prevented by CG treahnent within 2 weeks 
prior to irradiation. CG was ineffective when given after radiation. 
Similar observations we re rep01ted for CP by Bomford and Olivotto 
(1974). 
2. Comb·ination with Chemotherapy 
D espite the immunosuppressive nature of most cancer chemo-
therapy dJUgs, animal studies show that immunostimulation using 
CP can be successfully combined with drug therapy, often with 
additive, or even synerg istic effects. 
Most studies have used cyclophosphamide. Intrade rmal treatment 
of mice with CP 12 days after intraperitoneal injection of cyclophos-
phamide caused complete regression of a subcutaneously growing fi-
brosarcoma in about 70% of treated mice (Currie and Bagshawe, 1970). 
No comple te regressions were achieved, <tlthough a significant re ta r-
dation in the tumor growth was still present, when CP was injected 6 
or 16 days after chemotherapy. When g.iven before, or simultaneousl y 
with cyclophosphamide, CP was not effective but caused high toxicity. 
Using a similar tumor system Woodruff and Dunbar (1973) obtained 
results similar to those ofCunie and Bagshawe (1970). In their exper-
iments CP was given intraperitoneally and the best efl'ect was 
achieved when injected 9 days after cyclophosphamide. Treahnent of 
a murine leukemia with cyclophosphamide in combination with in-
traperitoneal CP was optimal when intraperitoneal CP was given 4 or 
8 days after cyclophosphamide. This was when the leuke mia was in 
remission. CP 12 days after cyclophosphamide, immediately plior to 
relapse, was ineffective (Pearson et al., 1975). Intrade rmal injections 
of CG, either 3 or 6 days afte r cyclophosphamide treatment of a rat 
leukemia has been described to be no more effective than drug b·eat-
ment alone (Pearson et al. , 1974a). The unpublished results of one of 
the authors (M. T. S.) are that the most effective treatment of a sub-
cutaneously growing mouse fibrosarcoma occurs when a single dose of 
CP is given intravenously, or given subcutaneously mixed with ir-
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radiated tumor cells, 4 days after a single intraperitoneal injection of 
cyclophosphamide. Fisher et al. (1975a,b) have studied the effects of 
prolonged adminisb·ation of CP alone, and in combination with cyclo-
phosphamide, on the treahnent of mouse mammary carcinomas. The 
best effects were obtained when systemic CP was administered asyn-
chronously at weekly intervals in combination with cyclophos-
phamide. The optimal time interval between cyclophosphamide in-
jections was 7 days, and so was the interval between CP injections. 
Best results were obtained when the CP was given 4 days after cyclo-
phosphamide, i.e., cyclophosphamide on days 0, 7, 14 and CP on 
days 4, 11, 18, etc. 
There are also data describing CP in combination with other drugs. 
A murine leukemia has also been successfully b·eated, with 76% com-
plete remissions, using a combination of 1,3-bis(2-chloroethyl)-1-
nitrosourea (BCNU) follo:wed 3 days later by intradermal CG: in-
jections of drug or CG alone were considerably less effective, as was 
CG 6 or 12 days after BCNU (Pearson et al., 1972). A different mouse 
leukemia responded well to a single intradermal injection of CG 3 
days after BCNU, but repeated injections ofCG at 3, 7, 9, and 11 days 
after drug were less effective (Pearson et al., 1974b). Intravenous in-
jection of CP 1 day after procarbazine fully protected all mice against 
leukemia cells, whereas with procarbazine alone there were no sur-
vivors (Amiel and Berarde t, 1970). There is also a preliminary report 
that adriamycin in combination with CP is more effective in increasing 
the life-span of mice with leukemia than either drug or CP alone 
(Houchens and Gaston, 1976). 
It is apparent that the com bination ofCP with drugs may be a prom-
ising form of cancer therapy and data concerning the p1inciples under-
lying this form of therapy are clearly required: e .g., what are the drug 
susceptibilites of the various CP antitumor effects? The protective 
effect of intravenous CP against the formation of lung metastases fol-
lowing intravenous injection of tumor cells is still detectable in 
cyclophosphamide-treated mice, and CP almost entirely abolishes the 
enhancement of metastases by cyclophosphamide (van Putten et al., 
1975). Scott ( 1975a) has shown that an injection of co1tisone acetate in 
CP-stimulated mice transiently inhibited the in vitro nonspecific an-
titumor activity of their macrophages and was sufficient to abolish in 
vivo resistance to a live tumor ce ll challenge. Studies by Fisher et al. 
(1976a) have, however, combined prolonged administration of cor-
tisone acetate with repeated cyclophosphamide and CP injections and 
shown no inhibition of antitumor effects. 
CP has already been described to increase the number of colony-
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forming cells in the bone marrow, and a possible indirect antitumor 
effect in future clinical situations may be the toleration of more inten-
sive chemotherapy due to a marrow protective effect. Further data in 
this area are also required, since a recent report describes that CP-
stimulated mice are more susceptible to the toxic effects of high doses 
of 5 fluorouracil (Foster, 1976). 
3. Combination with Su.rgery 
No general principles underlying the combination of CP treatment 
with the surgical removal of solid tumors are yet apparent from the few 
animal data available. 
Combined intradermal and intraperitoneal CP at 7 and 14 days after 
surgical removal of a subcutaneously growing rat hepatoma inhibited 
the fom1ation of lung metastases. CP injected before amputation was 
ineffective. If large numbers of irradiated hepatoma ce lls were in-
jected before surgery the number of lung metastases was increased, 
and this effect was abolished by simultaneous injection ofCP (Proctor 
et al., 1973). CP before amputation has been found to be effective in 
mouse models. Sadler and Castro (1976) reported that single inb·ave-
nous or intraperitoneal, but not subcutaneous, injections of CP within 
4 days before surgery reduced the incidence of lung metastases from a 
Lewis lung carcinoma. Similar data for systemic CP in a mouse mam-
mary carcinoma model has been presented by Milas et al. (1976). CP 
or CG injected after removal of the mammary carcinoma were ineffec-
tive, and injections of CG 4 and 10 days after surgery slightly en-
hanced metastases. 
F. ANTITUMOR ACTIVITY OF CP FRACTIONS 
It will be apparent from the clinical data (see Section VIII,B) that 
some of the side effects commonly observed with whole bacterial vac-
cines are serious. It is hoped that studies attempting to characterize 
the active principle of CP will result in retention of antitumor activity 
with a reduction in toxicity. 
A phospholipid exb·act ofCP has been reported to be less toxic than 
whole organisms in mice. It failed to cause splenomegaly and 
hepatomegaly but did inhibit the multiplication of bacteria in the liver 
and spleen. Its antitumor properties were not examined (Fauve and 
Hevin, 1974). A lipid exb·acted from the surface of CP has also been 
shown to be a chemoattractant for mouse and guinea pig macrophages 
and for human monocytes (Russel et al., 1976). An exb·act of CP pro-
duced by mild hydrolysis has re taine d some antitumor activity, a!-
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though considerably less than whole organisms. A lipid component 
seemed to be responsible, and antitumor activity was increased if the 
extract was adsorbed onto latex to facil itate its phagocytosis (McBride 
et al., 1976). Zola {1975) has shown that the in vitro B-cell mitogenic 
property of CP is lack ing in a deli p i dated preparation of cell walls. I f 
stimulato1y activity is associated with a lipid component, then other 
components may be similarly active. Adlam et al. (1975) have shown 
that lipid-free cell walls of CP retained thei r lymphoreticular stimulat-
ing and antitumor activity against a llogeneic sarcoma 180. Water-
soluble exh·acts prepared from delipidated cell walls of CP have also 
been shown to stimulate carbon clearance, antibody foxmation and 
DTH, as well as protecting against encephalomyocarditis virus and 
MSV (Migliore-Samour et al., 1974; Jolles et al., 1975). 
Various cell wall preparations of anaerobic coxynebacteria were 
shown by Kouznetzova et al. (1974) to possess reticuloendothelial 
stimulating activity, adjuvant properties, and protective effects against 
experimental mouse leukemias. A chemical analysis of CP ce ll walls 
has been presented by Azuma et al. (1975), who also found tha t adju-
vant activity for antibody fonnation and DTH was present in cell walls, 
but that cell-mediated antitumor immunity was not augmented. The 
adjuvant active unit of the cell wall sh·ucture is considered to be a 
peptidoglycan, and a similar dissociation betv,reen adjuvant and an-
titumor activity has been described for synthe tic peptidoglycans 
(Azuma et al., 1976; Yamamura et al., 1976). 
G. MODES OF ACTION 
l. Nonspecific Activity of CP-Activated Macrophages 
The in vivo antitumor effects of systemically injected CP in mice 
have been shown to be resistant to a variety of immunosuppressive 
procedures, suggesting an immunologically nonspecific mechanism 
(i.e., not amplifying a specific antitumor response) to be operating. 
They a re resistant to subsequent whole-body irradiation (Bomford and 
Olivotto, 1974; Milas et al., 1974b). They are also still apparent in 
mice deprived ofT lymphocytes by thymectomy, irradiation, and bone 
manow reconstitution (TIR) (Woodmff et al. , 1973; Scott, 1974b) and 
antilymphocyte serum treatment (Hattori and Mori, 1973; Cash·o, 
1974b). The inhibito1y effects of systemic CP on various T-
cell-dependent immune phenomena (discussed in Section IV,B) are 
also in keeping with a noninvolvement of lymphocytes in the CP-
mediated antitumor respon se . That antibody is unlikel y to be involved 
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is suggested by the demonstration that splenectomy, a procedure 
likely to impair antibody production, did not abrogate the in v·ivo 
antitumor effects of a subsequent injection of CP (Castro, 1974b; 
Mazurek et al., 1976). CP effects were also apparent in mice ge-
netically selected for low antibody responses (Biozzi et al., 1972). 
The resistance of systemic CP effects to immunosuppression is com-
patible with a macrophage-mediated response, and CP-activated mac-
rophages exe1t antitumor effects in vitro. This is not a property unique 
to anaerobic corynebacteria, but is shared by many other microor-
ganisms, such as BCG (Hibbs et al., 1972; Hibbs, 1973; Cleve land et 
al. , 1974). Toxoplasma gondii, (Hibbs et al., 1972; Hibbs, 1973; 
Krahenbu hl and Re mington , 1974), Listeria monocytogenes (Hi bbs et 
at., 1972; Hibbs, 1973; Krahenbuhl and Re mington, 1974), and Bes-
noitia jellisoni (Krahenbuhl and Remi ngton, 1974). 
Pe ritoneal macrophages from mice treated with CP inhibit the in 
vitro growth and D NA synthesis of syngeneic mastocytoma cell s 
(Scott, l974b), radiation -induced leukemia cells (Olivotto and Born-
ford, 1974; Bomford and Christie, 1975; Christie and Bamford, 1975), 
fibrosarcoma cells (Olivotto and Bomford, 1974; GhaffaT et al., 1974, 
1975), and RBL-5 lymphoma ce ll s (Kirchner et al., 1975b). The ulti-
mate fate of the target tumor cells in such cytostatic assays is not clear, 
but a direct cytotoxic effect of CP-activated macrophages on Lewis 
lung carcinoma has been described by Morahan and Kaplan (1976). 
Similarly, Basic et al. (1974, 1975a) fou nd that peritoneal m acrophages 
from mice treated with CG destroy in vitro cultures of a syngeneic 
fibrosarcoma, tumorigenic mouse L-P 59 cells, transformed Chinese 
hamster ovary cells, and human melanoma cells. 
The antitumor activity of peritoneal macrophages has been detected 
within 2 days following intravenous injection ofCP, was maximal after 
5 days, and the reafte r declined but was still present at 20 days . In 
contrast, the antitumor activity of lung macrophages was maximal 14 
days after CP (Olivotto and Bomford, 1974). The activity of splenic 
macrophages cou ld be first d e tected 7 days after intrape i;toneal CP; it 
peaked at 14 days and usually disappeared after 18-21 days (Kirchner 
et al., 1975b). 
It is apparent that these in ·v·it·ro cytostatic or cytotoxic effects are 
exclusive to the macrophages. The effector cells used by Olivotto and 
Bomford (1974) were almost exclusively macrophages by both 
morphologic and functional criteria. Non adherent peritoneal cells 
from CP-stimulated mice did not inhibit tumor cell growth in vitro 
(Ghaffar et al., 1974), and procedmes for removing lymphocytes from 
peritoneal cell s, such as extensive washing, trypsinization, or irradia-
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tion, did not impair their antitumor activity (Ghaffar et al., 1974; Scott, 
1974b; Basic et al., 1975a). Similarly, the activity of spleen cells was 
found to be unaffected by treatment with anti-8-serum and comple-
ment, whereas macrophage removal using rayon adherence columns, 
iron-magnetic techniques, or carageenin b·eatment, almost entirely 
abol ished it (Kirchner et al., 1975b). 
The mechanisms by which CP-activated macrophages kill, or in-
hibit the growth of, tumor cells in vitro is not clear. Medium removed 
from cultures of activated macrophages (Olivotto and Bomford, 1974; 
Basic et al., 1975a) or from cultures containing both, CP-stimulated 
macrophages and tumor cells (Ghaffar et al., 1974) did not inhibit the 
growth of tumor cells in vit·ro. This suggested that the antitumor activ-
ity of activated macrophages was not mediated through substances 
released into the growth medium, &nd that macrophage-tumor cell 
contact may be required. After several hours of culture, adherence of 
macrophages to tumor cells is already apparent (Olivotto and Bomford, 
1974; Basic et al., 1975a), and electron microscopy studies have shown 
a close apposition between the two cell sUtfaces (Puvion et al., 1975, 
1976). Adherent tumor cells subsequently undergo lysis (Basic et al., 
1975a). Hibbs (1974) rep01ted that, upon contact with target cells, 
macrophages activated by BCG or Toxoplasma appear to secrete 
lysosomal enzymes directly into the cytoplasm of target cells, which 
then lyse. This was inhibited by b·ypan blue, an inhibitor oflysosomal 
enzyme function (Hibbs, 1974). The in vivo antitumor effects of sys-
temic CP are similarly sensitive to trypan blue (Morahan and Kaplan, 
1976). Cortisone acetate also inhibits the in vitro antitumor activity of 
CP-activated macrophages (Scott, 1975a), the presumed effect being 
the prevention of exocytosis of lysosomal enzymes through stabiliza-
tion of the macrophage membrane (Weissmann and Dingle, 1961; de 
Duve et al., 1962; Allison and Davies, 1972). The lysosomal enzymes 
that may be involved in the in vitro killing of tumor cells by activated 
macrophages are not known. However, Puvion et al. (1976) recently 
repo1ted no con-elation between the level of acid phosphatase in CP-
activated macrophages and tumor cell-killing ability. 
The mechanisms of macrophage activation by CP have been the 
subject of recent studies by Christie and Bomford (1975) and Bomford 
and Christie (1975) . No1mal mouse peritoneal macrophages could not 
be activated in vitro, as assayed by inhibition of tumor cell prolifera-
tion, by exposure to CP alone, but only by mixtures of CP and spleen 
cells from CP-immune mice. Treatment of the spleen cells with anti-8 
serum and complement abolished this activation. Supernatants from 
cultures of the CP-immune spleen cells and CP were also capable of 
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activating normal macrophages. This indicated an immunological 
pathway of macrophage activation mediated by a release of soluble 
factors from CP-sensitized T lymphocytes on contact with the antigen . 
Participation of such an immune mechanism in the in vivo CP activa-
tion of macro phages was evidenced by the acceleration of macrophage 
activation by CP in mice which had been immunized with CP 60 or 
130 days earlier. Macrophages from notmal mice became cytostatic 5 
days after CP b·eatment, but those from previously sensitized mice 
were already cytostatic within 1 day (Bomford and Christie, 1975). It 
seems that CP can also activate macrophages in vivo by an alternati ve, 
immunologically independent pathway, since macrophage activation 
in both TIR mice (Bomford and Christie, 1975) and athymic nude mice 
(Ghaffar et al., 1975) is equal to that in n01mal mice. 
The fact that CP activates complement by the alternative pathway in 
both nonnal human and guinea pig serum (McBride et al., 1975c) 
allows speculation as to a further pathway of macrophage activation 
mediated by cleavage products of complement component C3. Activa-
tion of complement by the alternative pathway generates the C3 
cleavage product C3b, and Schorlemmer et al. ( 1976) report exper-
iments in which attachment of C3b to mouse macrophages in culture 
results in macrophage activation as evidenced by release oflysosomal 
enzymes into the culture. Similarly, activated mouse macrophages 
have recently been shown to nonspecifically inhibit mouse tumor cell 
growth in v·itro (A. C. Allison, personal communication). 
The in vitro cytotoxicity mediated by macrophages stimulated with 
anaerobic corynebacteria seems to be limited to cells with malignant 
growth characteristics. CG-stimulated macrophages do not desb·oy 
syngeneic or allogeneic fibroblasts, or allogeneic kidney epithelial 
cells in vitro (Basic et al., 1975a). These observations accord with 
findings by Hibbs, group that in vitro cu ltures of notmal allogeneic 
cells, but not cultures of cells with neoplastic properties, were resis-
tant to destruction by murine macrophages activated with Toxo-
plasma, Listeria monocytogenes, or BCG (Hibbs et al., 1972; Hibbs, 
1973). The reasons for this discriminatory behavior of activated mac-
rophages are not known but may be related to membrane properties of 
both activated macrophages and neoplastic cells facilitating, or initiat-
ing, close contact between them. Membranes of malignant and 
transformed cells differ from n01mal cells in electrical charge (Am-
brose et al ., 1956), surface glucoprotein (Roberts et al., 1973), 
glycolipid and glycosylb·ansferase activity (Hakomori and Murakami, 
1968; Roth and White, 1972), and lectin agglutinability (Aub et al., 
1963; Burger, 1969). Activated macrophages exhibit increased sticki-
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ness (Basic et al., 1975a), membrane motility (Nathan eta!., 1971), and 
membrane glycosamine incorporation (Hammond and Dvorak, 1972). 
What is the evidence that a nonspecific desh·uction of tumor cells by 
CP-activated macrophages operates in vivo? Most of the evidence to 
date is indirect. The resistance of the in vivo antitumor effects of sys-
temic CP to various immunosuppressive procedures, including radia-
tion, has already been commented upon. Mouse tumors regressing 
following inh·avenous CP or CG treatment are heavily infi]b·ated with 
macrophages (Milas et al. , 1974a,d ). It is, however possible that these 
cells may merely be removing the remnants of tumor cells killed by 
other host mechanisms. An involvement ofmacrophages is implied by 
the findings of McBride et al. (1975b). They showed that go ld salts 
(sodium aurothiomalate), which inhibit macrophage lysosomal en-
zyme activity, suppressed the in vivo protective action of CP against 
both intravenously and subcutaneously injected mouse fibrosarcoma 
cells. Scott (1975a) has also rep01ted similar suppressive effect using 
cortisone in a murine mastocytoma model. Current experiments in one 
of our laboratories (Peters et al., 1977) provide more direct evidence for 
in vivo involvement of activated macrophages. Addition of peritoneal 
macrophages from CP-stimulated mice to fibrosarcoma cells resulted in 
the suppression of tumor growth when this mixture was transferred 
intraperitoneally or subcutaneously into syngeneic recipients. Normal 
peritoneal cells or heat-killed activated cells had no effect. 
It should be borne in mind that these nonspecifically activated mac-
rophages which kill tumor cells in vitro, and are presumed to have a 
similar role in vivo, may be the same cells that have already been 
described to inhibit T lymphocyte responses in v ·it·ro (Scott, 1972a,b; 
Kirchner et al., 1975b). Kirchner et al. (1975a) have presented data that 
CP-activated macrophages may also be the cell type responsible for 
suppressing the specific seconda1y cytotoxic response of immune 
spleen cells against tumor cells in vitro. Systemic CP pretreatment has 
been described to depress the in vivo protective effects of specific 
immunization with inadiated tumor cells in an experimental leukemia 
model (Smith and Scott, 1972), and there thus may be a balance be-
tween the beneficial antitumor effects of CP and its immunosuppres-
sive effects. 
2. Potentiation of Tu.mor-Specific Immunity 
Studies using local injections ofCP have revealed a further mode of 
action which is immunologically specific, i.e., potentiates the host's 
immune response to tumor-specific antigens . 
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Subcutaneous injection of mixtures of CP with viable mouse mam-
mary carcinoma or rat Shay chloroma cell s into the con esponding 
syngeneic hosts resulted in the deve lopment of tumors that grew for 
about 2 weeks and then rapidly regressed. Animals whose tumors had 
undergone regression were found to be specHically resistant to tumor 
rechallenge (Likhite and Halpe rn, 1973). An analogous situation is the 
injection of CP directly into an established tumor, and animals whose 
tumors have undergone regression following intralesional CP therapy 
are similarl y specifically immune to recha llenge (Likhite and Hal-
pem., 1974; Scott, 1974c). The specific resistance resulting from local 
CP-tumor cell inte raction is lcng lasting and has been de tected up to 
20 months afte r injection of CP mixed with viable mouse mammary 
carcinoma cell s (Likhite, 1976). 
The foregoing studies suggested that, under conditions of close con-
tact between CP and tumor cells, CP may be augmen ting a specific 
antitumor immune response. Fisher et al. (1974) observed that the ·in 
v'it1·o cytotoxic ity of tumor drain ing lymph node cell s for mouse mam-
mary carcinoma cells was increased after injection of CP directly into 
the tumor or between the tumor and the dTaining lymph node. Since 
treatment of normal mice with CP did not result in any cytotoxicity, 
the augmentation in tumor-bearing mice was ascr.ibed to a CP-
mediated potentiation of the specific tumor immune response. Poten-
ti ation of specific antitu mor activ ity by CP is also evident from exper-
iments in which subcutaneous injections of CP mixed with irradiated 
mastocytoma cells have specifically immunized mice against tumor 
rechallenge, while injection s of CP or irradiated cells alone were 
without e ffect. The injection sites of CP and irradiated tumor cells did 
not need to be coinciden t but required common lymphoid drainage for 
immunity to occur (Scott, 1975b). Similar spec ific immunity arising 
from therapeutic injections of CP-irradiated mouse fibrosarcoma cell 
mixtures have been reported by Bomford (1975). It was reduced in T 
cell-deprived mice (Bomford, 1975; Scott, 1975b) and could be trans-
fen·ed by lymph node cells draining the site of mixture injection, but 
not by serum (Scott, 1975b). Tuttle and North (1976a,b) were a lso un-
able to b·ansfer immunity with serum and further presented evide nce 
that the lymphoid cell involved was a re latively short-lived T cell, 
which probably does not require macrophages or other lymphocytes to 
effect its antitumor activity. That such a cell-mediated immune mech-
anism may be operative in the local destruction of tumor cell s follow-
ing intralesional injection of CP is suggested b y the comple te T cell 
dependence of this form of CP therapy (Scott, 1974c; Woodmff and 
Dunbar, 1975). Tumors regressing following intralesional injection of 
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CP are heavily infiltrated with lymphocytes and macrophages (Likhite 
and Halpern, 1973, 1974). 
In Section VII,G,1 it has been reasoned that the antitumor effects of 
systemically injected CP are predominantly nonspecific and mac-
rophage-mediated. There are data, however, showing that poten-
tiation of specific immunity is not exclusive to locally injected CP but 
may also be a component in systemic CP therapy. Halpern et al. (1973) 
reported that the in vitro specific cytotoxicity of lymph node cells of 
mice bearing leukemia was greatly augmented and prolonged by in-
traperitoneal h·eatment of mice with CP. Yuhas et al. (1975) observed 
that neither specific immunization of mice with tumor cells nor treat-
ments with intravenous CP caused resistance to line 1 carcinoma cells, 
but that combination of the two was very efficient. Furthe1more, CP 
has required the presence ofT cells to induce optimal resistance to 
pulmonary deposits of a murine fibrosarcoma (Milas et al., 1975d). 
The role of antitumor antibodies in CP-induced resistance is less 
certain than that of immune cells. Transfer of serum from mice pos-
itively immunized by mixtures of CP and irradiated tumor cells was 
ineffective in conferring resistance upon normal mice (Scott, 1975b). 
Cytotoxic antibodies have been rep01ted after regression of living 
tumor cells mixed with CP (Likhite, 1975), but these may be a result of 
the temporary growth of the tumor itself. In an allogeneic mouse tumor 
model, CP pretreatment did not modify the level of complement-
dependent cytolytic antibody. It did, however, increase the antibody-
dependent cellular cytotoxicity (ADCC) of spleen cells (Mantovani et 
al., 1976). We are aware of no similar data concerning ADCC in a 
syngeneic tumor system. A noninvolvement of antibodies may be in-
ferred from the undiminished protective effects of CP in splenec-
tomized mice (Castro, 1974b; Mazurek et al., 1976) and genetically 
low antibody producers (Biozzi et al., 1972). 
The mechanism(s) of the potentiating activity of CP on specific an-
titumor immunity is as yet unclear. The processing of tumor antigens 
within CP-stimulated lymphoid organs may be modified. Wiener and 
Bandieri (1975) have shown that macrophages from CP-treated mice 
retain more antigen on their surface than nonnal macrophages which 
may improve antigen presentation to lymphocytes. Another contribut-
ing factor could be the increased and prolonged lymphocyte h·apping 
in lymph nodes of CP-stimulated mice (Frost and Lance, 1973). 
3. Immunity to CP 
In addition to its adjuvant properties, CP is itself a potent immuno-
gen producing both agglutinating antibodies (Woodruff et al., 1974; 
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Scott and Warner, 1976) and DTH (Scott, 1974a,c; Tuttle and North, 
1975). There is evidence that the expression of an immunological re-
sponse to CP antigens is impottant for local destruction of tumor cells 
following intralesional CP injection. Scott (1974c) described that the 
therapeutic effects of an inn·alesional injection of CP into an estab-
lished mouse mastocytoma were reduced if the specific reactivity of 
the tumor-draining node to CP had been preempted by a large amount 
of the bacteria injected intravenously. Tuttle and No1th (1975) were 
unable to achieve regressions of a mouse fibrosarcoma following in-
tralesional injection of CP unless the mice had been previously sen-
sitized to show DTH to CP, and the intralesional injection was at the 
time of maximum CP sensitivity. The destruction of tumor cells at the 
site of a DTH reaction to CP was associated with the influx of phagocy-
tic mononuclear cells. These may be activated macrophages si nce 
Christie and Bomford (1975) have shown that ·in vit·ro macrophages 
can be nonspecincally activated to kill tumor cells as a resu lt of local 
inte raction of CP with CP-sensitized T lymphocytes . 
Immunity to CP would also be likel y to influence its antitumor activ-
ity in any si tuation where tumor antigens might cross-react with CP 
antigens (James et al., 1976). Another si tuation would be if CP anti-
gens were to become absorbed onto the smface of tumor cells. They 
have been shown to be absorbed onto syngeneic red ce lls in vitro (Cox 
and Keast, 1974). 
4. Other Considerations 
Tumor-bearing mice conta in in the ir c ircu lation soluble tumor anti-
gens and antibody-antigen complexes that may block the efficiency of 
immune effector cells. CP h·eatment may, through nonspecific stimu-
lation of phagocytic activity, cause these factors to be removed. Exam-
ples of this may be the abolition of enhancing effects of active im-
munization with irradiated tumor cells rep01ted for a rat hepatoma 
(Proctor et al. , 1973) an d a murine mastocytoma (Scott, 1975b). Are-
lated observation may be the abrogation by CP of the enhanced spon-
taneous pulmonary metastases that resulted from local irradiation of a 
primary tumor (Milas et al., 1976). CP treatment also alters disb·ibu-
tion of tumor cells released into circulation (Bamford and OJ ivotto, 
1974) and may affe ct the process of metastases in this manner. 
Serum from mice treated with CP and several days late r with en-
dotoxin contains a substance which, upon injection into tumor-bearing 
mice, causes hunor necrosis (Carswell et al., 1975; Green et al., 1976). 
This tumor necrosis factor (T NF) is not produced by treatments with 
CP or endotoxin alone and is considered to be released by host CP-
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activated macrophages on contact with endotoxin (Carswell et al., 
1975). Whether TNF represents a component of the in vivo CP-
activated macrophage antitumor process remains to be determined. 
Processes facilitating the accumulation of host effector cells at a 
tumor site would be expected to contribute to the degree of damage 
inflicted by immunotherapy. In this respect, two such repotts seem 
relevant to the effects of locally injected CP. Various strains of 
anaerobic c01yneforms, including CP, have been found to produce 
chemotactic factors that attract macrophages specifically (Wilkinson et 
al., 1973b). Moore and Hall (1973) have also observed that local in-
jections of CP caused a local change in capillaries resulting in exb·ava-
sation of lymphoblasts. 
Most of the data presented in this section may be consid ered as 
evidence th at the CP organism is not itself toxic for tumor cells, and 
our own unpublished results suppott this. CG added to mouse sar-
coma cells in vitro did not alter their subsequent ability to f01m col-
onies in vitro (L. M.), and CP added to mouse mastocytoma cells in 
vitro did not inhibit their DNA synthesis (M. T. S.). 
VIII. Cl inical Experience 
A. THERAPEUTIC EFFECTS 
The first preliminary study of the clinical use of CP involved 141 
patients with various metastatic carcinomas who received either 
chemotherapy (cytoxan , 5-Auorouracil, methob·exate, vinblastine, and 
rufocromomycin) or a combination of chemotherapy with CP twice a 
month (Halpern and Israel, 1971; Israel and Halpern, 1972). Two mil-
ligrams of CP were given subcutaneously in each arm every week. 
Therapy was continued throughout the lifetime of patients, except 
when discontinued during periods of low white blood cell and throm-
. bocyte counts. The patients were monitored only for survival, and CP 
was found to have a significant effect. The mean survival time was 3.8 
months for patients rece iving chemotherapy alone, and 8.7 months for 
those who received CP and chemothe rapy. 
Further studies by the same group (Israel, 1973, 1975; Israel and 
Edelstein, 1975) showed that CP could be used effectively as an ad-
junct to chemotherapy of lung tumors, breast caxcinomas, sarcomas, 
and melanomas. Mean survival of patients with disseminated car-
cinoma of epidem1oid origin under chemotherapy alone was 5.6 
months; it was 9.8 months if treabnent with CP was included. Simi-
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larly, patients with oat-cell carcinoma survived 9.1 months if given CP 
and chemotherapy, but only 5.0 months if they were on chemotherapy 
alone. I n advanced breast carcinoma, survival of patients treated with 
the combined modalit ies was 85% at 1 year and 41% at 2 years, com-
pared with 41% and 16% of patients receiving chemotherapy alone. 
The 1-year survival of patients with advanced nonlymphomatous sar-
comas and malignant me lanomas was also significantly increased by 
add ition of CP (Israel and Edelstein, 1975). 
Immunocompetent patients, as judged by the positivity of purified 
protein derivative of tuberculin (PPD) skin tes ting, responded better 
to treatment with CP. An interesting observation was that CP was 
capable of converting negative skin tests (PPD, mumps, candidin, 
killed BCG, and DNCB) in about 50% of patients previously nonre-
sponsive to these antigens. 
A further observation in studies by the Israel group was that CP 
tJ·eatment greatly improved hematopoietic tolerance to chemotherapy. 
The number of chemotherapeutic interruptions due to low white 
blood cell and platelet counts was one-half as frequent as that in the 
group receiving chemotherapy alone (Israe l and Edelstein, 1975), and 
patients treated with CP also tolerated larger doses of chemotherapy. 
Some recent studi es have not confitmed these findings. Myelosup-
pression was no less severe, and the amount of chemotherapy tolerated 
was no greate r in breast carcinoma patients who were given weekly 
subcu taneous injections of 4 mg of CP in addition to cyclophos-
phamide, ad riamycin , me thotrexate, and 5-Auorouracil (D e Jager et 
al., 1976). In this study CP also did not improve the effectiveness of 
chemothe rapy. Intravenous CP (2.5 mg/m~) also failed to reduce the 
myelosuppressive effects of chemotherapy in patients with breast car-
cinoma (Haske ll et al., 1976). 
Subcutan eo us injec tions of CP and CG have been used as an adju-
vant to radiotherapy w ith H°Co of patients with head and neck malignant 
tumors, and, in comparison with irradiation alone, slightly increased 
the survival rate (Mahe et a.l., 1975). Treatment with 1mg of the 
bacteria commenced 6 weeks after comple tion of the radiation therapy. 
Bacteria were administered weekly for the first 6 weeks, and then once 
every 2 weeks for the duration of the trial. 
Other preliminary repotts have provided encouraging results con-
ceming the use of subcu taneous CP in combination with smgical re-
section ofmalign<lntme lanoma (Ishmae l et al. , 1976) and in combination 
with chemotherapy of advanced ovarian cancer (Ochoa et al., 1976). 
Intramuscular injections of anaerobic coty nebacte ri a have been 
used in immunothe rapy of patients with acute lymphoid leukemia 
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(Schwarzenberg and Mathe, 1975). Immunotherapy was started after 
remission was achieved by previotts chemoradiotherapy. One group of 
13 patients received BCG and irradiated leukemic cells, and another 
12 received this the rapy plus CG once a week, given on the day of 
adm inistration of BCG and tumor ce lls. Two-year survival was in-
creased in the group receiving CG. Adults were given 1.5 mg of CG 
and children 0.75 mg of CG per injection. 
Intravenous injections of CP have also been used clinically. Most 
studies have thus far dealt with the toxicologic and immunologic ef-
fects ofCP (see below); however, several preliminary rep01ts describ-
ing antitumor activity have alread y appeared. Band et al. (1975) 
treated 19 patients with various progressive metastatic solid tumors 
who had previously been treated with either chemotherapy, radiation 
therapy, or both. Doses of CP ranged from 0.5 to 6 mg/m2 and were 
given by intravenous infusions daily for 10 days. Objective regressions 
were observed in 4 patie nts and include the following tumors: colon 
carcinomas, breast cancer, and pulmonary me tastases of bone sarcoma. 
Israe l et al. (1975) b·eatecl20 te1minaJly ill patients with various solid 
tumors in whom previous chemotherapy b·eatment had failed. In-
travenous CP at a close of 4 mg was given dail y, 5 times a week, for 
4-16 weeks . In 8 patients (40%) the tumors regressed to more than 
50% of their original size. These were all metastases at various 
anatomical locations from lung adenocarcinoma, malignant 
melanomas, reticulum cell sarcoma, gasb·ic cancer, testicular 
seminoma, and mediastinal teratoma. Partial regressions caused by CP 
were successfully maintained by subsequent chemotherapy and 
weekly subcutaneous injections of CP. Different immunological func-
tions were evaluated during immunotherapy, and the most characteris-
tic finding was a decrease in C3 complement which conelatecl directl y 
with the clinical improvement of patients. 
Impressive data on CP therapy of disseminated malignant 
melanoma were recently reported by Reed (1976). Single intravenous 
injections of CP at 5 mg/m2 were given 19 clays after chemotherapy 
with imidazole carboxamicle (DTIC). In addition to CP, irradiated 
cultured melanoma cells (6 x 107 cells) were given subcutaneously. 
Seven of 11 patients (64%) treated in this way showed objective re-
gression of liver metastases, compared with only 2 of 13 (15%) re-
sponses in patients treated with OTIC alone ( P < 0.05). Patients who 
received the combined b·eatment li ved longer than patients in the 
chemotherapy group: median surviva l 7.5 and 4 months, respectively. 
The effect on lung metastases was not as striking; 45% of patients 
responded to immunochemotherapy and 25% to chemotherapy. 
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Another study involving malignant melanoma showed that intrave-
nous CP (2 injections of 5 mg/m2 given a week apa1t) can increase the 
therape utic effect of cyclophosphamide and OTIC (Presant et al., 
1976). 
Single intravenous treatments with CP, 5 mg/m\ decreased tumor 
growth and prolonged su rvival of patients with metastatic breast 
cancer (Minton et al., 1976), and appreciably improved chemotherapy 
treatments of lung carcinoma (Takita and Moayeri, 1976; Valdivieso et 
al., 1976). 
Intratumor injection ofCP, which is very efficient at producing com-
plete regression of experimental animal tumors, has also been tried in 
patients (Cunningham-Rundles et al., 1975; Hirshaut et al., 1975; Is-
rae l, 1975). Israel (1975) rep01t ed that 11 out of 11 cutaneous 
melanomas and 1 out of 2 skin metastases of oat-cell carcinoma com-
plete ly regressed when injected with 4-8 mg of CP for 5 consecutive 
days. Intratumor injections induced local inflammation within a few 
days, and this was sometimes followed by suppuration. Injections 
were also painnd , causing discontinuation of prolonged treatment. In 
studies by Cunningham-Rundles et al. (1975), the mean maximum 
tolerated dose of intralesional CP was 18 mg. In their study 3 out of 14 
injected tumors unden.vent complete regression and another 3 par-
tially regressed. All six patients who responded to CP had tumors 
localized in the skin, whereas nonresponders had tumors which, in 
addition to the skin , involved subcutaneous tissues and visceral or-
gans. T he growth of uninjected tumors was not affected by this 
treatment. 
B. TOXICITY 
Many Phase I clinical studies with CP have recently been con-
ducted, and most of these have used the intravenous route of injection 
(Band et al. , 1975; Hirs haut et al., 1975; Israel et al., 1975; Ossorio et 
al. , 1975; Reed et al., 1975b; Woodruff et al., 1975; Cheng et al., 1976; 
Fishe r et al., 1976b; Humphrey et al. , 1976; Minton et al., 1976). 
Patients in volved in these studies had various malignant tumors of 
very advanced clinical stages and were resistant to currently available 
therapies. The fi.rst study (Reed et al., 1975b) employed the initial 
intravenous CP dose of 1 mg/m2 ; after this dose was shown to be safe, 
2, 3, 5 , and 7.5 mg/m2 were investigated. The bacteria were given by 
infusions in 5% dextrose in water over a period ranging from 1 to 4 
hours. The doses of CP employed by other investigators were usually 
5 mg/m2 or lower and have been administered by infusion in 250- 500 
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ml of either saline or 5 % dextrose in water over 1-4 hours. We shall 
summarize the side effects of intravenous CP repo1ted in the various 
published studies . For the initial 2-3 hours after the start of the infu-
sion patients have no symptoms. A chill reaction then develops in most 
patients, which, in an appreciable number, can be vigorous, lasting 
from 20 to 40 minutes. Occasionally, recurrent chills may appear after 
a few minutes or hours after cessation of the first chill. A high 
proportion of patients develop peripheral vasoconstriction manifested 
as a mild cyanosis or blanched appearance. Following the onset of the 
chill reaction, mild hypertension may occur and an increase in the 
pulse rate is regularly observed. Toward the end of the chill pe1iod 
most patients develop a fever up to l05°F, and at this time most pa-
tients have nausea, vomiting, and mild headache. Some patients may 
feel sl ightly apprehensive. The temperature usually subsides within a 
few hours, but may last up to 3 days . Some patients sweat profusely 
during the regressive phase of the fever and some of them become 
mildly hypotensive. Myalgias and muscle weakness are rarer 
symptoms that develop at higher doses of CP. T he overall symptoms 
associated with intravenous CP are usually more intensive with in-
creasing doses of CP. Patients receiving a second intravenous dose of 
CP develop the same, but less intensive, symptoms. After a few re-
peated infusions of CP, the symptoms are minimal or may not appear 
at all . Even progressively increasing daily doses soon result in de-
creased toxicity symptoms. Fisher et al. (1976b) observed that a single 
intravenous administration of 100 mg of hydrocortisone 0.5 hour prior 
to CP infusion markedly diminished CP toxicity. 
In most studies renal and hepatic functions were not affected. How-
ever, with very high single doses ofCP (more than 20 mg per patient), 
slight rises in serum alanine aminotransferase levels and jaundice 
have been detected (Woodruff et al., 1975). 
A case of angina pectoris associated with a sudden rise of blood 
pressure (Band et al., 1975) and of a generalized Schwartzman reaction 
with acute azotemia and severe thrombocytopenia (Reed et al., 1975b) 
was also reported. Although cardiovascular changes have generally 
been minimal, they may be sufficient to contraindicate CP in patients 
with compromised cardiovascular status (Band et al., 1975). 
Most of the symptoms that accompany inb·avenous CP injection are 
also associated with subcutaneous injections, but in a milder fonn. 
Fever, headache, and malaise are observed most often. At the injection 
sites, soreness, induration, and erythema develop and may last from 
several hours to a few days (Reed et al., 1975b). Local soreness has 
persisted occasionally for about a week. To counteract pain at the in-
ANTITUMOR ACTIVITY OF Corynebacte·rium parvum 295 
jection sites, CP has been mixed with 2% xylocaine or 1% lignocaine 
(Israel and Halpern, 1972; I srael and Edelstein, 1975) . Similar 
symptoms are associated with the inb·alesional injections of CP (Cun-
ningham and Rundles et al., 1975). 
C. IMMUNOLOGIC PARAMETERS 
Various immunologic paramete rs have been monitored in patients 
undergoing therapy with CP. Tota l white blood ce ll counts are ra re ly 
affected; however, alterations in the absolute number of lymphocytes 
and monocytes frequently occur. A decrease is a lready apparent 
within a day ofCP infusion, but cell numbers return to normal within a 
week (Ossorio et al., 1975; Reed et al., 1975a; Woodruff et al., 1975; 
Cheng et a.l., 1976; Minton et al., 1976; Ochoa et al., 197.6). Several 
investigators have reported great variability in indiv idual total lym-
phocyte and T-cell counts (Israel et al., 1975; Hirshaut et al., 1975; 
Humphrey et al., 1976); however, Ochoa et al. (1976) found decreased 
lymphocyte and T-cell counts in all patients. The number of circulat-
ing B cells may be increased moderate ly (Hirshaut et al., 1975). 
The PHA responsiveness of perip heraJ blood lymphocytes is de-
p ressed 1-5 days after intravenous CP but then recovers, occasionall y 
rising above the base line (Reed et al., 1975a; Minton et al., 1976). 
After 1-2 months, patients receiving multiple CP injections have 
shown increased reactivity toT-cell mitogens, PHA, and concanavalin 
A (Con A), whereas responses to poke weed mitogen and streptol ysin 
"0" have remained unchanged (Reed et al., 1975b). A similar ten-
dency toward increased PHA and Con A reacti vity has also been de-
scribed by Israel et al. (1975). 
The effects of CP on skin testing with de layed-h ypersensitivity anti-
gens: de rmatophytin, candida, streptokinase-sb·eptodornase, mumps, 
DNCB, and others have been monitored. In studies by Reed et al. 
(1975b), 9 of 25 patients rece iving inb'avenous CP showed an im-
provement in skin test responses. Cheng et al. (1976) reported that 10 
positive reactions were converted to negative and 4 negative reactions 
to positive. Variable results on skin tests were also rep01ted by I srae l 
et al. (1975) and by Hirshaut et al. (1975). Of 6 patients initially unre-
sponsive to DNCB, 4 became positive to the same antigen shortly after 
receiving their first CP dose (Hirshau t et al., 1975). 
James et al. (1975) found a constant increase in the circulating I gG 
levels of all patients with maJignant melanoma, breast or gastric cancer 
who had received 20 mg of CP intravenously followed by weekly 
intramuscu lar injections of 2 mg for 10-11 weeks. All 4 su bel asses of 
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I gG were increased, but particularly IgG:z. IgA, IgM, and IgE levels 
were inconsistently affected. The rise in immunoglobulin levels was 
attributed largely to the development of antibodies against CP. 
Preexisting antibodies were noted in all patients and titers rose with in 
2 weeks after the initial CP injection and remained e levated through-
out the 100-day period of observation. D evelopment of anti CP an-
tibodies in CP-b·eated patients has also been observed by Minton et 
al. (1976), and they found no con-elation with the antitumor activity of 
CP. Other studies dealing with the effects of CP on antibody produc-
tion in patients with various malignant tumors have shown no 
significant changes in immunoglobulin leve ls (Dimitrov et al., 1975b; 
Israel et al., 1975; Hirshautet al., 1975). Only occasionally I gE (Wood-
ruff et al., 1975) and IgM (Hirshaut et al., 1975) may be e levated. 
Intravenous CP may be associated with complement activation in 
cancer patients. Serum levels of C3 (Dimih·ov et al., 1975b; Israel et 
al., 1975) and C3 and C4 (Biran et al., 1975) have been found to be 
decreased after intravenous CP. A similar deple tion in C3 and C4 
levels has occurred in normal human serum in vitro after addition of 
CP. Addition of CP to guinea pig serum, which, unlike the human 
serum did not contain antibodies against CP, only resulted in de-
creased C4 levels (McBride et al., 1975c) . The depl e tion of C3 and C4 
levels in patients occulTed more fi·equently if the patients were im-
munocompetent, and the suggestion is that CP activates complement 
in patients both directly via the alte rnative pathway (C3), and via the 
classical pathway (C1, 4, 2, . .. ) when natural or induced anti-CP 
antibodies are present (Biran et al. , 1975; McBride et al. , 1975c). Is-
rael et al. (1975) found that decrease in C3 levels in the serum of 
patients correlated directly with the e ffectiveness of CP therapy. We 
have already discussed a possible role for C3 cleavage products in the 
activation of mouse macrophages (Schorlemmer et al., 1976). 
IX. Perspectives and Prospects 
The results achieved using CP in the b·eatrnent of experimental 
animal tumors have been impressive, and the overall clinical results to 
date are encouraging. Other than for the toxicity studies, however, the 
human data are as yet too preliminary to f01m the basis for discussing 
future perspectives. For this we have drawn on the large amount of 
animal data available, but, in doing so, are aware that there are, thus 
far, no human dat:'l indicating whe ther or not what we consider to be 
the modes of action of CP in animals, also operate in man. Results 
concerning the in vitro perf01mance of macrophages and lymphocytes 
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from CP-treated patients in both nonspecific and specific antitumor 
assays are eagerly awaited. 
Tumor size is a critical consideration in CP immunotherapy. 
Throughout the animal studies, small tumor masses, even strongly 
antigenic ones, have responded best to treatment. Clinically these 
situations are likely to be seen in patients with newly diagnosed 
tumors at early stages, or those whose tumor burden has been reduced 
by prior irradiation, surgery, or chemotherapy. 
The combination of CP with chemotherapy in the treatment of some 
animal tumors has been exo·emely successful , the individual an-
titumor effects being additive, or even syne rgistic. Clinical shtdies 
using CP as an adjunct to chemothe rapy have been pre liminary, but at 
least they indicate that immunostimulant therapy is not incompatible 
with immunosuppressive chemotherapy. The combination chemoim-
munotherapy approach is likely to benefit from further animal studies 
using appropriate tumor models. Screening for potential synergistic or 
antagonistic CP-drug combinations could be rewarding. It may be that 
CP potentiates the antitumor activity of some dmgs as it does the 
effects of local inadiation, or that CP-mediated antitumor effects, once 
established, are sensitive to subsequent drug treatment. 
It is apparent that some of the therapeutic effects of CP may not be a 
direct result of its antitumor acti vity. Infection is the cause of death in 
some cancer patients immunosuppressed either directly as a resu lt of 
the disease, or because of conventional therapies . Increased survival of 
any such patients receiving CP may be attributable, at least in part, to 
enhanced bacterial resistance resulting from reticuloendothelial 
stimulation. Another " i ndixect, antitumor effect might be that more 
intensive radio- or chemotherapy can be tolerated because of CP-
mediated protection against their myelodepressive side effects. 
Small disseminated microfoci of tumor cells persisting or appearing 
after successful treatmen t of the primary tumor mass are often the 
ulti mate cause of death in cancer patients. It is for this reason that the 
establishment of systemic antitumor immunity should be the ultimate 
goal of any immunotherapeutic regimen. The designers of clinical 
trials involving CP should take into consideration the fact that differ-
ent kinds of systemic antitumor immunity (specific or nonspecific) may 
be preferentially selected under diffe rent circumstances. The intensity 
and durability of the specific ce ll-mediated antitumor immu nity that 
has resulted from local interaction of CP and tumor antigen in mice 
suggests this to be a desirable situation to achieve clinicall y. Optimal 
immunity may be reso·icted to situations where either direct inhale-
sional injection or stimulation of the tumor-draining nodes is practical, 
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or specific active immune therapy using CP mixed with attenuated 
tumor cells when these are obtainable. In some cases a surgically 
resectable tumor may be accessible to preoperative intralesional CP 
injection, e.g., gastric cancers via endoscopy, thereby establishing 
specific tumor immunity that may not result from surgical resection 
alone. A reasonably strong tumor-associated antigen and high degree 
of patient immunocompetence would both be expected to facilitate 
specific immunization. Animal studies indicate that optimal immuni-
zation requires a balance between the amount of CP and tumor anti-
gen. However, given our poor understanding of the antigenicity of 
human tumors, clinical trials attempting specific immunization must 
be empirical. 
The immunologically nonspecific, macrophage-mediated, systemic 
antitumor activity that seems to predominate after systemic injections 
of CP does not require close contact between CP and tumor and is 
likely to be independent of tumor antigenicity and patient im-
munocompetence . Theoretically, therefore, in the case of tumors at 
inaccessible sites, those of low antigenicity, and patients with poor 
immunocompetence, nonspecific therapy may be appropriate. Anergic 
patients may benefit particularly from the antibacterial effects that 
have been described for systemic CP. Although little nonspecific sys-
temic stimulation has resulted from a single subcutaneous injection of 
CP in mice, the systemic effects of repeated subcutaneous injections 
have been shown to be additive. The final degree of stimulation 
achieved, however, was less than for the same amount of CP given as 
repeated systemic injections (Scott and Warner, 1976). In widely dis-
seminated tumors, the wider distribution of CP following systemic 
injection would be expected to maximize the chance of CP reaching 
either tumor sites or draining nodes, thereby engaging specific im-
mune mechanisms as well. Combination of systemic and regional CP 
injections designed to elicit both nonspecific and specific immunity 
may prove to be particularly effective. Suit et al. (1976b) found com-
bination of intralesional and systemic CP to be more effective in mice 
than e ither individual treatment. Scott (1974c), however, has shown 
that systemic CP may diminish the effectiveness of subsequent in-
tralesional therapy, although it did not diminish the ability of CP-
irradiated tumor cell mixtures to immunize (Scott, 1975b). 
The individual doses of CP that can be administered systemically in 
humans are considerably less than those required for effective tumor 
therapy in mice. However, unlike the mouse situation with rapidly 
growing experimental tumors, the human situation allows for repeated 
injections over an extended period. The eflects of repeated low doses, 
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both systemic and subcutaneous are additive in the mouse and in-
terestingly the antitumor protection afforded by repeated low doses of 
CP may be greater than the total dose given as a single injection (Milas 
et al., 1975c). In specific cell-mediated immunity resulting from CP-
irradiated tumor cell mixtures in mice, the doses of CP have been in 
the human equivalent range (Bomford, 1975; Scott, 1975b). 
Despite the fact that experimental conditions in CP animal tumor 
studies have been exh·emely uniform-i.e., the same tumor cells, in 
similar sites in genetically uniform, often specific pathogen-free 
animals-the responses of individual tumors to CP have varied. Some 
have regressed completely and some pattially, whereas others have 
been unaffected (Milas et al., 1974d). That CP responsiveness is af-
fected also by genetic constitution is apparent from the differing de-
grees of lymphoreticular stimulation that occur in different strains of 
inbred mice (Stiffel et al., 1970). This may be associated with diffe ring 
degrees of natural immunity to CP. All these considerations would 
indicate that, in the considerably Jess uniform human situation, a wide 
range in the responses of "similar" tumors to CP therapy may be 
expected. 
The identification of clinical situations in which CP may b e effective 
is a major problem. It is apparent, however, that the basic mechanisms 
underlying the antitumor activity of CP, i.e., macrophage activation 
and potentiation of specific cell-mediated immunity, aTe similar to 
those described for BCG (see review by Bastet al., 1974). The clinical 
assessment of BCG is more advanced than that of CP, and, given the 
basic similarities between the two organisms, the evaluation of CP in 
situations where results with BCG have been promising seems logical. 
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